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Preface to “Identification and Characterization of 
Antimicrobial Peptides with Therapeutic Potential” 
Antimicrobial peptides are key defense molecules adopted by all life forms. The Antimicrobial 
peptide field is advancing rapidly as a result of the following: First, the antibiotic resistance issue has caught 
the attention of politicians, scientists, and the general public. There is the consensus that measures should 
be taken to curb the growth of antibiotic resistance. Efforts in this direction may range from discovering 
alternative antimicrobials to exploring different applications of existing antibiotics [1]. Second, there is a 
great desire to understand the functional roles of antimicrobial peptides in humans, animals, and plants. 
Studies in this direction will elucidate when and where such peptides are expressed in response to invading 
pathogens and how they work together with other components in the immune system to maintain a healthy 
host. Third, it is now appreciated that commensal bacteria play an essential role in human health. An elegant 
example is human microbiota. A current view is that a loss of beneficial commensal bacteria opens the door 
to infection by microbial intruders [2]. This view indicates the importance to maintain the homeostasis of 
our microbiota to prevent related diseases. It also implies that one may try to restore the commensal 
microbes as a therapeutic option [3]. Whichever the direction may be, the identification and characterization 
of naturally occurring antimicrobial peptides clearly constitute an important step toward these goals. 
Consequently, there is an increasing effort in discovering novel antimicrobial peptides from natural 
resources by genomic mining or proteomic approaches [4]. Identification and Characterization of 
Antimicrobial Peptides with Therapeutic Potential, an eBook consisting of three parts, is constructed to tell 
the story of antimicrobial peptides discovered from a variety of kingdoms or classes. These articles were 
selected from the two Special Issues on antimicrobial peptides originally published in the open access 
journal Pharmaceuticals during the period 2014–2016. 
The first part (Chapter 1) highlights leaps made in peptide discovery, new function, mechanisms of 
action, and potential applications of antimicrobial peptides. Based on the antimicrobial Peptide Database 
(APD; http://aps.unmc.edu/AP), roughly 100–300 new peptides with demonstrated antimicrobial activity 
are discovered each year [5], including unique sequences, which cannot be predicted by modern machine 
learning algorithms. Then, my research team and I continue to describe new mechanisms for existing 
antimicrobial peptides that have been known for decades. We propose that multiple functions of 
antimicrobial peptides are realized by their ability to recognize and interact with different molecular targets 
or cells. Finally, we discuss various potential applications of antimicrobial peptides, ranging from peptide 
therapeutics, surface coating, nanoparticle-based drug delivery systems and biosensors to detection devices. 
The second part is the main body of this eBook that contains a series of articles on natural 
antimicrobial peptides from diverse sources. Fungi, as eukaryotes, provide a useful source for antimicrobial 
peptides. There are well-known examples such as plectasin, eurocin, micasin, and copsin. Among them, 
plectasin is extensively characterized in terms of structure, activity, and potential applications [6]. In 
Chapter 2, Shunyi Zhu and colleagues describe the great opportunity to identify many more defensin-like 
peptides from the sequenced fungal genomes. A sequence similarity search leads to 69 new peptides from 
26 fungal species. A recent article from the same lab demonstrates that, however, not all such peptides 
possess antimicrobial activity, at least based on the in vitro tests of select bacterial strains [7]. It is likely that 
numerous peptides expressed simultaneously are endowed with distinct functions to maximize the benefits 
to the host. 
Plants constitute another important source for novel antimicrobial peptides (341 entries in the current 
APD). Many plant antimicrobial peptides comprise disulfide bonds that usually form β-sheet structures. 
Additionally, disulfide-linked sequences can also form α-helical structures. In Chapter 3, James Tam and 
colleagues systematically deal with the sequence, structure and activity of these plant peptides. Cyclotides, 
circular peptides stabilized by three disulfide bonds, are a special class of plant peptides whose antimicrobial 
activity remains to be tested. Their stable scaffold and recognition of bacterial phosphatidylethanolamine (PE) 





Animals are diverse and can be broadly separated into invertebrates and vertebrates. Most animals 
are invertebrates, such as insects, spiders, and scorpions. In Chapter 4, Václav Čeřovský and his associate 
vividly tell the story of lucifensin, which is believed to be the long-sought-after magic molecule for Maggot 
therapy. For spiders and scorpions, Xiuqing Wang and I have recently conducted a structural and 
bioinformatics analysis [8]. While spiders use both glycine-rich and helical peptides for defense, scorpions 
use only helical peptides. Vertebrates are also versatile, covering fish in water, reptiles on land, and birds 
in the sky. In Chapter 5, Gill Diamond and his associate discuss a variety of fish antimicrobial peptides that 
kill both human and fish pathogens. In addition, these peptides also modulate immune responses. Of 
particular interest is that fish antimicrobial peptides may work at high concentrations of salts or low pH, 
useful properties for developing the next generation of antimicrobials. In Chapter 6, Michael Conlon and 
his colleague describe select antimicrobial peptides from skin secretions of frogs (~1000 in the current APD). 
The authors comment that “the therapeutic potential of frog skin peptides as anti-infective agents has  
not been realized so that alternative clinical applications as anti-cancer, anti-viral, anti-diabetic, or 
immunomodulatory drugs are being explored.” In Chapter 7, Monique van Hoek discusses antimicrobial 
peptides from reptiles. Recently, she and her colleagues have proposed an innovative approach that 
enriches peptides from reptile blood [9]. This method accelerates the discovery of additional reptile 
peptides. Chapter 8, by Guolong Zhang and his associates, summarizes the biology and therapeutic 
potential of avian antimicrobial peptides. Structure–activity relationship studies help identify candidates 
for antimicrobial use or vaccine adjuvants. Dietary additives have been utilized to modulate the expression 
of antimicrobial peptides to prevent diseases in chicken. In Chapter 9, I describe human antimicrobial 
peptides, covering discovery, antimicrobial/anticancer activities, mechanisms of action, three-dimensional 
structure and therapeutic strategies. Provided in Table 1 is a timeline for the discovery of select human 
antimicrobial peptides (over 100 in the APD). These peptides and proteins can adopt various structural 
scaffolds to attack pathogens by different mechanisms. These include disruption of membranes, inhibition 
of metal uptake or cell wall synthesis, and association with ribosomes. Finally, various factors such as 
isoleucine, sunlight and vitamin D can be utilized to induce the expression of human antimicrobial 
peptides, opening a new avenue to curb pathogen infection. 
The third part of this book highlights the therapeutic potential of antimicrobial peptides. The 
moonlighting of antimicrobial peptides (i.e., multiple functions) lays the foundation for us to explore their 
potential uses. Interestingly enough, bacteria also produce antimicrobial peptides (generally called 
bacteriocins). Several bacterial peptides (e.g., daptomycin, gramicidin, and nisin) are already in use. In 
Chapter 10, Anne Ulrich and her colleagues report the treatment of patients with root canal infections using 
gramicidin S. Antiviral effects of antimicrobial peptides are also of high interest considering viral infections 
such as SARS, Zika, and Ebola in the news. In Chapter 11, Kevan Hartshorn and his colleague describe the 
role and therapeutic potential of antiviral antimicrobial peptides, including human α-defensins, β-
defensins, retrocyclins, LL-37, histones, amyloid peptides, lactoferrin and bacterial/permeability increasing 
protein (BPI) derived peptides. While intact LL-37 itself lost activity, its central fragment (GI-20) remained 
effective against a pandemic influenza virus strain H1N1 of 2009. Antimicrobial peptides may also be useful 
in preventing undesired pregnancies and as anti-HIV microbiocides [10]. In Chapter 12, Nongnuj 
Tanphaichitr and her colleagues discuss spermicidal AMPs. They propose that human cathelicidin LL-37 is 
the most promising peptide for this purpose. Many peptides are currently under active development for 
therapeutic applications [1]. It appears that the potential of these natural peptides is unlimited and remains 
to be unlocked by the young generation of researchers for the benefit of our biosphere. I hope that this 
eBook provides a useful introduction to newcomers and refreshes the minds of the veterans. Finally, I 
would like to take this opportunity to thank all the authors who contributed their insightful work to this 
eBook and the Pharmaceuticals editorial team for publishing it. 
 
Guangshun Wang 
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Abstract: This article highlights new members, novel mechanisms of action, new functions, and
interesting applications of antimicrobial peptides reported in 2014. As of December 2014, over
100 new peptides were registered into the Antimicrobial Peptide Database, increasing the total
number of entries to 2493. Unique antimicrobial peptides have been identified from marine bacteria,
fungi, and plants. Environmental conditions clearly influence peptide activity or function. Human
α-defensin HD-6 is only antimicrobial under reduced conditions. The pH-dependent oligomerization
of human cathelicidin LL-37 is linked to double-stranded RNA delivery to endosomes, where the
acidic pH triggers the dissociation of the peptide aggregate to release its cargo. Proline-rich peptides,
previously known to bind to heat shock proteins, are shown to inhibit protein synthesis. A model
antimicrobial peptide is demonstrated to have multiple hits on bacteria, including surface protein
delocalization. While cell surface modification to decrease cationic peptide binding is a recognized
resistance mechanism for pathogenic bacteria, it is also used as a survival strategy for commensal
bacteria. The year 2014 also witnessed continued efforts in exploiting potential applications of
antimicrobial peptides. We highlight 3D structure-based design of peptide antimicrobials and
vaccines, surface coating, delivery systems, and microbial detection devices involving antimicrobial
peptides. The 2014 results also support that combination therapy is preferred over monotherapy in
treating biofilms.
Keywords: antimicrobial peptide; bacterial detection; biofilms; mechanism of action; nanoparticle;
peptide discovery; sensors; structure-based design; surface coating
1. Introduction
Antimicrobial peptides, or host defense peptides, are important components of innate immune
systems. This field is currently moving rapidly. On one hand, there is an urgent demand for novel
antimicrobials due to the current trend of reduction in the potency of commonly used antibiotics. On the
other hand, our research now pays more attention to innate immune systems where antimicrobial
peptides play an essential role. An imbalanced expression of antimicrobial peptides has been implicated
in human disease [1–5]. All these research activities around the world led to a substantial increase in
the number of scientific papers on antimicrobial peptides. In 2014 alone, a search of the PubMed using
“antimicrobial peptides and 2014” returned 7562 publications (~20 articles per day) [6]. About 10% of
these publications are review articles. However, a summary in the style of annual report is lacking.
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During our regular update of the Antimicrobial Peptide Database (APD) (http://aps.unmc.edu/AP) [7–9]
in the past years, we noticed new peptides of outstanding interest and created a website for them
(http://aps.unmc.edu/AP/timeline.php) [10]. We also felt the need to write a story on these interesting
molecules. Since the antimicrobial peptide field is rather broad, a detailed report on every aspect of
the research is out of the scope of this review. Instead, we chose to highlight the antimicrobial peptide
research by focusing on the following topics: (1) Of the new peptides discovered in 2014, are there any
unique members that expand our current knowledge of natural antimicrobial peptides? (2) For known
peptides, have we uncovered new functions that fill in our knowledge gap? (3) What progress have
we made in mechanistic studies? Have any of our existing views been challenged? What about the
genetic basis of bacterial resistance? (4) Are there advances in peptide applications? In the following,
we discuss these four aspects of the antimicrobial peptide research based on the new discoveries made
during 2014. We apologize if your important work did not fit into the scope of this article or escaped
our attention.
2. New Host Defense Peptides Reported in 2014
This section features new antimicrobial peptides discovered in 2014. Two major methods were
utilized for peptide discovery: a combination of chromatographic approaches [11–21] and genomic and
proteomic approaches [22–25]. The proteomic approach has the potential of identifying a large number
of peptides. However, we only registered peptides into the APD database if they have a known amino
acid sequence (usually less than 100 amino acids) and demonstrated antimicrobial activity. In 2014,
104 new antimicrobial peptides were registered in the APD [7,8]. This 2014 total is comparable to
those annual totals of peptides (over 100) collected into the APD since 2000 [26]. In the following, we
highlight unique peptides from various life kingdoms.
Of the 104 new antimicrobial peptides, 29 bacteriocins (i.e., bacterial antimicrobial peptides) were
isolated from the bacterial kingdom. The peptide BacFL31 is unusual in that its N-terminal amino acid
sequence contains six hydroxyprolines (X in the sequence GLEESXGHXGQXGPXGPXGAXGP) [11].
Baceridin, a non-ribosomally synthesized circular peptide with only six amino acids (50% D-amino
acids), was isolated from a plant-associated Bacillus strain [12]. This peptide can inhibit cell cycle
progression and causes apoptosis in cancer cells independent of p53. It is the most hydrophobic
peptide (100%) and the shortest circular peptide in the APD (Table 1). Lassomycin was found to be
similar to lassos since its aspartic acid 8 forms a bond with the N-terminal glycine. This peptide kills
Mycobacterium tuberculosis by binding to ATP-dependent protease ClpC1P1P2 [13]. It is exciting that
humans have reached organisms deep in the sea. Using transformation-associated recombination (TAR)
technology, Yamanaka et al. succeeded in cloning and expression of a silent lipopeptide biosynthetic
gene cluster from the marine actinomycete Saccharomonospora sp. CNQ-490 to produce taromycin A,
a daptomycin analog [14]. In addition, several lipopeptides were found from a marine bacterium
Bacillus subtilis. One of them, gageotetrin A, consists of only leucine and glutamic acid followed
by a new fatty acid 3-hydroxy-11-methyltridecanoic acid at the C-terminus [27]. Interestingly, these
peptides displayed rather good antibacterial activity (0.01–0.06 μM) against Staphylococcus aureus, B.
subtilis, Salmonella typhimurium, Pseudomonas aeruginosa, Rhizoctonia solani, Colletotrichum acutatum,
and Botrytis cinera. Although gageotetrin A is a conjugate, it possesses the shortest peptide sequence
(Table 1) in the APD. The structure of anionic gageotetrin A (peptide + fatty acid) is clearly different
from synthetic ultra-short lipopeptides (fatty acid + peptide), which are usually cationic to mimic
cationic antimicrobial peptides [28]. Gageotetrin A has a simpler molecular design compared to
anionic daptomycin, the first lipopeptide antimicrobial approved by FDA in 2003 [29]. Another
peptide, sonorensin with broad activity spectrum against both Gram-positive and Gram-negative
bacteria, was also identified from a marine bacterium Bacillus sonorensis MT93. It possesses a unique
amino acid sequence with multiple copies of the CWSCXGHS motif, where X is methionine or
alanine (Table 1). Sonorensin is the first characterized bacteriocin from the heterocycloanthracin
4
Pharmaceuticals 2015, 8, 123–150
subfamily [30]. These successful examples prove that it is likely to identify novel antimicrobial peptides
from unexplored organisms.
The discovery of new antimicrobial peptides from the fungal kingdom is lagging behind other life
kingdoms. In 2014, we collected only one defensin-like peptide from Coprinopsis cinerea. Like fungal
plectasin and eurocin [31,32], copsin inhibited cell wall synthesis by binding to lipid II [33]. These
fungal peptides share the same 3D fold, comprising one α-helix packed with a two-stranded β-sheet.
Differing from plectasin and eurocin with three disulfide bonds, however, copsin is stabilized by six
disulfide bonds. In addition, the N-terminus of copsin is modified into a pyroglutamate (17 peptides
in the APD with such a modification [8]), furthering conferring stability to the peptide against high
temperatures and protease digestion. Thus, fungi constitute yet another important kingdom for novel
antimicrobial discovery.
In 2014, five new antimicrobial peptides were characterized from the plant kingdom and one of
them is quite unique. Different from many disulfide bond stabilized defensins with a β-sheet structure,
EcAMP3 is a disulfide-stabilized hairpin-like α-helical peptide. It is the first such peptide that inhibits
phytopathogenic bacteria [20]. Hispidalin from winter melon Benincasa hispida [34] shows only 31%
sequence similarity to tachycitin from horseshoe crabs [35] and amphibian brevinin-1PRb [36] based
on sequence alignment in the APD [7]. Since hispidalin is a newly discovered peptide, it has not been
trained in the existing programs. Not surprising, several online machine-learning programs were
unable to predict it as an antimicrobial peptide [37–39].
Table 1. Select antimicrobial peptides discovered in 2014.
APD ID Name Source Peptide amino acid sequence Unique features 1




































2424 Crotalicidin Animals KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF Rich in lysine (38%)
1 Additional peptide properties can be found in the APD database (http://aps.unmc.edu/AP) [8] using peptide ID in
the table. A full list of the 2014 antimicrobial peptides can also be studied there.
Of the 104 antimicrobial peptides found in 2014, 69 originated from animals. This is consistent
with the overall picture in the APD that antimicrobial peptides from the animal kingdom dominate [26].
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Moreover, amphibians remain a major source for discovering natural antimicrobial peptides,
accounting for 35% of the 2014 total (38.8% of the entire database entries). Most of these new sequences
resemble the known frog antimicrobial peptides, which are linear and have the potential to form a
helical structure [18,19]. Although cathelicidins have been identified from a variety of animals, ranging
from birds, fish, and reptiles, to mammals [40], candidates from amphibians were not reported until
2012 [41]. In 2014, two new members appeared [42], leading to a total of six amphibian cathelicidins
in the APD (five helical and one glycine-rich). These cathelicidins are quite distinct from the main
body of amphibian peptides. For example, cathlicidin RC-1 has a high content of lysines (32%).
Crotalicidin [17], a homologous snake cathelicidin, contains an even higher content of lysines (38%)
(Table 1).
Also in 2014, some known human peptides or proteins were demonstrated to be antimicrobial.
These include human α-defensin 6 (HD-6), β-defensin 120 (DEFB120), chemokine CCL24 (eotaxin-2),
CCL26 (eotaxin-3), and human ribonuclease 6 (RNase 6). While HD-6 is active against Bifidobacterium
adolescentis [43], recombinant DEFB120 is active against Escherichia coli, S. aureus, and Candida
albicans [44]. Eotaxin-1 (CCL11), eotaxin-2, and eotaxin-3 are known chemokines, which are also
active against the airway pathogens Streptococcus pneumoniae, S. aureus, Haemophilus influenzae, and
P. aeruginosa [45]. In addition, human RNase 6 is inducible and shows activity against uropathogens,
underscoring its defense role in the urinary tract [46]. These characterized members further expand
the known reservoir of human host defense peptides and proteins reviewed in 2014 [47].
3. New Light on Known Human Antimicrobial Peptides
Antimicrobial peptides may be constitutively expressed to keep defined loci in a healthy state [1,48].
Compared to neonatal and adult keratinocytes, the corresponding fetal cells express much more human
antimicrobial peptides for host defense [49]. Alternatively, these molecules can also be induced upon
bacterial invasion. For example, a human cathelicidin peptide is induced in skin fat cells upon S. aureus
infection, underscoring the significance of adipocytes in host defense [50]. Previously, Gallo and
colleagues also found that overexpression of cathelicidin PR-39 protected animals from group A
Streptococcus (GAS) infection [51]. Interestingly, the gut possesses both constitutively expressed
and induced antimicrobial peptides. While human cathelicidin LL-37 and β-defensins 2-4 (hBD-2 to
HBD-4) are induced, human α-defensin 5 (HD-5), HD-6, and β-defensin 1 (hBD-1) are constitutively
expressed [52]. These constitutively expressed human peptides also play a special role in host defense.
In 2014, HD-5 was shown to be especially potent against the most virulent form of Clostridium difficile,
thereby preventing its infection of small intestine. This is a significant observation considering that
C. difficile can evade the action of other host microbicidal peptides and disturb the balance of gut
microbiota [53]. Human papillomavirus (HPV) infections can lead to cervical cancer and HD-5 can
prevent viral entry [54]. In addition, Wiens and Smith showed that HD-5 directly interferes with a
critical host-mediated viral processing step, furin cleavage of L2, at the cell surface [55]. Structurally,
HD-5 can form a disulfide bond swapped dimer in vitro [56]. It should be interesting to test whether
this dimer is linked to host defense in vivo.
How HD-6 plays the defense role in human gut has been puzzling for years. Similar to human
hBD-1 [57], Schroeder et al. found that human Paneth cell HD-6 only exerted antibacterial activity
under reduced conditions, establishing it as a bona fide antimicrobial peptide [43]. This reduction may
be achieved in vivo by the NADPH thioredoxin-reductase system. In vitro, removal of the N-terminal
two amino acid residues of HD-6 enabled a full reduction by dithiothreitol without influencing its
activity. Such a truncated form was isolated previously from ileal neobladder urine [58]. In addition,
HD-6 can form neutrophil extracellular traps (NETs) to trap invading microbes [59]. Thus, recent
breakthroughs have uncovered two possible mechanisms for HD-6 in host defense.
The importance of environmental conditions for antimicrobial activity is not limited to α-defensins.
In 2014, Abou Alaiwa et al. showed that the composition of the airway surface liquid is critical for
human LL-37 and hBD-3 to kill inhaled and aspirated bacteria. A decrease in pH from 8 to 6.8 in
6
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pulmonary airway reduced the activity of both peptides against S. aureus as well as synergistic effects
between innate immune peptides [60].
It is known that pH modulates the oligomerization state of human LL-37. At acidic pH,
LL-37 is monomeric; it aggregates at physiological pH [61]. The mode of oligomerization was also
studied in 2014 by using disulfide-linked dimers [62]. NMR studies confirmed this pH-dependent
phenomenon [63]. However, the link of this phenomenon to biology was not clear. In 2014, Gao and
colleagues reported that LL-37 enhancement of signal transduction by Toll-like receptor 3 (TLR3) is
regulated by pH [64]. Upon acidification in endosomes, oligomerized LL-37 dissociates, allowing the
release of delivered dsRNA to act as an agonist for TLR3 signaling. In contrast, LL-29, a natural
fragment of human LL-37 that lacks the C-terminal portion [65], is unable to do so. Since our
previous NMR studies found that nearly all the residues of LL-37 (residues 1-36) are involved in
oligomerization [63,66], the C-terminal portion of LL-37 might be involved in the tetramer formation
of LL-37. The salt bridges, likely involving R34 and/or E36, can be disrupted at acidic pH, providing a
molecular basis for pH-dependent oligomer dissociation and dsRNA release.
All these examples above underscore that environmental conditions are an important mediator of
the function of antimicrobial peptides. There are also other mediators that regulate peptide activity,
including proteases, metals, salts, and chemical modifications. While 3D triple-resonance NMR
studies show that the helical region (residues 2-31) of LL-37 is responsible for both membrane and
lipopolysaccharides (LPS) binding [63], citrullination of arginines can reduce its ability in preventing
endotoxin-induced sepsis [67]. Likewise, ADP-ribosylation of four out of the five arginines of human
LL-37 may regulate this property [68]. A more recent discovery reveals that during S. aureus invasion,
skin adipocytes can replicate rapidly and produce a cathelicidin peptide longer than LL-37 to prevent
infection [50]. Previously, a different form of human cathelicidin, ALL-38, was also isolated from the
human reproductive system [69]. Therefore, human proteases at a defined location play an important
role in determining the exact molecular form of mature antimicrobial peptides required for host
defense [47].
4. Mechanisms of Action of Antimicrobial Peptides and Genetic Basis of Bacterial Resistance
4.1. Peptide at Work
Although there are anionic peptides, natural antimicrobial peptides are usually cationic with an
average net charge of +3.2 [7,8]. A leading view is that these cationic peptides target negatively
charged bacterial membranes. However, other mechanisms are possible [4,5,47,63]. In the case
of membrane targeting, how it damages the membranes remains debatable. A variety of possible
membrane-weakening mechanisms have been summarized by Vogel [70] and three of them are
depicted in Figure 1. These models are helpful and may inspire the design of new experiments to check
their validity. In the carpet model [71], antimicrobial peptides are assumed to locate on the membrane
surface. Is the peptide flat? In 2014, solid-state NMR studies of piscidins revealed peptide tilting
to achieve an optimal interaction. The extent of tilting depends on both peptide sequence and lipid
composition. The glycine at position 13 may be important for peptide plasticity [72]. Numerous peptide
examples, including human cathelicidin LL-37 [66], possess a similar glycine that may modulate
peptide activity against different bacteria. However, there are only a few examples with a defined pore.
Structural determination yielded evidence for channel or pore formation. Gramicidin and alamethicin
are two known examples [73,74]. Recently, the crystal structure of human dermcidin implies another
possible channel [75,76]. In 2014, a C-type lectin is proposed to form a pore in bacterial membranes
based on a combined structural determination by X-ray diffraction with electron microscopy data.
In this model, six copies of human RegIIIα assemble into a ring structure with a hole in the center [77].
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Figure 1. Mechanisms of action of antimicrobial peptides in 2014. Membrane channel formation
(A) is proposed for dermicidin [76] and transmembrane pore formation for C-type lectin RegIIIα [77].
While human LL-37 [78] may form a toroidal pore (B), it started with a carpet model [79] (C) where
antimicrobial peptides such as piscidins [72] are located on the membrane surface. Receptor mediated
binding was observed for Lactococcin G and Enterocin 1071, which bind to UppP, an enzyme involved
in cell wall synthesis (D) [80]. In addition, Gravicin ML binds to maltose ABC receptors (E) [81].
Further, RTD2, as well as lantibiotic Pep5, interacts with membranes causing the release of autolysin
(F) [82]. Beyond membranes, bacterial MccJ25 could inhibit RNA polymerase (G) [83], while apidaecins,
oncocins [84] and Bac7 [85] inhibit protein synthesis by binding to ribosomal proteins (H). Abbreviations
used in the figures are OM, outer membrane; IM, inner membrane; PGN, peptidoglycan; LTA,
lipoteichoic acid; MLT, maltose transporter. In addition, refer to the text.
Human α-defensin HNP1 and β-defensin hBD-3 are known to inhibit cell wall synthesis [86,87].
What about θ-defensins [16]? In 2014, Selsted and colleagues asked this question. In collaboration with
Sahl, they found that RTD-2 did not bind to lipid II. Rather, it interacted with bacterial membranes
in the presence of glucose. In addition, they detected the release of peptidoglycan lytic enzymes (or
autolysins) by S. aureus. Interestingly, bacterial lantibiotic Pep5 can work in the same manner [82].
There is precedence for such a similarity. Like defensins, it is common for lantibiotics to inhibit cell
wall synthesis by binding to lipid II [88]. In addition, some lantibitics and cyclotides share the same
phosphatidylethanolamine (PE) lipid target [89,90]. Such a cyclotide binding to PE-rich membrane
rafts is proposed to be responsible for activity against cancer and HIV-1 [91]. The similarity between
cyclotides and lantibiotics was initially suggested by their similar amino acid composition plots [63].
The mechanistic similarities between thioether bonded lantibiotics and disulfide bonded defensing-like
peptides are remarkable (Table 2), supporting a recent universal peptide classification that groups
them into one big class: sidechain-sidechain linked peptides [9].
Table 2. Mechanistic similarities between thioether-bonded lantibiotics and disulfide-boned peptides.
Mechanism Lantibiotic Examples Disulfide-Linked Examples
Inhibition of cell wall synthesis 1




Membrane and autolysin release Pep5 θ-defensins such as RTD-2
Binding to lipid PE Duramycins, cinnamycin Kalata B1, cycloviolacin O2
1 Selected from the APD [7,8]. A more complete list can be searched in the APD.
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For years, proline-rich peptides were proposed to act by binding to heat shock proteins [92]. Two
papers published in 2014 challenged this view. Krizsan et al. found that insect-derived proline-rich
apidaecins and oncocins inhibited bacterial protein translation at the 70S ribosome [84]. Both cationic
and hydrophobic amino acids of the peptides were involved in such binding. Interestingly, Mardirossian
et al. also observed that Bac7(1-35), another proline-rich peptide corresponding to N-terminal 35
residues of bovine cathelicidin Bac7, could accumulate within E. coli to a high concentration of 340 μM
and inhibits protein synthesis by targeting ribosomal proteins [85]. These studies indicate that the
well-documented chaperone DnaK is unlikely the major target for proline-rich peptides. Of note,
bacterial lasso peptides such as microcin J25 (MccJ25) can inhibit RNA polymerase [83].
Some antimicrobial peptides can associate with DNA. In 2014, Ghosh et al. found that the WW
motif of indolicidin is essential for DNA binding. They provided high-resolution structural information
for the interaction of indolicidin with duplex DNA [93]. Such a structure can be useful for designing
novel antibiotics.
Interestingly, some bacteriocins use receptors as the target. While garvicin ML recognizes a
maltose ABC transporter, LsbB uses metallopeptidase as the targets [81]. In 2014, Kjos et al. found
lactococcin G and enterocin 1071 (two-chain bacteriocins) used UppP as the receptor. UppP is an
enzyme involved in cell wall synthesis [80]. Such findings not only enrich our view on the mechanisms
of action of antimicrobial peptides, but also open new opportunities for antimicrobial development.
Although it is likely that some antimicrobial peptides mainly utilize one mechanism to inhibit
bacteria, a single peptide may also deploy multiple mechanisms, rendering it difficult for pathogens to
develop resistance. In 2014, Wenzel et al. illustrated this using a model arginine and tryptophan-rich
peptide RWRWRW-NH2 (C-terminal amidation) [94]. The peptide is primarily membrane targeting
(e.g., D and L-forms have same activity) and only a very small population can enter the bacterial cell.
As a new mechanism, the authors found that multiple surface proteins could be delocalized by the
peptide. While the replacement of cytochrome C hinders bacterial energy metabolism, delocalization
of MinD interferes with bacterial replication. Another surface protein, MurG, can also be delocalized,
leading to impaired bacterial cell wall synthesis. The authors proposed that such bacterial surface
protein delocalization by cationic antimicrobial peptides may be a general mechanism. Our own recent
findings may provide additional insight into this protein delocalization. Surface attachment is usually
mediated by a short amphipathic sequence, which weakly interacts with bacterial membranes [95].
In contrast, cationic antimicrobial peptides are able to better interact with bacterial membranes since
they have a broader hydrophobic surface or higher membrane perturbation potential [96]. Such a
membrane-binding difference could be one of the fundamental reasons for surface proteins to be
replaced by cationic antimicrobial peptides. In addition, membrane binding of short amphipathic
sequences requires anionic lipids [95]. When short cationic peptides cause lipid domain formation [94,
97,98], the migration of anionic lipids toward cationic antimicrobial peptides could weaken the
attachment of surface proteins to the re-organized membranes, causing protein delocalization and loss
of function as demonstrated by Wenzel et al. [94].
A single peptide can also possess multiple functions and human cathelicidin LL-37 is a typical
example for this [99]. The observation that LL-37 can associate with DNA led to the idea that DNA
binding may be part of the bacterial killing mechanism as well. However, Mardirossian et al. showed
that only 5% of LL-37 inhibited protein synthesis [85]. In agreement, we did not observe a correlation
between peptide activity and DNA retardation (Lau, K.; Lushnikova, T.; Wang, G., unpublished
results). However, we did observe a correlation between membrane permeation and antimicrobial
activity of LL-37 fragments [100]. These results support the existing view that membrane permeation
and disruption by the helical region (residues 2-31) is the major mechanism via which LL-37 kills
bacteria [78,79,97]. It appears that nucleic acid binding plays a more important role in RNA delivery
into endosomes [101] and in stabilizing neutrophil extracellular traps to prevent DNA cleavage [102].
Moreover, human LL-37 can associate with cell receptors to trigger signal transduction [103,104].
Interestingly, LL-37 also modulates innate immunity by promoting macrophages to phagocyte
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bacteria [105] or influencing neutrophil responses to influenza A virus [106]. In addition, overexpressed
LL-37, as an antigen, can be specifically recognized by CD4+ and/or CD8+ T cells in psoriasis [107].
It is clear that the multifunctional roles of human LL-37 are realized by its ability to recognize and
interact with different molecular targets and immune cells.
4.2. Resistance Genes for Pathogens and Survival Skills for Commensal Bacteria
It has been appreciated that bacteria have been co-evolving with host defense peptides [108].
Some have learned how to avoid the attack by cationic peptides. The major mechanism appears to
alter cell envelope charge and composition. In addition, an ATP-binding cassette (ABC) transporter
coupled with an adjacent two-component system (TCS) also constitutes a resistance module against
antimicrobial peptides [109,110]. Elucidation of the genetic basis of bacterial resistance may be helpful
for the design of more potent antibiotics. In the following sections, we highlight progress made in this
direction during 2014.
4.2.1. Gram-Positive Bacteria
One can identify the bacterial genes involved in peptide response by two methods: proteome
analysis or genome analysis. Using proteome analysis of bacitracin-treated and untreated cells,
Gebhard et al. identified an ABC transporter EF2050-2049 of Enterococcus faecalis that mediates resistance
against bacitracin [109]. To validate this, they transferred the resistance and regulatory pathway to B.
subtilis, leading to bacitracin resistance. Thus, the ABC transporter and the TCS are indeed required
for resistance to antimicrobial peptides. Nevertheless, a previous genomic analysis identified two
such ABC transporters [110], which were induced by bacitracin [109]. Based on these results, the
authors proposed a model for the bacitracin resistance network of E. faecalis. The presence of bacitracin
is initially detected by the EF2752-51 ABC transporter, which relays this signal to an adjacent TCS
(EF0926-27). Activation of the regulatory domain of the TCS leads to an increase in expression of the
EF2050-49 ABC transporter that confers resistance to antimicrobial peptides. This two transporters and
one TCS network mechanism [109] differs from those single ABC transporter and TCS cases where the
transporter senses the peptide and relays this signal to the adjacent TCS that upregulates the same
ABC transporter for resistance [110].
The five-component system GraXSR-VraFG of S. aureus is well-established as the major sensing and
resistance system [111] that reduces the toxic effect of cationic antimicrobial peptides by upregulating
genes such as mprF and dltABCD. While MprF can put lysines on anionic phophatidylglycerols (PGs),
DltABCD can modify the cell wall by transferring of D-alanine into teichoic acids [108,112]. GraSR was
found to regulate the dltABCD and mprF genes [113,114]. In 2014, a loop region of sensor protein GraS
was identified to recognize cationic peptides. Cheung et al. generated mutants of graS from the MRSA
strain MW2. Deletion of graS (ΔgraS strain) or its 9-amino acid extracellular loop region (ΔEL strain)
made the strain more susceptible to daptomycin, polymyxin B, human neutrophil defensin 1 (HNP-1),
and RP-1 (a platelet factor 4 derived peptide that retains activity in blood). Meanwhile, these mutants
became less infectious in vivo in an endocarditis model. Interestingly, a synthetic trimeric loop region
EL mimic, i.e., (DYDFPIDSL)3, could protect the parental MW2 strain from killing by those cationic
peptides. These results suggest that the acidic residues in the extracellular loop region of GraS can
directly interact with cationic peptides for sensing and activation [115].
It has been elucidated that Group A Streptococcus responds to the human antimicrobial peptide
LL-37 by upregulating virulence factors controlled by the CsrRS system. In 2014, Velarde et al. identified
RI-10, the smallest LL-37 fragment required to bind to CsrRS using a series of synthetic LL-37 fragments.
RI-10 can directly bind to sensor kinase CsrS to activate the expression of virulence factors [116]. The
same peptide was previously found by us to have no antibacterial activity against bacteria [97,98].
Since antimicrobial activity is not required for this recognition by kinase receptor, such a response
could occur in vivo at a very low level of LL-37, which is not high enough to kill the bacteria. We
propose that interfacial cationic residues R23 and K25, which are important for membrane permeation
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and bacterial killing [100], are also important residues for interaction with the acidic amino acids on
the CsrS receptor.
4.2.2. Gram-Negative Bacteria
Different from Gram-positive bacteria, LPS is the major component in the outer membranes of
Gram-negative bacteria [66]. Modifications of bacterial LPS provide a general mechanism that confers
resistance to cationic antimicrobial peptides [117]. The 2014 research on the genetic basis of bacterial
resistance yielded additional support for this. First, pathogenic Vibrio cholerae strains can be >100-fold
more resistant to polymyxins by modifying LPS (i.e., glycylation). Henderson et al. confirmed AlmF
as an aminoacyl carrier protein, which is activated by the enzyme AlmE. Interestingly, these proteins
in the AlmEFG trio system function in a manner similar to nonribosomal peptide synthetases [118].
Second, the resistance of human pathogen Neisseria gonorrhoeae results from phosphoethanolamine
(PEA) decoration of lipid A by transferase encoded by the lptA gene [119–121]. Kandler et al. found
that high-frequency mutation in a polynucleotide repeat of the lptA gene influences bacterial resistance.
An lptA mutant is highly susceptible to cationic peptides [122]. In addition, the PEA-modification of
lipid A has an immunostimulatory role during infection [123]. Third, in the case of the gastrointestinal
pathogen S. typhimurium, resistance genes involving both LPS defects and mutation in phoP were
found from a transposon library in 1992 [124]. The PhoPQ two-component system regulates peptide
resistance, bacterial lipid A remodeling, and intracellular survival within acidified phagosomes. In
2014, the PhoPQ system was found to also regulate acidic glycerophospholipid content in the outer
membrane [125]. These authors have recently summarized the resistance strategies of S. typhi [126,127].
In summary, both Gram-positive and Gram-negative bacteria are able to decorate their cellular
surfaces to make them less attractive to cationic antimicrobial peptides. Interestingly, a recent study
reveals that gut bacteria can use a similar mechanism by removing a phosphate group from LPS [128].
Here a resistant mechanism for “bad bugs” has become a survival strategy for “good bugs”. Therefore,
such surface decorations achieved by a different chemistry provide a general mechanism that enables
bacteria, for good or bad, to “work under an umbrella” to dodge the “bullets” of the host.
5. Potential Applications of Antimicrobial Peptides
5.1. Toward Therapeutic Uses
There is continued interest in developing therapeutic uses for antimicrobial peptides. Because of
molecular simplicity and easy synthesis, linear peptides have been extensively explored for favorable
properties. Here we highlight a structure-based design based on the human cathelicidin LL-37. Wang
identified a chymotrypsin-resistant template by screening an LL-37 peptide library [129]. This template
contains partial D-amino acids and has a novel amphipathic structure [130]. However, it is not
active against community-associated methicillin-resistant S. aureus (MRSA) USA300. Based on the 3D
structure, we enhanced anti-MRSA activity of the peptide by inserting a bulkier hydrophobic group
into the structural cavity. One of the peptide analogs, 17BIPHE2, not only eliminated MRSA, but also
recruited monocytes to the infection site [129]. In addition, other approaches were explored to make use
of LL-37 or hBD-2. Since cathelicidin can reverse intestinal fibrosis in models of colitis [131], this peptide
may be used to treat inflammatory bowel disease (IBD) by introducing cathelicidin-overexpressing
bacteria. Using an adenoviral vector to deliver the gene of hBD-2, Woo et al. found both viral inhibition
and clearance for experimental otitis media [132]. In 2014, LL-37-containing vector was electroporated
to promote skin wound healing [133]. In addition, 1,25-dihydroxyvitamin D3 (active form) was also
used to induce both LL-37 and hBD-2 production in keratinocytes from diabetic foot ulcers, promoting
wound healing [134]. UV light or sunlight may be an alternative since hydroxylation of vitamin D
can occur [135]. It is notable that traditional practice can also boost our immune systems. While yoga
stretching significantly increases human hBD-2 [136], green tea helps the production of lactoferrin in
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saliva after exercise [137]. Although at the early stage, these positive results on antimicrobial peptides
imply that our traditional life styles can be helpful to keep us healthy.
Unlike linear peptides that can be rapidly degraded by proteases in hours, circular peptides have
inherent stability. This is because these peptides such as cyclotides comprise three conserved disulfide
bonds in addition to a peptide bond that connects the N- and C-termini. Consequently, there is great
interest in utilizing these natural templates to engineer useful therapeutics [138,139]. In 2014, Craik
and colleagues demonstrated the molecular grafting technology where a desired antigenic peptide
was inserted into an exposed loop region of kalata B1 [140]. This technology confers protease stability
to the sequence motif, which can otherwise be rapidly degraded when tested alone. MOG3, one out of
the seven peptides grafted to loop 5, was used to vaccinate mice and found to display in vivo efficacy
in an animal model of multiple sclerosis, an inflammatory disease of the central nervous system. Taken
together with previous examples [138,139], these authors proved the concept of segment grafting
at loops 5 and 6 of cyclotides. It appears that sequence composition rather than length determines
whether the grafted segment is tolerated without disrupting the protein fold. To obtain a sufficient
amount of material for research, cyclotides were initially isolated from plants [141]. Later, chemical
synthesis was established [142]. In 2014, two laboratories reported an alternative approach by using
engineered sortase A to make the circular molecule [143,144]. A more efficient synthesis will bring us
one step closer to practical use of these interesting templates.
5.2. Peptide Surface Coating
Immobilization of antimicrobial peptides (either covalently or adsorbed) onto solid supports
extends their capabilities as surface-active molecules. This direction of research aims at improving
biomedical devices, drug delivery systems, bio-sensor and detection, and so on. Recent advances
in the field include simplification of the chemistry for surface attachment, development of novel
substrate-attaching platforms, including nanomaterial for wider applications, product development
with promising proof of concepts and in vivo testing in animal models.
Of all the problems related to loss in efficiency of medically implantable medical devices is
the development of microbial biofilms. Peptide immobilization has been shown to reduce bacterial
colonization and biofilm formation. However, the major challenges that often hinder the immobilization
of antimicrobial peptides are the inefficiency of the conjugation chemistries and their inability to achieve
a sufficient surface concentration of peptides, along with the limited number of usable biomaterials.
A recent study by Lim et al. [145] demonstrated a simple dopamine based chemical reaction for the
functionalization of antimicrobial peptides onto a commonly used Silicon Foley catheter. Not only
did the catheter prototype reduce biofilm formation by common pathogens that caused a urinary
tract infection, it was also stable for 21 days. In addition, hLF1-11 immobilized onto titanium [146]
has been shown to possess excellent anti-biofilm properties. There have also been improvements
in other chemical platforms, including the development of thiolated self-assembled monolayer on
a gold surface to which small peptides, temporin-SHf, can be tethered, resulting in broad-spectrum
activity [147].
To understand the possible influence of structure and dynamics on immobilized antimicrobial
peptides and to apply rational design, molecular dynamics simulation studies were carried out on
cecropin P1 immobilized on silane-EG4-maleimide self-assembled monolayers [148]. Other factors
governing immobilization reactions, such as spacer chain length, reactant concentration and energy
dependence, are demonstrated by Mishra et al. [149]. Additional coating strategies can be found in a
recent review [150]. Moving toward practical applications, a significant in vivo study is presented by
Dutta et al. [151]. Melimine immobilized eye lenses are not only cytotoxically safe but also possess
antibacterial activity after worn as tested in both rabbit and human. In addition, another peptide
SESB2V immobilized on titanium surfaces prevents perioperative corneal infection in a rabbit keratitis
model [152].
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5.3. Nanoparticle-Based Drug Delivery Systems
Apart from the anti-biofilm and antibacterial functions, antimicrobial peptides tagged to
nanoparticles impart a site-specific targeting and delivery of drug molecules. It can be used in treating
a variety of diseases, including cancer. Currently, dermaseptin entrapped chitosan nanoparticles
have been shown to possess excellent antitumor activities [153]. Moving one step forward, dual
targeting nanoparticles with both blood−brain barrier (BBB) and blood−brain tumor barrier (BBTB)
including glioma cell were achieved by functionalizing lactoferrin to the surface of poly(ethylene
glycol)−poly(lactic acid) nanoparticles. Administration with tLyP-1, a tumor-homing peptide that
mediates tissue penetration through the neuropilin-1-dependent internalization pathway, resulted in
deep penetration of the nanoparticle into the glioma parenchyma [154]. It opens a new direction for
administration of antitumerogenic drugs with high penetration capability.
Additionally, glutamic acid substitution of basic residues in LL-37, melittin, and bombolitin V
linked to lipid nanoparticles could be used for endosomal escape and efficient gene delivery using
intravenous injections. These yield expression levels comparable to those obtained using Lipofectamine
2000 and the probable mode of action resembles viruses [155]. Antimicrobial peptides have also been
shown to have superb drug releasing properties in PEG-PLGA microparticles [156]. The direct evidence
is presented by encapsulating LL-37 in PLGA nanoparticles by Chereddy et al. [157]. PLGA-LL-37
nanoparticles as a biodegradable drug delivery system were found to promote wound closure.
It functions due to the sustained release of both LL-37 and lactate, and induction of enhanced cell
migration without effects on the metabolism and proliferation of keratinocytes. Moreover, peptides as
short as dimer conjugated to naphthalene could be used as antimicrobial nanomaterials in eliminating
biofilm infections and for drug delivery [158].
5.4. Biosensors and Detection
Antimicrobial peptides can also serve as indicators and diagnostic agents. The approach is more
cost effective than standard PCR or antibody-based techniques. Detection of bacterial pathogens in a
microfluidic chip where antimicrobial peptides are immobilized via cysteine-gold interaction could
produce a rapid electrical detection with sufficient sensor signal that allows the detection of pathogens
(both Gram-negative and Gram-positive) at a density as low as 105 cfu/mL within 25 min [159]. While
another platform for the detection of only Gram-positive bacterial strains could reach 103 cfu/mL via
immobilizing class IIa bacteriocins [160]. In addition, specific detection of fungal C. albicans can also be
made by using peptide nucleic acid probes [161].
6. Perspectives
It is great news that acquired resistance did not become an issue after decade-long use of
antimicrobial peptides such as tyrothricin [162]. Such an observation is encouraging to the current
effort in development of antimicrobial peptides into novel therapeutic molecules [63]. From 2000
to 2014, about 100 new antimicrobial peptides were entered into the APD every year [26]. As of
December 2014, there were 2493 peptides in this database [7–9]. We anticipate that the important
work on the isolation and characterization of novel antimicrobial peptides from new organisms will
continue. Scientifically, new peptide sequences will improve our knowledge of natural antimicrobial
peptides. As shown in Table 1, the new members can refine the boundary parameters for natural
antimicrobial peptides [9]. With the identification of a sufficient number of representative peptide
sequences, the APD database will more accurately identify natural peptides most similar to the input
sequence. It will facilitate the development of new programs to better predict the likelihood of a new
peptide to be antimicrobial. In addition, a unique peptide may directly become a candidate lead for
the development of novel antimicrobials to meet the challenge of the antibiotic resistance problem.
However, it is important to validate whether a bacteriocin has any undesired virulent property that
promotes infection [21].
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The 2014 research also enabled us to connect the dots for known human antimicrobial peptides,
leading to an improved understanding of their functional roles in innate immunity. Surprisingly, a
different form of human cathelicidin peptide can be rapidly expressed by skin fat cells in response
to the S. aureus invasion, underscoring a direct defense role of human cathelicidin peptides [50]. It is
remarkable that a single LL-37 molecule can perform multiple functions by recognizing a variety of
molecular partners or receptors on immune cells. In 2014, pH-dependent oligomerization of LL-37
is connected to the delivery of dsRNA into endosomes for subsequent interactions with TLR3 [64].
Although the details are to be elucidated, we propose that the terminal regions of LL-37 contain an
important molecular switch based on NMR data [63]. It is demonstrated that local conditions are
essential for a proper function of human antimicrobial peptides. While human HD-6, like hBD-1, is
active only after disruption of disulfide bonds under reduced conditions [43], many other defensins
in the folded form can directly recognize specific lipids in pathogen’s membranes [163,164]. During
such a molecular recognition process, the flexible residues in the loop regions of these small defense
proteins are found to be essential based on several structural studies [163–166].
The 2014 results further expanded our view on the mechanism of action of antimicrobial peptides
(summarized in Figure 1). While select antimicrobial peptides are known to inhibit cell wall synthesis,
many target bacterial membranes. Surface-binding peptides are shown to be able to replace weakly
attached membrane proteins, thereby interfering with bacterial physiology globally [94]. Beyond
membranes, bacteriocins can use cell receptors as a target [81]. It has been known for a while that
proline-rich peptides interact with heat shock proteins [92]. However, the molecular target has now
been traced to ribosomal proteins. The binding of proline-rich peptides leads to inhibition of protein
synthesis [84,85].
Although there are few examples, structure-based design has been demonstrated [129,140],
leading to antimicrobials or vaccines with desired properties. The overall goal of peptide engineering
is to establish or identify a proper peptide template with desired potency, stability, and cell selectivity.
In addition, one may also mimic nature’s wisdom. Based on the precursor protein construction, one
can design pro-peptide forms to minimize potential cytotoxicity and protease degradation. In 2014,
Forde et al. illustrated this strategy as a potential therapy for cystic fibrosis [167,168]. Nature has
created other strategies to circumvent rapid peptide degradation by forming a complex structure. For
instance, human LL-37 can oligomerize at physiological pH into nanoparticles to resist the action
of proteases [63]. Likewise, LL-37 can bind to DNA to stabilize the entire NETs structure [169]. In
2014, Bachrach and colleagues showed that human LL-37 could also be protected by actin, thereby
maintaining its antimicrobial activity in vivo [170,171]. There are also natural ways to reduce potential
cytotoxicity of antimicrobial peptides. In 2014, Svensson et al. discovered that peptide p33 expressed on
the surface of various cell types can reduce the potential cytotoxicity of human LL-37 [172]. Moreover,
Hiemstra et al. discovered the nanoparticle-like vesicles in the human urinary tract [173]. It is
predictable that novel functional modes of human innate immune peptides will continue to emerge.
All these natural mechanisms may hold the key to future therapeutics.
We anticipate continued efforts in the development of potential applications of antimicrobial
peptides, including peptide production methods. Peptide engineering, formulation, and delivery
technologies may further expand the horizon of antimicrobial peptides in benefiting human
beings [174]. Such applications can vary from medical surface cleaning, water quality monitoring and
disinfection, sterile surface materials, to new drugs for infectious diseases [175,176]. Antimicrobial
peptides may be included in existing detergent formulation and disinfectants to reduce bacterial
biofilms on hospital surfaces [177]. Bovicin HC5 and nisin can be used to treat food-contact surface to
reduce bacterial attachment and subsequent biofilm formation [178,179]. It has been demonstrated
that injection of an engineered LL-37 peptide or coating peptides to the device surface can prevent
biofilm formation [129,145,146]. Importantly, a combined use of antimicrobial peptides with traditional
antibiotics can be a more effective strategy to treat bacterial biofilms [180–182]. Finally, molecules that
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interfere with or even weaken the process of biofilm formation [183–189] can also be combined with
antimicrobial peptides to achieve an optimal treatment of bacterial biofilms.
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Abstract: Fungi are an emerging source of peptide antibiotics. With the availability of a large number
of model fungal genome sequences, we can expect that more and more fungal defensin-like peptides
(fDLPs) will be discovered by sequence similarity search. Here, we report a total of 69 new fDLPs
encoded by 63 genes, in which a group of fDLPs derived from dermatophytes are defined as a new
family (fDEF8) according to sequence and phylogenetic analyses. In the oleaginous fungus Mortierella
alpine, fDLPs have undergone extensive gene expansion. Our work further enlarges the fungal
defensin family and will help characterize new peptide antibiotics with therapeutic potential.
Keywords: peptide antibiotic; gene duplication; exon-intron structure; cysteine-stabilized α-helical
and β-sheet motif
1. Introduction
Fungal defensin-like peptides (fDLPs) are emerging as attractive anti-infective agents due to
their therapeutic efficacy, low toxicity and high serum stability [1,2]. On the basis of a combined
analyses of sequence, structural, and phylogenetic data, we has identified seven fDLP families [2,3], in
which three members (plectasin, micasin and eurocin), classified as ancient invertebrate-type defensins
(AITDs) [1,2,4,5], have been structurally and functionally characterized. These fDLPs exhibit activity
against several antibiotic-resistant clinical isolates with significant therapeutic potential [1,2,5,6]. Some
efforts have been taken to improve antimicrobial efficacy and to reduce undesirable side effects of
fDLPs. For example, an improved mutant of plectasin (NZ2114) is superior to two conventional
antibiotics (vancomycin and daptomycin) in inhibiting methicillin-resistant Staphylococcus aureus
(MRSA) with even more enhanced serum stability and extended in vivo half-life [7–9]. In this work,
we describe 69 new fDLPs in terms of their sequences, structural characteristics, and phylogenetic
relationship. This provides an array of candidates for development of new anti-infective agents against
antibiotic-resistant human pathogens.
2. Discovery of New fDLPs
The database search strategy used here has been described previously [3]. Through an exhaustive
search of 26 fungal species, we retrieved a total of 69 new fDLPs. As previously stated, overall this
class of molecules exhibits a taxa-specific distribution pattern in the fungus kingdom, of which 21
fDLPs are derived from Ascomycota, 39 from Zygomycota, eight from Basidiomycota and one from
Glomeromycota. In the basal fungi (Microsporidia and Chytridiomycota), no typical fDLP has been
identified (Figure 1). The general features of these peptides are listed in Tables 1 and 2. They can be
grouped into six families based on sequence similarity, five of which are classified into the previously
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known families (fDEF1, fDEF2, fDEF3, fDEF4, and fDEF6) [3] (Figures 2 and 3). This grouping is
consistent with the phylogenetic analysis supported by high bootstrap values (Figure 4).
 
Figure 1. Phylogenetic distribution of fDLPs. The left: A parsimony tree of fungal species, animalia is
used as an outgroup. This tree is a modification of the SSU and LSU r-RNA analyses of Lutzoni et al.
for the fungal kingdom [10]. The right: “+” means presence and “−” means absence.
All the fDLPs characterized here have a signal peptide located in the N-terminus. In comparison
with fDEF1 and fDEF2 that possess a propeptide located between signal and mature peptides, fDEF6
and fDEF8 lack a propeptide. Five precursors (maglosin, beauvesin2, manisin, pochlasin2 and asosin)
could release two defensins from a single precursor after the removal of a spacer propeptide (Figure 5).
The malpisin family from Mortierella alpine exhibits two types of precursor organization: (1) the first type
contains 10 members, all having a propeptides identified by its acidic feature and single or two basic
amino acids at their ends as putative cleavage site of proprotein convertase [11]; (2) the second type
contains 14 members that lack a propeptide and thus no further processing step is needed (Figure S1).
Table 1. Sources and characteristics of newly discovered non-Mortierella fDLPs.




Pezizomycotina: Pezizomycetes) 40 4317 +1.2
Pyronesin2|CATG01000243 (G) P. omphalodes 40 4402 +0.2
Pyronesin3|CATG01000243 (G) P. omphalodes 40 4389 +1.2
Pyronesin4|CATG01000243 (G) P. omphalodes 40 4416 +2.2
Pyronesin5|CATG01000243 (G) P. omphalodes 40 4375 +1.2
Pyronesin6|CATG01000243 (G) P. omphalodes 40 4291 +2.4
Abisin1|AEOK01000166 (G) Agaricus bisporus (Basidiomycota:Agaricomycotina: Agaricomycetes) 40 4097 -3.8
Abisin2|AEOK01000166 (G) A. bisporus 40 4097 -3.8
Abisin3|AEOK01000166 A. bisporus 39 3926 -2.8
Beauvesin1|ADAH01000714 (G) Beauveria bassiana (Ascomycota:Pezizomycotina: Sordariomycetes) 52 5475 +2.9
Pyrelysin|GAJI01023341 (T) Pyrenochaeta lycopersici (Ascomycota:Pezizomycotina: Dothideomycetes) 55 5858 +5.4






Lecasin|AWYC01000479 Lecanosticta acicola (Ascomycota:Pezizomycotina: Dothideomycetes) 42 4314 −4.8
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Table 1. Cont.




Pezizomycotina: Sordariomycetes) 43 4339 −3.5











Maglosin2N|AAYY01000024 (G) M. globosa 40 4022 +0.2
Maglosin1C|AAYY01000039 (G) M. globosa 41 3910 +2.7
Maglosin2C|AAYY01000024 (G) M. globosa 40 3835 +2.7
Beauvesin2C|ADAH01000123 (G)
fDEF3
B. bassiana 41 4243 +0.9
ManisinC|ADNJ01000735 Metarhizium anisopliae (Ascomycota:Pezizomycotina: Sordariomycetes) 41 4211 −0.1
Pochlasin2C|AOSW01005877 P. chlamydosporia 41 4381 +0.2
AsosinC|BACA01000303 Aspergillus sojae (Ascomycota:Pezizomycotina: Eurotiomycetes) 38 4002 −1.0
Beauvesin2N|ADAH01000123 (G)
fDEF4
B. bassiana 48 5067 +2.9
ManisinN|ADNJ01000735 M. anisopliae 46 4921 +0.2
Pochlasin2N|AOSW01005877 P. chlamydosporia 49 5185 +2.9




Mucoromycotina: Mucorales) 45 4867 +10.0
Rhimisin2|ANKS01000620 R. microsporus 44 4638 +3.4
Rhimisin3|ANKS01001486 R. microsporus 44 4768 +1.5
Rhimisin4|ANKS01001486 R. microsporus 45 4811 +8.0
Rhidesin1|AACW02000043 Rhizopus delemar (Zygomycota:Mucoromycotina: Mucorales) 55 5885 +10.4
Rhidesin2|AACW02000259 R. delemar 48 5270 +0.5
Mirresin|AZYI01000143 Mucor irregularis (Zygomycota:Mucoromycotina: Mucorales) 60 6424 +13.4
Mucisin|AOCY01001156 (G) Mucor circinelloides (Zygomycota:Mucoromycotina: Mucorales) 53 5548 +2.2




Pezizomycotina: Eurotiomycetes) 41 4323 +3.7
TrequiDLP|ABWI01000729 (G) Trichophyton equinum (Ascomycota:Pezizomycotina: Eurotiomycetes) 41 4323 +3.7
TriveDLP|ACYE01000402 Trichophyton verrucosum (Ascomycota:Pezizomycotina: Eurotiomycetes) 42 4403 +4.7
ArgyDLP|ABQE01000293 Arthroderma gypseum (Ascomycota:Pezizomycotina: Eurotiomycetes) 41 4247 +3.7
ArbeDLP|ABSU01000004 Arthroderma benhamiae (Ascomycota:Pezizomycotina: Eurotiomycetes) 42 4493 +4.7
TriruDLP|ACPH01000567 (G) Trichophyton rubrum (Ascomycota:Pezizomycotina: Eurotiomycetes) 42 4479 +4.7
MicaDLP|ABVF01000093 Arthroderma otae (Ascomycota:Pezizomycotina: Eurotiomycetes) 43 4745 +3.2
Note: MW: molecular weight; NC (net charge) is estimated at pH 7.0 with protein calculation V3.4. “E” means
peptides from the Expressed Sequence Tags (EST) database and “T” means peptides from the Transcriptome Shotgun
Assembly (TSA) database. “G” means proteins currently annotated in the GenBank database as hypothetical proteins
(http://www.ncbi.nlm.nih.gov/) [12].
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Figure 2. Multiple sequence alignment of fDLPs. Cysteines are shadowed in cyan. Conserved glycines
are highlighted in grey. Negatively (D and E) and positively (R, K and H) charged residues are
boldfaced in red and blue, respectively. Introns are shown by arrows (phase 0) or small boxes (green:
phase 1, yellow: phase 2). Functionally characterized fDLPs were indicated by “*”. The N-terminal
extension sequence in micaDLP belonging to the family fDEF8 is italicized. Defensins from Pyronema
omphalodes have been predicted and investigated by RNA-seq [13]. Extra residues for C-terminal
amidation are underlined once.
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Table 2. Sources and characteristics of the malpisin family.





55070–55405 41 4048 −0.0
Malpisin1-2|AZCI01001104 55870–56127 48 5166 −3.3
Malpisin1-3|AZCI01001104 56393–56635 45 5047 +0.7
Malpisin1-4|AZCI01001104 63869–64117 39 4117 −1.0
Malpisin1-5|AZCI01000882
Contig 7180000084767
22045–22248 37 4259 -2.8
Malpisin1-6|AZCI01000882 25851–26051 39 4543 −3.5
Malpisin1-7|AZCI01000882 42456–42677 33 3624 −1.0
Malpisin1-8|AZCI01000882 43573–43800 47 5078 +1.7
Malpisin1-9|AZCI01000882 45037–45261 48 5203 +3.0
Malpisin1-10|AZCI01000882 45559–45738 35 3914 −0.0
Malpisin1-11|AZCI01000882 46707–46913 43 4941 +5.4
Malpisin1-12|AZCI01001135 jtg7180000084204f_7180000084205f_7180000084206f 135437–135676 44 4722 −0.0
Malpisin1-13|AZCI01001084 jtg7180000084699f_7180000084700f 362415–362627 47 4919 −1.8






9785–10114 39 4105 +1.0
Malpisin2-2|ADAG01001070 10532–10792 48 5187 −2.3
Malpisin2-3|ADAG01001070 11052–11297 44 4783 −0.0
Malpisin2-4|ADAG01001070 11773–12021 39 4052 −1.8
Malpisin2-5|ADAG01000791 Contig 791 4894–5097 37 4259 −2.8
Malpisin2-7|ADAG01000903
Contig 903
13145–13357 33 3899 +1.2
Malpisin2-8|ADAG01000903 14223–14450 47 5065 +1.7
Malpisin2-9|ADAG01000903 15634–15852 45 4917 +4.0
Malpisin2-10|ADAG01000903 16158–16337 35 3937 +0.2
Malpisin2-11|ADAG01000903 17264–17446 39 4531 +5.0
 
Figure 3. Multiple sequence alignment of malpisins. Color codes and symbol notes used here are the
same as those in Figure 2. Pink box indicates the N-terminus of DLPs with variable length. Sequence
identity (%) to micasin is shown on the right.
31








































































































































































































































































































































































Pharmaceuticals 2014, 7, 866–880
Peptides in fDEF8, all derived from dermatophytes, are characterized as a new family with a
short N-terminus and an extra C-terminal extension rich in arginines, prolines and glycines (Figure 2).
The C-terminal extension has been considered as a common mechanism for the complexity increase
of some invertebrate antimicrobial peptides (AMPs). For example, the hymenopteran defensin-1
subfamily has an extended C-terminus relative to its ancestral defensin-2 subfamily by a so-called
intron exonization-mediated mechanism [14,15]. It thus appears that fungal and invertebrate defensins
both convergently evolved their C-termini. The extension of a C-terminal sequence via convergent
evolution was also recently observed in interleukin 6 (IL-6), a class-I helical cytokine, of two leporids
(Oryctolagus and Pentalagus) [16]. The presence of C-terminal Gly-Arg or Gly-Arg-Arg in some
dermatophyte-derived fDLPs suggest that they may be amidated, as previously observed in some
animal toxins, e.g., the Mesobuthus α-toxins [17]. Interestingly, the mature peptide of micaDLP is
larger in size than that of other members in this family, as identified by an N-terminal extension of 38
amino acids (Figure 2). High content of glycines together with a cationic characteristic hints a putative
antimicrobial role of this extended unit.
M. alpine is a saprophytic species of Mucoromycotina, known as an oleaginous fungus [18]. The
draft genome sequences of two M. alpina isolates (B6842 and ATCC 32222) [18,19] provide a possibility
to undertake comparative study of their fDLPs. We found that the M. alpine B6842 genome encodes
14 fDLPs (Figure 3) but only 10 were found in M. alpine ATCC 32222. The failure to detect the
four homologs (i.e., malpisin1-6, 1-12, 1-13, 1-14) in M. alpine ATCC 32222 could be due to the
incompletely-assembled genome sequences. Our phylogenetic analysis divides all malpisins into
fDEF1 and fDEF6 (Figure 4). Some malpisin members of fDEF1 extended their N-termini with diverse
sequences and variable lengths (Figure 3).
3. Gene Duplication of fDLPs
Gene duplication extensively occurs in antimicrobial peptides from insects to humans [15,20,21].
In fungi, initial annotation of defense molecules of Pyronema omphalodes also identified gene duplication
as a minor multigene family of fDLPs (herein termed pyronesin1 to pyronesin6) [13]. These fDLPs
are highly similar to plectasin (Figure 6A). Our studies revealed new gene duplication event in other
fungal species. Malpisin is a representative example of gene duplication. As mentioned previously,
there are 14 and 10 members in M. alpine B6842 and M. alpine ATCC 32222, respectively. Malpisin1-1,
1-2, 1-3 and 1-4 are tandem located on one contig (jtg7180000084593f _7180000084594f), and malpisin1-5
to malpisin1-11 on another contig (Contig 7180000084767). In addition, malpisin1-12, malpisin 1-13
and malpisin 1-14 reside on other three contigs, as shown in Figure 6B. In M. alpine ATCC 32222,
malpisin2-1 to malpisin2-4 are located on contig 1070 and malpisin2-7 to malpisin2-11 on contig 903.
Only malpisin2-5 is located on contig 791.
In the widely cultivated mushroom Agaricus bisporus, there are three paralogous fDLPs (abisin1
to abisin3) (Figure 6C), two of which (abisin1 and abisin3) share completely identical amino acid
sequences in the mature peptide region but exhibit four synonymous substitutions at the nucleotide
level. In the Pochonia chlamydosporia paralogues, pochlasin1 is highly similar to CITDs and pochlasin2
possesses two defensin-domains. In addition, a putative pseudogene (herein named pochlasin-pseu)
was also identified in scaffold 1191 and assigned to AITDs in view of its high sequence similarity
to micasin in the first exon. Pochlasin1 and pochlasin-pseu share a conserved phase 0 intron within
the α-helical region. The loss of the last two exons (2 and 3) results in the lack the last four cysteines
involved in the Csαβ folding of a mature peptide (Figure 2).
Gene duplication also occurs in the Mucorales-derived fDLPs, which leads to four and two gene
copies in Rhizopus microsporus (Figure 6D) and R. delemar, respectively. In a Neighbor-Joining (NJ)
tree, rhimisin1 and rhimisin4 (R. microsporus) constitutes a single clade clustering with the other three
fDLPs (rhidesin1 from R. delemar, phycomycin from Phycomyces blakesleeanus and mirresin from Mucor
irregularis) whereas rhimisin2 and rhimisin3 (R. microsporus) cluster with rhidesin2 (R. delemar) and
34
Pharmaceuticals 2014, 7, 866–880
mucisin (M. circinelloides) (Figure 4), suggesting that the gene duplication event could have occurred in
the ancestor of the Mucorales prior to their speciation.
 
Figure 6. The arrangement of defensin genes in chromosomes. Color arrows refer to different
orientation of the genes. A to D represent the genome location of defensins in four species: Pyronema
omphalodes, Mortierella alpine, Agaricus bisporus and Rhizopus microsporus. Malpisins in M. alpine B6842 is
indicated in red and blue while in pink and green in M. alpine ATCC 32222. Pseudogenes of pyronesins
are shown in gradient blue.
4. Variable Gene Structures of fDLPs
Analysis of the exon-intron structures of the newly-discovered fDLPs revealed their variability
that can be described as follows: (1) all the fDLPs retain the integrity of the signal peptide except
risin (Rhizophagus irregularis) and malpisin1-1 (or malpisin2-1) that have a phase 1 or phase 0 intron
disrupting their signal peptides; (2) all of the genes in fDEF8 and three genes in fDEF2 (i.e., lecasin,
pochlasin1 and perisin) have the same gene organization as previously identified dermatophytic
defensins (micasin, arbesin, trivesin, tritosin and trirusin) and they contain two introns: the first intron
(phase 0) disrupting the α-helical region; the second intron (phase 2) disrupting the c-loop; (3) the
pyronesin and abisin multi-gene family in fDEF1 have only one intron disrupting either the α-helical
or the c-loop region; (4) In addition to these intron-containing fDLP genes, there are some members
without introns (Figures 2 and 5).
The highly variable gene structures in fDLPs are reminiscent of invertebrate defensins that also
exhibit diverse gene structures [22,23] (Figure 5 and Figure S2). Compared with invertebrate defensins
of 5'-biased intron positions, introns of fDLPs occur preferentially in the 3'-end of the precursor-coded
sequences. Because all eukaryotic Csαβ-type defensins are hypothesized to be originated from a
common bacterial ancestor [24], it is reasonable to infer that considerable intron gains might have
occurred in defensins from some eukaryotic lineages, and later they differentially lost in some specific
species. Such a dynamic intron evolution thus shapes the biased intron location pattern between fDLPs
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and animal DLPs after the animal-fungi split. It is also worth mentioning that some recognizable
orthologues of defensins in Branchiostoma floridae [25,26], the basal chordate amphioxus, also contain a
phase 0 intron located in their c-loop (Figure 5 and Figure S2). Given a remote evolutionary distance
between fungi and amphioxus, their intron position conservation could be a consequence of convergent
insertion in a similar position due to the existence of “protosplice sites” [27,28]. However, the evolution
via ancestral origin can be not completely ruled out in the case of the lack of gene structure information
in many animal defensins from different lineages.
5. Conclusions
It is estimated that there are as many as 1.5 million species of fungi in this world. However, only
a small fraction has been described and even fewer have been sequenced. To date, only about six
hundred genomes were being sequenced or completely sequenced. Fungal genome project (FGP)
allows us to systematically exploit peptide antibiotics instead of accidental discovery or complicated
biochemical screening. This work sheds light on the persistent discovery of fDLPs from model fungal
genome data. Despite this, in the lack of experimental data, it cannot be stated that all these fDLPs
possess antibacterial function because in fact a classical insect-type fungal defensing - pechrysin was
found to lack antibacterial activity [29] likely due to the absence of cationic residues on its molecular
surface. In addition, anisin1, a DLP from Aspergillus giganteus, was found to be involved in the
fitness of the species by linking stress signaling with developmental regulation [30]. Recent studies
have also shown that although some peptides of fungal origin contain a similar defensin structure,
they exhibit diverse or alternative biological functions beyond antimicrobial activity. An interesting
overview is given by Hegedüs and Marx [31]. Therefore, further biochemical characterization of these
newly-discovered fDLPs will help evaluate their potential as human medicines.
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Abstract: Plant antimicrobial peptides (AMPs) have evolved differently from AMPs from other life
forms. They are generally rich in cysteine residues which form multiple disulfides. In turn, the
disulfides cross-braced plant AMPs as cystine-rich peptides to confer them with extraordinary high
chemical, thermal and proteolytic stability. The cystine-rich or commonly known as cysteine-rich
peptides (CRPs) of plant AMPs are classified into families based on their sequence similarity, cysteine
motifs that determine their distinctive disulfide bond patterns and tertiary structure fold. Cystine-rich
plant AMP families include thionins, defensins, hevein-like peptides, knottin-type peptides (linear
and cyclic), lipid transfer proteins, α-hairpinin and snakins family. In addition, there are AMPs
which are rich in other amino acids. The ability of plant AMPs to organize into specific families
with conserved structural folds that enable sequence variation of non-Cys residues encased in the
same scaffold within a particular family to play multiple functions. Furthermore, the ability of plant
AMPs to tolerate hypervariable sequences using a conserved scaffold provides diversity to recognize
different targets by varying the sequence of the non-cysteine residues. These properties bode well
for developing plant AMPs as potential therapeutics and for protection of crops through transgenic
methods. This review provides an overview of the major families of plant AMPs, including their
structures, functions, and putative mechanisms.
Keywords: plant antimicrobial peptides; cysteine-rich peptides; cystine knot; thionin; defensin;
hevein; knottin
1. Introduction
Higher plants have a broad range of defense mechanisms to counter physical, chemical and
biological stress such as drought, cold, heavy metal, pollutants and pathogen attacks from fungi,
bacteria and viruses. In response to infection by a variety of pathogens, plants display up-regulation of
a set of genes associated with systemic acquired resistance [1]. General resistance is accomplished by
the release of secondary metabolites like phytoalexins, tannins and polyphenolic compounds, and the
generation of pathogenesis-related (PR) proteins. PR proteins were first discovered in the early 1970s
in tobacco leaves in response totobacco mosaic virus infections and were later defined as the induced
proteins that are released during pathogenic attacks [2,3]. According to a recent review, there are at
least 17 families that have been detected and isolated that possess a wide range of defense-related
properties, including antibacterial, antifungal, antiviral, anti-oxidative activity, chitinase and proteinase
inhibitory activities [1–4]. This review will focus on peptides which possess antimicrobial activity,
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namely thionin (PR-13 family), defensin (PR-12 family), hevein-like peptide, knottin, α-hairpinin, lipid
transfer protein (PR-14 family) and snakin.
Antimicrobial peptides (AMPs) are ubiquitous and found as host defenses against pathogens and
pests in diverse organisms ranging from microbes to animals [5]. AMPs exist in different molecular
forms, although the majority of them are linear peptides from insects, animals, and plants. Nevertheless,
bacteria produce polycyclic peptides such as lantibiotics, and all major forms of life produce circular
peptides which include bacteriocins from bacteria, cyclotides from plants and theta-defensins from
animals [6–9]. In plants, the majority of AMPs are Cys-rich [10], a feature that enables the formation of
multiple disulfide bonds (usually two to six) that contribute to a compact structure and resistance to
chemical and proteolytic degradation.
In general, plant AMPs share several common characteristics with those from microbes, insects
and animals. They include features such as their molecular forms, positive charge and amphipathic
nature, all of which are primarily related to their defensive role(s) as membrane-active antifungals,
antibacterials, and antivirals. These features, in addition to being Cys-rich, are well represented
by two plant AMP families, thionins and plant defensins. Other families of plant AMPs act on
pathogens differently from animal AMPs. For example, hevein-like peptides bind chitins, knottin-type
peptides inhibit enzymes such as proteases, and lipid transfer proteins bind lipids to disrupt microbial
penetration into cell membranes.
Classification of plant AMP families is largely based on their Cys motifs which exhibit a
characteristic Cys pattern with a defined number of non-Cys residues between the two neighboring Cys.
Currently, the number of AMPs isolated from a limited number of plants already exceeds a thousand
and is likely to increase in the future. Sequence analysis and genomic data mining using these Cys
motifs have revealed that Cys-rich peptides (CRPs) with AMP characteristics are under-predicted [11].
In model plants, such as rice and Arabidopsis, CRPs may account for about 3% of the expressed proteins.
Like animal AMPs, AMP expression in plants is constitutive or induced and often tissue-specific.
Moreover, plant AMPs are evolvable with hypervariable sequences encased in a particular scaffold
characteristic of a given family of AMPs, which is analogous, but to a much lesser extent, to the
molecular diversity of vertebrate immunoglobulin-based immunity.
This review aims to provide a general overview of the major families of plant AMPs, including
their structures, functions, and putative mechanisms of defense. Additional details on plant AMPs
can be found in a number of excellent previous reviews [12–25]. Furthermore, information on AMPs
from diverse organisms can be accessed through several databases, such as APD, APD2 [26,27],
YADAMP [28], DAMPD [29], and PhytAMP (specific for plant AMPs) [10].
2. Classification and Characteristics
Plant AMPs are divided into families based on their sequence similarity, Cys motifs, and
distinctive disulfide bond patterns which, in turn, determine their tertiary structure folding. Table 1
lists the major families of plant AMPs based on these criteria; families include thionins, defensins,
hevein-like peptides, knottin-type peptides (linear and cyclic), lipid transfer proteins, α-hairpinin
families, snakins, and unclassified CRP-AMPs. In addition, non-CRP AMPs, which may be rich in
other amino acids, are also described in this review, including the Gly-rich peptide (GRP) Pg-AMP1,
the Gly- and His-rich peptide shepherins, and peptides of less than 10 amino acids (aa), such as
Cn-AMP1 and Cr-ACP1. The following defining features are found in plant AMPs:
1. Mostly characterized as moderate-size (MW of 2–6 kDa), basic, CRPs with two to six
intra-molecular disulfide bonds.
2. Members within a family are classified based on Cys motif, sequence similarity and are conserved
in secondary and tertiary structure.
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3. One or two additional disulfide bonds are found in members of thionins, defensins, and
hevein-like peptides. These additional bonds bolster structural stability without affecting the
general scaffold. Because the varying number of Cys residues can create confusion, we refer to
AMPs within a family based on the number of Cys when necessary throughout this review (e.g.,
6C-thionins contain six Cys and 8C-thionins have eight Cys).
4. In addition to being antimicrobial, AMPs also display “peptide promiscuity”, which refers to the
multiple functions displayed by a single peptide.
5. All are ribosomally derived and bioprocessed from precursors, which often contain three
domains: N- and C-terminal pro-domains and a mature AMP domain. Mature sequences
are often hypervariable and display more variation than the conserved terminal domains in the
preproprotein to give sequence diversity for adaptation.
6. Because of cross-bracing by multiple disulfide bonds, most CRP-AMPs with a molecular weight
(MW) of 2–6 kDa are structurally compact with high thermal, chemical, and enzymatic stability.




Name AA No. Disulfide Motif
6C-Thionin 3 Crambin 46 Gamma (Г) fold
β1-α1-α2-β2-coil motif8C-Thionin 4 β-Purothionin 45
8C-Defensin 4 NaD1 47 CSαβ motif
β1-coil-α-β2-β310C-Defensin 5 PhD1 47
6C-Hevein 3 Ac-AMP1 29 Gly & Cys rich Central β
strands & (short helical)
side coils
8C-Hevein 4 Hevein 43
10C-Hevein 5 EAFP1 41
Knottin 3 PAFP-S 38 Cystine knot Short β
strand & coilCyclic Knottin 3 Kalata B1 29
α-Hairpinin 2 Ec-AMP1 37 α1-turn-α2
LTP 4 Maize LTP1 93 Hydrophobic cavity
α1-α2-α3-α4-coilLTP 4 Wheat LTP2 67
Snakin * 6 Snakin-1 63 α -helices
* The disulfide and structural motif of Snakin-1 is predicted based on homology modelling.
2.1. Thionins
α-/β-Thionins are the prototypic plant AMP; they are cationic peptides of 45–48 aa with three or
four disulfide bonds [12]. Initially, they were known as plant toxins because of their toxicity towards
bacteria [30], fungi [31], plant and animal cells [32], as well as insect larvae [33]. The prototypic thionin
with antimicrobial activity, α-purothionin, was isolated in the endosperm of wheat [30,34]. Following
the discovery of α-purothionin, subsequent thionins isolated from other plants are labeled with
descending letters of the Greek alphabet in the order of their discovery (e.g., α-thionins, β-thionins,
and γ1/γ1-thionins).
Classification of thionins is largely based on α-purothionin and includes the α-/β-thinoins
of crambin, viscotoxins, phoratoxin A, hordothionins, and purothinoins. However, γ-thionins are
considered part of the plant defensin family based on structural considerations. Thus, α-/β-thionins
share a similar structural fold different from that of γ-thionins. For convenience, α/β-thionins with
eight Cys residues will be hereafter referred to as 8C-thionins and those with six Cys designated
6C-thionins (Figure 1A,B).
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Figure 1. Sequences (A) and structures (B) of representative thionins. The secondary structure is represented
by different colors: cyan-α helix; magenta-β strand; pink-random coil and yellow-disulfide bonds.
2.1.1. Occurrences, Distribution, and Biosynthesis
Thionins have been identified from monocots and dicots and are expressed in different tissues,
such as seeds, leaves, and roots [35–37]. The expression of thionins can be induced by infection with
various microbes [38,39] and has been shown to be related to the release of the hormone methyl
jasmonate upon plant wounding or microorganism invasion [38,40,41]. Thionins are ribosomally
derived and expressed as preproproteins, wherein the prothionin domain is flanked by two conserved
sequences, the N-terminal signaling peptide and C-terminal acidic domain [35,38,42]. Mature thionin
sequences display more variation than the conserved terminal domains in the preproprotein due to
evolutionary pressure [43]. The three-domain precursor of plant AMPs in CRP families is typical and
found in other CRP families, including defensins, hevein-like peptides, and knottin-type peptides.
2.1.2. Structure
From the limited number of members identified thus far, thionins have relatively conserved amino
acid sequences compared to other plant defense peptides (Figure 1A). They also share a conserved
β1-α1-α2-β2-coil secondary structural motif, which forms a gamma (Г) fold, a special turn consists of
three amino acid residues with the first and third residue connected by a hydrogen bond in the tertiary
structure (Figure 1A,B).
Thionins can be loosely classified as pseudocyclics because of an end-to-end disulfide bond
linking the N- and C-termini, conferring a circular structural topology. They are, however, not true
pseudocyclics because there are additional non-cysteine amino acids located at both the N- and
C-termini. 8C-Thionins contain four conserved stabilizing disulfide bonds between CysI-CysVIII (Cys
numbering in Roman numerals from N-to-C-termini) linking β1 to the C-terminal coil, CysII-CysVII
linking the end of β1 with the beginning of β2, CysIII-CysVI linking α1 and the loop after α2, and
CysIV-CysV linking α1 and α2. The 6C-thionins have the same Cys pairing as 8C-thionins except for the
absence of the CysII-CysVII disulfide bond. The structure of 8C-thionins, including α-/β-purothionins,
α-/β-hordothionin, and hellethionin D, are similar to that of 6C-thionins with the Г-shape but with
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minor differences in the C-terminal coil region [44–46]. The long arm of the Г fold comprises the
α1-α2 region, and the short arm consists of β1 and the β2-coil. The large groove between the two
arms is proposed to be important for the interaction between thionins and membrane lipids [43]. Most
hydrophobic side chains cluster around the outer surface of the long arm, while the hydrophilic chains
are located on the surface within the groove or outer face of the short arm (Figure 2A).
2.1.3. Structure-Function Relationship
The 6C-thionins with three disulfide bonds include crambin, viscotoxins, and phoratoxin A.
Most 6C-thionins are highly basic, amphipathic, and toxic, with the exception of crambin. Crambin
is a neutral, hydrophobic, non-toxic peptide identified from Crambe abyssinica with two isomers,
P22/L25 and S22/I25 [47,48]. High resolution structures of crambin have been determined by NMR
and X-ray/neutron crystallography in both water and detergent [47,49–53]. Viscotoxins (including
A1, A2, A3, B, B2, C1, and 1-PS) and phoratoxins from the mistletoes share a similar Г-shape with
β1-α1-α2-β2-coil motif [54–60].
8C-Thionins with four disulfide bonds include α-/β-purothionins, α-/β-hordothionins,
hellethionin-D, Pyrularia Pubera thionin (PpTH), and Tulipa gensneriana bulb-purified AMPs (Tu-AMPs).
The monomeric conformation of the 45-aa α-hordothionin isolated from barley [61,62] was previously
determined by NMR [62], while X-ray crystallography revealed a dimeric structure [61]. A study by
Vila-Perello showed that removal of one disulfide bond from PpTH is sufficient to significantly alter its
folding [63]. A 45% size-reduced form of PpTH was synthesized, which only contains residues 7–32
with the two antiparallel α-helices stabilized by two disulfide bonds. Size-reduced PpTH appeared
to display the same antimicrobial activity and mechanism of action as intact PpTH in selected test
microorganisms [64].
Figure 2. Cartoon illustration and surface plot of representative members of different antimicrobial
peptides. The orientation of surface plot (left) of each representative member is the same as the cartoon
illustration, while that of the right one is evolved from the left one by 180◦ turn around the y axis.
Color representation rules for different amino acids are as follows: blue-positively charged (R, K & H),
red-negatively charged (D & E), orange-hydrophobic (I, L, V, A, P & M), cyan-hydrophilic (S, T, E & Q),
magenta-aromatic (F, Y & W), yellow-cysteine (C) and gray-glycine (G).
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Tu-AMP1 and Tu-AMP2 are antibacterial, antifungal, and can reversibly bind chitin, a key
constituent of the cell wall of fungi and exoskeletons of invertebrates, such as insects, anthropods,
and nematodes. Initially, they were suggested to be thionin-like peptides, although Tu-AMP2 is a
heterodimer of two chains joined by disulfide bonds [65]. However, it is worthwhile to point out that
in our review of plant CRPs, the occurrence of heterodimer is exceedingly rare. In our view, it remains
to be determined whether the heterodimeric formation occurs during the isolation process.
2.1.4. Mechanism of Action
Thionins are hydrophobic and likely elicit their toxicity to bacteria, fungi, and animal and plant
cells via membrane interactions with their hydrophobic residues or/and positive surface charge [12,
13,18,66–68]. The proposed mechanism of toxicity is attributed to lysis of cell membranes, but it is
still under investigation [30,39,68–70]. Stec proposed a structural model of the thionin-phospholipid
interaction to explain the solubilization and lysis of cell membranes [43].
Thionins are known to directly interact with membrane lipids apart from protein receptors [67,
71,72]. Pyrularia thionin from the nuts of Pyrularia pubera mediates the influx of Ca2+ during certain
cellular responses, while Tyr iodination reduces its hemolysis, phospholipase A2 activation, and
cytotoxicity [32]. Structure-function studies have demonstrated that Lys1 and Tyr13 in thionins are
highly conserved and proposed to be crucial to their toxicity, with the exception of non-toxic, non-lytic
crambin. Instead, crambin contains Thr1 and Phe13 residues [32,43,73,74]. Furthermore, Arg10 is
suggested to be important to the folding stability of all thionins, as it is an abundant source of hydrogen
bonds between β1, α1, and the C-terminal coil [75].
2.2. Plant Defensins
Plant defensins are the best known, and likely most abundant, of all plant AMPs with
membranolytic functions, according to data mining of selected plant genomes. They are cationic
peptides of 45–54 aa with four to five disulfide bonds [76]. Plant defensins have diverse biological
functions which include antifungal [77–81], antibacterial [82,83], and α-amylase and trypsin inhibitory
activity [84,85]. In addition to being antimicrobial, plant defensins are also involved in the biotic stress
response, as well as plant growth and development.
Plant defensins were first identified as γ-thionins, γ1-hordothionin, and γ1-/γ2-purothionins
from wheat and barley grains [86,87]. Thus, they were initially classified as γ-thionins due to their
limited sequence identity (25%) with α-/β-thionins. Later, they were found to be unrelated to thionins
based on structural features [88]. In 1995, they were grouped as plant defensins based on their sequence,
structure, and function similarities with mammalian and insect defensins [76,78,88,89].
2.2.1. Occurrences, Distribution, and Biosynthesis
Plant defensins include over 100 members from a wide range of plants, including wheat, barley,
tobacco, radish, mustard, turnip, arabidopsis, potato, sorghum, soybean, cowpea, and spinach, among
others [15,90]. They have been identified in multiple tissues, tubers [79,91], leaves [79], pods [92], and
flowers [93–95], with the majority identified from seeds and roots [96]. Two types of precursors have
been identified in plant defensins, wherein the dominant group is composed of the N-terminal signal
peptide and a mature plant defensin domain [97], while the minor group is composed of an extra
C-terminal acidic pro-domain of 33 aa reportedly associated with the vacuolar sorting mechanism
since defensins with this domain were found in vacuoles and those without were found in the outer
cell layers [16,79,95].
2.2.2. Structures
Plant defensins are generally characterized by four conserved disulfide bonds (except for PhDs, a
10C-plant defensin isolated from Petunia hydrida) with the outer disulfide pair as an end-to-end inner
disulfide bridge and the inner three pairs of disulfide bonds forming a cystine knot (see knottins).
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A secondary structure characteristic of plant defensins is a Cys-stabilized αβ (CSαβ) motif of the
cysteine knot. The CSαβ motif was first characterized in charybdotoxin, a K+ channel blocker isolated
from scorpions [98] and named by Cornet et al. [99]. This motif forms a β1-coil-α-β2-β3 pattern in
the secondary structure, where the α-helix is parallel to three antiparallel β-strands (Figure 3A,B).
The CSαβ scaffold is stabilized and characterized by: (1) two disulfide bonds between the CXXXC
motif from the α-helix and the CXC motif in the central β3 strand; (2) one disulfide bond between
the β2 strand and the first loop before the α-helix; and (3) an end-to-end disulfide bond between the
N- and C-termini, a disulfide connective similar to thionins. However, plant defensins (γ-thionins)
differ greatly from α-/β-thinoins in their secondary and tertiary structures. In the secondary structure,
α-/β-thionins show a typical β1-α1-α2-β2-coil motif, whereas γ-thionins display a β1-coil-α-β2-β3
motif. At the tertiary structural level, β1 and β2 orient antiparallel in α-/β-thinoins, whereas the
corresponding β1and β3 in γ-thionins are oriented in parallel.
Figure 3. Sequences (A) and structures (B) of representative plant defensins. The secondary
structure is represented by different colors: cyan-α helix; magenta-β strand; pink-random coil and
yellow-disulfide bonds.
Similar to thionins, plant defensins are pseudocyclics (see thionins), with conservation of the
disulfide bond between the first and last Cys, conferring a circular structural topology by connecting
the side chains of the N- and C- termini.
Plant defensins have been reported to be stable in harsh conditions that mimic the digestive
system and decoction process, including high temperature (~85 ◦C), low pH (~2.0), and oxidative and
proteolytic environments [100–102]. Although defensins show conservation of the CSαβ motif, there
are variations in the number of disulfide bonds, primary sequences, and tertiary structures [89,103,104].
It has been shown that Ala substitutions of non-Cys residues on VrD1 are tolerated in the CSαβ motif
although the structural stability and inhibitory effects vary among the mutants [105].
45
Pharmaceuticals 2015, 8, 711–757
2.2.3. Structure-Function Relationship
Based on the number of Cys, plant defensins are further divided into 8C-plant defensins with
four disulfides and 10C-plant defensins with five disulfide bonds.
The 8C-plant defensins include NaD1, VrD1, AlfAFP, ω-hordothionin, Cp-thionin II, Rs-AFPs,
Psd1, Fabatins, and Ms-Def1 (Figure 3A,B). NaD1 (47 aa) was identified from the outer cell layers of
different flower parts of the ornamental tobacco Nicotiana alata. Its distribution is consistent with its
protective roles in reproductive organs. In vitro results showed that NaD1 inhibits the growth of plant
pathogens Botrytis cinerea and Fusarium oxysporus [95,106]. VrD1 (46 aa) from the mung bean Vigna
radiata not only inhibits protein synthesis, but is also antimicrobial and insect (bruchids)-resistant [107,
108]. ω-Hordothionin (48 aa) purified from barley endosperm inhibits translational activity in both
eukaryotic and prokaryotic cell-free systems [109]. The crystal structure of SPE10, identified from
Pachyrrhizus erosus seeds [110], shows a dimer with each unit adopting the typical CSαβ motif [111].
Based on structural analysis and mutation studies, the dimeric conformation of SPE10 was suggested
to be associated with its function, while the hydrophobic patch on the molecular head is necessary for
its antifungal activity.
AlfAFP from Medicago sativa seeds is an antifungal peptide that provides robust resistance
to the fungal pathogen Verticillium dahliae in transgenic potato plants [77,106]. Rs-AFPs (51 aa)
purified from Raphanus sativus radish seeds are highly basic oligomeric proteins with an N-terminal
pyroglutamic acid. They have a broad antifungal spectrum with an IC50 = 0.3–100 μg/mL [78,79,81].
Rs-AFPs are abundant in near-mature and mature seeds and released to create a fungal-suppressing
microenvironment after disruption of the seed coat [79]. Ms-Def1 from Medicago sativa seeds strongly
inhibits the fungal growth of Fusarium graminearum in vitro [112]; the inhibitory effect is reduced in the
presence of Ca2+ ions. Homologous antifungal peptides were also reported from seeds of Aesculus
hippocastanum, Clitoria ternatea (Ct-AMP1), Dahlia merckii (Dm-AMP1), Lens culinaris (Lc-def) and
Heuchera sanguine (Hs-AFP1) [80,97,113].
Cp-thionin II (47 aa) was identified from Vigna unguiculata cowpea seeds and is antibacterial
against both Gram-positive and Gram-negative bacteria such as Staphylococcus aureus, Escherichia
coli, and Pseudomonas syringae with minimal inhibitory concentrations of 128, 64, and 42 μg/mL,
respectively [90]. Psd1, a 46 aa peptide identified from seeds of the pea Pisum sativum, is antibacterial
and acts as a K+ channel inhibitor based on a surface charge distribution analysis [114]. Fabatins
isolated from the broad bean Vicia faba are active against both Gram-positive and Gram-negative
bacteria, but inactive against the yeasts Saccharomyces cerevisiae and Candida albicans [115].
PhDs are 10C-plant defensins. From flowers of Petunia hybrids, Lay et al. reported two AMPs with
antifungal activity, PhD1 (47 aa) and PhD2 (49 aa) [95]. A fifth disulfide bond exists between the α-helix
and the loop after β1 within these defensins that do not alter the typical CSαβ topology [108]. The
fifth disulfide bond appears only to change the corresponding hydrophobic interaction and hydrogen
bond, as in 8C-plant defensins, to a covalent disulfide bond in PhD1 without altering the side-chain
orientation of substituted residues.
The γ-thionins which have been reclassified as defensins, γ-hordothionin and ω-hordothionin
from Hordeum vulgare, were shown to inhibit protein translation in rabbit reticulocytes and mouse
liver extracts [87]. However, this inhibitory effect was not observed on plants, such as Triticum
aestivum, Cucumis sativus, Vicea sativa and H. vulgare, and which may indicate a certain specificity in its
mechanism of action. Similarly, no direct interaction was observed between the plant defensins and
nucleic acids, which is the proposed mechanism of the inhibitory activity of protein synthesis by the
plant thionin family [116]. Instead of protein translation, Mendez et al. suggested that ω-hordothionin
may act on protein synthesis at the initiation and elongation step [109].
Defensins isolated from the seeds of Sorghum bicolor, S1α1, S1α2 and S1α3, were demonstrated to
display inhibitory activity against α-amylase activity [84]. They are able to inhibit α-amylase obtained
from the gut of the insects Periplaneta americana and Locusta migratoria migratorioides, and weakly inhibit
the α-amylase from human saliva. Defensins from Vigna unguiculata and ω-hordothionin, from H.
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vulgare, also exhibit similar inhibitory activity against insect α-amylase [109,117,118], however, no
significant inhibitory effect was observed on porcine α-amylase by plant defensins [119]. Several plant
defensins exhibit the ability to inhibit ion channels. Kushmerick et al. showed that γ1-zeathionin and
γ2-zeathionin from maize kernels block voltage-gated Na+ channels reversibly in intact mammalian
GH3 cells using the patch-clamp technique [120]. These authors postulated that the ion channel
inhibitory effect of defensins may be related to the similar 3D structure with scorpion neurotoxin,
a well-known Na+ channel blocker. Plant defensins were also shown to inhibit Ca2+ channels [112].
However, no significant inhibitory effect was observed on K+ channels by plant defensins [119].
Two homologous peptides that display high sequence similarity to plant defensins were isolated
from the plant Cassia fistula, denoted 5459 and 5144 according to their molecular weight [85]. The 5459
defensin was demonstrated to exhibit trypsin inhibitory activity, whereas no inhibitory effect was
observed by the 5144 defensin. Another defensin peptide, Cp-thionin from V. uguiculata seeds, was
reported to display inhibitory activity against pancreatic bovine trypsin [121].
An enzymatic activity was attributed to a plant defensin. Huang et al. cloned the defensin SPD1
from the roots of Ipomoea batatas and showed that it has the ability to regenerate dehydroascorbate
(DHA) to ascorbic acid (AsA) in the presence of glutathione [122]. The peptide is also able to convert
monodehydroascrobate (MDA) to AsA in the presence of NADH, functioning as a glutathione-dependent
dehydroascorbate reductase. SPD1 is likely to function as a regulator of the redox state of AsA, which has
been implicated in the response of the plant cell to reactive oxidative stress [123].
2.2.4. Mechanism of Action
The structure-function relationship of plant defensins has been suggested to correlate with
their positive charge and amphipathic nature, as illustrated by the structure-surface plot of NaD1 in
Figure 2B. Thus, plant defensins could initially bind to microbial membranes through interactions with
specific binding sites (“receptors”), as reported for Rs-AFP2, Hs-AFP1, and Dm-AMP1 [16,124,125].
Binding of plant defensins, such as Rs-AFP2 and Dm-AMP1, to the cell membrane results in the influx
and efflux of positive ions like Ca2+ and K+ [126,127]. Lastly, Ms-Def1 is able to block the Ca2+ channel
in a manner similar to the Ca2+ channel blocker KP4 [112]. Van der Weerden et al. demonstrated
that NaD1 does not cause membranes permeabilization via a canonical mechanism which involves
nonspecific insertion into membranes [128] but rather a cell wall dependent process, likely requiring a
specific receptor. The mechanism of the fungicidal action of NaD1 is likely through permeabilization of
the hyphae of Fusarium oxysporum, entering into the cytoplasm of the cell and inducing ROS oxidative
stress [129]. Hayes et al. reported that the high-osmolarity glycerol (HOG) pathway is involved in the
protection of the cell against NaD1 [130], indicating that the inhibition of the HOG pathway increases
the activity of antimicrobial peptides against Candida albicans. Several reviews have discussed in detail
the plant defensin mechanism of action [16,101,131,132].
2.3. Hevein-Like Peptides
Hevein-like peptides are basic peptides of 29–45 aa with three to five disulfide bonds. They are
rich in Gly and contain conserved aromatic residues found in the hevein domain of lectins. Hevein
domains bind to chitin [133–135], which is their primary target.
Hevein was first identified as the most abundant protein component from the latex of the rubber
tree Hevea brasiliensis and displays strong antifungal activity in vitro [136,137]. It was also reported to
be a major allergen from latex involved in human latex-fruit syndrome [138,139]. Similar to hevein,
hevein-like peptides inhibit the growth of chitin-containing fungi and defend plants against attack
from a wide range of fungal pathogens [133,140].
2.3.1. Occurrences, Distribution and Biosynthesis
As a chitin-binding domain, the hevein domain is found in several plant lectins, natural variants
of heveins (pseudo-hevein, wheat germ agglutinin, Urtica dioica agglutinin), and AMPs [134,141,142].
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Similar to other families of CRP-AMPs, the hevein-like peptide is processed from a three-domain precursor.
For example, the cDNA of the Ar-AMP precursor comprises a 25 aa N-terminal signal sequence, 30 aa
mature peptide, and 34 aa C-terminal region which is cleaved during post-translational processing [143].
In 10C-hevein (hevein-like peptide containing 10 cysteine residues), there are two different precursor
peptide structures in the C-terminal prodomain. The WAMP 10C-hevein from Triticum kiharae have
precursor similar to other families CRP-AMPs, with a 45aa C-terminal region [144], while Ee-CBP
10C-hevein from Euonymus europaeus is produced as a chimeric precursor consisting of the mature peptide
domain linked to a long C-terminal chitinase-like domain [145]. Andreev et al. [144] also showed that the
WAMP-1 and WAMP-2 gene may have originated from ancestral chitinase genes and that a frame-shift
deletion of the coding region for the catalytic domain led to the WAMP gene formation.
2.3.2. Structure
Hevein-like peptides share conserved Cys, Gly, and several aromatic amino acid residues. They
vary substantially in their primary sequences and number of disulfide bonds (from three to five;
Figure 4A,B). Thus, hevein-like peptides can be divided into 6C-, 8C-, and 10C-hevein-like peptide
subgroups based on the number of Cys they contain. All hevein-like peptides has a cysteine knot motif
(see knottins). The solid-state and solution structures of the hevein domain, as determined by X-ray
crystallography and NMR, respectively [142,146,147], provide the basis for analyzing the carbohydrate
binding ability of this domain. Generally, hevein-like peptides contain a coil-β1-β2-coil-β3 secondary
structural motif with variations based on the presence of short turns in the two long coils and β3
strand. Antiparallel β-strands form the central β-sheet of the hevein motif with the two long coils
located on each side stabilized by disulfide bonds.
Figure 4. Sequences (A) and structures (B) of representative hevein-like peptides. The secondary
structure is represented by different colors: cyan-α helix; magenta-β strand; pink-random coil and
yellow-disulfide bonds.
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2.3.3. Structure-Function Study
6C-Hevein-like peptides Ac-AMP1 and Ac-AMP2 isolated from Amaranthus caudatus seeds exhibit
antimicrobial activity against both Gram-positive bacteria and plant pathogenic fungi with an IC50 2–10
μg/mL [148]. Interestingly, their antimicrobial activity is antagonized by cations. Both Ac-AMP1 and
Ac-AMP2 are similar to chitin-binding proteins and known to reversibly bind chitin in the C-terminal
truncated fold of hevein [149]. This structure consists of a β-sheet with two antiparallel β-strands as
the main central element, an N-terminal coil region, and C-terminal helical turn. The N-terminal coil
region is linked to the two central β-strands by two disulfide bonds, while the C-terminal helical coil is
connected to the first β-strand through a third disulfide bond. Ar-AMP (30 aa) purified from the seeds
of amaranth (Amaranthus retroflexus) is another 6C-hevein-like peptide with antifungal activity [143].
Compared to Ac-AMPs, most hevein-like AMPs, including hevein, are 8C-hevein-like peptides
with an additional C-terminal sequence containing the fourth disulfide bond. Thus, 8C-hevein contains
a central β-sheet of three antiparallel β-stands, wherein the last β-strand is formed from the additional
C-terminal sequences and oriented parallel to the fourth disulfide bond. The 6C-hevein32, a truncated
form of hevein with the N-terminal 32 aa of hevein similar to Ac-AMP2, is defined as the minimum
hevein domain since it presents comparable binding affinity for chito-oligosaccharides as native
hevein [150]. Pn-AMP1 and Pn-AMP2 from seeds of the morning glory Pharbitis nil are highly basic (pI
12.02) and thermally stable. They exhibit potent antifungal activity against both chitin-containing and
non-chitin-containing fungi with an IC50 0.6–75 μg/mL, but lose their antifungal activity in acidic (pH
2.0) or reducing conditions [151]. As the first hevein-like peptides reported antifungal activity similar
to thionins, Pn-AMPs have been successfully cloned into tomato and tobacco plants, endowing these
transgenic plants with potent antifungal activities [152,153]. Fa-AMP1 and Fa-AMP2 from seeds of the
buckwheat Fagopyrum esculentum, have antifungal and antibacterial activities with an IC50 of 11–36
μg/mL [82]. Avesin A from seeds of the oat Avena sativa represents another chitin-binding peptide
with weak to moderate antifungal properties [154].
Several hevein-like AMPs contain five disulfide bonds (10C-hevein-like peptides), although the
location of the fifth disulfide bond varies by peptide. For example, EAFP1 and EAFP2, each 41 aa
long, were purified from the bark of the olive Eucommia ulmoides Oliv with an N-terminal pyroglutamic
acid [155]. These peptides show inhibitory effects on both chitin-containing and chitin-free fungi
with an IC50 18–155 μg/mL and can be antagonized by Ca2+. Both solution and crystal structures
indicate that EAFPs contain a chitin-binding domain similar to hevein-like peptides with a distinct
Cys7-Cys37 fifth disulfide bond bridging the N-terminal coiled region with the third β-strand [156,157].
In contrast, the fifth disulfide bond within WAMP-1a isolated from the wheat Triticum kiharae connects
the C-terminus to the central region of the structure [158,159]. Similarly, Ee-CBP from the bark of the
spindle tree Euonymus europaeus is a potent antifungal peptide with an IC50 1 μg/mL for the fungus
Botrytis cinerea [160]. Ee-CBP has a primary sequence similar to other hevein-like peptides but with the
fifth disulfide bond at the C-terminus.
2.3.4. Mechanism of Action
As a chitin-binding domain, hevein is an excellent model for studying the carbohydrate-peptide
interaction, which is reportedly mediated by hydrogen bonding and van der Waals forces. The
carbohydrate-induced conformational change to the hevein domain is small based on NMR
investigations of pseudo-hevein, a wheat germ agglutinin and truncated hevein mutant [142,161,162].
The interaction between the hydrophobic C-H groups of carbohydrates and the π-electron systems of
aromatic amino acids (Trp21, Trp23, and Tyr30 in hevein; Figures 3A and 8C) of hevein-like peptides
appear to play an important role in chitin binding, as observed in Ac-AMP synthetic mutants, hevein,
and a truncated form of hevein (hevein32) at key interacting positions [150,161,163,164]. Studies on
Pn-AMPs showed that they rapidly penetrate fungal hyphae, leading to hyphal tip bursting, which
disrupts the fungal membrane causing leakage of cytoplasmic materials [151].
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In addition to the chitin binding function of hevein, Slavokhotova et al. showed an alternative
function in which hevein plays a role in the plant defense against fungal infection [165]. WAMPs
which contains an additional Ser at position 36 is able to inhibit the proteolytic activity of the secreted
fungal protease fungalysin (Fv-cmp), a Zn-metalloproteinase, isolated from Fusarium verticillioides. This
protease is able to truncate corn and Arabidopsis class IV chitinases by cleaving within the Gly-Cys
site located in the chitin-binding domain of the plant chitinase. The presence of Ser36 prevents WAMP
from being digested by Fv-cmp, allowing it to bind to fungalysin, and displace the plant chitinase,
thus enabling the chitinase to remain intact and active [165].
2.4. Knottin-Type Peptides
Plant knottins belong to a superfamily, with members containing approximately 30 aa. They
include inhibitors of α-amylase, trypsin and carboxypeptidase families as well as cyclotides. In general,
they are among the smallest in size, but most diverse in functions of plant CRP-AMPs. Knottins
typically comprise six Cys residues with conserved disulfide bonds between CysI-CysIV, CysII-CysV,
and CysIII-CysVI, forming a cystine knot, but their Cys motifs differ among different subfamilies. Both
plant defensins and hevein-like peptides also contain a cysteine-knot motif but they differ in their
cysteine spacing.
One characteristic of this family is that they display a very broad range of bioactive functions
which include hormone-like functions as well as enzyme-inhibitory, cytotoxic, antimicrobial,
insecticidal, and anti-HIV activities [166]. Certain cystine-knot (CK) peptides with identical scaffold
structures involved in multiple biological functions has been viewed as “peptide promiscuity” [167].
Historically, the knottin-type peptides were discovered as protease inhibitors sharing in common
only in a cystine knot motif, and they are named collectively as cystine-knot inhibitor peptides, knottins.
The prototypic knottin scaffold was first discovered in the subfamily of potato carboxypeptidase
inhibitor (PCI) in 1982 [168]. The use of knottins also distinguishes the CK-CRPs from those initially
described in the structures of the protein growth factors found in animals [169]. As a superfamily, they
are believed to be the largest group of plant peptides associated with AMPs, surpassing defensins in
the number of molecular forms and sequence diversity.
Knottins in the cyclotide and trypsin inhibitor families are found in two molecular forms, cyclic
and linear, based on the presence or absence of backbone (head-to-tail) cyclization. In literature, cyclic
knottins of the squash trypsin subfamily are often included in the cyclotide subfamily. Apart from
their Cys residues, cyclic knottins and cyclotides share little sequence identity. Currently, both linear
(acyclotides) and cyclic (cyclotides) forms of the cyclotide subfamily are found in plants.
2.4.1. Occurrences, Distribution, and Biosynthesis
Linear knottins are found not only in plants, but also in other biological sources, including fungi,
insects, and spiders. Thus, CK peptides with identical or related scaffold structures found in diverse
life forms provide an example of parallel evolution of protein structures. Cyclotides and their acyclic
variants are found only in plants, from the dicot plants of the Rubiaceae, Violaceae, Cucurbitaceae, Fabaceae,
and Solanaceae families to a monocot plant of the Poaceae family, with predicted wide and abundant
distribution [170–177].
Cyclotides and certain members of cyclic knottins of the squash family are produced from
precursor proteins encoding one or more cyclotide domains. The precursor is composed of an
endoplasmic reticulum signal region, pro-domain, one (or more) mature cyclotide domain(s), and
a short C-terminal tail [172]. However, there are variations in their biosynthesis. A recent report
on cyclotides such as cliotides (cT1-cT12) identified from Clitoria ternatea showed that they originate
from chimeric precursors consisting of Albumin-1 chain A and cyclotide domains [173]. Studies
have shown that an asparaginyl endoproteinase could be involved in the backbone cyclization of
cyclotides [178–181]. Our laboratory has isolated one of the bioprocessing enzymes responsible for
the backbone cyclization process from C. ternatea, butelase 1 [181]. Butelase 1 acts as a transamidase,
50
Pharmaceuticals 2015, 8, 711–757
cyclase and ligase and is C-terminal specific to produce Asx-Xaa bonds, with Xaa being a diverse
group of residues. Butelase 1 cyclizes various peptides of plant and animal origin efficiently and is the
fastest peptide ligase known. Linear variants of cyclotides share high sequence identity and contain
a similar knottin scaffold but are biosynthetically unable to cyclize from their precursors [173,182].
Violacin A, a naturally occurring linear cyclotide from Viola odorata, lacks the essential bioprocessing
signal, the C-terminal Asn residue required for cyclization due to the presence of a stop codon earlier
in the C-terminal sequence [177].
Cystine knot α-amylase inhibitors (CKAIs) are plant-derived α-amylase inhibitors originally
isolated from Amaranthus hypocondriacus [183]. They are the smallest family of proteinacous α-amylase
inhibitors among the seven known families [184]. Unlike other knottins, these peptides are rich in
proline residues, with at least one of them existing in a cis- configuration [185]. In recent studies,
Nguyen et al. have isolated an additional three members of CKAIs from the leaves and flowers of
Wrightia religiosa [186] and another five members from the leaves of Allamanda cathartica [187]. These
CKAIs contain 30 residues, two residues shorter than AAI, and share high sequence homology to
each other.
2.4.2. Structure
A common knottin structural motif was initially defined in 1994 as a CK and triple-stranded
β-sheet with a long loop connecting the first and second β-strand [166]. The first two disulfide bonds
(between CysI-CysIV and CysII-CysV), together with their connecting backbone, form an embedded
ring that is penetrated by the third disulfide bond (between CysIII-CysVI). Studies on the subfamily of
squash trypsin inhibitors and PCIs showed that only two disulfide bonds (between CysII-CysV and
CysIII-CysVI) in the knottin scaffold are highly conserved and sufficient to maintain the Cys-stabilized
β-sheet motif [188,189]. It is worthwhile to point out that cystine-knot motifs appear to be common
occurrence in plant CRP-AMPs. They are found, at the primary structure level, in plant defensins and
heveins. However, they differ in the secondary and tertiary structure levels.
Despite the common knottin motif, knottin-type peptides have hypervariable sequences, differing
by their amino acid sequences, the length between CysIII-CysIV and CysIV-CysV, and the linear and
cyclic nature of the peptide backbone (Figures 4 and 5). Owing to the high sequence tolerance of the
knottin scaffold and its diverse biological functions, the knottin scaffold has been used as a template
for drug design. Knottins engineered by substitution of individual or several consecutive amino acids
and/or insertion of additional amino acids without changing the structural integrity have been shown
to provide novel bioactivity or increase stability [190].
Plant knottin-type peptides, particularly the subfamily of cyclotides, have been reported to
possess high thermal, chemical, and enzymatic stability [186,191,192]. Cyclotides are also resistant
to gastrointestinal proteases like trypsin, chymotrypsin, pepsin, or elastase [191,193], and certain
members of cyclotide family can even penetrate the intestinal mucosa excised from rats [194,195].
Disulfide bonds in the knottin scaffold are crucial to its chemical and enzymatic stability based on
studies of various members of cyclotides such as violacin A, kalata B1, and kalata B2 [177,191], whereas
the cyclized backbone is important for exopeptidase resistance. For example, stability tests show that
acyclic vilacin A is resistant to endopeptidase, trypsin, and thermolysin, comparable to cyclotides.
The exoprotease aminopeptidase M cleaves the first two N-terminal residues of violacin A but leaves
the third and fourth residues intact due to their proximity to the disulfide bond. Although no large
differences are observed in the structure and flexibility between cyclotides and their corresponding
linear analogs under standard conditions, simulation studies of linear and circular squash inhibitors
revealed that cyclization increases resistance to high temperatures by limiting structure unfolding [192].
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CKAIs exhibit another method in which these peptides are able to maintain stability against
exopeptidases without a cyclic backbone structure, a pseudocyclic structure [186]. In wrightides,
CKAIs isolated from the plant W. religiosa, the N-terminus and C-terminus are protected by the
formation of disulfide bonds at the ultimate or penultimate residues. Structural analysis showed that
this arrangement allows the termini to loop back to the peptide chain via the disulfide bonds especially
at the N-terminal, forming a pseudocyclic structure. Allotides, CKAIs from A. cathartica, and AAI also
exhibit similar structural features [183,187].
2.4.3. Structure-Function Relationship
With the exception of the cyclotide subfamily, the majority of knottins, are linear. They include
the subfamilies of PAFP-S, Mj-AMPs, insect α-amylase inhibitor, squash trypsin inhibitor CMTI-1 and
carboxypeptidase A inhibitor, as well as several linear homology analogs of cyclotides (violacin A and
panitide L2; Figure 5A,B). Several knottin-type peptides were identified as plant AMPs, such as PAFP-S,
Mj-AMPs, and Psacotheasin (Ps). PAFP-S was identified from seeds of Phytolacca americana and models
the typical knottin structure of antifungal peptides [196]. Mj-AMP1 and Mj-AMP2 extracted from
Mirabilis jalapa seeds have a broad spectrum of antimicrobial activity, being active against all 13 tested
fungal pathogens and two tested Gram-positive bacteria but inactive against Gram-negative bacteria
and cultured human cells. Reduced and non-reduced SDS-PAGE results suggest that Mj-AMP1 and
Mj-AMP2 exist as dimers in their native form [197]. Ps from Psacothea hilaris is a 34 aa antibacterial
peptide with a minimal inhibitory concentration of 12.5–25 μM [198].
Knottin-type peptides act as α-amylase or protease (carboxypeptidase A or trypsin) inhibitors
(Figure 5A,B) and propagate plant defense mechanisms by conferring resistance to insects, pests, and
pathogens [199]. The α-amylase inhibitor identified from A. cathartica and W. religiosa are the smallest
peptide inhibitor of α-amylase activity (30 aa) [186,187]. Wr-AI1 and Wr-AI2, CKAIs from the plant
W. religiosa, have been demonstrated to inhibit the α-amylase activity isolated from Tenebrio molitor
(yellow mealworm), but no inhibitory was observed in fungal or mammalian α-amylase. Similar
α-amylase inhibitory activity was observed from allotide Ac4. However, it was found that allotides
interact with TMA differently from AAI and wrightides due to variation in the N-terminal sequences
and high content of cis-proline. AAI confers pest resistance to plants by targeting insect α-amylase,
but does not interfere with α-amylase from mammalian digestive systems, suggesting that amaranth
seed AAI could be an attractive candidate to endow pest resistance to transgenic plants.
Squash trypsin inhibitors are 27–32 aa knottin-type peptides (e.g., CMTI-II of both pumpkin
Cucurbita maxima and fig leaf gourd Cucurbita ficifolia seeds) [200]. The first squash inhibitor containing
the knottin scaffold was reported from the seeds from squash of the Cucurbitaceae family [201]. Most
squash trypsin inhibitors have linear backbones, except for MCoTI-I and MCoTI-II. However, not all the
protease inhibitor peptides are knottin-type, such as sun flower trypsin inhibitor, a 14 aa cyclic peptide
braced by a central disulfide bond [202]. Another type of knottin with protease inhibitory function
includes carboxypeptidase inhibitors from potatoes [145] and tomatoes [203]. Potato carboxypeptidase
inhibitor (PCI) (39 aa) has long loops instead of the typical β-strands observed in other knottin-type
peptides. It binds the active site of carboxypeptidase A with the C-terminal tail as an active fragment
binding to protease in a stopper-like manner and uses some aromatic residues as secondary binding
sites [204,205].
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Figure 5. Sequences (A) and structures (B) of representative linear knottin-type peptides. The secondary
structure is represented by different colors: cyan-α helix; magenta-β strand; pink-random coil and
yellow-disulfide bonds.
A few linear variants of cyclotides have also been identified from the monocot rice plant Panicum
laxum of the Poaceae family as Panitide L1-12 [175]. Several Panitides are active against Escherichia
coli and cytotoxic to HeLa cells. The other subgroup of knottin-type peptides is cyclotides, including
typical cyclotides and cyclic knotttins such as MCoTIs (Figure 6A,B). Cyclotides are 29–37 aa in length
with a CK arrangement of three disulfide bonds which are widely involved in plant defense, as
deduced from their activity against insects, nematodes, and mollusks [206–208]. The first cyclotide was
identified in 1973 as an uterotonic agent from the African plant Oldenlandia affinis, a main component of
medicinal tea used to accelerate childbirth [209]. Cyclotides have potential pharmacological functions,
considering their antimicrobial, anti-HIV, anti-tumor, and neurotensin activities [22]. Cyclotides are
found mainly in Rubiaceae (coffee), Violaceae (violet) and families. They are highly variable in sequence,
but conserved in structure, and are divided into two types: Möbius and bracelet. Möbius types contain
one cis-Pro in loop 5 and a twist in the cyclic backbone, while the bracelet type does not [210]. Yet, both
types do not significantly differ from one another in the general scaffold structure.
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Figure 6. Sequences (A) and structures (B) of representative cyclic knottin-type peptides. The
secondary structure is represented by different colors: magenta-β strand; pink-random coil and
yellow-disulfide bonds.
Antimicrobial activity of cyclotides was first reported for four synthetically produced cyclotides
isolated from coffee plants, kalata B1, circulin A, circulin B, and cyclopsychotride [211]. Subsequently,
more cyclotides were reported to have antimicrobial activity. Cyclotides kalata B1 and B7 (29 aa
each) from the tropical plant Oldenlandia affinis display antibiotic effects both in salt and salt-free
medium [212]. While the 30 aa cycloviolacin O2 from Viola odorata is resistant to Gram-negative
bacteria [213], cliotides cT1 and cT4 from Clitoria ternatea show antimicrobial activity against
Gram-negative bacteria and cytotoxicity to HeLa cells [173]. Hedyotide B1, on the other hand, is
a positively charged bracelet cyclotide from Hedyotis biflora, rich in aromatic residues and active against
both Gram-positive and Gram-negative bacteria [214].
MCoTI-I and MCoTI-II are two squash trypsin inhibitors from Momordica cochinchinensis that
contain a cyclized backbone [215] and have large sequences differences from typical cyclotides,
as discussed above (Figure 6A). The C- to N-cyclization in MCoTI-II has no significant impact
on the protein structure, though cyclized squash inhibitors are postulated to be less sensitive to
exopeptidases [216]. Based on structural studies of MCoTI-II in free and complex forms, Heitz revealed
that the cyclization and active site loops of MCoTI-II are flexible in solution, but converge into a single,
well-defined conformation upon binding trypsin [217]. Compared to previously defined cyclotides,
such as kalata B1 or circulin A, MCoTI-I and MCoTI-II share similar motifs wherein two disulfide
bonds stabilize the β-sheet but differ greatly in their amino acid sequences and in loops 3 and 6 [217].
Furthermore, MCoTIs have an entirely charged surface versus the amphipathic nature of circulin
A. These differences may explain functional disparities such as squash inhibitor MCoTIs having no
antibacterial activity, unlike circulins and kalata B1.
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2.4.4. Mechanism of Action
Generally, knottin-type peptides with membranolytic functions are amphipathic in nature like
other AMPs, a characteristic necessary for membrane interactions which implement their antimicrobial
effects. For example, the surface plots of PAFP-S and kalata B1 show hydrophobic patches surrounded
by several hydrophilic residues (Figure 2E,F). However, in contrast the strongly cationic-charged
thionins and plant defensins, most cyclotides are unlikely to have a strong electrostatic interaction with
membranes since they are normally weakly positive or neutral at physiological pH (Figure 2F) [218].
The interaction of cyclotides with membranes has been previously investigated in vitro using the
detergent dodecylphosphocholine [219]. In this study, the structure of kalata B1 was not significantly
altered upon binding the detergent; binding was largely mediated by the strong hydrophobic
interactions between cyclotide loops and lipid tails of the detergent, as well as favored by the weak
interactions between positively charged kalata B1 and the polar head of the detergent However, similar
studies on kalata B2 and cycloviolacin O2 suggest that different cyclotides have different membrane
binding modalities because of the varied location of hydrophobic patches in cyclotides [220].
2.4.5. Knottin Scaffold in Pharmaceutical Engineering
The knottin scaffold is an excellent candidate for peptide-based pharmaceutical engineering [221]
as a result of several features: (1) remarkable proteolytic, thermal, and chemical stability due to the CK
and backbone cyclization of cyclotides; (2) feasibility of chemical synthesis due to small size; and (3)
excellent sequence tolerance due to sequence variation in loop regions.
Synthesis of cyclotides and cyclic knottins. To exploit cyclotides and cyclic knottins for agricultural
and medical use, it is necessary to develop efficient methods for their production. Methods employed to
date include solid phase peptide synthesis [9,211,222–227], as well as chemo-enzymatic and biological
methods using modified inteins [210–213] and Asn-endoprotease such as butelase-1 [228–231].
Irrespective of the means of its preparation, a linear precursor containing a macrocycle sequence
is first generated, followed by a macrocyclizaion step to give a head-to-tail backbone-cyclized
compound. The head-to-tail cyclization poses a substantial hurdle and challenge because it is highly
entropy-disfavored due to the great distance between the N- and C-termini, but has been solved
elegantly by the discovery of the thia zip cyclization reaction in 1997 [232]. Thia zip cyclization is an
entropic reaction, characterized by a series of entropic ring expansion by making use of the multiple Cys
residues in a CRP-linear precursor functionalized with an N-terminal Cys and a C-terminal thioester.
This construct enables a thiol-thioester to form a thiolactone and then thiol-thiolactone exchange
reactions in tandem, ending with a head-to-tail thiolactone which spontaneously forms a peptide bond
through an S, N-acyl shift. In 1997, the first report on both Möbius and bracelet cyclotides have been
synthesized by the thia zip reaction and regio-selective disulfide bond formation to guarantee the
correct knottin scaffold [225]. Since then, many successful syntheses of cyclic CRPs based on thia zip
cyclization have been reported. We have recently reviewed the progress of macrocyclization relevant to
cyclotides and cyclic knottins [9]. Since 2012, new advances based on amide-to-amide transpeptidation
reaction have made preparation of cyclotides, cyclic knottins and other macrocycles possible through
chemical or biological means [181].
2.5. α-Hairpinin Family
The α-hairpinin family is composed of Lys/Arg-rich plant defense peptides. α-Hairpinin AMPs
share a characteristic C1XXXC2-(X)n-C3XXXC4 motif in their primary sequence and, more importantly,
a helix-loop-helix secondary structure (Figure 7A,B). The helix-loop-helix or α1-turn-α2 motif has both
α-helices oriented antiparallel and is stabilized by two disulfide bonds in the tertiary structure. This
structure is a surprise finding in plant CRPs, and the α-hairpinin family is structurally distinguished
from the β-strand decorated CRP-AMPs, such as thionins, defensins, and knottin-type peptides.
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Thus far, only a limited number of α-hairpinin AMPs have been reported, including MBP-1,
MiAMP2s, Ec-AMP1, Luffin P1, VhT1, BWI-2c, Tk-AMP-Xs, and Sm-AMP-X. MBP-1, a 33 aa peptide
isolated from the maize kernel, inhibits spore germination and hyphal enlongation of several plant
pathogenic fungi and bacteria in vitro [233]. MiAMP2 peptides (50 aa) isolated from the nut kernel of
Macadamia integrifolia inhibit various plant pathogenic fungi in vitro [234]. They are produced from a
666 aa precursor protein homologous to vicilin 7S globulin. Ec-AMP1 from the seeds of the baryard
grass Echinochloa crus-gali was reported to have antifungal activity against several phytopathogenic
fungi with an IC50 = 1–10 μM. A confocal microscopy study showed that Ec-AMP1 binds the fungal
conidia surface and then internalizes and accumulates in the cytoplasm without disturbing membrane
integrity [235].
Tk-AMP-X1 and Tk-AMP-X2 extracted from the wheat Triticum kiharae and Sm-AMP-X from seeds
of the chickweed Stellaria media are another two α-hairpinin members with antifungal activity [236,237].
Both are produced from multimodular precursor proteins. The Tk-AMP-X-related sequences have
been shown to be widespread in crops such as barley, rice, and maize, which suggest the importance of
this type of plant defense peptide. VhT1 from the seeds of Veronica hederifolia and BWI-2c from seeds of
the buckwheat Fagopyrum esculentum represent a new family of trypsin inhibitors with an α-hairpinin
structure and act as defensive peptides in plants [238,239]. Luffin P1, extracted from the seeds of the
sponge gourd Luffa cylindrical, has been shown to have anti-HIV-1 activity in HIV-1-infected C8166
T-cell lines in vitro [240]. This study proposed that Luffin P1 displays a novel inhibitory mechanism
owing to its charge complementation with viral and cellular proteins.
Figure 7. Sequences (A) and structures (B) of representative α-hairpinins. The secondary structure is
represented by different colors: cyan-α helix; pink-random coil and yellow-disulfide bonds.
2.6. Lipid Transfer Proteins
Plant lipid transfer proteins (LTPs) and snakins (described in the following section) are two
families of CRP-AMPs with MW >7 kDa, and are considered proteins. LTPs are cationic proteins of
approximately 70 and 90 aa with eight Cys residues. They are distinguished from other CRP-AMPs by
their lipid transfer activity, in which they bind a wide range of lipids including fatty acids (C10–C14),
phospholipids, prostaglandin B2, lyso-derivatives, and acyl-coenzyme A. Consequently, they are also
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called non-specific LTPs [4,241,242]. LTPs can inhibit growth of fungus and some bacterial pathogens
and are involved in the plant defense system. LTPs are subdivided into LTP1s (MW = 9 kDa) and
LTP2s (MW = 7 kDa) based on their molecular mass.
2.6.1. Occurrences, Distribution, and Biosynthesis
Plant LTPs have been identified in various species, such as seeds of the radish, barley, maize,
Arabidopsis, spinach, grapevine, wheat, and onion [4,241–246]. They are synthesized as precursors
containing a signal peptide of 20–25 aa and a mature protein with eight Cys [247].
2.6.2. Structure
Although LTPs vary in their primary sequence, they share a defining structural feature, a
conserved inner hydrophobic cavity surrounded by α-helices (Figure 8A,B). Surface plots of LTP1
and LTP2 representatives are illustrated in Figure 2G, H. LTP1s and LTP2s share the same Cys
signature and similar tertiary fold, but vary in amino acid sequence and disulfide bonding at the CXC
motif [248,249]. LTP1 contains four α-helices stabilized by four disulfide bonds (between CysI-CysVI,
CysII-CysIII, CysIV-CysVII, and CysV-CysVIII) and a flexible C-terminal coil. In contrast to LTP1, LTP2
contains three extended helices, two single-turn helices, and four disulfide bonds between CysI-CysV,
CysII-CysIII, CysIV-CysVII, and CysVI-CysVIII (Figure 8A) [249,250]. The helices in LTP1 and LTP2
form a hydrophobic cavity which accommodates a variety of lipids [251–254].
Figure 8. Sequences (A) and structures (B) of representative lipid transfer proteins. The secondary
structure is represented by different colors: cyan-α helix; pink-random coil and yellow-disulfide bonds.
LTP1s and LTP2s have a conserved structure reported in rice [253,255,256], wheat [257,258],
barley [259,260], maize [261,262], lentils [263], and mung beans [264]. Their lipid-binding properties
can be modulated by subtle changes in their conserved global structure, as evidenced by structural and
functional differences of LTP1s in tobacco, wheat, and maize [265]. Mutagenesis studies have revealed
that different residues forming the hydrophobic cavity of LTP2 play various roles in maintaining
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structure and conferring function [266]. Although LTP2 is found to have a similar but smaller
hydrophobic cavity compared to LTP1 [249,250,253,254,259], it is quite flexible and can accommodate
voluminous sterol molecules [267].
2.6.3. Structure-Function Relationship
Plant LTPs inhibit the growth of bacterial and fungal pathogens to different degrees [243,246,268].
Transgenic expression of barley LTP2 in tobacco and Arabidopsis thaliana leaves endows higher tolerance
to bacterial pathogens [269]. The antifungal activity of LTPs from Brassica and mung beans is found to
be thermally, pH-, and pepsin/trypsin treatment-stable [268].
Ace-AMP1 (onion LTP1; Figure 8A) isolated from onion seeds, exhibits a higher antimicrobial
activity than the LTP extracted from radish seeds [89,243]. Ace-AMP1 shares a similar global fold as
LTP1s, but does not possess a continuous cavity for lipid binding nor does it bind fluorescently labeled
phospholipids in solution [252]. In addition, Ace-AMP1 does not exhibit characteristic LTP behavior,
such as transferring lipids between membranes in vitro. While DIR1 from Arabidopsis thaliana shares
similar structural and lipid binding properties with plant LTP2, it is distinguished by its acidic pI and
ability to bind two long-chain fatty acid derivatives in its cavity, suggesting DIR1 could be a new type
of plant LTP [270]. The functions of plant LTPs, such as defensive signaling, cuticle deposition and
plant defense, have been previously reviewed by Yeats and Rose [271].
2.6.4. Mechanism of Action
Initially, LTPs were reported to facilitate lipid transfer between membranes of vesicles or
organelles in vitro [272,273]. However, later discoveries have shown that LTP1s are extracellular
cell wall proteins, making in vivo intracellular lipid transfer activity unlikely [274,275]. Thus, LTPs
promote membrane permeabilization in pathogens rather than host cells [246,276]. Although structural
studies have shown that LTPs can “cage” lipid molecules in their hydrophobic cavity, a detailed
mechanism of antimicrobial activity mediated by lipid transport remains unclear [271].
2.7. Snakins
Snakin-1 (63 aa) and snakin-2 (66 aa) are AMPs with 12 Cys isolated from potato tubers (Solanum
tuberosum) [277,278] found to be active against fungal and bacterial pathogens at 1–20 μM. Snakins
induce the aggregation of both Gram-positive and Gram-negative bacteria and therefore, are recognized
as components of constitutive and inducible plant defense barriers. The structure of snakin is predicted
to have two long α-helices with disulfide bonds between CysI-CysIX, CysII-CysVII, CysIII-CysIV,
CysV-CysXI, CysVI-CysXII, and CysVIII-CysX, which demonstrates a small degree of structural
similarity to thionins and α-hairpinins [279].
A 64 aa homolog of snakin-2, also containing 12 Cys, was identified from the French bean to be
a domain of a 42 kDa Pro-rich protein with chitin-binding ability that is involved in plant-pathogen
interactions [280]. Snakin-Z (31 aa), identified from the fruit of Zizyphus jujuba, contains a sequence
similar to the C-terminal region of Snakin-2. It has antimicrobial activity against different bacterial and
fungal strains at minimal concentrations (7.65–28.8 μg/mL) [281].
2.8. Other Plant CRP-AMPs
In addition to the different classes of CRP-AMPs mentioned above, there are several unclassified
Cys-containing AMPs, such as Ps-AFP1, Ib-AMPs, Pp-AMPs, ToAMPs, and MiAMP1 that contain two
to eight Cys. Ps-AFP1 (38 aa) from the pea Pisum sativum root contains two disulfide bonds between
CysI-CysII and CysIII-CysIV, has been proposed to adopt a novel αβ-trumpet fold, and is capable of
binding the cell wall of fungi [282]. Ib-AMPs1-4, purified from the seed of Impatiens balsamina, are
four basic 20 aa peptides encoded by a single transcript. Ib-AMPs represent a novel class of AMPs
that lack homology to other peptides [283,284]. They contain four Cys which share a common CC
and CXXXC sequence motif and form two disulfide bonds between CysI-CysIII and CysII-CysIV. The
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structure of Ib-AMP1 is well-defined, with loops and turns stabilized by two disulfide bonds [285].
Ib-AMPs can inhibit the growth of a range of fungi and Gram-positive bacteria but is not cytotoxic to
most Gram-negative bacteria or cultured human cells. Studies of Ib-AMP1 analogs without disulfide
bonds have shown these bonds are not essential for its antimicrobial activity, and that Ib-AMP1 targets
intracellular components instead of bacterial cell membranes [286].
Pp-AMP1 and Pp-AMP2 are two chitin-binding AMPs from the shoots of the Japanese bamboo
Phyllostachys pubescens that have antimicrobial activity against pathogenic bacteria and fungi [287].
Pp-AMP1 contains four Cys in its 44 aa sequence, while Pp-AMP2 (45 aa) is composed of six Cys.
Although they share relatively high sequence homology with thionins, especially the N-terminal
continuous CC motif, their differences in the C-terminal sequence and Cys distribution pattern do not
suggest Pp-AMPs are thionins. ToAMPs1-4 are four basic 38–44 aa AMPs identified from Taraxacum
officinale flowers that have antifungal and antibacterial activity [288,289]. Sequence analysis has shown
that ToAMP1, ToAMP2, and ToAMP4 possess a novel peptide motif of six Cys with a –CC– motif
between CysII and CysIII, while ToAMP3 has eight Cys with a –CC– motif between CysVI and CysVII.
MiAMP1 is a 76 aa basic AMP identified from the nut kernel of Macadamia integrifolia. MiAMP1
inhibits several plant microbial pathogens in vitro [290], yet presents no sequence homology with other
plant AMPs and has a β-barrelin structure. The β-barrelins contain eight β-strands forming two Greek
key motifs that are stabilized by three disulfide bonds. MiAMP1 has a structure similar to that of a
yeast killer toxin from Williopsis mrakii, which inhibits β-glucan synthesis and thereby disturbs the cell
wall of yeast. The structural similarity between these two peptides suggests a similar antimicrobial
mode of action.
2.9. Non-CRP Plant AMPs
Although the majority of known plant AMPs are stabilized by multiple disulfide bonds, exceptions
include Cn-AMPs, Cr-ACP1, as well as GRPs Pg-AMP1 and shepherins. All of these plant AMPs either
do not contain Cys or contain only one and thus, possess high structural flexibility. Cn-AMP1 is a 9 aa
Cys-free AMP identified from green coconut (Cocos nucifera) water with “promiscuous” activity, as it is
antibacterial, antifungal, and immune stimulatory [291]. Cr-ACP1 is a 9 aa AMP from the seeds of
Cycas revoluta with pro-apoptotic and antimicrobial activities [292]. A previous bioinformatics study
suggests that these Cr-AMP1 activities are likely mediated by hydrogen bond-mediated DNA binding
within cells.
Pg-AMP1 is a 55 aa GRP extracted from seeds of the guava Psidium guajava. It contains 14 Gly
and only one Cys [293] and inhibits the growth of both Gram-positive and Gram-negative bacteria,
pathogens involved in urinary and gastro-intestinal infections [294]. Shepherins I and II are Gly- and
His-rich AMPs identified from the roots of Shepherd’s Purse, Capsella bursa-pastoris [295]. Shepherin I
(28 aa) and shepherin II (38 aa) are produced from a single 120 aa propeptide precursor composed of
an N-terminal signal peptide, shepherin I, a linker dipeptide, shepherin II, and a C-terminal peptide.
Both exhibit antimicrobial activity against Gram-negative bacteria and fungi with an IC50 of 2.5–8
μg/mL.
2.10. Mechanism of AMP Action
AMPs are generally moderate-to-large size, positively charged, amphipathic CRPs. Structurally,
AMPs fall into diverse and distinct groups (Table 1; Figure 2), including α-helical peptides (α-hairpinin
family and lipid transfer proteins), β-sheet peptides (hevein and knottin-type peptides) as well as
mixed α-helical and β-sheet peptides (thionins and plant defensins). Generally, the mechanism of
AMP interaction with microbes is believed to be associated with cell lysis due to membrane disruption
and/or peptide penetration of lipid membranes followed by attack of intracellular targets [14]. Various
mechanistic models have been proposed, such as the barrel-stave model, toroidal pore model, and
carpet model, in previous reviews by Barbosa, Rahnamaeian, and Nawrot [14,296,297]. Besides
perturbing the lipid membrane, AMPs can also form ion channels, which can induce ion leakage
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(e.g., K+) in addition to other intracellular contents [298,299]. All of these actions lead to inhibition of
microbial cell growth and cell death.
3. Conclusions and Perspective
A striking feature of plant AMPs is that the majority are families of CRPs, with each family
sharing a characteristic motif. In turn, these cysteinyl motifs enable plant AMPs to organize into
specific families with conserved structural folds that enable sequence variation of non-Cys residues
encased in the same scaffold within a particular family to play multiple functions. This evolvable
phenomenon is particularly evident in the family of knottins, and to a lesser extent, in the defensins.
Knottins are known to play diverse roles, being antimicrobial, insecticidal, enzyme inhibitory, and
agonistic/antagonistic to hormones. The ability of plant AMPs to tolerate hypervariable sequences
using a conserved scaffold mimic is, in certain respects, similar to that of immunoglobulins, which
recognize diverse targets by varying the sequence of complementary binding regions.
The presence of multiple disulfide bonds in a particular CRP family gives plant AMPs a
compact structure and a specific scaffold. In turn, they confer stability against thermal and chemical
denaturation and enzymatic degradation. These properties bode well for developing plant AMPs
as potential therapeutics and for protection of crops through transgenic methods [300,301]. A
cystine-stabilized structure opens the possibility to use it as a stable scaffold for grafting biological
active peptides sequences to intracellular targets. Specifically, the backbone portions between cysteine
residues can be modified to incorporate bioactive peptides which are normally unstable against
digestive enzymes and other physiological conditions [302,303]. This technique has successfully
been applied to graft bradykinin B1 antagonists onto kalata B1 as an orally active analgesic [221],
human kallikrein-related peptidase 4 inhibitor onto sunflower trypsin inhibitor-1 [228], angiogenic
peptides, laminin and osteopontin, onto Momordica cochinca cochinchinensis trypsin inhibitor-II [304]
and melanocortin onto kalata B1 [305]. More importantly, these grafted peptides have been shown to
possess the same biological property with similar potency as compared with the original bioactive
peptides, as well as resistance to digestive enzymes due to the robust scaffold. In addition, plants
AMPs, in particular defensin, have been shown to protect transgenic plants against microorganism
infection. Expression of alfalfa antifungal peptide defensin, from the seeds of Medicago sativa, in
transgenic potato plants has been found to provide resistance against phyto-pathogen Verticillium
dahilae [77,306].
AMPs offer several advantages as compared to current antibiotic drugs as they represent a
naturally occurring defense mechanism that has been used by plants for thousands of years in
combating external pathogenic challenges. Most of the recent studies included in this review were
focused on the anti-fungal and anti-bacterial effect of AMPs, while the anti-viral property of AMPs
was still under-explored. Further investigation in tackling this issue is urgently warranted. Since plant
AMPs have been identified in only a small fraction of plants, it is anticipated that many more plant
AMPs, both in molecular form and sequence, will be forthcoming.
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Abstract: Defensins are the most widespread antimicrobial peptides characterised in insects. These
cyclic peptides, 4–6 kDa in size, are folded into α-helical/β-sheet mixed structures and have a
common conserved motif of three intramolecular disulfide bridges with a Cys1-Cys4, Cys2-Cys5
and Cys3-Cys6 connectivity. They have the ability to kill especially Gram-positive bacteria and
some fungi, but Gram-negative bacteria are more resistant against them. Among them are the
medicinally important compounds lucifensin and lucifensin II, which have recently been identified in
the medicinal larvae of the blowflies Lucilia sericata and Lucilia cuprina, respectively. These defensins
contribute to wound healing during a procedure known as maggot debridement therapy (MDT)
which is routinely used at hospitals worldwide. Here we discuss the decades-long story of the
effort to isolate and characterise these two defensins from the bodies of medicinal larvae or from
their secretions/excretions. Furthermore, our previous studies showed that the free-range larvae of
L. sericata acutely eliminated most of the Gram-positive strains of bacteria and some Gram-negative
strains in patients with infected diabetic foot ulcers, but MDT was ineffective during the healing
of wounds infected with Pseudomonas sp. and Acinetobacter sp. The bactericidal role of lucifensins
secreted into the infected wound by larvae during MDT and its ability to enhance host immunity by
functioning as immunomodulator is also discussed.
Keywords: antimicrobial peptide; insect defensin; lucifensin; maggot therapy; Lucilia sericata;
Lucilia cuprina; peptide isolation; peptide identification
1. Introduction
Over the course of their evolution, insects have developed an amazing resistance to bacterial
infection, resulting in exceptional adaptation to a variety of natural environments often considered
rather unsanitary by human standards. Insects respond to bacterial challenge or injury by rapid
production of antimicrobial peptides (AMPs) that have a broad spectrum of activity against
Gram-positive and Gram-negative bacteria and fungi. These peptides are evolutionary conserved
components of the host’s innate immune system that form the first line of defence against infections
and have been identified in almost all classes of life. Among the more than 2,000 AMPs listed in
the Antimicrobial Peptide Database [1], peptides isolated from insects comprise the most abundant
group. AMPs are synthesised in the fat body (the equivalent of the mammalian liver), epithelial cells,
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and in the certain cells of the haemolymph (the equivalent of mammalian blood) and then spread
by the haemolymph over the entire body to fight infection [2]. The majority of these peptides belong
to the class of cationic AMPs of molecular masses below 5 kDa [3]. Upon interacting with biological
membrane or environments that mimic biological membranes, such as artificially made liposomes or
sodium dodecyl sulfate, most are able to fold into highly amphipathic conformations with separated
areas rich in positively charged and hydrophobic amino acid residues on the molecular surface [3–5].
The frequent occurrence of positively charged amino acid residues (Arg, Lys) in their molecules allows
them to interact with the anionic phospholipids of bacterial membranes. This is followed by integration
of the peptides into the lipid bilayer and disruption of the membrane structure via different modes that
lead to leakage of cytoplasmic components and cell death [4–6]. Some studies have revealed that the
killing process may proceed with relatively little membrane disruption but occurs rather by interfering
with bacteria metabolism or interactions with putative key intracellular targets [7]. In contrast to
conventional antibiotics, AMPs do not appear to induce microbial resistance and require only a short
time to induce killing [6].
The AMPs isolated from insects may be classified on the basis of their sequence and structural
features into three categories: (i) linear peptides which can form an α-helical structure and do not
contain cysteine residues, such as cecropins; (ii) cyclic peptides containing disulfide bridges of which
defensins are the most typical example and (iii) linear peptides with noticeable high content of one or
two amino acid residues, mostly proline and/or glycine residues (pyrrhocoricins and diptericins) [2].
In this study, we will focus on the lucifensins [8,9]—two almost identical cyclic peptides of 40 amino
acids residues and three intramolecular disulfide bridges belonging to the widely distributed family of
insect defensins [10,11]. Lucifensin are the key antimicrobial peptides involved in the defence system
of the blowfly larvae Lucilia sericata and Lucilia cuprina. These fly larvae are routinely used at hospitals
worldwide during a procedure known as maggot debridement therapy (MDT) [12,13].
2. Insect Defensins
The first insect defensins were isolated from an embryonic cell line of Sarcophaga peregrina (flesh
fly) [14] and from the haemolymph of immunised larvae of the black blowfly Phormia terranovae [15].
Since then, more than 70 defensins have been identified in various arthropods such as spiders, ticks,
scorpions and in every insect species of the orders Diptera, Lepidoptera, Coleoptera, Hymenoptera,
Hemiptera and Odonata investigated to date [10,11]. The defensins isolated from insects are 33 to 46
amino acid residues long with a few exceptions, such as the N-terminally extended defensin from the fly
Stomoxys calcitrans [16] and C-terminally extended defensin found in the bee [17] and bumblebee [18].
They show sequence similarities ranging from 58 to 95% [2]. They may be further classified in two
sub-families according to their in vitro activity against bacteria or filamentous fungi [11]: antimicrobial
defensins that possesses activity against Gram-positive bacteria, including human pathogens, but
are less effective against Gram-negative bacteria and fungi, and antifungal defensins that are mainly
effective against filamentous fungi. Structurally, insect defensins possess an N-terminal flexible loop,
a central α-helix and a C-terminal anti parallel β-sheet as has been determined by two-dimensional
1H-NMR spectroscopy carried out on isolated Sarcophaga peregrina defensin [19] and on a recombinant
Phormia terranovae defensin [20]. The antimicrobial defensins contain six cysteine residues engaged in
a characteristic conserved motif of three intramolecular disulfide bridges connected in a Cys1-Cys4,
Cys2-Cys5 and Cys3-Cys6 pattern. On the other hand, the antifungal defensin drosomycin from
Drosophila encompasses an additional short terminal β-strand and four disulfide bridges [21]. With the
exception of royalisin, the defensin of the royal jelly of the honeybee [17] and bumblebee defensin [18],
the C-terminal residue of insect defensins is not amidated. Although insect defensins were originally
thought to be structurally similar to mammalian defensins, their three-dimensional structure and
disulfide bridges pattern are different.
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3. Maggot Therapy
Maggot debridement therapy is a controlled application of cultured sterile larvae of the flies
L. sericata or L. cuprina to an infected chronic non-healing wound, especially in patients with impaired
healing due to underlying disorders (e.g., diabetes and cardiovascular disease). The maggots gently
and completely remove necrotic tissue by mechanical action (debridement) and by proteolytic digestion
over 3–5 days of application. They rapidly eliminate infecting microorganisms which pass through
their digestive tract [22], stimulate wound granulation and repair and thus enhance the healing
process [12,13]. In addition, the larvae both secrete (by salivary glands) and excrete into the wound
numerous substances including antimicrobial compounds, and alkalise the wound environment [23].
Since the introduction of maggot therapy into clinical practice by Baer [24], many researchers,
influenced by successful therapeutic experience, have been focusing on the identification of
antimicrobial agents secreted/excreted by maggots in the infected wound. It is quite surprising
that up to now only a few active compounds have been identified in maggot excretions/secretions (ES)
with explicitly determined chemical structures. These compounds include low molecular mass organic
compounds and recently discovered insect defensins—lucifensins [8,9].
4. The Brief History of the Search for Antimicrobial Agents in Medicinal Larvae
Starting in the 1930s, researchers began to investigate the underlying mechanisms which may be
responsible for some of the beneficial effects of maggot therapy. The main focus of interest has been
examining the antimicrobial activity of the components of larval secretions and faecal waste products.
In one of the initial studies of Simmons [25], published in 1935, it was found that the excretions
obtained from the washings of the non-sterile L. sericata maggots exhibited considerable antimicrobial
activity against several species of pyogenic bacteria which were killed during five- to ten-minutes of
exposure. The activity of the excretion was not destroyed by autoclaving. In the research carried out
two decades later by Pavillard and Wright [26], the washings of maggots combined with a suspension
of their excretions were fractionated using paper chromatography. The active fraction was active
against S. aureus. By means of a cellulose column and a modification of the chromatography technique,
it was possible to obtain relatively pure samples of the antibiotic fraction. A series of injections of this
preparation protected mice from the lethal effects of intraperitoneal inoculation with pneumococci.
The final purification of this active compound was never implemented. Subsequent research done
at several laboratories has demonstrated that larval excretions/secretions (ES) of L. sericata contain a
variety of alkaline components inhibiting bacterial growth and that the pH increase provides optimal
conditions for the activity of larvae-secreted proteolytic enzymes that liquidise necrotic tissues [23].
It also has been proposed that larvae release antimicrobial ingredients into the wound in response
to infection. Some of these ingredients are bacteriostatic low molecular weight compounds such as
p-hydroxybenzoic acid, p-hydroxyphenylacetic acid, proline dioxopiperazine [27] or an “enigmatic
compound” of the empirical formula C10H16N6O9 known as the antibiotic seraticin [13]. The other
compounds may possibly be antimicrobial peptides originating from the larval immune system which
are released into the wound and thus contribute to wound healing [28,29]. These peptides belong to
the groups of insect defensins, cecropins and diptericins [10,11].
Since 2000, several research groups have been aiming to isolate and characterise such antimicrobial
peptides from the ES by utilising current methods of protein purification. In the laboratory of Bexfield [29],
the ES of maggots was fractionated using an ultrafiltration device with a 10 kDa and 500 Da molecular
weight cut-off membrane generating three fractions of molecular weights: >10 kDa, 500 Da–10 kDa and
<500 Da. The activity against S. aureus was detected in <500 Da fraction and 500 Da–10 kDa fraction,
but not in the fraction above 10 kDa. Even though these fractions were investigated in further detail
regarding their physicochemical properties and antimicrobial activities [30], their constituents were
not identified. The antimicrobial properties of L. sericata larval ES and the attempts to characterise
its components were independently studied in several other laboratories [31,32]. For example, the
study of Kerridge et al. [32] revealed in the secretions the presence of small (<1 kDa) antimicrobial
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factors active against Gram-positive bacteria such as S. aureus, including both methicillin-resistant
S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA), and Streptococcus pyogenes. However,
Gram-negative Pseudomonas aeruginosa was less sensitive. This active factor passed through the filter
of the 3 kDa cut-off when the secretion was fractionated by ultrafiltration procedure. In this case,
anti-MRSA activity was also detected in the retenates of the 10 kDa and 5 kDa filters indicating
the presence of at least one additional larger antimicrobial agent. The authors concluded that the
activities in the secretions possess characteristics consistent with insect antimicrobial peptides and are
considered to be of low molecular weight, highly stable and a systemic part of the larva [32].
In 2013, Chinese researchers described the isolation of antimicrobial protein from an extract of the
homogenate of L. sericata larvae using an ultrafiltration procedure [33]. The crude material obtained
was named “antibacterial protein from maggots” (MAMP). MAMP demonstrated inhibitory activity
against both standard strains and clinically isolated antibiotic-resistant strains of S. aureus in vitro.
The topical use of MAMP effectively decreased the viability of S. aureus and promoted wound healing
in an S. aureus mouse skin infection model. Although the authors claim the molecular weight of MAMP
to be lower than 10 kDa, neither the chemical structure nor other specific identification of this “protein”
was published.
Russian researchers [34] detected several inducible antimicrobial compounds by the
“chromato-mass-spectrometry” method in the L. sericata larvae haemolymph and in the exosecretion
released by the larvae. According to the authors, some of these compounds correspond to insect defensins
and diptericins. Particularly, the molecular mass 4,117 Da of the peptide detected in the haemolymph
matches well the molecular mass of lucifensin [8]. All the other compounds were identified solely based
on their molecular masses, but their primary structures were not determined.
5. Lucifensin—The Defensin from L. sericata
5.1. Purification and Sequence Determination
Since 2007, we have been engaged in the identification of L. sericata AMPs by focusing on insect
defensins. We have aimed to detect defensins in larval ES as well as different parts of the larval bodies,
purify them and determine their primary structure. In our experience, it is evident that only the use of
modern separation techniques such as high performance liquid chromatography (HPLC) as a part of
the purification procedure may result in the discovery of the sought peptides.
The physicochemical properties of insect defensins (medium size, cationic molecule, contains
disulfide bridges) influenced us in the selection of the purification procedure. Starting with the
extractions of L. sericata larval guts, a strongly acidic acetonitrile/water/0.5% trifluoroacetic acid
mixture, which provides good solubility for cationic peptides while protecting its stability against
enzymatic digestion and disulfide bridges reshuffling, was the extraction solvent of choice. Successive
ultrafiltration of crude extract, the size exclusion HPLC and following reversed phase HPLC (RP-HPLC)
applied as the final steps of the purification procedure resulted in the peptide of the purity satisfactory
for sequencing by Edman degradation [8].
The Edman degradation using 40 cycles yielded the following N-terminal sequence:
Ala-Thr-X-Asp-Leu-Leu-Ser-Gly-Thr-Gly-Val-Lys-His-Ser-Ala-X-Ala-Ala-His-X-Leu-Leu-Arg-Gly-
Asn-Arg-Gly-Gly-Tyr-X-Asn-Gly-Arg-Ala-Ile-X-Val-X-Arg-Asn, assuming that all six undetermined
amino acid residues (X) were cysteines. The molecular mass of this defensin measured by ESI-QTOF
MS was determined to be 4113.6. This was in good agreement with the calculated value of 4113.89,
based on the sequence determined by Edman degradation and assuming that the six cysteine residues
form three disulfide bridges [8]. Our results showed that L. sericata defensin, which we term lucifensin,
differs from Phormia terranovae defensins A and B and from Sarcophaga peregrina sapecin by five amino
acid residues (Val11, Lys12, Arg33, Ala34, and ILe35).
Knowing the properties of lucifensin, we were able to detect its presence in the extracts of other
larval tissues such as the salivary glands, fat body, haemolymph as well as in the larval ES [8]. However,
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no antimicrobial peptide from other families such as cecropins, diptericins or Pro-rich peptides was
detected in the frame of our study.
5.2. Synthetic Lucifensin
In 2011, we reported a total chemical synthesis of lucifensin using the methodology of solid phase
peptide synthesis [35]. In the first step of the synthesis, we prepared the linear peptide of 40 amino acid
residues containing six cysteines in the sequence. Oxidative folding of this linear peptide yielded a
cyclic peptide with the disulfide bridges formed between Cys3-Cys30, Cys16-Cys36 and Cys20-Cys38;
this disulfide bridges pattern corresponds to that of natural lucifensin.
Synthetic lucifensin was highly active against M. luteus and Bacillus subtilis with MIC values of 0.6
and 1.2 μM, respectively, while lower but significant activity was observed against S. aureus with MIC
value of 41 μM. No activity was detected against E. coli, thus confirming the generally recognised fact
that insect defensins are more active against Gram-positive than Gram-negative bacteria. The peptide
showed slight antifungal activity against C. albicans (MIC = 86 μM) and was not haemolytic against
human red blood cells [35]. These findings corresponded to the clinical effect of maggot therapy and
supported our hypothesis that lucifensin is the long-sought antimicrobial factor of medicinal maggots.
To confirm the importance of disulfide bridges for its activity and structure, we synthesised three
lucifensin analogs, each of which was cyclised through only one native disulfide bridge in different
positions and having the remaining four cysteines substituted by alanine [35]. The analog cyclised
through a Cys16-Cys36 disulfide bridge showed weak antimicrobial activity, while the other two
analogs containing one disulfide bridge were inactive. These results indicate that the presence of
disulfide bridges in lucifensin is essential for its antimicrobial activity as it is necessary for preserving
its three-dimensional structure. The synthesis of truncated lucifensin at the N-terminal by 10 amino
acid residues resulted in an almost inactive analog [35].
5.3. Three Dimensional Structure and Mode of Action
The tertiary structure of lucifensin determined using NMR [36] showed a high degree of similarity
to the structure of other insect defensins: sapecin [19] and insect defensin A [20]. Lucifensin adopts
a characteristic insect defensin structure that includes an N-terminal loop (residues 1–12), followed
by an α-helix (residues 13–23), which is linked by a turn to a pair of β-strands (residues 28–31 and
34–38) folded into an antiparallel β-sheet (Figure 1). The Cys3-Cys30 disulfide bridge connects the
N-terminal loop with the first β-strand and the other two bridges (Cys16-Cys36, Cys20-Cys38) link
the α-helix and second β-strand [36]. The α-helix and β-structure connected by two disulfide bridges
form a common structural element typical for insect defensins, known as the cysteine-stabilised αβ
(CS αβ) motif, which is essential for their antimicrobial activity [19,20].
The action mechanism of lucifensin relates to the study on homologous sapecin—the defensin
of Sarcophaga peregrina for which a putative mechanistic model for membrane permeabilisation has
been already proposed [37]. According to this model obtained on the basis of NMR experiments,
sapecin oligomerises in the bacterial membrane and thus forms the channels therein which results
in consequent leakage of cytoplasmic components and bacterial cell death. This putative model of
sapecin oligomerisation is based on an electrostatic interaction between Asp4 of one sapecin molecule
and Arg23 of another sapecin molecule, as these two residues are situated at opposite ends of the
oligomerisation site. Since the sequences of the lucifensin differs from that of sapecin by only four
amino acid residues (positions 11, 12, 33 and 35) and residues Asp4 and Arg23 are conserved in
lucifensin, we may speculate that the mechanism of the lucifensins antimicrobial action is the same as
that proposed for sapecin [37]. We may then suppose that the absence of Asp4 in the truncated analog
of lucifensin might be the reason that its antimicrobial activity significantly decreased.
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Figure 1. An illustrated representation of the three-dimensional structure of lucifensin (L. sericata
defensin) which was generated in Pymol [38] by using the solution structure of lucifensin (PDB code
2LLD).
As illustrated in Figure 2, the treatment of B. subtilis by lucifensin followed by transmission
electron microscopy revealed significant changes in the bacterial envelope leading to final breakup
of bacterial cells [35], just demonstrating the generally accepted mechanism of the action for cationic
antimicrobial peptides, such as insect defensins.
Figure 2. Electron micrographs of negatively stained Bacillus subtilis either untreated (A) or treated by
lucifensin for 60 min (B). Scale bars represent 1 μm.
6. Lucifensin II—The Defensin from L. cuprina
The homolog of insect defensin designated lucifensin II was recently isolated from an extract of the
haemolymph of the fly larva Lucilia cuprina in our laboratory [9]. We applied an improved purification
procedure comprising of two ultrafiltration steps, RP-HPLC, modified size exclusion HPLC and a
final RP-HPLC purification leading to the successful determination of its full-length primary sequence.
This sequence determined by ESI-orbitrap mass spectrometry and Edman degradation shows almost
the same identity to the sequence of lucifensin (Lucilia sericata defensin). The lucifensin II sequence
differs from that of lucifensin by only one amino acid residue; that is by isoleucine instead of valine at
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position 11. The presence of lucifensin II was also detected in the extracts of other larval tissues such
as gut, salivary glands, fat body and whole body extract [9].
We isolated lucifensin II from the haemolymph of non-sterile maggots which has led to the
question of whether lucifensin II is produced in response to poly-microbial challenge or is it
constitutively expressed by the larval immune system. Accordingly, we analysed the anti-M. luteus
active RP-HPLC fractions of 50 kDa filtrate obtained either from the haemolymph of non-sterile
maggots or haemolymph of maggots treated individually with the S. aureus, P. aeruginosa and Proteus
mirabilis, by mass spectrometry. The presence of lucifensin II was detected in all corresponding
fractions independently of whether the maggots were challenged by infection or were kept sterile [9].
This observation is not in agreement with a hypothesis predicting no antibacterial activity in larvae
without bacterial challenge [39]. In addition, we were not able to detect any other cationic antimicrobial
peptides in the haemolymph of L. cuprina in the course of lucifensin II purification.
7. Molecular Biology Approaches for the Identification of Lucifensin in Medicinal Larvae
Using suppression subtractive hybridisation methodology, Altincicek et al. [40] identified numerous
genes that are up-regulated in larvae of L. sericata upon septic injury. These genes encode signalling
proteins, proteinases and homeostasis proteins and also potential antimicrobial peptides. The deduced
peptides share sequence similarities with insect defensins, diptericins and proline-rich peptides which
are conserved within Diptera. However, none of these deduced sequences match to that of lucifensin.
Danish researchers used for the identification of lucifensin in L. sericata maggots a
transposon-assisted signal trapping, a methodology specially developed for identification of secreted
proteins and peptides. They applied this method to L. sericata maggots induced with external stimuli
mimicking those encountered by the maggots during MDT [41]. The lucifensin sequence determined
in that laboratory [41] was identical to that published by us [8]. They also produced a few milligrams
of recombinant peptide and estimated its antimicrobial activity against both Gram-positive and
Gram-negative bacteria. Lucifensin was active against S. carnosus, Streptococcus pyogenes and Streptococcus
pneumoniae with MIC values of 2 mg/L, and against Enterococcus faecalis and S. aureus with MIC values of
32 and 16 mg/L, respectively, but did not show any antimicrobial activity towards the Gram-negative
bacteria tested at concentrations <128 mg/L. The MIC of lucifensin for a selection of 15 MRSA and
glycopeptide-intermediate S. aureus isolates tested ranged from 8 to 128 mg/L [41].
The expression of lucifensin in various larval tissues during L. sericata development and in
maggots exposed to infections was recently examined by Slovak researchers [42]. Using an in situ
hybridisation method, they revealed lucifensin expression in the salivary glands of all larval stages.
No differences were detected in the salivary glands after stimulation by bacteria. However, lucifensin
expression was strongly stimulated in the fat body in response to the infectious environment and it
was found that it is secreted solely from this tissue into the haemolymph [42].
8. Lucifensin Released by Maggots to the Wound
We analysed the extract of the swabs taken from the infected diabetic foot ulcers (DFU) during
maggot treatment or immediately after removal of the maggots from the wound (Figure 3). The extracts
of these samples were pre-purified by ultrafiltration through 10 kDa molecular weight cut-off
membrane to remove high molecular mass components and then the filtrates were lyophilised. The
HPLC profile of obtained material (Figure 3) indicates the presence of a tiny amount of lucifensin
together with two human α-defensins (HNP1 and HNP2). In a drop diffusion test against M. luteus, the
fraction of lucifensin exhibited almost equal antimicrobial activity against Gram-positive bacteria as the
fraction corresponding to the mixtures of these two HNPs (Figure 3). These two host defence peptides
were apparently produced and released into the wound by the components of the human immune
system, including some blood cells (neutrophils) as the innate immune response against infection.
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Figure 3. RP-HPLC profile (at 220 nm) of the lyophilised filtrate obtained by ultrafiltration through
10 kDa cut-off membrane of the swab extract taken from the wound (photo) immediately after removal
of the larvae. An elution gradient of solvents from 5% to 70% acetonitrile/water/0.1% TFA was applied
for 60 min at a flow rate 1 mL/min. Arrows indicate the anti-M. luteus active peak (10) containing
lucifensin. The larger peak at tR = 25 min (12) represents a mixture of two human α-defensins: HNP1
and HNP2. Inset: Anti-M. luteus activity (clear zones in the drop diffusion test) of selected peaks
delineated in the profile.
The antimicrobial effect of maggots was investigated in several in vivo studies by comparing
bacterial diversity in the wounds before and after their application. Our study in 91 patients
with DFU demonstrated that maggot therapy by free-range larvae applied to the wound for an
average 3 days acutely eliminated most of the Gram-positive and Gram-negative strains including
methicillin-resistant Staphylococcus aureus (MRSA), but maggots were ineffective against Pseudomonas sp.
and Acinetobacter sp. [43]. The antimicrobial effect persisted 7–13 days after removal of the larvae.
These results are in accordance with the observations of other researchers [31,44] and signify that
lucifensin, as an external antimicrobial peptide presented in DFU, may play a key role as a microbicide
and as a healing factor in the majority of maggot-treated DFU. In cases of ulcers infected by P. aeruginosa
or some other Gram-negative bacteria, we hypothesize that maggot therapy fails due to the specific
activity of lucifensin against Gram-positive bacteria.
In addition to killing bacteria directly, lucifensin and other antimicrobial compounds from
maggots have a number of immunomodulatory functions that may be involved in the clearance
of infection and support of wound healing, including the ability to influence host innate and adaptive
immune response. Regarding the innate immune system, a wide variety of human antimicrobial
peptides is expressed by the epidermal cells and neutrophils, such as human β-defensins and
HNPs [45]. Besides their antimicrobial effect, AMPs also support processes of wound healing, such
as proliferation and angiogenesis or keratinocyte migration [46]. In contrast to acute wound healing,
chronic wounds are marked by a prolonged and dysregulated inflammatory phase. Inflammatory cells
like neutrophils, monocytes and macrophages are not only present in excess numbers, they also have
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enhanced production and release of pro-inflammatory cytokines, proteases and reactive oxygen species,
leading to growth factor inactivation and tissue destruction [47]. Moreover, chronic ulcers from diabetic
patients showed β-defensins up-regulation; the production of these antimicrobial peptides might
be insufficient to mount proper antimicrobial control and wound healing [48]. Lucifensin and other
antimicrobial compounds from maggots may turn this unfavourable situation and transfer the wound
to satisfactory healing. Maggot secretions potently inhibit the pro-inflammatory responses of human
neutrophils without affecting their antimicrobial activities [49]. In addition to reducing the production
of proinflammatory cytokines and host antimicrobial peptides, maggot secretions also increased the
production of pro-angiogenic growth factors bFGF and VEGF in anti-inflammatory macrophages [50].
Simultaneously, the increased pro-angiogenic activity of anti-inflammatory macrophages may induce
neovascularisation and the concurrent formation of granulation tissue. In addition, maggots increase
the expression of bFGF in ulcer tissue and induce the formation of granulation tissue.
9. Perspectives on the Future of Lucifensins
Bacterial resistance to conventional antibiotics is a major concern and the main reason for
extensive, ongoing research to develop new therapeutics. Antimicrobial peptides could both affect
the pathogens and simultaneously activate and modulate innate and adaptive immune systems of
the host. Lucifensins have interesting features for topical application to treat wound infection and
promote wound healing. These peptides that act simultaneously on the pathogens as well as on the
host offer a unique opportunity to minimise the direct selective pressures for pathogen resistance.
For lucifensin, there are several different potential strategies for its therapeutic application: (i) as single
anti-infective agent, (ii) in combination with conventional antibiotics, (iii) in combination with other
antimicrobial peptides. The reason for using lucifensin with conventional antibiotics is a formation of
bacterial biofilm in the wound. Bacteria within chronic wounds often reside in biofilms that protect
them from antibiotics and the immune system. A combination of lucifensin and antibiotics may ensure
complete breakdown of the biofilms, thereby preventing bacterial re-growth from the remaining matrix,
and prompt antibiotic action against the bacteria released from the biofilms. Preclinical studies with
lucifensin for testing of safety, pharmacokinetics and toxicity are needed. After that, clinical studies
may be initiated.
10. Conclusions
We propose that lucifensins are key antimicrobial factors involved in the defence system of
medicinal larvae L. sericata and L. cuprina which protect maggots when they are exposed to the highly
infectious environment of a wound during maggot therapy. They act as a microbicide and healing
factor within the wound. Their discovery as a crucial disinfectant secreted/excreted by maggots to the
wound broadened the understanding of the healing mechanism of maggot therapy. As the deliberate
treatment of non-healing wounds by maggots has been in practice since the 1930s, can we possibly
consider lucifensin as a prime example of the practical application of antimicrobial peptide in medicine?
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Abstract: Antimicrobial peptides (AMPs) are found widely distributed through Nature, and
participate in the innate host defense of each species. Fish are a great source of these peptides, as they
express all of the major classes of AMPs, including defensins, cathelicidins, hepcidins, histone-derived
peptides, and a fish-specific class of the cecropin family, called piscidins. As with other species, the
fish peptides exhibit broad-spectrum antimicrobial activity, killing both fish and human pathogens.
They are also immunomodulatory, and their genes are highly responsive to microbes and innate
immuno-stimulatory molecules. Recent research has demonstrated that some of the unique properties
of fish peptides, including their ability to act even in very high salt concentrations, make them good
potential targets for development as therapeutic antimicrobials. Further, the stimulation of their gene
expression by exogenous factors could be useful in preventing pathogenic microbes in aquaculture.
Keywords: defensin; pleurocidin; cathelicidin; hepcidin; piscidin
1. Introduction
Antimicrobial peptides (AMPs) represent a broad category of different families of highly conserved
peptides widely found throughout Nature, which exhibit broad-spectrum antimicrobial activity in vitro
and in vivo. While vertebrate antimicrobial peptides were initially discovered in amphibians, humans and
rabbits in the mid-1980s [1–3], The antimicrobial activity of fish peptides was not described for another
decade. Initially, a toxic peptide from the Moses sole fish Pardachirus marmoratus, called pardaxin, was
characterized in 1980 [4], but its antimicrobial activity wasn’t observed until 1996 [5]. Shortly thereafter,
Cole et al. described a peptide isolated from the skin secretions of the winter flounder (Pleuronectes
americanus) [6] using antimicrobial activity as a screening method. Since then, the field has progressed
as with other vertebrate species, with the identification of homologous peptides in the piscidin family
(unique to fish, but homologous to cecropins), as well as the defensin, cathelicidin, and hepcidin families,
which are found in many other species. Many of the peptides were identified by purification of the
peptides with antibiotic activity, although as with other species, the increased use of bioinformatics
techniques has allowed the identification of even more peptides [7]. The results of the research described
here demonstrate that AMPs from fish exhibit many if not all of the same characteristics as other
vertebrate AMPs, like broad-spectrum (but often species-specific) antimicrobial activities, as well as
immunomodulatory functions. In addition, there appear to be interesting differences, specific to fish, that
have evolved to address the unique aquatic environments and microbes encountered by these species.
There has also been a recent effort to study the potential for using these peptides as therapeutic agents,
both in human medicine and in aquaculture. Below we will examine the various peptide families (whose
members are shown in Table 1), and discuss their role in host defense and potential for future use.
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2. Piscidins
Piscidins and pleurocidins comprise a family of linear, amphipathic AMPs, evolutionarily related
to similarly structured peptides found in amphibian skin and insects [85]. The first member of the
family identified was a 25-residue peptide isolated and characterized from skin mucous secretions
of the winter flounder, Pleuronectes americanus, called pleurocidin [6]. Further research identified
other homologous pleurocidins in related species [8,83]. These were shown to exhibit an amphipathic,
α-helical structure, similar to magainins and cecropins. A similarly structured peptide was identified in
the loach, Misgurunus anguillicaudatus, called misgurin [86], and a family of peptides, termed piscidins,
were identified in the mast cells of the hybrid striped bass [87], as well as numerous other fish taxa [88].
Other similar peptides, including moronecidin, epinecidin, dicentracin, have been identified [33,41,89].
An alignment of primary amino acid sequences of some members of this class are shown in Figure 1.
The similarities of the mature peptide predicted secondary structure [6,41,78,90] as well as an analysis
of their gene structures [33,50] suggested that they all belong to the same evolutionarily related family,
which we will refer to as the piscidins. In addition, positive selection has been found influencing
evolution of these peptides, where the highest diversity is found in the mature peptide that suggest
adaptation for attacking new pathogens or strains that are coevolving with the host [91,92].
Figure 1. Alignment of piscidins. Mature peptide sequences were obtained from published data and
from the PubMed protein database, and were aligned using MacVector software. The Drosophila
cecropin A1 sequences is provided for comparison as a representative member of the cecropin family.
Alignment of primary amino acid sequences shows that piscidins as a group have little direct
sequence identity (Figure 1), but are as a group predicted to possess an amphipatic α-helical
structure [6,41,78,90]. However, CD spectroscopy of the piscidin from brooding pouch suggests that it
might have a β-sheet or β-strand motif instead of α-helix [75]. Their gene structure is composed of four
exons and three introns, encoding a peptide precursor containing a signal peptide, a mature piscidin
and a carboxy-terminal prodomain [41,50,82]. However, in tilapia and grouper a three-exon/two-intron
and five-exon/four-intron structure, respectively was found [78,89]. Moreover, multiple piscidin
isoforms have been found in the same species [78,83].
Piscidins exhibit potent antimicrobial activity against a variety of microorganisms. They are
widely active against bacteria Gram-positive and -negative species, with the best antibacterial values
obtained against several Streptococcus, Pseudomonas, Bacillus and Vibrio species (for a full listing of fish
antimicrobial peptides and their activities, see Supplementary Table S1). Interestingly, chrysophsin-3
was observed to kill the three stages of Bacillus anthracis (sporulated, germinated and vegetative), being
able to penetrate and kill the spores without full germination [93]. Piscidins have also been shown to
possess anti-fungal activity [47,94,95], anti-parasitic activity [47,96–98], and anti-viral activity [99,100].
An interesting study showed that piscidin-2 was highly potent against the water mold Saprolegnia sp.
(Oomycetes) with a MIC within the physiological piscidin-2 levels [98].
Piscidins are mainly expressed in gill, skin and intestine, although can be also found in head-kidney
and spleen [10,43,47,50,58,101,102]. However, in Atlantic cod piscidin was found to be ubiquitous,
being detected in chondrocytes, heart, oocytes, exocrine and endocrine glands, swim bladder, and other
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tissues [103]. Nevertheless, the expression profiles vary depending on the isoform [39,78,83]. Moreover,
specifically among the cell types where piscidin has shown to be expressed are mast cells, rodlet
cells, phagocytic granulocytes and eosinophilic granular cells [43,88,102,104,105]. Interestingly, there
is evidence that granulocytes can destroy bacteria in phagosome by intracellular release of piscidin,
meaning that piscidin can act against extra and intracellular bacteria [102]. In addition, pleurocidin
expression is expressed at 13 days post-hatch in the winter flounder, which is suggested to play an
important role in defense during development [101].
Like AMP genes from mammals, piscidin genes can be induced by a variety of stimuli, including
Gram-positive and -negative bacteria [78], bacteria cell components like LPS [43,50,58] or the bacterial
antigen ASAL [10]. The LPS-mediated induction of epinecidin-1 in zebrafish was shown to require
hepatocyte nuclear factor 1 [89]. Furthermore, piscidin genes are induced by parasites [47,104,106],
viruses [107], and poly I:C [43,58]. Another study demonstrated that high biomass density (i.e., a
higher concentration of fish per volume water in an experimental tank) used as an acute stressor
component, led to an to up-regulation of dicentracin in gills and skin as well [74].
Besides microorganisms, piscidin-mediated anti-tumor activity has been shown by the growth
inhibition and/or killing of a variety of different cancer-derived cell lines like A549 [108], HT1080 [108–
110], U937 [111], HL60 [112], U937 [110], HeLa [110] and different breast cancer-derived cell lines
including MDA-MB-468, T47-D, SKBR3, MCF7, MCF7-TX400 (paclitaxel-resistant MCF7), MDA-MB-231
and 4T1 [113]. Furthermore, pleurocidin is able to kill breast cancer xenografts in NOD SCID mice,
where cell death was caused by mitochondrial membrane damage and ROS production [113]. In
addition, disruption of cancer cell membrane has been also shown to occur [110]. Moreover, in vitro
inhibition of proliferation of U937 and HT1080 was suggested to occur by inducing apoptosis in
response to cytokine production like TNF-α, IL-10, IL-15, IL-6, the tumor suppressor p53 [111], and
caspases [110]. Also, pleurocidin showed the ability to inhibit HT1080 migration in a dose-dependent
manner [109] as well as the rapid killing of a human leukemia cell line [112]. In contrast, pleurocidin
showed no lysis of human dermal fibroblasts, umbilical vein endothelial cells and erythrocytes [113].
Several studies have shown that piscidin can disrupt the plasma membranes and cause cellular
material efflux by pore formation [114,115]. However, use of membrane models has suggested
that membrane composition is an important factor in the lytic capacity of piscidin to disrupt cell
membranes [116]. In addition, using site-specific high-resolution solid-state NMR orientational
restraints and circular dichroism it was shown that piscidin-1 and -3 induce a membrane-AMP
interaction by parallel orientation of the α-helical in membrane model surfaces where fast and large
amplitude backbone motions occur [117,118]. Moreover, at very low inhibitory concentrations piscidin
does not cause significant cell membrane damage but is capable to inhibit macromolecular synthesis
in bacteria [119]. Against fungi, pleurocidin was active against C. albicans by causing protoplast
regeneration and membrane disruption [95,112] and it has been suggested to cause oxidative stress,
triggering apoptosis in C. albicans by inducing intracellular reactive oxygen species (ROS) and activation
of metacaspases, leading to externalization of phosphatidylserine [94].
Among other attractive features of piscidin includes their ability to retain antibacterial activity
at high salt concentrations [41], thermostability (piscidin from seahorse brooding pouch retained
full activity after exposing from 20–80 ◦C for 30 min, and only 20% loss of activity when boiling at
100 ◦C for 30 min) [75], and relatively low cytotoxicity against mammalian cells [120]. However, in
tilapia some piscidin isoforms were hemolytic for tilapia red blood cells. The peptide with the greatest
hemolysis activity was also the one with the best antibacterial activity, which is associated with the
amphiphilic α-helical cationic structure [78].
The immunomodulatory capacity of piscidins is another feature that has been widely assessed.
In fish, they are able to modulate the expression of pro-inflammatory and other immune-related
genes like IL-1β, IL-10, IL-22, IL-26, TNF-α, IFN-γ, NF-κB, lysozyme, NOS2, MyD88, TLR4a, TLR1,
TLR3, [121–125]. Moreover, in mice this immunomodulatory effect also has been observed, with
the modulation of the genes encoding IL-6, IL-10, IL-12, MCP-1, TNF-α, IFN-γ and IgG1 [126–128].
93
Pharmaceuticals 2014, 7, 265–310
Recently, some pleurocidins have shown to be able stimulate human mast cell chemotaxis increasing
Ca2+ mobilization, and inducing the production of pro-inflammatory cytokines (like CCL2, 1β/CCL4)
in mast cells, which was suggested to occur through G-proteins. In addition, it is able to cause mast
cells to adhere, migrate, degranulate, and release cysteinyl leukotrienes and prostaglandin D2 [129].
Overall, it appears that piscidins represent an evolutionarily conserved family of peptides, which,
while unique to fish, exhibit broad homology to the linear, amphipathic classes of antimicrobial
peptides found in many other species.
3. β-Defensins
A general term for cysteine-rich, cationic antimicrobial peptides found in plants, fungi,
invertebrates and vertebrates [130–132], defensins exhibit a general conformation made by
cysteine-stabilized α-helical and β–sheet folds (reviewed in [131,133]). In mammals three types of
defensins have been identified based on their structure, α-, β-, and θ-defensins (last one found only in
certain nonhuman primates, including the rhesus macacque) [130,134,135]. However in fish, sequence
and structural analysis have revealed that fish defensins are solely β-defensin-like proteins [35,44,51,64]
including the conserved 6-cyteine motif (Figure 2). To date, up to four genes and five isoforms of
defensins have been found in a single species [57,65], apparently as result of gene duplication events
that had occurred in vertebrate β-defensins [133]. Fish defensins were first identified in zebrafish,
Fugu and tetraodon by a database mining approach [44], but currently defensins have been identified
in many other marine and freshwater fish species (see Table 1). Interestingly, a phylogenetic analysis
using defensins from human and fish revealed that hBD-4 is the only human defensin that clustered
with fish defensins, suggesting possible similar biological properties [35].
The human β-defensin gene has two exons and one intron, fairly typical of most β-defensin genes.
Furthermore, mammalian β-defensins are translated as prepeptides, with the mature peptide sequence
immediately downstream from the signal sequence [136]. However, in fish three exons and two introns
are found [65], encoding a prepropeptide (including signal peptide, propeptide and mature peptide)
comprised of 60 to 77 amino acids, and a mature peptide from 38 to 45 amino acids with cationic
nature with a pI around 8 (except for those in olive flounder, which are around 4, indicating anionic
nature [57]). Due its cationic nature they present a net positive charge that can go from +1 to +5. As
with all vertebrate β-defensins, there are six conserved cysteines, although in human and birds these
are located in a single exon, while in fish they span two exons [57].
Figure 2. Alignment of β-defensins. Precursor peptide sequences were obtained from published data
and from the PubMed protein database, and were aligned using MacVector software. The bovine
β-defensin, Tracheal Antimicrobial Peptide (TAP) is shown for comparison. The conserved β-defensin
cysteine spacing is shown in the consensus line. The first residue of the mature peptide region (based
on the isolated TAP sequence) is denoted with an asterisk.
Fish β-defensins have proven to be active against both Gram-negative and -positive bacteria
(for specific inhibitory values see Supplementary Table S1), although with rather moderate activity.
Exceptions to those reports of MICs in the high μM range are Planococcus citreus (Gram-positive) [11]
and Aeromonas hydrophila (Gram-negative) [52], with low MIC values. Other studies using supernatant
of lysates HEK293T cells transfected with β-defensins from the Chinese loach or the gilthead seabream
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showed significant growth inhibition of the Gram-negative A. hydrophila and the Gram-positive B.
subtilis [30,35]. Moreover, β-defensins are also active against fish-specific viruses such as Singapore
grouper iridovirus (SGIV), viral nervous necrosis virus (VNNV), haemorrhagic septicaemia virus (VHSV),
and the frog-specific Rana grylio virus (RGV) [59,60,64]. In addition it has been shown that the
α-defensin human defensin-1 (HD-1) is highly active against VHSV, a salmonid rhabdovirus, causing
its inactivation and inhibition [137]. However, no assessment has been carried out testing fish-derived
defensins against human viruses so far, nor about their potential mechanism of action. Similarly, there
are no published studies examining the activity of fish defensins against parasites. A small number
of studies demonstrate the activity of human defensins against parasites, showing, for example, that
HD-1 is capable to destroy the parasite Trypanosoma cruzi by pore formation and induction of nuclear
and mitochondrial DNA fragmentation [138], and that hd-5 is able to reduce Toxoplasma gondii viability
by aggregation [139]. This is an area with great potential both for fish and human biology. As with
parasites, there are no studies related to the antifungal activity of fish defensins, in spite of the many
studies showing such activity of β-defensins from other species (e.g., those described in [140–142].
In addition to their antimicrobial activities, β-defensins have been shown to exhibit multiple
immunomodulatory activities (reviewed in [143]). For example, recombinant mBD4 and hBD2
(both β-defensins in mice and human, respectively) have shown to possess chemotactic activity
for CCR6-expressing cells (which include monocytes, dendritic cells and T-lymphocytes), which was
confirmed using its chemokine ligand CCL20 that competed with these β-defensins [144]. Similar
activity has been observed in a fish homologue. β-defensins from the gilthead seabream exhibited
chemotactic activity, showing the capacity to attract head-kidney leukocytes [35]. There is evidence
of CCR6 mammalian orthologs in zebrafish [145] and rainbow trout [146] that may help address
the mechanism. In addition, chemotactic capacity of HNP1 (human α-defensin) towards trout
leucocytes has been shown [147]. Furthermore, a β-defensin from Atlantic cod is capable of stimulating
antimicrobial activity in phagocytes [11]. Together, the studies suggest that fish β-defensins function
similarly to their mammalian counterparts, contributing to the innate host defense in multiple ways.
In mammals, β-defensin expression was initially identified and studied predominantly in
skin and mucosal membranes from respiratory, gastrointestinal and genitourinary tracts (reviewed
in [148]. More recently, however, numerous β-defensin isoforms have been identified in sperm, with
associations to reproduction being demonstrated [149]. While some β-defensins (mostly hBD-1 and
its homologue) are constitutively expressed, the expression of most β-defensins can be induced by a
variety of factors, including many innate immune mediators and microbe-associated molecular patterns
(reviewed in [150]). Furthermore, their expression is observed not only in adult tissues, but during
embryonic development as well [151,152]. In fish, constitutive expression seems to start early in the
development probably as part of the need of defense in vulnerable stages that rely significantly in the
innate immune response [11,57]. However, it is hard to establish specific expression patterns, because
this appears to vary between species and isoform [31,44,59,60,65], although in most of the characterized
fish β-defensins, skin is one of the tissues with the highest basal expression [31,35,44,65], a widely
distributed feature among vertebrate defensins [148,153]. After skin, head-kidney and spleen are the
tissues with also high expression, which are the main immune organs in fish [51,52,65]. Nevertheless,
in some studies some isoforms of fish β-defensins have shown to possess a widespread constitutive
expression [30,52,65]. Furthermore, high expression in eye has been found, suggesting a relevant role
in ocular infections [30,52]. In addition, a study in the orange-spotted grouper suggest a relationship of
fish β-defensin and reproduction endocrine regulation, finding an isoform that is exclusively expressed
in pituitary and testis, where such expression is up-regulated from intersexual gonad to testis in sex
reversal, and a deeper analysis proved that the pituitary-specific POU1F1 transcription binding site
and the testis-specific SRY site are responsible for this phenomenon [60]. Fish β-defensin genes are
induced by a variety of stimuli including cell wall components like LPS [52,59], β-glucans [31] and
peptidoglycan [154]. They are stimulated by bacterial challenges from A. hydrophila [30], Y. ruckeri [65],
V. anguillarum [11] and E. tarda [57]; and by viral challenges, including SGIV [59] or the TLR-3 agonist
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poly(I:C), to emulate a viral infection [59,65]. In addition, supplemented diets with the diatom Naviluca
sp. and the lactobacillus Lactobacillus sakei have shown to induced β-defensin in gilthead seabream [155].
Thus, β-defensins in fish are true orthologues, exhibiting both structural and functional similarities to
mammalian peptides, as well as their patterns of expression. This further supports the hypothesis that
β-defensins are an ancient and highly conserved mechanism of host defense in animal species [133].
4. Hepcidins
Hepcidins are cysteine-rich peptides with antimicrobial activity that were first discovered in
humans [156,157]. Since then, hepcidins have been identified in many other vertebrates including
reptiles, amphibians and fish. Although, in birds the existence of a hepcidin needs to be better
confirmed [158]. Fish hepcidin was first identified and isolated from the hybrid striped bass [42] and
since then hepcidins have been identified in at least 37 fish species. The general structure of human
hepcidin is a β-sheet-composed harpin-shaped with four disulfide bridges (formed by eight cysteines)
with an unusual vicinal bridge at the hairpin turn [159], which is also the general structure in fish
hepcidin [76,79]. However, sequence analysis of fish hepcidins has shown the presence of hepcidins
containing 7, 6 or 4 cysteines [9,48].
Fish hepcidin genes have undergone duplication and diversification processes that have produced
multiple gene copies [9], and up to eight copies have been identified [22,34,73]. Hepcidin genes are
composed of three exons and two introns encoding a signal peptide, a prodomain and a mature
peptide [22,34,72]. The pre-prohepcidin size can range from 81 to 96 amino acids, and the mature
hepcidin from 19 to 31, with a molecular weight around 2–3 kDa. Representative sequences are shown
in Figure 3. An average pI generally above 8 demonstrates their cationic nature. However, a predicted
low pI of 5.4 of the orange-spotted grouper, indicates the existence of anionic hepcidin [61].
Figure 3. Alignment of hepcidins. Representative precursor peptide sequences were obtained from
published data and from the PubMed protein database, and were aligned using MacVector software.
Human hepcidin is shown for comparison. The first residue of the mature peptide region is denoted
with an asterisk.
Fish have two types of hepcidins, HAMP1 and HAMP2. However, although HAMP1 is present
in actinopterygian and non-actinopterygian fish, HAMP2 has been only found in actinopterygian
fish [54,63,158]. Moreover, a phylogenetic study has shown positive Darwinian selection in HAMP2
(but not HAMP1 and its mammalian orthologue) that suggest adaptive evolution probably associated
with the host-pathogen interaction in different environments [9,54,160].
Hepcidin expression can be detected as early as in the fertilized egg in blunt snout bream [27] or
at 8 h after fertilization in channel catfish [26]. However, in winter flounder and tongue sole it was
not detected until day 5 and 6, respectively (larvae stage) [16,37]. Nevertheless, it has been shown
that hepcidin isoforms have different expression pattern and kinetics in larval development [70]. In
addition, different hepcidin types in a single species can have different rates of expression within the
same tissue [80] that can be affected by different stimuli [24,70,73,79]. Interestingly, some isoforms
have high basal hepcidin expression in liver, but some have not, where the highest expression often
occurs in spleen, kidney and intestine [9,70,73,79].
Similar to other AMP genes, fish hepcidins can be induced by exposure to both Gram-positive
and Gram-negative bacteria [12,19,25–27,34,36,37,42,48,53,56,61,63,72,73,161–166]. Moreover, fungi
like Saccharomyces cerevisiae [36,61], and tumor cell lines like L-1210 and SAF-1 have shown to induce
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hepcidin expression as well [36]. Hepcidin genes in fish are also induced by viruses [36,61,73,165],
and poly I:C [12,36,164], as well as mitogens [36]. Moreover, environmental estrogenic endocrine
disrupting chemicals like 17β-estradiol down-regulates one of the hepcidin isoforms expression in
liver in largemouth bass [46].
In humans, hepcidin acts as a type II actue-phase protein [167]. Related to this, time-course
experiments under bacterial challenge of fish have shown that the highest expression of hepcidin
occurs at 3–6 h and decay after that [23,32,163]. Also, the expression of hepcidin occurs along with
other acute phase response proteins like IL-1β, serum amyloid A and precerebellin after infection with
Yersinia ruckeri in rainbow trout [168]. Related to this, mud loach infected with Gram-negative bacteria
showed a high IL-1β-like gene expression-mediated response [56]. Together, these results suggest that
hepcidins can also act as a type II acute phase protein, and function as part of a broad innate immune
response in fish.
Fish hepcidins are active against a wide variety of bacteria, both Gram-positive and -negative at the
low μM range, including potent activity against a large number of fish pathogens (see Supplementary
Table S1 for a complete listing). This includes rapid killing kinetics against S. aureus and Pseudomonas
stutzeri [23,62]. Furthermore, synergy between bass hepcidin and moronecidin against S. iniae and Y.
enterocolitica has been demonstrated [161]. In addition, they are active against a number of viruses [80,
99,169–171], and a recent study indicates that human Hepc25 is able to affect HCV replication in cell
culture by inducing STAT3 activation leading to an antiviral state of the cell [172]. In contrast, their
quantified activity against fungi appears to be rather low [23,48,161].
A few studies have tried to elucidate the mechanism of action of hepcidin against bacteria.
With human Hepc25, the lack of SYTOX uptake showed that membrane permeabilization does not
occur [173] in contrast to most antimicrobial peptides [150]. Similar results have been observed with
fish peptides, using light emission kinetics, which showed that Medaka recombinant pro-hepcidin and
synthetic hepcidin also do not cause membrane permeabilization in E. coli [171]. However, human
Hepc25 has shown binding to DNA with high efficiency in a retardation assay [173].
Fish hepcidins have also shown the capacity of affect cancer cells viability. For example, tilapia
hepcidin TH2-3, have shown inhibition of proliferation and migration of human fibrosarcoma cell line
HT1080a in a concentration-dependent manner. Furthermore, TH2-3 was able to cause cell membrane
disruption in HT1080 and results also suggest that TH2-3 down-regulates c-Jun leading to apoptosis [174].
TH1-5 inhibit the proliferation of tumor cells (HeLa, HT1080 and HepG2) altering membrane structure
and inducing apoptosis at low dose. Also, TH1-5 showed modulation of immune-related genes [175].
A study with medaka hepcidin showed 40% decrease in HepG2 cell viability by addition of 25 and
5 μM of synthetic mature Om-hep1 and recombinant pro-Om-hep1 (prohepcidin), respectively [171].
Interestingly, Pro-Omhep1 has better anti-tumor activity compared with Om-hep1, using HepG2
cells [171].
Fish hepcidins have also shown the ability to modulate the expression of different immune-related
genes not only in fish but also in mice. Transgenic zebrafish expressing TH1-5 showed upregulation
of IL-10, IL-21, IL-22, lysozyme, TLR-1, TLR-3, TNF-α and NF-κB [176]. However, TH2-3 showed to
downregulate some of those upregulated by TH1-5 [177]. In the same context, TH2-3 reduced the
amount of TNF-α, IL-1α, IL-1β, IL-6 and COX-2 in mouse macrophages challenged with LPS [178].
Related to this, in turbot it has been shown that hepcidin is able to increase the activation of
NF-κB (which control a variety of inflammatory cytokines) through an undetermined yet signaling
pathway [165]. TH2-3 have also shown to be able to modulate protein kinase C isoforms in the mouse
macrophage RAW264.7 cell line [179], and was also capable to induce morphology changes in these
cells similar to PMA-induced changes [179]. Moreover, TH1-5 modulates the expression of certain
interferons and annexin (viral-responsive genes) in pancreatic necrosis virus-infected fish [170].
However, despite the potential antimicrobial and immunomodulatory effect, hepcidin is better
known for being a key iron regulator controlling ferroportin, which is able to degrade by its
internalization, which decrease iron transfer into blood [180]. In fish, although ferroportin internalization
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by hepcidin has not been proven yet, there is evidence suggesting that fish hepcidin also controls
iron [34,56,73,80,162,165,166,181]. It may also serve as a pleiotropic sensor for other divalent metals,
because it is up-regulated by exposure to other metals like copper [56] and cadmium [182], which can
be considered waterborne or toxic.
5. Cathelicidins
Unusual among the AMPs, cathelicidins share little sequence homology between the mature
peptides. Rather, they are defined by a homologous N-terminal region of the precursor peptide, called a
cathelin domain, found just after a conserved signal domain (reviewed in [183]). The active, mature
peptide is released upon protolytic cleavage by elastase and possibly other enzymes [184]. In mammals,
the mature AMP sequence varies greatly, not only between species but also among the often multiple
cathelicidin peptides within a single species. In general, however, all mammalian cathelicidin mature
peptides are cationic and exhibit an amphipathic characteristic, as well as broad-spectrum antimicrobial
activity in vitro. As can be seen by the alignment of primary amino acid sequences in Figure 4, there
are significant sequence similarities in the C-terminal region, and in several short domains, which are
highly cationic and glycine-rich.
The first cathelicidins identified in fish were initially isolated as antimicrobial peptides from
the Atlantic hagfish, Myxine glutinosa [15]. Upon sequence analysis of the cDNA that encoded these
peptides, it was discovered that they exhibited homology to cathelicidins, previously only found in
mammals to this point. As cathelicidins were discovered in other more conventional fish species,
primarily by sequence homology from the cathelin region (e.g., [17,28,77,185]), or more recently by
peptide isolation [186], new patterns emerged. In some of the more recently studied fish cathelicidins,
while a high degree of homology is maintained in the cathelin domain (see [185] for a comprehensive
alignment), there appears to be a higher degree of sequence similarity of the mature peptide than seen
in mammals. Thus, fish cathelicidins can now be subdivided into two classes—the linear peptides,
and those that exhibit a characteristic disulphide bond. In contrast to mammalian cathelicidins, there
is significant sequence homology among members of the classes (up to 90%), and little homology
between the classes. In addition, the recently identified cathelicidins found in cod appear to comprise
a third class, based on sequence homology between themselves, and a lack of homology with either of
the other two classes [185]. An alignment of representative fish cathelicidins is shown in Figure 4.
Figure 4. Alignment of fish cathelicidins. Mature peptide sequences were obtained from published data
and from the PubMed protein database, and were aligned using MacVector software. Characteristic
cysteine residues found in certain classes of fish cathelicidins are underlined. As, Atlantic salmon; Rt,
Rainbow trout; Cs, Chinook salmon; Btr, Brown trout; Ac, Arctic char; Bt, Brook trout; Je, Japanese eel.
As cathelicidin peptides are purified from more species, their in vitro antibacterial activities appear
to exhibit significant variability with respect to selectivity, depending on the species. For example, cod
cathelicidin (codCATH) is highly active against those Gram-negative bacterial species examined, but
almost inactive against the Gram-positive species. It also exhibits potent antifungal activity against C.
albicans [13]. In contrast, the hagfish cathelicidins are active against both Gram-positive and -negative
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bacteria, but inactive against Candida [15]. Even more specifically, rainbow trout cathelicidins are
active against Y. ruckeri, while Atlantic salmon cathelicidins are not [187]. Thus, the variability in
the mature peptide sequence of these molecules appears to direct the antimicrobial activities, and is
probably a result of an evolutionary divergence to address specific pathogens.
Based on their antimicrobial activity, most of the work to elucidate their role in vivo has examined
the expression of the cathelicidin genes in the various fish species with respect to induction by innate
immune regulators, such as bacteria and to different pathogen-associated molecular patterns (PAMPs).
Importantly, cathelicidin expression is observed early in embryonic development, suggesting that its
role in immunity is present early on [186]. In vitro, both bacteria and bacterial DNA were sufficient
to induce cathelicidin expression in a cultured embryonic salmon cell line [188], suggesting that
like mammalian cathelicidins, the fish homologs play a similar role in antibacterial host defense.
Surprisingly, purified LPS (that is, treated with DNase I) could not induce the gene. This regulation has
been further elucidated by the demonstration of a wide variability of the Chinook salmon embryonic
cell line’s response to different bacteria and to poly I:C, LPS and flagellin [189]. Further in vitro evidence
of this role was demonstrated by the induction of rainbow trout cathelicidin in a macrophage cell
line from that species by IL-6, an important mediator of the innate immune response [190], and by a
novel TNF-α isoform [191]. Similarly, stimulation of a cell line from Atlantic cod with poly I:C induced
expression of the gmCath1 (from cod) gene promoter [192]. In addition to bacteria and their products,
trout cell lines were shown to induce cathelicidin gene expression upon incubation with the oomycete
Saprolegnia parasitica [193].
In vivo studies further support this hypothesis. When ayu were injected with live pathogenic
bacteria, there was a time-dependent induction of cathelicidin expression in numerous tissues,
including gill, liver, spleen and intestine [20]. Further, Atlantic salmon and rainbow trout infected
with Y. ruckeri led to an induction in cathelicidin expression [187,194]. In the Atlantic cod, a difference
in inducibility was observed. Cathelicidin experession in the gills was induced by a 3-h incubation
with Aeromonas salmonicida, but not V. anguillarum, suggesting a more complex role is played by these
peptides in host defense.
In mammals, cathelicidins have been demonstrated to exhibit multiple activities, both immune and
non-immune, well in excess of their in vitro antimicrobial activities (reviewed in [195]). While research
in fish has not approached this level, a recent study demonstrated that two Atlantic salmon cathelicidins
induced the rapid and transient expression of IL-8 in peripheral blood leukocytes [187]. This suggests
that the immunomodulatory activities seen by mammalian cathelicidins may be shared by their fish
counterparts, and may thus be an evolutionarily conserved mechanism of innate immune regulation.
6. Histone-Derived Peptides
While examining an amphibian species for novel antimicrobial peptides, Park et al. [196] described
a new peptide from the Asian toad, Bufo bufo gargarizans, which they called Buforin I. This turned out
to be identical to the N-terminal portion of histone 2A. This led to the demonstration of antimicrobial
activity of histone fragments from numerous species (reviewed in [197]), suggesting that these
proteolytic fragments are part of an ancient innate immune mechanism. Histone-derived AMPs
have been identified in a number of fish species, with broad-spectrum activity against both human
and fish pathogens (reviewed in [198]), including water molds [199] and a parasitic dinoflagellate [69].
They are expressed and secreted in fish skin, and found in other tissues, including gill, speen and the
gut. They are not limited to the N-terminus of the histones, as was found for the Buforin peptide, but
can be found as fragments of both termini, from histones H1, H2A, H2B and H6 (see Figure 5). Further
evidence that they play a role in host defense of the fish comes from studies showing that expression
of histone-derived AMP genes are induced under conditions of stress in specific tissues of different
fish species [74,200].
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Figure 5. Alignment of histone-derived peptides. Representative peptide sequences were obtained
from published data and from the PubMed protein database, and were aligned using MacVector
software. Since the sequences are homolgous to different histone peptide fragments, there is no shared
sequence homology.
7. Therapeutics
All AMPs have common characteristics that support their development as therapeutic
antimicrobials. These include broad-spectrum activity against a wide variety of pathogens; potent
activity under a wide range of conditions, including temperature and in secretions such as saliva; and a
reduced capacity to the development of resistance by bacteria. The identification and characterization of
peptides from fish has provided a unique contribution in this arena. While the structural characteristics
of fish peptides do not appear particularly different from their mammalian, insect or amphibian
homologues, there may be specific differences with respect to activity. It appears that overall their
antimicrobial activities against human pathogens is in the same range as AMPs from other species.
However, it is possible that they are more active against fish pathogens, as they most likely have
evolved together with those pathogens. It is difficult to know this, however, as few studies have
compared non-fish peptides with fish peptides against fish pathogens. One area where fish peptides
may provide an advantage is in food preservation [201], as they are derived from a natural food source,
and thus may be more amenable to being consumed.
Since many AMPs are sensitive to high salt concentrations [202–204], the ability of some fish
AMPs to kill microbes even at extremely high salt concentrations, such as those found in the marine
environment, make them important targets for investigation. Pleurocidin, for example, maintains its
antibacterial activity even up to 300 mM NaCl [6], similar to other piscidins [41,205]. Understanding
the structural foundation that supports this salt-independent activity could aid in the design of
novel peptides [206] or mimetics that could address infections under a wide range of normal and
abnormal salt concentrations, whether in serum, tear film hyperosmolarity, or in saliva to address
dental caries [207]. In addition to their potential uses as antimicrobials, some fish AMPs have been
observed to exhibit in vitro cytotoxic activity against a variety of cancer cells [113,208].
Different applications of piscidin have been promising. For example, epinecidin-1, when
administrated orally or injected (in pre-, co- and post-infection) can significantly enhance survival
in zebrafish and grouper that were challenged with Vibrio vulnificus [58,123,124]. Related to this,
electrotransfer of epinecidin-1 in zebrafish and grouper muscle showed significant reduction in V. vulnificus
and Streptococcus agalactiae bacterial counts [121,122,125]. Moreover, treatment of lethally-challenged
methicillin-resistant S. aureus (MRSA) mice with epinecidin-1 allowed mice to survive by decreasing
considerably the bacterial counts, where also there was evidence of wound closure and angiogenesis
enhancement [128].
In oral disease treatment piscidins are also promising due to the potent effect of chrysophsin-1 in
killing the cariogenic pathogen Streptococcus mutans [209]. Furthermore, pleurocidin also demonstrated
anti-cariogenic activity by being able to kill both S. mutans and S. sobrinus, where killing of biofilms
occurred in a dose-dependent manner. In addition, it showed to retained its activity in physiological
or higher salt concentration, and was relatively stable in presence of human saliva and no hemolysis
was found [207,210].
Epinecidin-1 showed to be a potential candidate for topical application that can prevent vaginal
or skin infections due to the synergistic effect that possess with commercial cleaning solutions, where
such effect was not affected by low pH or after being stored at room temperature and at 4 ◦C for up
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to 14 days [211]. The synergistic effect of pleurocidin and several antibiotics [212], bacteroricin [213]
and histone-derived [214] has also been shown [212,213]. Furthermore, the creation of antimicrobial
surfaces has been made by the immobilization of chrysophsin-1 resulting in a surface with antibacterial
activity capable to killed around 82% of E. coli bacteria [215].
A recent interest finding is the ability of epinecidin-1 to create inactivated virus for vaccination
purposes. Huang et al. found that mice injected with Epi-1-based inactivated Japanese encephalitis
virus (JEV) reached 100% survival (in a dose-dependent manner), and the performance was better than
the formalin-based JEV-inactivated vaccine. This was caused by the modulation of immune-related
genes, including the increase of anti-JEV-neutralizing antibodies in serum, which suppressed the
multiplication of JEV in brain sections [126].
Fish hepcidins are also under examination for development as therapeutics. One example of
this is the study carried out by Pan et al. [216], where injections with pre-incubated tilapia hepcidin
TH2-3 and 108 cfu of Vibrio vulnificus for 30 min enhanced the survival of infected and re-infected
mice, obtaining up to 60% of survival with a dose of 40 μg/mice. In addition, TH2-3 also showed
significant prophylactic effect by administration prior infection, where survival rates of 100% were
obtained after 7 days of infection. Also, curative effects were shown when fish were first infected and
later injected with 40 μg/mice of TH2-3, obtaining survival rates up to 50%. But more interesting,
was the fact that TH2-3 had better bacteriostatic effect than tetracycline in controlling the bacterial
burden in blood, although in liver there was no significant difference, demonstrating the capacity of
TH2-3 to control multiplication of V. vulnificus in mice. Although the direct in vivo TH2-3-mediated
killing was not confirmed, a microarray analysis showed that TH2-3 clearly altered the gene expression
profiles improving the host response in mice [216]. In addition, a transgenic zebrafish expressing
TH2-3 showed to be able to decrease V. vulnificus burden significantly, but not S. agalactiae [177].
Zebrafish expressing TH1-5 exhibited enhanced bacterial resistance by decreasing the bacterial burden
of both same pathogens [176]. In addition, TH1-5 has showed to be effective at increasing survival and
decreasing the number of infectious bacteria in ducks challenged with Riemerella anatipestifer, which
also showed to be able to modulate the expression of immune-related genes [114].
However, as with other AMPs, they share the similar problems that hinder their further
development, especially for use in human medicine. These include a tendency to be inactivated
in the body, increased expense of peptide synthesis, and sensitivity to protease digestion. Attempts
to address these issues with fish peptides, include the identification of smaller peptide fragments
that might exhibit better activity with smaller molecules [217], and the observation of high levels of
synergy with bacterial AMPs [213,214], as well as conventional antibiotics [218] allowing for reduced
concentrations. One strategy that may have some success is the design of small molecule peptide
mimetics that incorporate the structural characteristics of the peptides necessary for their activity
(reviewed in [219]). Initial in vitro and in vivo results with molecules designed from magainins and
defensins have been encouraging, demonstrating antibacterial [220] and antifungal [221] activities,
as well as immunomodulatory activity [222]. Another strategy that has been examined extensively
in other species (reviewed in [223]) is the use of exogenous agents to modulate the expression of
endogenous AMPs in the fish. Terova et al. have demonstrated the induction of an AMP initially
isolated from sea bass [33] by feeding them a cell wall extract from S. cerevisiae [224], suggesting a
novel method for enhancing the natural defense mechanism of the fish. Incorporation of an enhancer
of AMP expression in the diet could be a cost-effective part of an overall strategy of modulating the
innate immune system of the fish to control infection in aquaculture (reviewed in [198]).
8. Conclusions
The comprehensive characterization of AMPs from fish, on the structural, genetic and functional
levels, has provided a wealth of information. Examination of AMPs in a single species, such as the
Atlantic cod, where members of all five groups of AMPs have been identified can help understand
the role of these peptides in innate host defense of the fish. Studies on the similarities and differences
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with peptides from non-fish species contribute to our understanding of the evolutionary relationships
of innate host defense mechanisms among vertebrates. Furthermore, they can provide important
information for the better design of novel therapeutic agents, both for microbial infections as well
as cancer and other conditions. Unique for the field of fish AMPs is the potential application to
aquaculture. The constant risk of large-scale microbial infection that can lead to significant economic
losses demands new strategies to prevent or treat these pathogens. Many of the studies described above
have demonstrated that specific fish AMPs have potent activity against fish pathogens. Furthermore,
other studies have shown that some pathogens induce potent innate immune responses in the fish.
Complicating this is the evolutionary battle with the pathogens. For example, challenge of Atlantic
cod with the pathogen V. anguillarum induces the expression of a β-defensin, which is antibacterial
against other species, but not the inducing V. anguillarum [11]. Thus, the large body of work described
above provides a solid foundation for strong future work to better understand both the role of these
peptides in host defense of the fish, as well as the development of these peptides and their derivatives
as potential therapeutics.
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Abstract: Skin secretions from frogs belonging to the genera Xenopus, Silurana, Hymenochirus, and
Pseudhymenochirus in the family Pipidae are a rich source of host-defense peptides with varying
degrees of antimicrobial activities and cytotoxicities to mammalian cells. Magainin, peptide
glycine-leucine-amide (PGLa), caerulein-precursor fragment (CPF), and xenopsin-precursor fragment
(XPF) peptides have been isolated from norepinephrine-stimulated skin secretions from several
species of Xenopus and Silurana. Hymenochirins and pseudhymenochirins have been isolated from
Hymenochirus boettgeri and Pseudhymenochirus merlini. A major obstacle to the development of these
peptides as anti-infective agents is their hemolytic activities against human erythrocytes. Analogs
of the magainins, CPF peptides and hymenochirin-1B with increased antimicrobial potencies and
low cytotoxicities have been developed that are active (MIC < 5 μM) against multidrug-resistant
clinical isolates of Staphylococcus aureus, Escherichia coli, Acinetobacter baumannii, Stenotrophomonas
maltophilia and Klebsiella pneumoniae. Despite this, the therapeutic potential of frog skin peptides
as anti-infective agents has not been realized so that alternative clinical applications as anti-cancer,
anti-viral, anti-diabetic, or immunomodulatory drugs are being explored.
Keywords: frog skin; magainin; PGLa; caerulein-precursor fragment; xenopsin-precursor-fragment;
hymenochirin
1. Introduction
The emergence in all regions of the World of strains of pathogenic bacteria and fungi with resistance
to commonly used antibiotics constitutes a serious threat to public health and has necessitated a
search for novel types of antimicrobial agent to which the microorganisms have not been exposed.
Although effective new types of antibiotics against multidrug-resistant Gram-positive bacteria
such as methicillin-resistant Staphylococcus aureus (MRSA) have been introduced or are in clinical
trials, the situation regarding new treatment options for infections produced by multidrug-resistant
Gram-negative pathogens such as Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae,
and Stenotrophomonas maltophilia is less encouraging [1]. There is an urgent need for new types
of antimicrobial agents with activity against these microorganisms that also possess appropriate
pharmacokinetic and toxicological profiles.
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Peptides with potent antibacterial and antifungal activity play an important role in the system
of innate immunity that predates adaptive immunity and constitutes the first-line defense against
invading pathogens for a wide range of vertebrate and invertebrate species. Skin secretions from
many species of Anura (frogs and toads) contain cytotoxic peptides, often in very high concentrations,
with broad-spectrum antibacterial and antifungal activities and the ability to permeabilize mammalian
cells [2,3]. Although usually referred to as antimicrobial peptides, these components are multifunctional,
displaying cytokine-mediated immunomodulatory properties as well as anti-cancer, anti-viral,
chemoattractive, and insulin-releasing activities. Consequently, it is more informative, therefore,
to refer to them as host-defense peptides rather than as exclusively antimicrobial peptides [4]. It is a
common fallacy that all anurans produce host-defense peptides in their skin secretions. At the time
of writing peptides with antimicrobial activity have been identified in the skins of frogs from species
belonging to the Alytidae, Bombinatoridae, Hylidae, Hyperoliidae, Leiopelmatidae, Leptodactylidae,
Myobatrachidae, Pipidae, and Ranidae families [2,3]. The sporadic species distribution suggests
that production of cytotoxic peptides in the skin may confer some evolutionary advantage to the
organism, but is not necessary for survival. It has been suggested that cutaneous symbiotic bacteria
may provide the major system of defense against pathogenic microorganisms in the environment with
antimicrobial peptides assuming a supplementary role in some species [2]. In the laboratory or in
the field, mild electrical stimulation or injections of norepinephrine into the dorsal sac are effective
methods of inducing secretion of skin peptides that do not appear to cause harm or undue distress to
the animal [5].
Frog skin host-defense peptides vary in size from as small as eight up to 63 amino acid residues.
A comparison of their amino acid sequences reveals the lack of any conserved domains that are
associated with biological activity. However, with few exceptions, the peptides are cationic, generally
with a charge of between +2 and +6 at pH 7 due to the presence of multiple lysine residues, and contain
about 50% hydrophobic amino acids. At the time of writing, the Antimicrobial Peptide Database
(http://aps.unmc.edu/AP) lists 929 amphibian host-defense peptides, 96% of which have a charge of
between +1 and +6 and 90% have between 40% and 70% hydrophobic residues. Circular dichroism and
NMR studies have shown that they generally lack stable secondary structure in aqueous solution, but
have the propensity to form an amphipathic α-helix in the environment of a phospholipid vesicle or in
a membrane-mimetic solvent such as 50% trifluoroethanol-water [2,3]. There is no single mechanism
by which peptides produce cell death, but their action does not involve binding to a specific receptor
rather a non-specific interaction with the bacterial cell membrane that results in permeabilization
and ultimate disintegration [6,7]. Consequently, the frog skin peptides are usually active against
microorganisms that are resistant to currently licensed antibiotics due to their markedly different and
highly destructive mode of action.
The frog skin host-defense peptides may be grouped together in sets or families on the basis of
limited similarities in amino acid sequence. Skin secretions from a single species frequently contain
several members of a particular peptide family that are presumed to have arisen from multiple
duplications of an ancestral gene. The molecular heterogeneity of the peptides within a particular family
is considerable and this variation in primary structure is reflected in a wide variability in antimicrobial
potencies and specificities for different microorganisms. It has been suggested that this multiplicity may
provide a broader spectrum of defense against the range of pathogenic microorganisms encountered in
the environment [8] but conclusive evidence to support this assertion is still required.
A major obstacle to the development of frog skin peptides as therapeutically valuable anti-infective
agents, particularly if they are to be administered systemically, is their varying degrees of cytotoxicity
to mammalian cells and their short-lives in the circulation. However, effective strategies have
been developed to design analogs of the naturally occurring peptides that maintain or increase
antimicrobial potency while displaying reduced cytotoxicity to human cells, such as erythrocytes [9–11].
Peptides administered to infected skin or skin lesions can penetrate into the stratum corneum to kill
microorganisms so that future therapeutic applications are more likely to involve topical rather than
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systemic administration. This review will examine possible clinical application of well characterized
peptides that have been isolated from skin secretions from African clawed frogs belonging to the
family Pipidae together with analogs of the naturally occurring peptides that show improved
therapeutic potential.
2. The Family Pipidae
The Pipidae are the only principally aquatic group of frogs and, at this time, the taxon comprises 33
well characterized species distributed in five genera: Hymenochirus, Pipa, Pseudhymenochirus, Silurana,
and Xenopus [12]. All are found in Africa south of the Sahara, except for members of the genus
Pipa which are found in South America. Pipidae is sister-group to Rhinophrynidae (represented by
a single species, the Mexican burrowing toad Rhinophrynus dorsalis) and the two families are united
in the Pipoidea [13]. Phylogenetic relationships within the Pipidae are not entirely clear. Molecular
analyses based upon the comparison of the nucleotide sequences of mitochondrial [14–16] and multiple
nuclear [17] genes strongly support sister-group relationships between Silurana and Xenopus, united in
the monophyletic clade Xenopodinae. Molecular data also provide support for Pipa as sister-group to
all other extant pipids [16,18,19]. The origin of the Pipidae is at least Late Jurassic (150 MYA) and it is
suggested that the breakup of Gondwanaland led to the establishment of Pipa in South America and
the remaining genera (Xenopus + Silurana + Hymenochirus + Pseudhymenochirus) in Africa [17,20].
The clawed frogs of the genus Xenopus currently comprise 19 well characterized species although
several unnamed species have been reported [12]. The genus has a complex evolutionary history
involving both bifurcating and reticulating modes of speciation [14,15]. Allopolyploidization events, in
which two species hybridize and the descendant inherits the complete genome of both ancestors, have
given rise to tetraploid, octoploid, and dodecaploid species with no extant Xenopus species retaining
the diploid status that is thought to be related to the ancestral state existing prior to one or more
whole genome duplications. At this time, the ten tetraploid Xenopus species have been divided into
three species groups on the basis of similarities in morphology, advertisement calls, and/or nucleotide
sequences of mitochondrial genes: the laevis group includes X. laevis, X. gilli, X. largeni, X. petersii, and
X. victorianus; the muelleri group includes X. muelleri, X. borealis, and X. clivii; and the fraseri group
includes X. fraseri and X. pygmaeus [14,21]. It has been proposed that the seven extant octoploid species
arose from three distinct allopolyploidization events [22]. Thus, X. lenduensis and X. vestitus share
a common tetraploid ancestor; X. amieti, X. andrei, and X. boumbaensis form a second group; and X.
itombwensis and X. wittei constitute a third group. Further allopolyploidization events involving a
tetraploid species and an octoploid species within the second group have given rise to the dodecaploid
species X. longipes and X. ruwenzoriensis.
The tropical clawed frog Silurana tropicalis retains the diploid status (chromosome number 2n = 20)
that is thought to be related to the ancestral state but putative allopolyploidization events within the
Silurana lineage have given rise to the Cameroon clawed frog S. epitropicalis with chromosome number
2n = 40 as well as at least two further unnamed tetraploid species [12,23]. The monotypic genus
Pseudhymenochirus is accepted as sister group to genus Hymenochirus (African dwarf frogs) which
includes four described species [12]. No allopolyploidization and higher level of ploidy have been
reported for species belonging to these two genera [17].
3. Peptides with Antimicrobial Activity
Although peptides with hemolytic activity had been identified in skin secretions of frogs from the
genera Bombina and Rana earlier, X. laevis was the first amphibian species in whose skin peptides with
antimicrobial activity (magainin-1 and -2) were unambiguously identified [24]. Subsequent analysis
of X. laevis skin secretions has led to the isolation and characterization of peptide glycine-leucine
amide (PGLa) and additional antimicrobial peptides with varying potencies and specificities that
are derived from the post-translational processing of the biosynthetic precursors of caerulein and
xenopsin [25,26]. These peptides have been termed caerulein precursor fragment (CPF) and xenopsin
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precursor fragment (XPF). A comparison of the amino acid sequences of procaerulein, promagainin,
and proxenopsin, deduced from the nucleotide sequences of cDNAs, reveals significant structural
similarity in the N-terminal regions of the precursors suggesting that the peptides may have evolved
from a common ancestral gene by a series of duplication events [27]. Orthologs of magainin-1 and -2,
PGLa, and CPF, and XPF have been identified in skin secretions of range of frog species belonging
to the genus Xenopus (X. amieti [28], X. andrei [29], X. borealis [30], X. clivii [31], X. lenduensis [32], X.
muelleri and an incompletely characterized species from West Africa referred to as “Xenopus new
tetraploid 1” and provisionally designated X. muelleri West [33], X. petersii [32], X. pygmaeus [32], and X.
victorianus [34]). Host-defense peptides have also been isolated from laboratory-generated F1 hybrids
of X. laevis × X. muelleri [35] and X. laevis × X. borealis [36]. Evolutionary pressure to conserve the
primary structures of the antimicrobial peptides from Xenopus species has not been strong and the
sequences of the procaerulein- and proxenopsin-derived peptides are particularly variable.
Peptides that belong to the PGLa family (PGLa-ST1, originally designated XT-5), the CPF family
(CPF-ST1, -ST2, and -ST3, originally designated XT-1, XT-6, and XT-7), and the XPF family (XPF-ST1,
-ST2, and -ST3 originally designated XT-2, XT-3, and XT-4) have been isolated from skin secretions
of the diploid frog S. tropicalis [37]. Although a magainin peptide was not identified in S. tropicalis
skin secretions, a search of the S. tropicalis genome database reveals the presence of a gene encoding a
magainin-related peptide (referred to in this article as magainin-ST1) [38]. Peptides belonging to the
magainin family (magainin-SE1), the PGLa family (PGLa-SE1 and -SE2), the CPF family (CPF-SE1,
-SE2 and -SE3), and the X PF family (XPF-SE1, SE-2, SE-3 and -SE4), have been isolated from skin
secretions of the tetraploid from S. epitropicalis [39].
More recently, peptidomic analysis of norepinephrine-stimulated skin secretions from the
Congo dwarf clawed frog Hymenochirus boettgeri [40] and Merlin’s clawed frog Pseudhymenochirus
merlini [41] has led to identification of a family of structurally related host-defense peptides, termed
the hymenochirins, with broad-spectrum antimicrobial activity. The hymenochirins show very low
structural similarity with the antimicrobial peptides isolated from skin secretions of Silurana and Xenopus
species consistent with the proposed ancient divergence of the Xenopodinae and the sister-group genera
Hymenochirus and Pseudhymenochirus [17,18]. The strongly conserved hymenochirins from P. merlini
show closest structural similarity to hymenochirin-1 and hymenochirin-5 from H. boettgeri. Peptides with
novel structural features and broad spectrum antimicrobial activity, termed pseudhymenochirin-1Pa,
-1Pb, and -2Pa, were also isolated from P. merlini secretions [41]. Unexpectedly, skin secretions from
those frogs from the genus Pipa examined to date (Pipa pipa and Pipa parva) do not appear to contain
cytotoxic peptides (unpublished data).
3.1. Magainins
The primary structures of the magainin peptides isolated to date from species in the genera
Xenopus and Silurana are shown in Figure 1. Although probably the most intensively studied of all
frog skin host-defense peptides, the magainins from the South African clawed frog X. laevis have
only low or moderate antimicrobial potency against microorganisms. The hemolytic activity against
human erythrocytes of magainin-2 in phosphate-buffered saline is low (the concentration producing
50% hemolysis, LC50 > 100 μM) but the peptide is strongly hemolytic when tested in 1 mM potassium
phosphate buffer supplemented with 287 mM glucose (LC50 = 7 μM) [42]. Several recent studies
have investigated in detail the mechanism of action by which magainin-2 produces bacterial cell
death [43–45].
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Magainin 
X. laevis-1 GIGKFLHSAGKFGKAFVGEIMKS 
X. laevis-2 GIGKFLHSAKKFGKAFVGEIMNS 
S. tropicalis-ST1 GLKEVAHSAKKFAKGFISGLTGS 
S. epitropicalis-SE1 GLKEVLHSTKKFAKGFITGLTGQ 
X. petersii-P1 GIGKFLHSAGKFGKAFVGEIMKS 
X. petersii-P2 GIGQFLHSAKKFGKAFVGEIMKS 
X. borealis-B1 G**KFLHSAGKFGKAFLGEVMIG 
X. borealis-B2 GIGKFLHSAGKFGKAFLGEVMKS 
X. muelleri-M1 GIGKFLHSAGKFGKAFIGEIMKS 
X. muelleri-M2  GFKQFVHSLGKFGKAFVGEMIKPK 
X. muelleri West-MW1 GIGKFLHSAGKFGKAFLGEVMKS 
X. laevis × X. muelleri-LM1 GIGKFLHSAKKFAKAFVGEIMNS 
X. clivii-C1 GVGKFLHSAKKFGQALASEIMKS 
X. clivii-C2 GVGKFLHSAKKFGQALVSEIMKS 
X. pygmaeus-PG1 GVGKFLHAAGKFGKALMGEMMKS 
X. pygmaeus-PG2 GVSQFLHSASKFGKALMGEIMKS 
X. lenduensis-L1 GIGKFLHSAKKFGKAFVGEVMKS 
X. lenduensis-L2 GISQFLHSAKKFGKAFAGEIMKS 
X. amieti-AM1 GIKEFAHSLGKFGKAFVGGILNQ 
X. amieti-AM2 GVSKILHSAGKFGKAFLGEIMKS  
X. andrei-AN1 GIKEFAHSLGKFGKAFVGGILNQ 
X. andrei-AN2 GVSKILHSAGKFGKAFLGEIMKS 
Figure 1. Primary structures of the magainin peptides isolated from skin secretions of frogs belonging
to the genera Xenopus and Silurana. The amino acid sequence of magainin-ST1 was deduced from the
corresponding nucleotide sequence of genomic DNA. In order to maximize structural similarity, gaps
denoted by * have been introduced into some sequences. Strongly conserved residues are shaded.
A large number of analogs of magainin-2 have been synthesized with a view to increasing
antimicrobial potency while decreasing hemolytic activity [46,47]. These include hybrid peptides
comprising fragments of magainin-2 coupled to fragments of other antimicrobial peptides such as
cecropin A(1-8)-magainin-2(1-12) which displays strong antimicrobial activity against a range of
antibiotic resistant bacterial and fungal strains and low hemolytic activity [48]. Adopting the strategy
of increasing cationicity to promote antimicrobial potency has led to the development of the analogue,
pexiganan (MSI-78) which represents an analogue of magainin-2 that contains an additional five lysyl
residues and an α-amidated C-terminus [49]. It was developed initially as a topical anti-infective
agent for the treatment of infected foot ulcers in diabetic patients and as a possible treatment for
impetigo. Pexiganan showed broad-spectrum antibacterial activity when tested against 3,109 clinical
isolates of Gram-positive and Gram-negative aerobic and anaerobic bacteria [50]. The minimum
inhibitory concentration (MIC) at which 90% of isolates were inhibited (MIC90) was less than or equal
to 32 μg/mL for several pathogens that are commonly recovered from diabetic foot wounds, including
Staphylococcus spp., Streptococcus spp., Corynebacterium spp., Pseudomonas spp., Acinetobacter spp.,
Bacteriodes spp., Peptostreptococcus spp., and Escherichia coli. For 92% of the isolates tested, minimum
bactericidal concentration (MBC) was the same or within a twofold difference of the MIC, consistent
with a bactericidal action. A related study involving 2,515 bacterial isolates from infected foot ulcers
from diabetic patients produced similar results with MIC90 values for pexiganan of 16 μg/mL or less
for a range of Gram-positive aerobes, Gram-negative aerobes and facultative anaerobes [51]. Proteus
spp. and Serratia spp. are also known to colonize foot ulcers but, in common with most frog skin
peptides, pexiganan was inactive against strains of Proteus mirabilis and Serratia marcescens. In phase
III multicentre, randomised, double-blind trials in diabetic patients with infected foot ulcers, topical
application of pexiganan acetate (1%) achieved clinical cure or improvement in about 90% of patients,
a success rate comparable to oral ofloxacin (800 mg/day) used in the control group [52]. The study
indicated that the agent was well tolerated. However, the Food and Drug Administration did not
approve marketing of this agent on the grounds that efficacy has not been sufficiently demonstrated.
Other examples of activity of magainin-2 and its analogues against important human pathogens
include Helicobacter pylori [53], Salmonella typhimurium [54], the anaerobic periodontal pathogens,
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Porphyromonas gingivalis, Fusobacterium nucleatum, and Prevotella loeschei [55], and Acanthamoeba
polyphagia, a protozooan responsible for ocular infection in contact lens wearers [56].
3.2. Peptide Glycine-Leucine-Amide (PGLa) Peptides
The primary structures of the PGLa peptides isolated to date from species in the genera Xenopus
and Silurana are shown in Figure 2. Although PGLa from X. laevis has often been used as a model
peptide to study membrane-peptide interactions, its therapeutic potential as an anti-infective agent
has not been extensively investigated. PGLa from X. laevis is active against amphotericin B-resistant
Candida albicans, Candida krusei, and Aspergillus fumigatus strains and against a fluconazole-resistant
Candida glabrata isolate [57]. PGLa acts synergistically with magainin-2 both in killing E. coli and
permeabilizing protein-free liposomes so that the peptides are much more potent when added together
than when added alone [58]. The mechanism of action of the peptide alone [59] and in combination
with magainin-2 [60] has been studied in detail.
PGLa-AM1 from X. amieti shows broad spectrum bactericidal activity with MIC values ≤ 25 μM
against reference strains of E. coli and S. aureus combined with very low toxicity to human red blood
cells (LC50 > 500 μM) [28]. PGLa-AM1 shows potent growth-inhibitory activity against clinical isolates
of antibiotic-resistant A. baumannii, including strains that are resistant to colistin (MIC in the range
4–32 μM) [61]. The peptide is also active against multiple clinical isolates of antibiotic-resistant
S. maltophilia (MIC in the range 2–16 μM) (unpublished data).
PGLa-AM1 from X. amieti showed potent growth-inhibitory activity against reference stains of
both Gram positive (Streptococcus mutans MIC = 1.2 μM) and Gram negative (F. nucleatum MIC = 1.5 μM)
oral bacteria that are associated with tooth decay and periodontal disease. When tested against the
opportunistic yeast pathogen C. albicans, PGLa-AM1 also proved to be highly effective (MIC = 7.5 μM).
PGLa-AM1 showed no cytotoxicity to primary dental pulp fibroblasts at concentrations up to 10 μM
and did not stimulate production of the proinflammatory cytokine IL-8 (unpublished data).
PGLa 
X. laevis GMASKAGAIAGKIAKVALK*ALa 
S. tropicalis-ST1 GMATKAGTALGKVAKAVIGAALa 
S. epitropicalis-SE1 GMATKAGTALGKVAKAVIGAALa 
S. epitropicalis-SE2 GMATAAGTTLGKLAKFVI*GAVa 
X. petersii-P1 GMASTAGSIAGKIAKVALK*ALa 
X. borealis-B1 GMASKAGTIAGKIAKTAIKLALa 
X. borealis-B2 GMASKAGSIVGKIAKIAL*GALa 
X. muelleri West-MW1 GMASKAGSVLGKITKIAL*GALa 
X. muelleri West-MW2 GMASKAGAIAGKIAKTAIKLALa 
X. laevis × X. muelleri-LM1 GMASKAGSVAGKIAKFAL*GALa 
X. pygmaeus-PG1 GMASKAGTIVGKIAKVAL*NALa 
X. lenduensis-L1 GMASTAGSIFGKLAKTAL*GALa 
X. lenduensis-L2 GMASTAGSVLGKLAKVAIKAALa 
X. lenduensis-L3 GMASTAGSVLGKLAKVAL*GALa 
X. lenduensis-L4 GMASTVGSIFGKLAKTAL*GALa 
X. amieti-AM1 GMASKAGSVLGKVAKVALKAALa 
X. amieti-AM2 GMASTAGSVLGKLAKAVAIGALa 
X. andrei-AN1 GMASKAGSVLGKVAKVALKAALa 
X. andrei-AN2 GMASKAGSVLGKLAKVAI*GALa 
Figure 2. Primary structures of the peptide glycine-leucine-amide (PGLa) peptides isolated from skin
secretions of frogs belonging to the genera Xenopus and Silurana. a denotes C-terminal α-amidation.
In order to maximize structural similarity, gaps denoted by * have been introduced into some sequences.
Strongly conserved residues are shaded.
3.3. Caerulein Precursor Fragment (CPF) Peptides
The primary structures of the CPF peptides and CPF-related peptides isolated to date from
species in the genera Xenopus and Silurana are shown in Figure 3. CPF-C1, the most abundant
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antimicrobial peptide in skin secretions of X. clivii, inhibits the growth of the Gram-negative bacteria
E. coli, A. baumannii, K. pneumoniae, and P. aeruginosa (MIC in the range 3–25 μM), suggesting potential
for development into an anti-infective agent for use against these emerging antibiotic-resistant
pathogens [31]. CPF-AM1 from X. amieti shows broad spectrum bactericidal activity with MIC values
≤ 25 μM against reference strains of E. coli and S. aureus combined with moderate toxicity to human red
blood cell (LC50 = 150 μM) [28]. The peptide shows potent growth-inhibitory activity against clinical
isolates of multidrug-resistant A. baumannii, including strains that are resistant to colistin (MIC in the
range 2–8 μM) [61]. CPF-AM1 is also active against multiple clinical isolates of antibiotic-resistant
S. maltophilia (MIC in the range 2–8 μM) (unpublished data). Like PGLa-AM1, CPF-AM1 showed
potent growth inhibitory activity against reference strains of a range of microorganisms associated with
the oral cavity, such as S. mutans (MIC = 2.5 μM), Lactobacillus acidophilus (MIC = 2.5 μM), F. nucleatum
(MIC = 2.2 μM), and C. albicans (MIC = 9.9 μM) and was not cytotoxic to primary dental pulp fibroblasts
at concentrations up to 10 μM (unpublished data).
CPF 
X. laevis-1 GLASFLGKALKAGL*KIGAHLLGGAP*QQ 
X. laevis-2 GFASFLGKALKAAL*KIGANMLGGTP*QQ 
X. laevis-3 GFGSFLGKALKAAL*KIGANALGGSP*QQ 
X. laevis-4 GLASLLGKALKAGL*KIGTHFLGGAP*QQ 
X. laevis-5 GFGSFLGKALKTAL*KIGANALGGSP*QQ 
X. laevis-6 GFASFLGKALKAAL*KIGANMLGGAP*QQ 
X. laevis-7 GFGSFLGKALKAAL*KIGANALGGAP*QQ 
S. tropicalis-ST1 GFLGPLLKLAAKGVAKVIPHLI**PSRQQ 
S. epitropicalis-SE1 GFLGPLLKLGLKGVAKVIPHLI**PSRQQ 
S. epitropicalis-SE2 GFLGPLLKLGLKGAAKLLPQLL**PSRQQ 
X. petersii-P1 GFGSFLGKALKAAL*KIGANALGGAP*QQ 
X. petersii-P2 GLASFLGKALKAGL*KIGSHLLGGAP*QQ 
X. petersii-P3 GFGSFLGKALKAAL*KIGANVLGGAP*QQ 
X. petersii-P4 GFGSFLGKALKAAL*KIGANVLGGAP*EQ 
X. petersii-P5 GFGSFLGKALKAAL*KIGADVLGGAP*QQ 
X. borealis-B1 GLGSLLGKAFKIGL*KTVGKMMGGAPREQ 
X. borealis-B2 GLGSLLGSLFKFIP*K****LL**PSIQQ 
X. muelleri-M1 GLGSLLGKAFKFGL*KTVGKMMAGAPREQ 
X. muelleri-M2 GLGSLLGKAFKFGL*KTVGKMMAGAPREE 
X. muelleri West-MW1 GLGSLLGKAFKFGL*KTVGKMMGGAPREQ 
X. muelleri West-MW2 GLGSLLGKAFKFGL*KTVGKMMGGAPREE 
X. laevis × X. muelleri-LM1 GFGSFLGSLFKTGL*KIIPKLL**PSIQ 
X. clivii-C2 GLGSLLGKALKFGL*KAAGKFMGGEP*QQ 
X. pygmaeus-PG2 GFGSFLGKALKAGL*KLGANLLGGAP*QQ 
X. pygmaeus-PG3 GFGSLLGKALKAGL*KLGANLLGGAP*QQ 
CPF-related 
S. tropicalis-ST2 GFLGSLLKTGLKV****GSNLLa 
S. tropicalis-ST3 GLLGPLLKIAAKV****GSNLLa 
S. epitropicalis-SE3 GFLGSLLKTGLKV****GSNLLa 
X. clivii-C1 GFGSLLGK*ALRL****GANVLa 
X. lenduensis-L1 GIGSLLAK*AAKL****GANLLa 
X. lenduensis-L2 GIGSALAK*AAKL****VAGIVa 
X. lenduensis-L3 GLGTFLGN*ALKTGLKIGANLLa 
X. amieti-AM1 GLGSVLGK*ALKI****GANLLa 
X. amieti-AM2 GIGSALAK*AAKL****VAGIVa 
X. amieti-AM4 GLGSLVGN*ALRI****GAKLLa 
X. andrei-AN1 GFASVLGK*ALKL****GANLLa 
Figure 3. Primary structures of the caerulein precursor fragment (CPF) peptides isolated from skin
secretions of frogs belonging to the genera Xenopus and Silurana. a denotes C-terminal α-amidation.
In order to maximize structural similarity, gaps denoted by * have been introduced into some sequences.
Strongly conserved residues are shaded.
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The CPF-related peptide, CPF-ST3 from S. tropicalis (formerly described as peptide XT-7 [37]),
shows potent broad spectrum antimicrobial activity but is moderately hemolytic against human
erythrocytes (LC50 = 140 μM) thus limiting its therapeutic applicability. However, the analog [G4K]
CPF-ST3 is non-hemolytic (LC50 > 500 μM) and retains potent antimicrobial activity [62]. Proton NMR
spectroscopy has demonstrated that the reduced toxicity of the analog correlates with a decrease in
helicity as well as an increase in cationicity [63]. CPF-SE2 (MIC = 2.5 μM) and CPF-SE3 (MIC = 5 μM)
from S. epitropicalis show potent growth-inhibitory activity against a range of clinical isolates of
MRSA but their utility as systemic anti-infective drugs is again limited by appreciable hemolytic
activity against human erythrocytes for CPF-SE2 (LC50 = 50 μM) and moderate activity for CPF-SE3
(LC50 = 220 μM) [39]. Nevertheless, the peptides may find application as topical agents in treatment of
MRSA skin infections and decolonization of MRSA carriers.
3.4. Xenopsin Precursor Fragment (XPF) Peptides
The primary structures of the XPF peptides isolated to date from species in the genera Xenopus and
Silurana are shown in Figure 4. XPF peptides are widely distributed in skin secretions of clawed frogs
and have also been identified in the gastrointestinal tract of X. laevis [64]. However, the antimicrobial
potencies of XPF peptides are generally lower than those of CPF peptides and their potential for
development into anti-infective agents has not been well studied. Of those XPF peptides studied to date,
XPF-C1 from X. clivii shows relatively high growth-inhibitory potency against E. coli (MIC = 12.5 μM)
but was inactive against S. aureus [31].
XPF  
X. laevis-1 GWASKIGQTLGKIAKVGLQGLMQPK 
X. laevis-2 GWASKIGQTLGKIAKVGLKELIQPK 
S. tropicalis-ST1 GLASTLGSFLGKFAKGGAQAFLQPK 
S. tropicalis-ST2 GVWSTVLGGLKKFAKGGLEAIVNPK 
S. tropicalis-ST3 GVFLDA***LKKFAKGGMNAVLNPK 
S. epitropicalis-SE1 GLFLDT***LKKFAKAGMEAVINPK 
S. epitropicalis-SE2 GLASTIGSLLGKFAKGGAQAFLQPK 
S. epitropicalis-SE3 GFWTTAAEGLKKFAKAGLASILNPK 
S. epitropicalis-SE4 GVWTTILGGLKKFAKGGLEALTNPK 
X. borealis-B1 GFKQFVHSM*GKFGKAFVGEIINPK 
X. borealis-B2 GWASKIGTQLGKMAKVGLKEFVQS 
X. muelleri-M1 GWASKIGQTLGKMAKVGLKDLIQA 
X. muelleri West-MW1 GWASKIGQTLGKLAKVGLKEFAQS 
X. clivii-C1 GWASKIGQALGKVAKVGLQQFIQPK 
X. amieti-AM1 GWASKIAQTLGKMAKVGLQELIQPK 
X. andrei-AN1 GWVSKIGQTLGKMAKVGLQELIQPK 
Figure 4. Primary structures of the xenopsin precursor fragment (XPF) peptides isolated from skin
secretions of frogs belonging to the genera Xenopus and Silurana. In order to maximize structural
similarity, gaps denoted by * have been introduced into some sequences. Strongly conserved residues
are shaded.
3.5. Hymenochirins
The primary structures of the hymenochirins isolated to date from H. boettgeri and P. merlini
are shown in Figure 5. Hymenochirin-1B was first isolated from norepinephrine-stimulated skin
secretions from the Congo dwarf clawed frog H. boettgeri [40]. The peptide is cationic (molecular
charge = +6 at pH 7) and has the propensity to adopt an amphipathic α-helical conformation in a
membrane-mimetic environment. Hymenochirin-1B displays moderate growth-inhibitory activity
against reference strains of Gram-negative (E. coli MIC = 25 μM) and Gram-positive bacteria (S. aureus
MIC = 12.5 μM) and its hemolytic activity against human erythrocytes is relatively low (LC50 = 213 μM).
Analogs in which the Pro5, Glu6 and Asp9 on the hydrophilic face of the α-helix are substituted by one
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or more L-lysine residues show increased antimicrobial potency (up to 8-fold) but the peptides are
more hemolytic. Increasing the cationicity of hymenochirin-1B while reducing helicity by substitutions
with D-lysine generates analogs that are between 2- and 8-fold more potent than the native peptide and
are equally or less hemolytic. [E6k,D9k]hymenochirin-1B represents a candidate for drug development
as it shows high potency against clinical isolates of MRSA and a range of Gram-negative bacteria,
including multidrug-resistant strains of A. baumannii and S. maltophilia (MIC in the range 0.8–3.1 μM)
and New Dehli Metallo-β-Lactamase-1 (NDM-1)-producing clinical isolates of K. pneumoniae, E. coli,
Enterobacter cloacae and Citrobacter freundii (MIC in the range 3.1–6.25 μM), and low hemolytic activity
(LC50 = 302 μM) [65].
Hymenochirins 
H. boettgeri-1 IKLSPETKDNLKKVLKGAIKGAIAVAKMVa 
H. boettgeri-2 LKIPGFVKDTLKKVAKGIFSAVAGAMTPS 
H. boettgeri-3 IKIPAVVKDTLKKVAKGVLSAVAGALTQ 
H. boettgeri-4 IKIPAFVKDTLKKVAKGVISAVAGALTQ 
H. boettgeri-5 IKIPPIVKDTLKKVAKGVLSTIAGALST 
P. merlini-1Pa LKLSPKTKDTLKKVLKGAIKGAIAIASMAa 
P. merlini-1Pb LKLSPETKDTLKKVLKGAIKGAIAIASLAa 
P. merlini-5Pa ITIPPIVKDTLKKFFKGGIAGVMGKSQ 
P. merlini-5Pb FKIPPIVKDTLKKFFKGGIAGVMGQ 
P. merlini-5Pc ITIPPIIKDTLKKFFKGGIAGVMGKSQ 
P. merlini-5Pd ITIPPIVKDTLKKFFKGGIAGVMGQ 
P. merlini-5Pe ITIPPIVKDTLKKFIKGAISGVMa 
P. merlini-5Pf ITIPPIVKDTLKKFFKGGIAGVLGQ 
P. merlini-5Pg ITIPPIVKDTLKKFIKGAISSVMa 
P. merlini-5Ph ITIPPIVKNTLKKFIKGAVSALMS 
Pseudhymenochirins 
P. merlini-1Pa IKIPSFFRNILKKVGKEAVSLMAGALKQS 
P. merlini-1Pb IKIPSFFRNILKKVGKEAVSLIAGALKQS 
P. merlini-2Pa GIFPIFAKLLGKVIKVASSLISKGRTE 
Figure 5. Primary structures of the hymenochirins isolated from skin secretions of the frogs
Hymenochirus boettgeri and Pseudhymenochirus merlini, and the pseudhymenochirins from P. merlini. a
denotes C-terminal α-amidation. Strongly conserved residues are shaded.
Close upPreliminary data indicate that hymenochirin-1Pa, pseudhymenochirin-1Pb, and
pseudhymenochirin-2Pa from P. merlini also show potent growth-inhibitory potency against
multidrug-resistant clinical isolates of S. aureus, Staphylococcus epidermidis, A. baumannii, and S. maltophilia
but are more hemolytic than hymenochirin-1B (unpublished data).
4. Peptides with Anti-Cancer Activity
The problems posed by the emergence of multidrug resistance in the treatment of bacterial
infections are also encountered in cancer chemotherapy. Because of their non-specific and destructive
mechanism of action, cell-penetrating peptides show therapeutic potential for development into
anti-cancer agents in cases where the tumor is not responsive to conventional pharmaceutical therapy.
In addition, certain cationic antimicrobial peptides can produce tumor cell death by instigating
apoptosis via mitochondrial membranes disruption and act as anti-angiogenic factors [66]. Analogs of
naturally occurring frog skin host-defense peptides, including those from species within the family
Pipidae, have been developed that show selective cytotoxicity against tumor cells and so have potential
for development into anti-cancer agents.
Magainin-2 and its C-terminally α-amidated, carboxypeptidase-resistant analog, magainin G
show potential as anticancer agents displaying tumoricidal activity against human small cell lung
cancer cell lines [67], the RT4, 647V, and 486P bladder cancer cell lines [68], and against suspension
cultures of a wide range of hematopoietic cell lines [69]. Out of a range of antimicrobial peptides
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tested, the magainin-2 analog, pexiganan shows the greatest cytotoxic activity against the U937 human
histiocytic lymphoma cell line [70]. The anti-tumor activity of protease-resistant all D-amino acid
magainin-2 amide (MSI-238) is markedly superior to the parent compound displaying high potency
in vitro against non-small cell lung adenocarcinoma A549 cells and in vivo against P388 leukemia, S180
ascites, and a spontaneous ovarian tumor [71]. The cytotoxic mechanism of [F5W]magainin-2 against
HeLa cells, has been investigated and involves initial interaction of the peptide with cell surface
gangliosides [72].
Hymenochirin-1B shows high cytotoxic potency against A549 cells (LC50 = 2.5 μM), breast
adenocarcinoma MDA-MB-231 cells (LC50 = 9.0 μM), colorectal adenocarcinoma HT-29 cells
(LC50 = 9.7 μM), and hepatocarcinoma HepG2 cells (LC50 = 22.5 μM) with appreciably less hemolytic
activity against human erythrocytes (LC50 = 213 μM) [73]. Structure-activity relationships were
investigated by synthesizing analogs of hymenochirin-1B in which Pro5, Glu6 and Asp9 on the hydrophilic
face of the peptide helix are replaced by one or more L-lysine or D-lysine residues. The [D9K] analog
displays the greatest increase in potency against all four cell lines (up to 6-fold) but hemolytic activity also
increases (LC50 = 174 μM). The [D9k] and [E6k,D9k] analogs retain relatively high cytotoxic potency
against the four tumor cell lines (LC50 in the range 2.1–21 μM) but show reduced hemolytic activity
(LC50 > 300 μM).
CPF-ST3 (peptide XT-7) from S. tropicalis shows only moderate cytotoxic potency against
HepG2 cells (LC50 = 75 μM) but increasing the cationicity of the peptide by appropriate amino
acid substitutions by L-lysine that preserve amphipathicity results in a progressive increase in activity
([S15K] CPF-ST3, LC50 = 24 μM; ([S15K,N16K]CPF-ST3, LC50 = 10 μM; ([P5K,S15K,N16K] CPF-ST3,
LC50 = 5 μM) [62].
5. Peptides with Anti-Viral Activity
Viruses cannot reproduce independently and instead use host cells for replication. Finding targets
for an antiviral drug that would interfere specifically with the virus without harming the host cells
poses a challenge for designing of safe and effective antivirals. Viral life cycles vary in their precise
details depending on the species of virus but all share a general pattern: binding to a specific receptor
on the surface of the host cell, uncoating of the virus inside the cell to release its genome, replication
using host-cells machinery, assembly of virus progeny and release of viral particles to infect new host
cells. Viruses that have a lipid envelope must also fuse their envelope with the target cell, or with a
vesicle that transports them into the cell, before they can uncoat. Certain peptides that are present
in frog skin secretions have demonstrated potent antiviral activity, either by directly inactivating the
virus particles or by interfering with the initial steps of the viral reproductive cycle such as binding to
specific cell surface receptors and subsequent entry into the cytoplasm. These properties, combined
the short contact time required to induce killing, have led to their consideration as candidates for
development into novel antiviral agents.
Magainin-1 and -2 from X. laevis show antiviral properties against herpes simplex virus type
1 (HSV-1) and herpes simplex virus type 2 (HSV-2) but were inactive against the arenavirus, Junin
virus The peptides do not appear to inactivate the HSV particles directly but rather target important
steps in the viral reproductive cycle [74]. Magainin-2 and PGLa from X. laevis markedly reduced the
infectivity of channel catfish virus but were less potent against frog virus 3 [75]. Magainin-1 was
ineffective against both viruses. Mechanistic studies have shown that an Ala-substituted magainin-2
amide analog directly inactivates vaccinia virus by disrupting and removing the outer membrane
envelope [76].
Both CPF-AM1 and PGLa-AM1 from X. amieti are capable of destroying more than 90% of
extracellular HSV-1 virions within the first 5 min of direct contact (unpublished data). In addition, these
two peptides inhibit the viral penetration and replication in Madin-Darby Bovine Kidney (MDBK) cells
when applied at non-toxic concentrations (≤200 μM). Similarly, CPF-ST3 (peptide XT-7) can destabilize
HSV-1 particles and block virus entry and/or replication with EC50 = 87 μM (unpublished data).
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For additional amphibian peptides with anti-bacterial, anti-viral and anti-cancer activities, interested
readers may refer to the antimicrobial peptide database at http://aps.unmc.edu/AP.
6. Conclusions
The antimicrobial and hemolytic activities of the peptides showing the greatest potential for
development into therapeutically valuable anti-infective agents are summarized in Table 1. Over 25
years have passed since the discovery of the magainins in the skin of the African clawed frog, X. laevis.
Despite displaying potent activity against strains of antibiotic-resistant bacteria and against certain
pathogenic fungi and protozoa, the therapeutic potential of frog skin antimicrobial peptides has yet
to be realized. Currently, no anti-infective peptide based upon their structures has been adopted in
clinical practice. Consequently, interest is moving away from their use as antimicrobials towards other
potential clinical applications.
Table 1. Minimum Inhibitory Concentrations (μM) and hemolytic activities against human erythrocytes





















[G4K]CPF-ST3 12.5 6.25 ND 1.6–3.1 ND ND >500
PGLa-AM1 12.5 25 ND 4–32 2–16 ND >500
CPF-AM1 12.5 6.25 ND 2–8 2–8 25 150
CPF-C1 6.25 6.25 ND 3.1 ND 25 140
CPF-SE2 40 2.5 2.5 ND ND ND 50
CPF-SE3 40 2.5 5 ND ND ND 220
[E6k,D9k]
hymenochirin-1B 3.1 1.6 3.1–6.25 1.6 0.8–3.1 3.1–6.25 300
ND: not determined.
Several frog peptides that were first identified on the basis of their abilities to inhibit growth of
bacteria have been shown to stimulate release of insulin from BRIN-BD11clonal β-cells and improve
glucose tolerance in mice and so show potential for treatment of patients with Type 2 diabetes (reviewed
in [77]). For example, CPF-1, CPF-3, CPF-5 and CPF-6 from X. laevis and CPF-SE1 from S. epitropicalis
produced a significant increase in the rate of insulin release from BRIN-BD11 cells at concentrations
as low as 0.03 nM. Similarly, magainin-AM1, magainin-AM2, CPF-AM1, and PGLa-AM1 stimulated
release of the incretin peptide, GLP-1 from GLUTag cells with magainin-AM2 exhibiting the greatest
potency (minimum concentration producing a significant stimulation = 1 nM) and CPF-AM1 producing
the maximum stimulatory response (3.2-fold of basal rate at a concentration of 3 μM) [78].
Several frog skin peptides with cytotoxic properties have subsequently been shown to possess
complex cytokine-mediated immunomodulatory activities. Effects on the production of both
pro-inflammatory and anti-inflammatory cytokines have been observed (reviewed in [79]). Endotoxemic
complications, such as severe sepsis and septic shock, following infection by Gram-negative bacteria
are caused by release of lipopolysaccharide from bacterial membrane into the bloodstream and
result in high levels of mortality. The importance of agents that modulate the immune function
of the host in the treatment of sepsis is recognized [80]. The [E6k,D9k] analog of hymenochirin-1B
increases the production of anti-inflammatory cytokine IL-10 from both unstimulated and concanavalin
A-stimulated human peripheral blood mononuclear cells without increasing the rate of production of
the pro-inflammatory cytokines TNF-α and IL-17 suggesting a possible therapeutic role in attenuating
the inflammatory response triggered by bacteria [65].
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Abstract: Reptiles are among the oldest known amniotes and are highly diverse in their morphology
and ecological niches. These animals have an evolutionarily ancient innate-immune system that is
of great interest to scientists trying to identify new and useful antimicrobial peptides. Significant
work in the last decade in the fields of biochemistry, proteomics and genomics has begun to reveal
the complexity of reptilian antimicrobial peptides. Here, the current knowledge about antimicrobial
peptides in reptiles is reviewed, with specific examples in each of the four orders: Testudines (turtles
and tortosises), Sphenodontia (tuataras), Squamata (snakes and lizards), and Crocodilia (crocodilans).
Examples are presented of the major classes of antimicrobial peptides expressed by reptiles including
defensins, cathelicidins, liver-expressed peptides (hepcidin and LEAP-2), lysozyme, crotamine, and
others. Some of these peptides have been identified and tested for their antibacterial or antiviral
activity; others are only predicted as possible genes from genomic sequencing. Bioinformatic analysis
of the reptile genomes is presented, revealing many predicted candidate antimicrobial peptides genes
across this diverse class. The study of how these ancient creatures use antimicrobial peptides within
their innate immune systems may reveal new understandings of our mammalian innate immune
system and may also provide new and powerful antimicrobial peptides as scaffolds for potential
therapeutic development.
Keywords: antimicrobial peptides; antibacterial; reptile; biofilm; broad-spectrum; Gram-positive;
Gram-negative
1. Introduction
Reptiles are among the oldest amniotes. They are cold-blooded (ectothermic) vertebrates with
dry and scaly skin that usually lay soft-shelled eggs with amniotic membranes. They thrive in diverse
environments, ranging as far north as Hudson’s Bay in Canada, and as far south as Cape Horn, Chile.
They range from very small geckos to enormous crocodiles and have survived millennia of evolution.
They are highly adapted to their environment, including their innate immune systems, allowing them
to be such successful animals. Antimicrobial peptides are part of the innate immune system, and may
contribute to the survival of these animals in microbe-filled, challenging environment. This paper
will review the known and predicted antimicrobial peptides of reptiles. A set of known host defense
antimicrobial peptides is collected in the Antimicrobial Peptide Database [1,2] and the examples from
reptiles have been annotated (Table 1). Recently, many reptilian genomes have been sequenced. From
these genomes, potential antimicrobial peptide genes have been predicted here by bioinformatics
analysis (Tables 2–8), which should be synthesized and tested for activity in future work. Overall,
the Reptile class thrives in diverse and challenging environments, partly due to their robust innate
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immune system, and our hypothesis is that antimicrobial peptides contribute to the evolutionary
success of reptiles as they do in mammals and other species.
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(*) Activity abbreviations: G+, G−, inhibiting both G+ and G− bacteria; G+, Gram-positive bacteria only, G−,
Gram-negative bacteria only; V, antiviral; F, antifungal; P: antiparasitic, Tx: Toxin activity to mammals.
2. Four Orders of Reptiles
The structural and sequence diversity of antimicrobial peptides is impressive (see below), but it
is useful to first review the phylogenetic and physiological diversity of the Reptilia class in order to
appreciate all the ecosystems and environments that they live in and the prey that they eat.
All living reptiles fall within the kingdom Animalia, the phylum Chordata, the class Reptilia,
and the clade Sauropsida [22]. There are four orders within the class Reptilia: turtles and tortoises
(Testudines), tuataras (Sphenodontia), snakes and lizards (Squamata), and crocodilans (Crocodilia).
Each order will be briefly introduced below. Many reptile species are endangered, including the painted
turtle, and the Siamese crocodile. Although considered by phylogenetic analysis to be “monophyletic”
with avians (Sauropsida; See Cladogram, Figure 1), reptiles are still generally considered to be separate
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from birds. Some researchers use the term avian reptile and non-avian reptile to distinguish the two
groups [23]. Within the non-avian reptilians, the crocodilians are considered to be the most closely
related to the avian branch. Interestingly, this evolutionary connection is reflected in the antimicrobial
profile in that neither avians nor reptilians encode α-defensin antimicrobial peptides, for example,
which are a critical part of mammalian innate immunity. In contrast, avians do not appear to express
hepcidin peptides, while reptiles do, highlighting a potential difference.
 
Figure 1. Cladogram showing the relationships of extant members of the Sauria (Sauropsida) which
includes birds and reptiles. Branch lengths are not representative of divergence time. 1. Tuataras;
2. Lizards; 3. Snakes; 4. Crocodiles; 5. Birds. Cladogram by Benchill, licensed under the Creative
Commons Attribution 3.0 Unported license [24].
2.1. Testudines (Turtles and Tortises)
The testudine order includes the turtles and tortosises. The western painted turtle (Chrysemys
picta bellii) is a small turtle of North America, commonly found in ponds and other slow-moving fresh
water [25].
(a) (b) 
Figure 2. Western Painted Turtle Chrysemys picta bellii. (a) Western painted turtle. Photo by Gary M.
Stolz, U.S. Fish and Wildlife Service in the Public domain [26]. (b) Underside of a Western Painted
Turtle. Photo by Matt Young [27].
This intensely colorful turtle (Figure 2) has existed for approximately 15 million years, according
to the fossil record [25]. The genomes of three turtles have recently been sequenced, including the green
sea turtle (Chelonia mydas) and the Chinese softshell turtle Pelodiscus sinensis [28], as well as the western
painted turtle, Chrysemys picta bellii [29,30]. Interestingly, these papers place the turtles as a sister group
to crocodiles and birds, which is different than their prior morphological classification [31]. The precise
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evolutionary relationship of the testudine class with other reptiles is a matter of current debate [32–36].
Their genomes appear to encode cathelicidin antimicrobial peptides that are “snake-like” but encode
defensin type peptides (gallinacin-like) that may be more similar to “avian” antimicrobial peptides.
2.2. Sphenodontia (Tuataras)
The family Sphenodontidae (within Lepidosauromorpha) contains the genus of Sphenodon,
which has one species, S. puctatus (previously thought to have three species including S. guntheri, and
S. diversum, now considered sub-species) all commonly referred to as tuatara lizards [37,38], although
they are not classified as lizards. The tuatara (Figure 3) is the farthest removed from the avian lineage
in terms of evolution and is considered to be the most “ancient” extant reptile, in existence in its current
form for 100 million years.
 
Figure 3. Sphenodon punctatus, Tuatara, Nga Manu, Waikanae, New Zealand. Photo by PhillipC [39].
The tuatara lives only on the costal islands of New Zealand [40]. There are currently significant
efforts underway to sequence the tuatara genome [41]. However, until the genomes and transcriptomes
can be analyzed for antimicrobial peptides and verified from tuatara samples, there are no known
antimicrobial peptides from the tuatara.
2.3. Squamata (Snakes and Lizards)
The Squamata order of Lepidosauromorpha includes lizards and snakes. In the group of snakes
which although limbless are considered tetrapod vertebrates and are descended from four legged
ancestors, we will consider elapid snakes and pythons. Elapid snakes are venomous, fanged snakes
commonly found in warm climates. Pythons are nonvenomous snakes that are found in Africa, Asia
and Australia. The King cobra (Ophiophagus (O.) hannah) is one of the longest venomous snakes [42],
with lengths up to 18 ft (Figure 4a). The genus Naja is a group of venomous elapid snakes in southern
Africa and South Asia, including the species Naja (N.) atra, the Chinese King cobra (Figure 4b).
The Banded Krait (Bungarus (B.) fasciatus) is commonly found in Southeast Asia and India and has
distinctive banding markings (Figure 4c). The Burmese python (Python bivittatus) is typically found
in tropical areas including Southeast Asia and is one of the largest snakes, typically reaching 12 ft
long. This snake is also found as an invasive species in the Florida Everglades in the Southeast United
States [43]. Snakes encode well-studied cathelicidin peptides that appear to be generally similar
throughout the reptiles, despite the well-known sequence diversity of cathelicidin antimicrobial
peptides in general.
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(a) (b) (c) 
Figure 4. Elapid snakes (a) The King cobra (O. hannah) [44] (b) A juvenile Chinese cobra (N. atra) [45]
(c) Banded Krait (B. fasciatus) [46].
The Squamata order also includes the lizards. Unlike snakes, lizards have four legs and external
ears. There are more than 6,000 species of lizards, making it the largest group of reptiles. Lizards
inhabit a wide range of ecological niches, from hot, dry desserts to cool, moist forests. The main
groups of lizards include Gekkota, Iguania, Scincomorpha and Platynota (Varanoidea). Although the
tuatara looks much like a lizard, it is excluded from the lizard group. The Gekkota suborder includes
geckos, while skinks fall into the suborder Scincomorpha. Monitor lizards, Komodo dragons and Gila
monsters are classified as Platynota (Varanoidea). The suborder Iguania includes chameleons, anoles
and iguanas. The Carolina green anole lizard (Anolis carolinensis) is a small tree-living lizard, often
green or brown, commonly found in the southeastern United States. It has intense green, blue and
white coloring, especially evident on the male, and has a pink dewlap on its throat (Figure 5). The
Anole lizard genome encodes for many β-defensin antimicrobial peptide genes and lysozyme genes.
 
Figure 5. Male Carolina Anole with partially expanded dewlap [47].
The genomes of several members of the Squamata have recently been sequenced including the
anole lizard [23], the elapid snakes O. hannah [15], B. fasciatus, and N. atra [30]. High-throughput
sequencing and mass-spectrometry proteomics has been recently performed on snake venom, which
should provide a deep view of proteins and peptides produced in the venom [48]. Antimicrobial
peptides have been identified in the anole (defensins) [49], as well as cathelicidins in all three species
of elapid snakes (see below) [3]. Very recently, the python genome has been sequenced [30]. Genome
projects are also underway for other reptiles, such as the common garter snake (Thamnophis sirtalis) [23].
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2.4. Crocodilia (Crocodilians)
The order of crocodilians (Crocodilia) within the group Archosauromorpha includes alligators
and caimans (family Alligatoridae), crocodiles (family Crocodylidae), and gharials (gavials, family
Gavialidae) (Figure 6). Most species live in fresh-water, but a few have also adapted to salt-water
conditions. These animals are evolutionarily ancient, and along with birds, are considered the only
surviving relatives of dinosaurs (Archosauria). Within their semi-aquatic ecosystems, these large
animals are the apex predators, using their powerful jaws to capture large and small prey [50]. They are
cold-blooded and egg-laying. They can be found around the world, in the Americas, in Asia, South
America, and Africa [51]. The ancestors of alligators and crocodiles first emerged in the Late Cretaceous
era, and the modern alligators and crocodiles are estimated to be as much as 83 million years old.
 
(a) (b) 
Figure 6. Crocodilians. (a) The American alligator, Alligator mississippiensis [52]. (b) The Siamese
crocodile, Crocodylus siamesnsis [53].
Today, the American alligator is commonly found all around the Gulf of Mexico and Southeastern
United States, having made a comeback from near extinction due to overhunting. The meat and skins
of farmed alligators are now harvested for consumption and use. This large animal is typically 8–11
ft long and 200–500 lbs depending on gender and age [54]. The alligator has a broad snout and the
top teeth come down over the bottom lips, unlike the crocodile. Alligators inhabit swamps such as
the Great Dismal Swamp, rivers and streams, ponds and lakes, with a preference for fresh water over
brackish water, and intolerance for salt water. Alligators can be infected by Mycoplasma alligatoris [55]
as well as other bacterial pathogens. In terms of temperature preference, alligators are more cold
tolerant than most other crocodilian species, accounting for their location as far north as South Carolina
in the United States [54].
The Siamese crocodile (Crocodylus siamensis) [56,57] is a critically endangered freshwater
crocodilian found in Southeast Asia (Cambodia, Vietnam, Thailand, Indonesia and Burma for example).
Like most crocodiles, it is a tropical animal with low tolerance for the cold [3]. This animal is smaller
than the alligator, typically about 7 ft long and 80–150 lbs when fully grown, although larger specimens
have been recorded [4]. These animals are being intensively studied as part of their conservation, and
are bred in captivity, and thus are accessible to researchers for DNA or blood samples [58–60].
Crocodilians such as alligators can carry a high burden of fecal coliforms from their aquatic
environment [61], yet despite their potentially near-constant exposure to potential pathogens, alligators
and other crocodilians do not seem to be susceptible to infection by these organisms, either systemically
or on their skin, via wounds or lesions. This has led to the idea that these animals may have highly potent
antimicrobial components to their immune systems [57,62–67]. Several crocodilian genomes have been
published [68] or are underway [69]. The peptides that have been discovered in crocodilians are outlined
in the sections below and include lysozyme, defensin, hepcidin, hemocidin and other antimicrobial
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peptides. Several important crocodilian genomes have been sequenced, including the Chinese alligator
(Alligator sinensis), the American alligator (Alligator mississippiensis), the saltwater crocodile (Crocodylus
porosus) and the Indian gharial (Gavialis gangeticus) [69,70]. It will be very interesting to compare
freshwater species to saltwater species in terms of their innate immune response profiles, as the
environmental organisms will be significantly different between the two types of water.
3. Antimicrobial Peptides of Reptiles
Reptiles are highly adapted to their environments, which often include many bacteria, allowing
them to be such successful animals. Antimicrobial peptides are part of the innate immune system, and
may contribute to the survival of reptiles. However, to date there has been no direct data in reptiles such
as gene knock-out experiments to demonstrate their importance to overall survival, development and
resistance to infection, as has been done in mice [71]. There has been some suggestion that β-defensin
peptides are associated with fur color in dogs [72,73], but again no studies of this kind have yet been
done on reptiles. This area of research presents many opportunities for scientists to explore the role of
antimicrobial peptides in these animals. This paper will review the known (Table 1) and predicted
antimicrobial peptides of reptiles. Recently, new reptilian genomes have been sequenced. From these
genomes, additional antimicrobial peptide genes have been predicted here by bioinformatics analysis
(Tables 2–8), which should be synthesized and tested for activity.
Antimicrobial peptides are well-characterized peptides, and exhibit significant structure-function
specificity. Following the identification of magainin peptides in amphibians in 1987 [74], scientists have
been exploring the diversity of peptides expressed in different animals, looking for new structures and
new functions of antimicrobial peptides. The structure and function of each of the major classes of
antimicrobial peptides is described below, in addition to the data pertaining to its known or predicted
expression in reptiles.
3.1. Defensin Peptides in Reptiles
Defensins are one of the major classes of antimicrobial peptides in higher vertebrates. These 3–4
kDa cationic peptides are characterized by having six cysteines arranged in three disulfide bonds, with
the characteristic pairing of the bonds highly characteristic for each type of defensin. Defensins have
predominantly β-sheet characteristic with some α-helices. Defensins are encoded in the genome and
are processed from a pro-defensin molecule by proteases [75].
3.1.1. Three Sub-Classes of Defensins
Defensins are known to be critical components of innate immunity in many animals [76]. The three
main sub-classes of defensins are α, β- and θ-defensins. In humans, α-defensins are commonly found
in neutrophils and other leukocytes (for example, Human Neutrophil peptide HNP-1 = α-defensin 1),
and are important in the ability of white blood cells to deal with pathogens [77]. The β-defensins are
defined as having a Cys1-Cys5, Cys2-Cys4, and Cys3-Cys6 bonding pattern of cysteines. In humans,
β-defensins are commonly expressed in epithelial cells, and are widely expressed in the body [78].
The expression of these cationic antimicrobial peptides are often induced following bacterial or viral
infection as part of the innate immune response, except for hBD1 which appears to be constitutively
expressed in humans. The third class of defensins is the θ-defensins. θ-Defensins are not known
outside of primates, and are not expressed in humans [21] but are very active antiviral peptides [76].
Within the reptiles, there are no known genes for α-defensins, and only the β-defensins appear to
be expressed, similar to what is found in avians. Within some species of reptiles, β-defensin genes
and peptides have been identified, for example in the red-eared slider turtle [79]. Lizards are known
to be highly resistant to infection, and recently genes encoding up to 32 different β-defensin-like
peptides were identified in the Anole carolinensis genome [49]. Indeed, using an antibody that reacts
to AcBD15 (one of those β-defensin-like peptides in anole), staining was observed in some (but not
all) of the granules of heterophilic and basophilic granulocytes in lizards, a snake, a turtle and the
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tuatara, but not alligator nor chicken granulocytes. Cells from other tissues such as epidermis were
negative for staining. Alibardi et al. describe that not all the granules within a granulocyte stained
with the antibody, suggesting that there may be different types of granules as is seen in mammalian
neutrophils [22].
Similarly, turtle leukocytes were found to contain TBD-1, the first β-defensin identified in reptile
leukocytes [14]. In the turtle system, TBD-1 was also identified in other tissues, such as the skin [18,80,
81]. These fascinating and unique results suggest that further study of the antimicrobial peptidome of
reptilian granulocytes should be performed.
3.1.2. Inducible Expression of β-Defensins in Wounded Lizards
The first extensive report of an in vivo role for β-defensin peptide expression was in the anole
lizard (Table 2). It has long been known that lizards can lose their tails as a method of predator escape,
and that these tail then regenerate from the wound site. In this process, a wound is formed, which does
not typically get infected. β-Defensin peptides are found to be expressed both within the azurophilic
granulocytes in the wound-bed as well as in the associated epithelium [82,83], and are observed in
phagosomes containing degraded bacteria. While there is a distinct lack of inflammation in the wound,
which is associated with regeneration, there is a high level of expression of AcBD15 and AcBD27
(two of the most highly expressed β-defensins in that tissue) [84,85]. Overall, there appears to be a
fascinating role of AcBD15 and AcBD27 in the wound healing and regeneration in the anole lizard.
Table 2. Predicted defensin-like protein genes in multiple reptilian species.
Organism Peptide annotation aa Locus- Accession #
Alligator mississippiensis Gallinacin-14-like 58 XP_006270781.1
Alligator sinensis Gallinacin-14-like 58 XP_006033878.1
Anolis carolinensis β-Defensin-like protein 5 62 CBY85058.1
Anolis carolinensis β-Defensin-like protein 8 65 CBY85059.1
Anolis carolinensis β-Defensin-like protein 9 66 CBY85060.1
Anolis carolinensis β-Defensin-like protein 10 67 CBY85061.1
Anolis carolinensis β-Defensin-like protein 15 63 CCA62931.1
Anolis carolinensis β-Defensin-like protein 21 89 CBY85062.1
Anolis carolinensis β-Defensin-like protein 22 95 CBY85063.1
Anolis carolinensis β-Defensin-like protein 27 81 CBY85064.1
Anolis carolinensis Gallinacin-10-like 68 XP_003225602.1
Anolis carolinensis Gallinacin-13-like 60 XP_003225598.1
Anolis carolinensis Hypothetical protein LOC100555370 XP_003227809.1
Anolis carolinensis Hypothetical protein LOC100555565 XP_003227810.1
Anolis carolinensis Hypothetical protein LOC100555756 XP_003227811.1
Anolis carolinensis Hypothetical protein LOC100562305 XP_003225604.1
Anolis carolinensis Hypothetical protein LOC100562502 65 XP_003225605.1
Anolis carolinensis Hypothetical protein LOC100562898 XP_003225607.1
Anolis carolinensis Hypothetical protein LOC100563098 XP_003225608.1
Chrysemys picta bellii β-Defensin 1-like 80 XP_005308390.1
Chrysemys picta bellii Gallinacin-5-like XP_005290738.1
Chrysemys picta bellii Gallinacin-5-like, partial XP_005314963.1
Chrysemys picta bellii Gallinacin-14-like 58 XP_005308403.1
Pelodiscus sinensis Gallinacin-1 α-like XP_006137072.1
Pelodiscus sinensis Lingual antimicrobial peptide-like isoform X2 XP_006127561.1
Bothrops neuwiedi β-Defensin-like protein AGF25392.1
Bothrops jararacussu β-Defensin-like protein AGF25388.1
Bothrops leucurus β-Defensin-like protein AGF25389.1
Bothrops matogrossensis β-Defensin-like protein AGF25391.1, AGF25390.1
Bothrops diporus β-Defensin-like protein AGF25384.1
Bothrops pauloensis β-Defensin-like protein AGF25393.1
Bothrops jararaca β-Defensin-like protein AGF25386.1, AGF25387.1
Bothrops atrox β-Defensin-like protein AGF25383.1
Bothrops erythromelas β-defensin-like protein AGF25385.1
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3.1.3. Expression of β-Defensins in Reptile Eggs
Reptile eggs are a good biological sample for the purification of peptides and proteins, since
there is so much material within each egg. Recently, it was found that while the β-defensin-like
peptide pelovaterin (Table 1) identified in the eggshell of the Chinese soft-shelled turtle does indeed
have antimicrobial activity, these peptides may also play an additional role in the formation of the
eggshell, through aggregation [15]. This is similar to the role of the gallin defensin-like peptide in
avian eggs [86–90].
3.2. Cathelicidin Peptides in Reptiles
Cathelicidins are a second major class of antimicrobial peptides in higher eukaryotes. They are
characterized as being antimicrobial peptides derived by proteolytic cleavage from a pre-propeptide
that includes the cathelin domain in mammals and less-well conserved cathelin domain in other
eukaryotes [91,92]. In humans, cathelicidins are stored in the azurophilic granules of neutrophils as the
inactive prepropeptide, and are processed by enzymes (neutrophil elastase [93] or a serine protease [19])
to the mature active peptide [94]. In humans and higher vertebrates, the active cathelicidin peptide is
always encoded on Exon 4 of the cathelicidin encoding gene [91,95,96]. Four cathelicidin-like peptides
have been identified in the chicken (Gallus gallus domesticus) [97], including fowlicidin-1, -2 and -3
(also known as chCATH-1, chCATH-2/CMAP27, chCATH-3) [98], and chCATH-B1/chCATH-4 [99].
In humans, the hCAP18 cathelicidin is processed by proteinase 3 inside the granule [19] or neutrophil
elastase in the extracellular space [4] to its active form. In the case of chicken cathelicidin, the
pre-pro-cathelin domain peptide is cleaved by a serine protease to release the mature peptide following
stimulation of heterophils with LPS [100].
3.3. Cathelicidin Peptides in Snakes
Cathelicidin peptides have been identified and characterized in the snake family (Table 1) [1,2],
although there may be similar genes in other reptiles by genomic analysis (see below). Highly related
cathelicidins were identified in B. fasciatus, O. hannah and N. atra [3] (Table 3). We identified additional
genes for antimicrobial peptides by BLAST searching the genomes of the pit vipers (Bothrops atrox,
Trimeresurus wagler and Crotalus durissus) [13] and the Eastern brown snake (Pseudonaja textilis) (Table 3).
The genes of these cathelicidins have the general structure of the cathelicidin genes, including a poorly
conserved cathelin domain and the c-terminal active peptide. The snake cathelicidins have been well
studied. The functional cathelicidin peptide of the snake family is highly divergent from the functional
cathelicidin peptide of humans, for example, confirming the “general rule” of cathelicidins, which is
that the active peptides are highly divergent, but the pre-pro-regions in the gene and the peptide are
more highly conserved [101].
3.3.1. King Cobra (Ophiophagus (O.) Hannah)
Zhao et al. determined the hemolytic and antimicrobial activity of the predicted O. hannah
cathelicidin, OH-CATH [3] (Table 1). The OH-CATH peptide proved to be an excellent inhibitor
of bacterial growth and demonstrated broad-spectrum activity against bacterial isolates including
multi-drug resistant strains. The OH-CATH peptide displayed greater potency than the human
cathelicidin LL-37 against a variety of known human bacterial pathogens and the antimicrobial potency of
OH-CATH was not significantly impacted by the concentration of salt in the media. They demonstrated
that OH-CATH showed no hemolytic activity against erythrocytes, even at a concentration of 200 μg/mL,
suggesting low cytotoxicity of the peptide to eukaryotic cells [3]. Additional studies with smaller
fragments of OH-CATH (Table 1) have also been tested and found to be active both in vitro and in vivo,
even against antibiotic resistant bacteria [4,6]. Their strong antimicrobial activity and lack of hemolytic
activity make the reptile cathelicidins strong candidates for development into new therapeutics.
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Table 3. Known and predicted cathelicidin open reading frames in multiple snake species. The active
antimicrobial peptides NA-CATH, BF-CATH and OH-CATH are highlighted.
Protein name [Organism] Accession Sequence
Cathelicidin-NA antimicrobial































































































3.3.2. Chinese King Cobra (Naja (N.) Atra)
The genus Naja is a group of venomous elapid snakes in the southern Africa and South Asia,
including the species N. atra, the Chinese King cobra. The cathelicidin peptide from the Chinese King
cobra, N. atra (NA-CATH) (Table 1), has been well studied. The full-length NA-CATH peptide was
synthesized and was found to be antimicrobial against a wide variety of bacteria [102–105]. Smaller
fragments of this peptide have been identified and found to be effective [102–105].
Interestingly, while the human cathelicidin peptide (LL-37) was found to exert antibiofilm activity
against bacterial pathogens such as Pseudomonas [103] and Staphylococcus [105], NA-CATH did not
exhibit antibiofilm effect against Pseudomonas, despite similar overall biophysical properties (length,
size, charge) to LL-37.
The smallest identified fragment of NA-CATH is an 11-amino acid peptide, called ATRA, which
imperfectly repeats in the NA-CATH sequence (Figure 7a) [102]. Variants of the ATRA peptide have
been found to be very informative regarding the role of charged residues and proline residues in the
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activity of small antimicrobial peptides [102]. The peptide ATRA-1 is almost identical to the ATRA-2
peptide, with the exception of the 3d (A/F) and 10th (L/P) residues. Variants of these peptides were
made to switch out the 3rd and 10th position amino acids, such that ATRA-1A contains alanine at
position 3 rather than phenylalanine (F). Another variant was ATRA-1P, which contains proline at
position 10 rather than leucine (L). All the peptides were the same length, similar molecular weight,
and the same net charge. It was found for multiple gram-negative bacteria that ATRA-1P was almost as
ineffective as ATRA-2, while ATRA-1A was as effective as ATRA-1 [102]. These results suggested that
the introduction of a proline in ATRA-1P may have affected the charge distribution on that peptide,
which then may disrupt the antibacterial activity of the peptide (Figure 7b,c).
Further studies have examined the D-amino acid enantiomer of the ATRA peptides [106], and
found that D-ATRA-1A is as effective as ATRA-1A, and as it is protease resistant, potentially has a longer
half-life. The ATRA peptides have also been demonstrated to be highly antimicrobial both in vitro
and in vivo against both gram-negative bacteria such as Escherichia coli K12 strain and Aggregatibacter
actinomycetemcomitans-Y4 [102], Pseudomonas aeruginosa [103] and Francisella novicida [104]. ATRA
peptides are also antimicrobial against the gram-positive bacteria Staphylococcus aureus [105].
3.3.3. Banded Krait (B. fasciatus)
The cathelicidin peptide from B. fasciatus (BF-CATH, Table 1, Table 3) is also very well studied. The
full-length BF-CATH peptide has been shown to have antimicrobial activity against a variety of bacteria
including antibiotic resistant bacteria [7,107]. Smaller fragments of BF-CATH have also been expressed
and studied [10,108] (Table 1). For example, BF-30 showed significant activity against drug-resistant
E. coli and S. aureus both in vitro and in vivo [109]. BF-15 is a shorter version of BF-CATH with lower
hemolytic activity, and broad-spectrum antimicrobial activity even against antibiotic-resistant bacteria [8].
Peptide Description Peptide Sequence 
NA-CATH Active Peptide KRFKKFFKKLKNSVKKRAKKFFKKPKVIGVTFPF 
ATRA-1 KRFKKFFKKLK 
ATRA-2  ------------------------------- KRAKKFFKKPK 
ATRA-1A KAFKKFFKKLK 
ATRA-1P KRFKKFFKKPK 
(a) Sequence of the Chinese King Cobra Naja atra cathelicidin and ATRA derivatives. 
 
(b) (c) (d) 
Figure 7. Naja atra cathelicidin peptide analysis. (a) Sequences of the NA-CATH active peptide and
derivatives [102–105]. (b) Helical wheel projection of NA-CATH. (c) Analysis of the active ATRA-1A
peptide (d) Analysis of the inactive ATRA-1P peptide. From Rzlab.ucr.edu/scripts/wheel/wheel.cgi:
“The hydrophilic residues are presented as circles, hydrophobic residues as diamonds, potentially
negatively charged as triangles, and potentially positively charged as pentagons. Hydrophobicity is
color coded as well: the most hydrophobic residue is green, and the amount of green is decreasing
proportionally to the hydrophobicity, with zero hydrophobicitycoded as yellow. Hydrophilic residues
are coded red with pure red being the most hydrophilic (uncharged) residue, and the amount of red
decreasing proportionally to the hydrophilicity. The potentially charged residues are light blue.”
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3.3.4. Predicted Cathelicidins in Other Snake Species
By performing BLAST analysis with the elapid snake cathelicidins against other snake sequences
in the database, we identified cathelicidin-like gene sequences in the venomous pit viper, Bothrops
atrox, and the Eastern brown snake, Pseudonaja textilis (Table 3). These genes should be further studied
to verify that cathelicidin-like peptides are produced and to determine the activity of these peptides.
3.4. Cathelicidin Peptides in Lizards
Cathelicidin-like peptides Ac-CATH-1, Ac-CATH-2a, Ac-CATH -2b, and Ac-CATH -3 have
been reported in the genome of the Carolina anole lizard (Anolis carolinensis) [110] (Table 4). In
addition, cathelicidin 1 and 2 antibody reactive peptides have been identified by immunocytochemistry
staining within granules of heterophilic and basophilic granulocytes [111]. This study also identified
cathelicidin-antibody staining material in wound epidermis and associated with bacteria within
wounds [111].
Table 4. Predicted active cathelicidin peptides in the anole lizard [91,92].
Organism Peptide annotation
Anolis carolinensis Ac-CATH-1 MGRITRSRWGRFWRGAKRFVKKHGVSIALAGLRFG (+10)
Anolis carolinensis Ac-CATH-2a/b DPQMTRFRGLGHFFKGFGRGFIWGLNH (+3)
Anolis carolinensis Ac-CATH-3—no active peptide encoded.
3.5. Cathelicidin Peptides in Turtles
Analysis of the recently published genomes revealed that there are many cathelicin-like genes in
turtles. While no active cathelicidin peptides have been demonstrated yet in the turtle (Table 1), there
are at many predicted cathelicidin-like peptide genes (Table 5). Many of these are annotated as being
similar to the snake cathelicidins (eg OH-CATH).
Table 5. Predicted cathelicidin pre-pro-protein genes in multiple turtle species.
Organism Peptide annotation Locus- Accession #
Chrysemys picta bellii Cathelicidin-OH antimicrobial peptide-like XM_005295113.1
Chrysemys picta bellii Cathelicidin-OH antimicrobial peptide-like XP_005295170.1
Chrysemys picta bellii Cathelicidin-2-like XP_005295171.1
Chrysemys picta bellii Uncharacterized LOC101951069 XR_255838.1
Chrysemys picta bellii Uncharacterized LOC101951243 XR_255839.1
Pelodiscus sinensis Cathelicidin-2-like XM_006114422.1
Pelodiscus sinensis Cathelicidin-2-like XM_006114419.1
Pelodiscus sinensis Cathelicidin-OH antimicrobial peptide-like transcript variant X1 XM_006129620.1
Pelodiscus sinensis Cathelicidin-OH antimicrobial peptide-like transcript variant X2 XM_006129621.1
Pelodiscus sinensis Cathelicidin-OH antimicrobial peptide-like XM_006129625.1
Pelodiscus sinensis Cathelicidin-BF antimicrobial peptide-like XP_006114480.1
Pelodiscus sinensis Cathelicidin-BF antimicrobial peptide-like XM_006114418.1
Pelodiscus sinensi Cathelicidin-2-like XP_006114484.
Pelodiscus sinensis Cathelicidin-2-like XP_006114481.1
Pelodiscus sinensis Cathelicidin-OH antimicrobial peptide-like isoform X1 XP_006129682.1
Pelodiscus sinensis Cathelicidin-OH antimicrobial peptide-like isoform X2 XP_006129683.1
Pelodiscus sinensis Cathelicidin-OH antimicrobial peptide-like XP_006129687.1
Chelonia mydas Hypothetical protein UY3_13361 EMP29519.1
Chelonia mydas Hypothetical protein UY3_13360 EMP29518.1
3.6. Cathelicidin Peptides in Crocodilians
Analysis of the databases revealed that there are many cathelicidin-like genes in alligators. While
no active cathelicidin peptides have been demonstrated yet in the alligator (Table 1), there are at many
140
Pharmaceuticals 2014, 7, 723–753
predicted cathelicidin-like peptide genes (Table 6). Many of these genes are annotated as being similar
to the snake cathelicidins (e.g., OH-CATH).
Table 6. Predicted cathelicidin pre-pro-protein genes in Alligator species.
Organism Peptide annotation Locus- Accession #
Alligator mississippiensis Cathelicidin-2-like XM_006262429.1
Alligator mississippiensis Cathelicidin-2-like XP_006262491.1
Alligator mississippiensis Cathelicidin-OH antimicrobial peptide-like XM_006262431.1
Alligator mississippiensis Cathelicidin-OH antimicrobial peptide-like XM_006262430.1
Alligator mississippiensis Cathelicidin-OH antimicrobial peptide-like XP_006262492.1
Alligator mississippiensis Cathelicidin-OH antimicrobial peptide-like XP_006262493.1
Alligator sinensis Cathelicidin-2-like XM_006026412.1
Alligator sinensis Cathelicidin-2-like XP_006026474.1
Alligator sinensis Cathelicidin-2-like XP_006026475.1
Alligator sinensis Cathelicidin-3-like XM_006026409.1
Alligator sinensis Cathelicidin-3-like XP_006026471.1
Alligator sinensis Cathelicidin-OH antimicrobial peptide-like XM_006037224.1
Alligator sinensis Cathelicidin-OH antimicrobial peptide-like XM_006026410.1
Alligator sinensis Cathelicidin-OH antimicrobial peptide-like XM_006026411.1
Alligator sinensis Cathelicidin-OH antimicrobial peptide-like XM_006037211.1
Alligator sinensis Cathelicidin-OH antimicrobial peptide-like XP_006037286.1
Alligator sinensis Cathelicidin-OH antimicrobial peptide-like XP_006026472.1
Alligator sinensis Cathelicidin-OH antimicrobial peptide-like XP_006037273.1
Alligator sinensis Cathelicidin-OH antimicrobial peptide-like XP_006026487.1
3.7. Liver-Derived Peptides in Reptiles
3.7.1. Hepcidin (HAMP1)
Hepcidin antimicrobial peptides are liver-expressed peptides containing eight cysteines (four
disulfide bonds) that are broadly antimicrobial, binds iron and is involved in ferroportin binding [112,
113]. A gene encoding a hepcidin-like peptide (E8ZAD0_CROSI) was recently proposed to be encoded
by the Siamese crocodile (Crocodylus siamensis). A 26 aa peptide (Cshepc), representing the predicted
active peptide (FNSHFPICSYCCNCCRNKGCGLCCRT), was expressed in yeast, and the unpurified
product was found to have antimicrobial activity against both Gram-positive bacteria such as S. aureus
and Bacillus subtilis, as well as Gram-negative bacteria Escherichia coli and Aeromonas sobria [114].
Hepcidin-like sequences were also identified in the anole lizard, although interestingly hepcidins
appear to be missing in most avians [115].
3.7.2. LEAP-2, Liver Expressed Antimicrobial Peptide-2
Another liver-expressed peptide, LEAP-2, is expressed in many different organisms, has
broad-spectrum antibacterial and antifungal activity, and can be induced following bacterial
challenge [116–118]. This 40 aa, 4-cysteine, cationic peptide differs significantly from hepcidin in
sequence and predicted structure [119], but is also predominantly expressed in the liver.
The Leap-2 gene is annotated in many of the sequenced reptiles (Table 7), including Pelodiscus
sinensis, Chrysemys picta bellii, Alligator sinensis, Alligator mississippiensis, as identified by a BLAST
analysis we performed with the LEAP-2 from Anolis carolinensis. The antimicrobial activity or biological
role of this peptide in reptiles has not been studied.
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Table 7. Predicted LEAP-2 pre-propeptide amino-acid sequences identified in reptiles.
Species Predicted LEAP-2 full sequence Accession Number
Anolis carolinensis MTPLKITAVILICSALLFQTQGASLYPPNSQLVRQRRMTPFWRGISRPIGASCRDNSECSTRLCRSKHCSLRTSQE XP_003217432.1
Alligator sinensis MHWLKVIAVMLLFALHLFQIHCASLHQPNSQPKRQRRMTPFWRGVSSLRPIGASCRDDIECVTMLCRKSHCSLRTSRE XP_006023615.1
Alligator mississippiensis MHWLKVIAVMLLFALHLFQIHCASLHQPNSQPKRQRRMTPFWRGVSSLRPIGASCKDDGECITMRCRKSHCSLRTSRE XP_006263463.1
Pelodiscus sinensis MQCLKVIALLLFCAALLTQTHCASLHHSSSQLTRQRRMTPFWRGISLRPIGALCRHDNECISMLCRKNRCSLRISCE XP_006128591.1
Chrysemys picta belli MQYLKVIAVLLLCAALLSQIHSASLHRPSSHLTRQRRMTPFWRGISLRPIGAICRDDSECVSRLCRKNHCSIRISRA XP_005302895.1
3.8. Lysozyme in Reptiles
Lysozyme is a very important part of innate immunity in most animals. In humans, it is packaged
into neutrophil granules, released in tears and other secretions, and is very effective against a broad
spectrum of bacteria. Not surprisingly, reptiles have also been found to use lysozyme as part of their
innate immune response. In the crocodilians, a lysozyme-like enzyme was identified with broad-spectrum
antibacterial activity [67]. Lysozyme proteins very similar to chicken lysozymes (~130 aa) have been
identified from some species of turtles, including the soft shelled turtle (Trionyx sinensis), the Asiatic soft
shelled turtle (Amyda cartilagenea) and the green sea turtle (Chelonia mydas) [17,19,120–122], although the
antimicrobial activity of these molecules has not yet been proven. Lysozyme peptide has also been
identified from Crocodylus siamensis [67]. Lysozyme-like genes were identified by analysis of reptile
genomes (Table 8).
3.9. Crotamine Peptides in Reptiles
Defensins are one example of cysteine-stabilized polypeptides with antimicrobial function.
A similar family of peptides is the crotamine toxin family isolated from rattlesnakes with a
similar gamma-core motif to defensins [123,124], which is considered a cell-penetrating peptide The
sequence of crotamine is YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG (+8) [2].
This cationic peptide contains nine lysines (underlined), three disulfide bonds (6 cysteines, shown in
bold) and has a defensin-like fold (Figure 8).
 
Figure 8. The crotamine chemical structure. Crotamine, a Na+ channel-affecting toxin from Crotalus
durissus terrificus venom (PDB 1H5O) [125].
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Table 8. Selected predicted lysozyme genes identified in reptiles.
Reptile name Enzyme Name Accession Number
Softshell turtle lysozyme C(SSTL) Lysozyme C (1,4-β-N-acetylmuramidase C) Q7LZQ1.3
Asiatic softshell turtle lysozyme C (ASTL) Lysozyme C P85345.1
Pelodiscus sinensis Lysozyme ADR51676.1
Pelodiscus sinensis PREDICTED: lysozyme g-like isoform X2 XP_006113603.1
Pelodiscus sinensis PREDICTED: lysozyme g-like isoform X1 XP_006113602.1
Pelodiscus sinensis PREDICTED: lysozyme g-like XP_006113601.1
Chelonia mydas Lysozyme C EMP38935.1
Chelonia mydas Lysozyme G EMP27176.1
Chrysemys picta bellii PREDICTED: lysozyme C-like XP_005314893.1
Chrysemys picta bellii PREDICTED: lysozyme C-like XP_005312037.1
Chrysemys picta bellii PREDICTED: lysozyme g-like protein 2 XP_005283410.1
Chrysemys picta bellii PREDICTED: lysozyme G-like XP_005283294.1
Ophiophagus hannah Lysozyme C, partial ETE58503.1
XP_003225844.1,
Anolis carolinensis Lysozyme C, milk isozyme-like XP_003216710.1,
XP_003216704.1
Anolis carolinensis Lysozyme C II-like XP_003224512.1
Anolis carolinensis Lysozyme g-like XP_003227178.1
Alligator sinensis Lysozyme C-like XP_006027022.1,XP_006027021.1





Some reptiles are known to express crotamine-like peptides, and The X-ray structure of crotamine,
from the Brazilian snake Crotalus durissus terrificus, was recently solved (PDB 4GV5_A) [126]. We found
that some species of reptiles have genes that are annotated as crotamine-like (Table 9).
Table 9. Crotamine-like peptide genes in reptiles.
Reptile AA Name Accession numbers
Uromastyx aegyptia 67 crotamine-Uro-1 AGI97143.1














Crotalus oreganus helleri 65 crotamine 7 AEU60015.1
Crotalus oreganus helleri 65 crotamine 6 AEU60014.1
Crotalus oreganus helleri 65 crotamine 5 AEU60013.1
Crotalus oreganus helleri 70 crotamine 4 AEU60012.1
Crotalus oreganus helleri 70 crotamine 3 AEU60011.1
Crotalus oreganus helleri 83 crotamine 2 AEU60010.1
Crotalus oreganus helleri 70 crotamine 1 AEU60009.1
Pogona barbata 102 CLP-POGL1 AAZ75614.1
Pogona barbata 67 CLP-POGL2 AAZ75615.1
Pogona barbata 61 CLP-POGU3 AAZ75613.1
Pogona barbata 98 CLP-POGU2 AAZ75612.1
Pogona barbata 76 CLP-POGU1 AAZ75611.1
Varanus tristis 83 crotamine-Var-5 AGI97148.1
Varanus glauerti 83 crotamine-Var-4 AGI97147.1
Varanus glauerti 83 crotamine-Var-3 AGI97146.1
Varanus glauerti 83 crotamine-Var-2 AGI97145.1
Varanus glauerti 83 crotamine-Var-1 AGI97144.1
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It has been a matter of some debate whether crotamine peptides are antimicrobial or if they just
contain a similar cysteine-stabilized core structure. Recently, it was demonstrated that crotamine
toxin is expressed similarly on epithelial or mucosal surfaces, and displays some antimicrobial activity
against Bacillus subtilis, and was able to permeabilize Staphylococcus aureus cells, for example [20]. In
addition, crotamine has been shown to be antifungal [127]. Thus, it seems that crotamine should be
considered as an antimicrobial peptide of reptiles.
3.10. Other Peptides in Reptiles
3.10.1. Leucrocin
There are a handful of peptides identified in reptiles that were not easily classified in the categories
above. One interesting example is the peptide leucrocin, an antibacterial compound from white blood
cells of the Siamese crocodile (Crocodylus siamensis). Unlike Crocosin [65], which does not appear to be
peptide based, leucrocins are very small peptides with antibacterial activity. The amino acid sequence
of Leucrocin I is NGVQPKY, and of Leucrocin II is NAGSLLSGWG [66]. No known genes encode
for these peptides, so their source is unclear. Recently, a synthetic peptide based on the Leucrocin
sequence was found to have broad-spectrum antibacterial activity [128].
3.10.2. Omwaprin
Another example of an unusual antimicrobial peptide in reptiles is omwaprin, which is a member
of the waprin family of venom proteins (Sequence shown in Table 1) [11,12], and was isolated from
the Australian inland taipan (Oxyuranus microlepidotus), considered the most venomous snake (a
member of the Elapid family of snakes). This 50 aa peptide has relatively salt-tolerant antibacterial
activity against gram-positive bacteria and was found to be non-toxic to mice upon injection. Its
activity was found to be highly dependent upon the four disulfide-bonds, similar to the hepcidins and
defensins [11]. Thus, except for its large size, this peptide appears to have many favorable properties
as a potential therapeutic candidate.
3.10.3. Hemocidin
Fragments of hemoglobin have been found to have some antimicrobial activity, and have been
referred to as hemocidins [129–131]. In the study of the Siamese crocodile, 13 fragments of crocodile
hemoglobin were found to have antimicrobial activity, including peptides similar to hemoglobin β
subunit [59,60]. Recently, the hemoglobin α- and β-chains of crocodilian species (Crocodylus siamensis,
Alligator mississippiensis, Crocodylus niloticus and Caiman crocodilus) have been reported [132]. The in vivo
relevance of these peptides in the crocodile remains to be determined, but it represents a potential
other class of antimicrobial peptides from reptiles that should be investigated.
3.10.4. Other Peptides
Other peptides have been identified in reptiles that do not fall into the various classes of
antimicrobial peptides described above. These include a short, synthetic tryptophan-rich cationic
antimicrobial peptide, pEM-2 (KKWRWWLKALAKK) that was shown to have broad-spectrum
bactericidal activities, and was identified as a fragment of myotoxin II, a snake venom Lys49
phospholipase A2 [133,134]. Synthetic variants of this peptide were shown to have improved
antimicrobial activity, salt resistance and reduced hemolytic activity [135,136]. These peptides have
led to other advances in rational design of synthetic peptides, including peptides with exclusively
arginine and tryptophan residues [137].
Gomes et al isolated, but did not sequence, a small 1370 Da peptide from the venom of a pit viper
(Borthrops jaracaca), which showed very good activity against different fungi and yeast [138].
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Another group identified an antimicrobial peptide derived from N. atra venom, the vgf-1 peptide,
and found that this peptide had significant antimicrobial activity against drug-resistant clinical strains
of Mycobacterium tuberculosis [139].
4. Conclusions
Reptiles are evolutionarily ancient, found in diverse and microbially challenging environments
and appear to have robust immune systems. Some reptiles, especially lizards, have unique properties
such as tail regeneration. All of these features suggest that reptiles may express many interesting
antimicrobial peptides. A few reptilian antimicrobial peptides have been isolated and studied which
demonstrate broad-spectrum antimicrobial and antifungal activity. These include members of the
cathelicidin and defensin and lysozyme class.
Antimicrobial peptides are known in three of the four orders of reptiles: the testudines,
crocodilians, and the squamata. No peptides are known from the sphenodontia (tuataras), as this
organism has just been sequenced [41]. Reptile neutrophils appear to have granules that contain both
cathelicidin-like peptides as well as β-defensin peptides, although unlike mammals, there are no
genes encoding α-defensins. β-defensin-like peptides and lysozyme are also found in reptile eggs.
These peptides are expressed in wounds, such as when lizards lose their tails. Detailed study of the
Chinese cobra Naja atra cathelicidin peptides has revealed smaller peptides that could be useful for
therapeutic applications.
Overall, reptiles reflect the diversity of antimicrobial peptides within higher organisms. They
appear to express cathelicidins and β-defensins, and express hepcidins unlike avians. Additional
classes of antimicrobial peptides such as lysozyme, LEAP-2 and crotamine also appear to be highly
expressed in reptiles. With the advent of high-throughput genomics, new reptilian genomes have been
sequenced and their transcriptomes determined. Analysis of these sequences has revealed that there
are additional genes that may encode AMPs in reptiles. Future studies may reveal the in vivo role of
antimicrobial peptides in reptiles. In the face of the emerging challenges due to antibiotic resistant
bacteria, new and useful molecules that could be developed into future antibiotics may potentially be
found in the reptilian AMPs.
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Abstract: Host defense peptides (HDPs) are an important first line of defense with antimicrobial and
immunomoduatory properties. Because they act on the microbial membranes or host immune cells,
HDPs pose a low risk of triggering microbial resistance and therefore, are being actively investigated as a
novel class of antimicrobials and vaccine adjuvants. Cathelicidins and β-defensins are two major families
of HDPs in avian species. More than a dozen HDPs exist in birds, with the genes in each HDP family
clustered in a single chromosomal segment, apparently as a result of gene duplication and diversification.
In contrast to their mammalian counterparts that adopt various spatial conformations, mature avian
cathelicidins are mostly α-helical. Avian β-defensins, on the other hand, adopt triple-stranded β-sheet
structures similar to their mammalian relatives. Besides classical β-defensins, a group of avian-specific
β-defensin-related peptides, namely ovodefensins, exist with a different six-cysteine motif. Like their
mammalian counterparts, avian cathelicidins and defensins are derived from either myeloid or epithelial
origin expressed in a majority of tissues with broad-spectrum antibacterial and immune regulatory
activities. Structure-function relationship studies with several avian HDPs have led to identification of
the peptide analogs with potential for use as antimicrobials and vaccine adjuvants. Dietary modulation
of endogenous HDP synthesis has also emerged as a promising alternative approach to disease
control and prevention in chickens.
Keywords: host defense peptides; antimicrobial resistance; antibiotic alternatives; chicken
1. Introduction
Host defense peptides (HDPs), also known as antimicrobial peptides, constitute a large group
of small peptides that have been discovered in virtually all forms of life [1–3]. Natural HDPs are
generally positively charged and comprised of less than 100 amino acid residues with amphipathic
properties. HDPs represent an important first-line of defense particularly in those species whose
adaptive immune system is lacking or primitive. Most HDPs are encoded by distinct genes, and a
large number of structurally different HDPs normally exist in a single species. A majority of HDPs are
strategically synthesized in the host phagocytic and mucosal epithelial cells that regularly encounter
the microorganisms from the environment. Synthesized initially as precursors, HDPs are generally
processed by host proteases to release mature peptides upon infection and inflammation [1,2].
Mature HDPs are broadly active against Gram-negative and Gram-positive bacteria, mycobacteria,
fungi, viruses, and even cancerous cells [1,2]. Relying primarily on the physical membrane-lytic
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mechanisms, HDPs kill bacteria with a low risk of triggering resistance [4]. Additionally, HDPs were
recently found to interact specifically with several membrane-bound or intracellular receptors with
a profound ability to modulate the host response to inflammation and infection [5–7]. Because of
antimicrobial and immunomodulatory activities, HDPs are being actively explored for antimicrobial
therapy particularly against drug-resistant microbes [8]. A number of HDPs have been found with
preferential expression in the male reproductive tract and several are linked to sperm maturation and
might have potential for infertility treatment [9,10].
2. Classification of HDPs
HDPs are structurally diversified. Based on the secondary structure, HDPs are classified into
α-helical, β-sheet, αβ, and non-αβ families [1–3,11]. In general, α-helical peptides are amphipathic,
often with a bend around the central region disrupting an otherwise fairly perfect cylindrical structure.
The β-sheet HDPs are usually formed by the presence of disulfide bonds with amphipathic patches
scattered on the surface. The αβ-peptides consist of both α-helical and β-sheet structures, whereas
non-αβ HDPs are free of α-helical and β-sheet structures, often unstructured, and rich in proline,
arginine or histidine residues.
2.1. Cathelicidins
Among an ever increasing number of HDPs that have been reported, two major families,
namely cathelicidins and defensins, exist in vertebrate animals [12–14] (Figure 1). Cathelicidins
have been reported in a variety of vertebrate species including fish, amphibians, reptiles, birds, and
mammals [12,15]. Multiple cathelicidins normally exist in each species, except for euarchontogliers
(e.g., primates, rabbits, and rodents) and carnivorans (e.g., cats and dogs). Cathelicidins are named for
the presence of a cathelin-like domain in the N-terminal region of the peptide precursor (Figure 1).
Although the signal peptide and cathelin-like domain of cathelicidins are extremely conserved across
species, mature peptide sequences at the C-terminal region are highly diversified even within a
species. Neutrophilic granule proteins (NGPs) are a group of cathelicidin-related HDPs that have been
reported in rabbits, rodents, and many other mammalian species [16–18]. Although they apparently
have evolved from cathelicidins, NGPs are conserved throughout the entire sequence, including the
C-terminal region. Given rabbit NGP, also known as p15, is biologically active without proteolytic
cleavage [19], it is possible that other NGPs may not be processed to become biologically active.
Figure 1. Cont.
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Figure 1. Schematic drawing of vertebrate cathelicidin and defensin precursor peptides. (A) Cathelicidins
and cathelicidin-related peptides known as NGPs are highly conserved in the cathelin-like domain that
contains two disulfide bridges. Unlike cathelicidins whose C-terminal segments are highly variable
across species and proteolytically cleaved from the cathelicidin-like domain to become biologically active,
NGPs are conserved throughout the entire sequence and functionally active without being processed.
(B) The defensin family includes classical α-, β-, and θ-defensins with indicated disulfide bonds as well as
four subfamilies of defensin-related peptides with unknown disulfide bonding patterns. Avian-specific
ovodefensins contain six cysteines but with a different spacing pattern from that of classical defensins.
Rodent-specific CRS1C, CRS4C, and rattusin also exist with 11, 9, and 5 cysteine residues, respectively,
that presumably form intermolecular disulfide bonds. Positively and negatively charged amino acids
are indicated in red and green, respectively.
2.2. Defensins
Vertebrate defensins are further classified into three subfamilies including α-, β-, and θ-defensins that
are characterized by the presence of six cysteines with different spacing and bonding patterns (Figure 1) [9,
13,14]. The α-defensins are mammalian-specific with a C1-C6, C2-C4, and C3-C5 cysteine-bridging pattern,
whereas β-defensins are universal in vertebrates with a C1-C5, C2-C4, and C3-C6 bridging pattern. The
θ-defensins, on the other hand, have only been discovered in primates, with a pseudogene present
in the human genome [20]. The six cysteines of θ-defensins form a cyclic structure by a head-to-tail
ligation of two truncated α-defensins [20]. Three additional subfamilies of α-defensin-related peptides
have also been found in rodents [21,22]. Two groups of cryptdin-related sequence (CRS) peptides,
namely CRS1C and CRS4C, appear to exist only in mice with 11 and nine cysteines, respectively [21].
A unique rat-specific rattusin was recently reported to consist of five cysteines [22]. Although rodent
defensin-related sequences are located within theα-defensin gene cluster and highly similar toα-defensins
in the signal and pro-sequences, the disulfide bridging patterns of the C-terminal mature peptides are
totally different among them (Figure 1). Albeit with no reported tertiary structures, these defensin-related
peptides are likely to form homo- or hetero-dimers or oligomers because of the presence of an odd number
of cysteines. Another group of β-defensin-related molecules, recently classified as ovodefensins, appear
to be specific in birds [23]. Albeit with six cysteines in the C-terminal mature region forming a disulfide
bonding pattern identical to β-defensins [24], avian ovodefensins consist of a different cysteine spacing
pattern (Figure 1).
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3. Discovery of Avian HDPs
Both the cathelicidin and defensin families of HDPs exist in birds [25,26]. However, NGPs appear
to be specific to mammals and no NGP-like cathelicidins have been reported in any avian species. Only
β-defensins have been discovered in birds, and no α- or θ-defensins exist. Rodent-specific rattusin or
CRS peptides are also absent in birds. However, ovodefensins are uniquely present in several avian
species [23]. Excellent reviews are available on the general knowledge of avian HDPs [27,28], and this
review will focus on their biology and therapeutic applications, with more emphasis on the similarities
and differences between avian and mammalian HDPs.
3.1. Avian Cathelicidins
Four distinct cathelicidin genes have been reported in birds. The first two avian cathelicidins (CATH1
and CATH2) were reported in chickens in 2004 and 2005, respectively [29,30]. The same two peptides,
together with a third chicken cathelicidin (CATH3), were also independently reported as fowlicidin
1–3 [18]. The fourth chicken cathelicidin, known as CATH-B1, was discovered to be preferentially
expressed in the bursa of Fabricius [31], a specialized organ for hematopoiesis and B cell development
in birds. All four chicken cathelicidins were found to cluster densely together within a 7.5-kb distance
toward one end of chromosome 2 [18,31]. All four chicken cathelicidin genes adopt a 4-exon, 3-intron
structure, typical for a mammalian cathelicidin. The first three exons encode the 5′-untranslated region,
signal peptide, and a majority of the cathelin-like domain, while the last exon encodes primarily the
mature peptides, in addition to the 3′-untranslated region [18,31]. Chicken CATH1–3 share similar exon
sizes and a typical cathelin-like domain with mammalian cathelicidins, whereas CATH-B1 consists of an
alternatively spliced and unusually large first exon and an uncharacteristic cathelin-like domain [31].
Alignment of four chicken cathelicidin peptide sequences revealed that they are similar to each
other and also homologous to mammalian cathelicidins in the signal peptide and cathelin-like domain
(Figure 2). Among them, CATH1 and CATH3 are most closely related with >90% identity throughout
the entire sequence, while CATH-B1 is a distant member, sharing only 40% with CATH1 (Figure 2).
The orthologs of chicken CATH1–3 were also recently reported in several other avian species such as
the common quail and common pheasant [32,33]. With recent completion of genome sequencing for
the turkey, mallard duck, rock dove (Columba livia), ground tit (Pseudopodoces humilis), saker falcon
(Falco cherrug), Peregrine Falcon (Falco peregrinus), and budgerigar (Melopsittacus undulatus), a number
of avian cathelicidin sequences have been predicted and become available in GenBank.
Figure 2. Amino acid sequence alignment of four chicken cathelicidins. Conserved sequences are
shaded and identical residues are in red. Dashes are created to maximize the alignment. Each
cathelicidin precursor consists of a conserved signal peptide sequence, a cathelin-like domain, and a
variable C-terminal mature peptide sequence. Four cysteines in the cathelin-like domain are highlighted
in yellow. Note that an N-terminal, 117-amino acid segment of CATH-B1 was omitted for clarity.
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3.2. Avian β-Defensins
More than a dozen unique β-defensin genes are present, and no α- or θ-defensins exist in
birds. The first two avian β-defensins, known as gallinacins 1–2, were isolated in 1994 from chicken
heterophils [34], an equivalent of mammalian neutrophils. The turkey orthologs of gallinacins 1–2 were
also independently purified from heterophil granules later in the same year [34]. With the completion
of the chicken genome sequencing, a large number of additional chicken β-defensin genes were
independently reported by Lynn, et al. [29] and Xiao, et al. [35], respectively. Because of different
numbering systems used by the two groups, a new standard nomenclature for chicken β-defensins
was proposed [36]. To be consistent with the mammalian defensin nomenclature, the term “gallinacin”
was suggested to be dropped and a new term “avian β-defensin (AvBD)” be adopted [36]. The AvBD
numbering system was proposed to follow Xiao’s [35]. With deposition of a new chicken β-defensin,
i.e., AvBD14 (under the GenBank accession no. AM402954), after initial two publications, the chicken
genome now appears to encode a total of 14 distinct β-defensin genes (AvBD1–14) packed within a
85-kb distance toward one end of chromosome 3 [36]. In contrast with most mammalian β-defensin
genes, which primarily consist of two exons, at least five AvBDs (AvBD1, 2, 6, 7, and 8) are comprised
of a minimum of four exons [35]. The remaining AvBD genes contain three exons, while AvBD12 and
-14 appear to have only two exons.
Sequencing alignment of all 14 chicken β-defensins revealed that they are highly conserved at the
N-terminal signal peptide region (Figure 3). The spacing pattern of six cysteines are also conserved at
the C-terminal segment. Additionally, two glycines, with one preceding the second cysteine and the
other preceding the fourth cysteine, are also largely conserved (Figure 3). Most other residues are quite
diverse among AvBDs. In contrast to mammalian α-defensins with a long, often negatively charged
prosequence, β-defensins including AvBDs consist of a short prosequence, which is even absent in a
few cases. The C-terminal tails of AvBDs after the last cysteine are generally short, consisting mostly
of 3-6 amino acids. AvBD3, 11 and 13 are exceptions. AvBD3 and AvBD13 have up to 30 residues
after the last cysteine [35], while AvBD11 contains two tandem, but different six-cysteine motifs at the
C-terminus [35]. As a result, mature AvBD11 may form six, instead of three, intramolecular disulfide
bonds. AvBD11 is the only known β-defensin with such a sequence, and functional significance for the
existence of such two defensin motifs remain to be studied. A number of AvBDs have also been found
in several other species of birds including the turkey, ostrich, king penguin, zebra finch, duck, and
goose [37–43]. Many additional AvBD sequences have also been predicted and deposited in GenBank.
Figure 3. Amino acid sequence alignment of chicken β-defensins and ovodefensins. Conserved
sequences are shaded and identical residues are in red. Dashes are created to maximize the alignment.
Each β-defensin precursor is comprised of a conserved signal peptide, an optional short prosequence,
and a C-terminal mature sequence consisting of six cysteines. Note that the cysteine spacing patterns
are different between chicken ovodefensins (known as gallin 1–3) and classical β-defensins. Additional
C-terminal tail sequences of AvBD3, 11, and 13 were omitted for simplicity.
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Besides classical β-defensins, chickens have also been found to express three closely related
β-defensin-related peptides, namely gallin 1–3 [23,44,45]. In fact, multiple peptides with a similar
cysteine-spacing pattern have been reported earlier in the mallard duck, turkey, and black swan [46–
48]. This group of peptides were in turn classified as ovodefensins because of their preferential
expression in the oviduct with abundant presence in egg white [23]. Ovodefensins appear to be
avian-specific, containing a six-cysteine motif of C-X3-5-C-X3-C-X11-C-X3-4-CC, as opposed to that of
C-X4-8-C-X3-5-C-X9-13-C-X4-7-CC in classical avian β-defensins (Figure 3).
4. Evolution of Avian HDPs
4.1. Avian Cathelicidins
Phylogenetic analysis of all publically available avian cathelicidins revealed that they are clustered
into three distinct clades, namely CATH1/3, CATH2, and CATH-B1 (Figure 4), suggesting that these
three clades of cathelicidin genes have evolved before divergence of these bird species from each other,
unlike mammalian cathelicidin genes, a majority of which were duplicated after species separation [18].
Surprisingly, an initial analysis of the zebra finch (Taeniopygia guttata) genome failed to identify any
cathelicidin sequences [39]. If that is the case, it will be interesting to know why the cathelicidin genes
were lost in zebra finch, although it is likely that the genome segments containing the cathelicidin
genes failed to be sequenced, because the entire genome were only sequenced to 5.5 × coverage to
encompass 94% of the genome [49]. Consistent with our assumption, scores of gaps are present in
the syntenic cathelicidin region in the current zebra finch genome assembly (WUGSC 3.2.4/taeGut1)
released in July 2008.
Figure 4. Phylogenetic analysis of avian cathelicidins. The phylogenetic tree was constructed with the
full-length amino acid sequences using the neighbor-joining method, and the reliability of each branch
was assessed by using 1,000 bootstrap replications. Numbers on the branches indicate the percentage
of 1,000 bootstrap samples supporting the branch. The species and GenBank accession number of each
sequence are indicated.
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4.2. Avian β-Defensins
Phylogenetic analysis of all available avian β-defensins and related peptide sequences revealed
the presence of cross-species, gene-specific clusters for most genes, implying that a majority have
evolved before the split of the bird species from each other (Figure 5), reminiscent of avian cathelicidin
genes. However, species-specific AvBD genes do exist. For example, AvBD14 appears specific to
chickens, because no orthologs have been found in any other avian species, despite the availability
of several avian genome sequences. Supported by a bootstrap value of 52 (Figure 5), it is likely that
AvBD14 duplicated from AvBD13 after the separation of chickens from other birds. Zebra finch
lacks the AvBD6 gene [39,40], although it is present in the chicken, turkey, goose, and mallard duck
genomes. The AvBD1 gene is conserved in the chicken, turkey, goose, quail, and ostrich, but has
apparently duplicated and diversified into three paralogous genes (AvBD123, 124, and 125) in the zebra
finch [39,40] (Figure 5). Likewise, the AvBD3 gene has also expanded to a total of eight paralogous
genes in the zebra finch genome [39,40] (Figure 5).
Figure 5. Phylogenetic analysis of avian defensins (see Figure 4 legend for details).
Ovodefensins clearly form a distinct clade, which is further divided into two subgroups (Figure 5).
Small basic protein 1 (BPS1) in the mallard duck or rock dove is separated from the remaining
ovodefensins. A closer examination of their amino acid sequences indicated that BPS1 consists of a
cysteine-spacing pattern of C-X3-C-X3-C-X11-C-X4-CC, as opposed to C-X5-C-X3-C-X11-C-X3-CC in
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other ovodefensins. It remains to see whether these two subgroups of ovodefensins are present only
in certain species of birds. It is also important to know how they are functionally different from each
other and from classical defensins.
Importantly, ovodefensins are clustered with AvBD12 as supported by a bootstrap value of 32
(Figure 5), suggesting that ovodefensins might have duplicated and diversified from AvBD12 as a
result of gene duplication after separations of birds from other animal species. Consistent with the
notion that ovodefensins are derived from classical AvBDs, three chicken ovodefensin/gallin genes
are located in tandem on chromosome 3, approximately 260 kb centromeric to the AvBD gene cluster
on the current chicken genome assembly. To further support a possible origination of gallins from
AvBD12, the gallin genes consist of two exons separated by an intron, which is identical to the genomic
structure of the AvBD12 and AvBD14 genes, whereas all other AvBD genes are comprised of at least
three exons [35].
5. Expression and Regulation of Avian HDPs
5.1. Tissue Expression Pattern
Like mammalian counterparts, avian cathelicidins and β-defensins are derived from the bone
marrow and/or epithelial cells, with the majority expressing in a wide variety of tissues. CATH1–3 are
primarily of myeloid origin, while CATH-B1, a distant member of avian cathelicidins, is derived from
epithelial cells. Chicken CATH1–3 mRNAs are predominantly expressed in the bone marrow, but also
throughout the mucosal tissues of the digestive, respiratory, and urogenital tracts [29,30,50]. On the
other hand, chicken CATH-B1 mRNA shows a more restricted expression pattern, with preferential
expression in the secretory epithelial cells of the bursa of Fabricius [31,50]. Consist with the role
of cathelicidins in the first line of host defense, abundant CATH1–3 proteins can be detected in the
granules of heterophils, as in the case of chicken CATH2 [51], whereas mature CATH-B1 protein is
secreted from the epithelial cells and concentrated on the basolateral surfaces of the M cells in the
bursal lymphoid follicles [31].
Myeloid avian β-defensins include AvBD1, 2, and 4–7, whereas the remaining AvBD8–14 are
mainly of epithelial origin, although both myeloid and epithelial AvBDs are also expressed in a majority
of other tissues [29,35,52]. In agreement with their myeloid origin, AvBD1 and AvBD2 mRNAs have
been found abundantly in the bone marrow and their proteins in heterophil granules in the chickens,
turkey, and ostrich [34,42,53]. It will be interesting to know the tissue expression pattern of those
species-specific AvBDs such as AvBD115–125 in the zebra finch [40]. However, because they are
orthologous to AvBD1 and AvBD3 (Figure 5), they are expected to share a similar expression pattern to
AvBD1 and AvBD3.
Human cathelicidin LL-37 has been found in seminal plasma associated with sperm and
prostasomes [54]. A majority of β-defensins in rats (and likely in other mammalian species as
well) are expressed preferentially in the male reproductive system and the epididymis and testis
in particular [55]. Like their mammalian counterparts, many avian cathelicidins and β-defensins are
expressed adequately in the male and female reproductive organs, particularly in the testis, epididymis,
ovary, and oviduct [29,35,50,56], suggesting a possible role in reproduction. Ovodefensins have been
found to be among the major components of egg white in the chicken, turkey, and duck [44–48].
Consistently, chicken ovodefensin gallin 1–3 mRNA and proteins are the most abundantly expressed
in tubular gland cells in the magnum of the chicken oviduct [23], a segment that secretes egg white.
5.2. Developmental Regulation
The expression of chicken cathelicidins and β-defensins has been studied during the pre- and
post-hatch periods and found to be developmentally regulated. At the embryonic stage, most chicken
cathelicidin and AvBD mRNAs were detected as early as embryonic day 3 (E3), except for CATH-B1
and AvBD11, which did not appear until day E9 [57]. All four cathelicidin mRNA expression was
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generally increased as embryos develops, whereas the 14 β-defensins were differentially expressed [57].
AvBD3, 4, 5, 10, 11, 12, and 14 were largely enhanced during the embryonic development, whereas the
remaining chicken β-defensins showed a biphasic expression pattern. In the case of AvBD2, 6, and 7,
their expression was increased on day E6 relative to that in day E3, decreased on day E9, and then
increased gradually with the age of embryos [57].
After hatch, chicken cathelicidins and β-defensins are also developmentally regulated in both
gene- and tissue-specific patterns. During the first 28 days, CATH1–3 showed an age-dependent
increase both in the cecal tonsil and lung, whereas all four cathelicidins were peaked in the bursa on
day 4 after hatching, with a gradual decline by day 28 [50]. On the other hand, CATH1–3 showed a
peak expression in the cecum on day 28, while the highest expression of CATH-B1 was seen in both
the lung and cecal tonsil on day 14 [50]. AvBD1 and AvBD2 mRNA gradually reduced in different
segments of the intestinal tract in the first week post-hatch, but restored and increased gradually in
the following week [58]. In the reproductive tract, more than a half of AvBDs increased during the
sexual maturation in the vagina, ovary, and epididymis of chickens, whereas others showed little no
expression [56,59,60].
5.3. Regulation by Infection and Inflammation
HDPs are critically involved in the first line of host defense. Dysregulation of the HDP synthesis
often leads to immune deficiency or autoimmunity such as Crohn’s disease and psoriasis in humans [61,
62]. Many, but not all, HDPs are induced upon infection and inflammation in humans and mice. On the
other hand, certain pathogens suppress HDP synthesis as a strategy to evade the immune system [63–
65]. A number of studies have been conducted on the transcriptional response of cathelicidins and
β-defensins in chickens and several other avian species. Like their mammalian relatives, multiple
AvBDs are inducible in response to microbial products (e.g., lipopolysaccharides and CpG DNA), live
bacteria, viruses or parasites in the intestinal, reproductive, and respiratory tracts [38,56,59,60,66,67].
However, it appears that many avian HDP genes are regulated differently in different tissues in
response to different stimuli. For example, chicken CATH1 was induced in the cecal tonsil [66], but not
the jejunum of chickens in response to Salmonella infections [51]. On the other hand, chicken CATH1
was down-regulated by Campylobacter jejuni or Eimeria praecox [68–70], perhaps as a mechanism of
immune evasion.
5.4. Regulation by Dietary Compounds
Because suppressing HDP expression is a microbial strategy for immune subversion, inducing the
synthesis of endogenous HDPs will conversely augment the host capacity to fight off infections [71–73].
Unlike infection or injury that triggers HDP expression with an unwanted and often exaggerated
inflammatory response, butyrate and vitamin D3 have been found to be highly potent in augmenting
HDP synthesis without provoking inflammation in humans [74–78]. Several other compounds like
dietary histone deacetylase inhibitors, retinoic acid, forskolin, and sugars are also capable of inducing
HDP expression in humans [79–83].
In chickens, butyrate has been revealed as a strong inducer of HDP expression in vitro and
in vivo. Among all 14 AvBDs and 4 cathelicidins, half of them were induced with others largely
unchanged in chicken cells in response to butyrate [84]. Butyrate was further shown to enhance the
antibacterial activity of chicken monocytes, and supplementation of butyrate in the feed enhanced
clearance of Salmonella enteritidis in the cecum of chickens following an experimental infection [84].
Among all saturated free fatty acids with 1–18 carbons, butyrate was the most potent in stimulating
HDP expression in chicken cells [85]. Furthermore, butyrate synergizes with the agonists of the cyclic
adenosine monophosphate (cAMP) signaling pathway in inducing HDP expression [86]. Feeding with
butyrate and a plant extract containing forskolin, which is an adenylyl cyclase agonist, showed a strong
synergy in augmenting HDP expression in the crop and jejunum of chickens [86]. Mitogen-activated
protein kinase signaling pathways were revealed to be critically involved in the HDP-inducing synergy
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between butyrate and forskolin [86]. The results indicated the potential for use of these dietary
compounds in promoting HDP synthesis, host immunity, and disease resistance.
6. Biological Activities of Avian HDPs
6.1. Antimicrobial Activities
The antibacterial efficacy of all four chicken cathelicidins and many defensins have been evaluated.
Like their mammalian counterparts, most chicken HDPs are capable of killing a broad spectrum of
Gram-positive and Gram-negative bacteria, and fungi including antibiotic-resistant strains generally
in the low micromolar range. For example, chicken CATH1–3 are broadly active with the minimum
inhibitory concentration (MIC) values mostly between 0.5 and 2 μM against a range of bacteria [18,
87], and CATH-B1 also has the MIC values between 0.5 and 2.5 μM against E. coli, S. aureus, and
P. aeruginosa [31]. However, many HDPs showed varying efficiencies against different pathogens.
Chicken AvBD1 and AvBD2 kill 90% S. enteriditis, C. jejuni, and Candida albicans at <4 μM, but showed
a much reduced efficiency against Pasteurella multocida [41]. Similarly, AvBD9 is active against most
Gram-positive and Gram-negative bacteria tested with the MIC values in the range of 2–4 μM, but
with a minimum activity against S. typhimurium (>30 μM) [88]. On the other hand, AvBD13 was found
to be minimally active against a range of bacteria examined, with the MIC values in the range of 50–100
μM [89]. The antibacterial activity of chicken CATH1–3 is not affected by the presence of physiological
concentrations of salt [18]; however, that of chicken defensins is greatly reduced by salt [26], reminiscent
of mammalian defensins [13]. In the case of CATH1–3, AvBD2, and presumably most other avian
HDPs, non-specific membrane disruption and lysis is a major bactericidal mechanism [87,90,91].
Ovodefensins are unique in that they generally lack an obvious antibacterial activity as seen
with turkey meleagrin as well as duck BPS1 and BPS2 [46,48]. Chicken gallin is the only ovodefensin
with known antibacterial activities, but appears to have a narrow range. Among several common
Gram-negative and Gram-positive bacteria tested, chicken gallin1/2 showed an activity only against E.
coli, but not Salmonella, S. aureus or Listeria monocytogenes [24]. It is hence very unlikely that the major
biological function of ovodefensins is antibacterial.
6.2. Immunomodulatory Activities
Besides having direct microbicidal activities, HDPs have increasingly been appreciated to play
a profound role in regulating host immune responses to infections. Many peptides are shown to
be actively involved in chemotaxis and activation of immune cells, regulation of dendritic cell
differentiation, induction of angiogenesis and re-epithelialization, modulation of cytokine and
chemokine gene expression, and potentiation of antigen-specific adaptive immune response [5,92,93].
Importantly, many HDPs directly bind to and neutralize bacterial membrane components such
as lipopolysaccharides (LPS), lipotechoic acid, and peptidoglycan and suppress the production of
proinflammatory cytokines induced by bacteria and membrane components [94,95].
In chickens, CATH1 was shown to possess excellent immunomodulatory properties with a strong
capacity to specifically chemoattract neutrophils without affecting the migration of monocytes or
lymphocytes [96]. Furthermore, CATH1 and CATH2 activates macrophages or peripheral blood
mononuclear cells by inducing synthesis of an array of cytokines and chemokines at moderate levels,
which is distinct from that induced by LPS [96,97], CATH1–3 were shown to bind to LPS directly,
with 50% binding occurring at approximately 10 μM [18,87]. Moreover, three peptides at 10–20 μM
substantially abrogated LPS-induced production of proinflammatory cytokines in macrophages and
peripheral blood mononuclear cells [18,87,97]. CATH1 was further found to augment adaptive immune
response when administered into mice together with chicken ovalbumin, a model antigen [96]. In
the case of human cathelicidin LL-37, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
sequestosome-1/p62 were recently identified as intracellular receptors to mediate cytokine/chemokine
162
Pharmaceuticals 2014, 7, 220–247
production in monocytes [98,99]. It will be interesting to examine whether chicken cathelicidins also
utilize the same receptors to modulate the macrophage response.
7. Structures-Activity Relationships of Avian HDPs
7.1. Structural Features
To date, the tertiary structures of three chicken cathelicidins (CATH1–3), two β-defensins (chicken
AvBD2 and penguin AvBD103a/spheniscin-2), and a chicken ovodefensin (gallin1/2) have been
determined by nuclear magnetic resonance (NMR) in solutions. Unlike mammalian cathelicidins
that adopt various conformations, all three chicken cathelicidins are largely α-helical with a mild
kink or rather extensive bend around the center in aqueous solutions [87,90,100] (Figure 6). A mild
kink in CATH1 and CATH3 is induced by the presence of a glycine residue, whereas an extensive
bend in CATH2 is caused by proline (Figure 6A). Additionally, all three chicken cathelicidins consist
of a flexible unstructured segment at the N-terminal region [87,90,100]. Unlike typical amphipathic
α-helical HDPs, no obvious segregation of hydrophobic residues from hydrophilic residues is seen
with either CATH1 or CATH2; instead, the positively charged residues are mostly concentrated at both
ends (Figure 6B). On the other hand, CATH2 are rather amphipathic throughout the entire α-helix.
Three truncated analogs of chicken CATH1 consisting of amino acid residues 1–16, 8–26, and 5–26
were also revealed to adopt similar confirmations to the full-length peptide in the presence of LPS or
zwitterionic dodecylphosphocholine micelles [101,102].
Figure 6. Structures of avian cathelicidins and β-defensins. (A) Secondary structural features of
cathelicidins and β-defensins. (B) Tertiary ribbon structures of cathelicidins and β-defensins. Polar
residues are indicated in blue and nonpolar residues in red. Disulfide bonds of β-defensins are shown
in yellow. Protein Data Bank identification number for each molecule is indicated in parenthesis.
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Both penguin AvBD103a and chicken AvBD2 adopt a triple-stranded, antiparallel β-sheet structure
stabilized by three pairs of intramolecular disulfide bonds [91,103] (Figure 6B), typical of mammalian
β-defensins. Penguin AvBD103a also consists of an α-helical segment at the N-terminal region with
a hydrophobic patch on the surface [103]. However, AvBD2 lacks either the α-helical or an obvious
amphipathic feature [91]. A β-bulge that is formed by the G-X-C motif around the fourth cysteine
and highly conserved in both mammalian α- and β-defensins is also present in both AvBD2 and
AvBD103a (Figure 6B). Albeit with a different cysteine-spacing pattern, chicken gallin1/2 also consists
of a characteristic β-defensin fold with three antiparallel β-sheets [24]. However, unlike classical
β-defensins, gallin1/2 is comprised of two additional β-sheets formed separately by Val2-Leu3 at the
N-terminal end and Thr24-Ser25 preceding the fourth cysteine [24] (Figure 6).
7.2. Structure-Activity Relationships
Structure-activity relationship (SAR) studies with α-helical HDPs indicated that the antimicrobial
potency and target specificity are strongly influenced by structural and physicochemical parameters,
such as cationicity (net charge), helicity, amphipathicity, and hydrophobicity [11,104,105]. However, in
general there is no simple correlation between any of these physicochemical properties and peptide
functions. A delicate balance of these parameters often dictates the antimicrobial potency and target
selectivity [11,104,105]. Within a certain range, an improvement in these parameters is often positively
correlated with the antimicrobial activity of peptides, but sometimes is accompanied by unwanted
enhancement in cytotoxicity as well [104–107]. In several cases, the antimicrobial domain of the
peptides is located separately from the domain responsible for cytotoxicity [108,109], meaning that the
peptide derivatives devoid of the lytic domain could be identified with improved therapeutic potential.
In the case of β-sheet HDPs and defensins in particular, antimicrobial and immunomodulatory
activities are strongly influenced by structural integrity, cationicity, and hydrophobicity [11,110,111].
The presence of three intramolecular disulfide bonds in many cases is dispensable for the antibacterial
activity, but essential for other activities such as chemotactic activity [112] and the ability to resist
proteolysis [113]. On the contrary, the antibacterial activity of human β-defensin-1 drastically increases
when the peptide is reduced [114]. In fact, some defensins may be naturally reduced in the intestinal
tract by thioredoxin, a redox enzyme [114]. Cationicity of defensins is believed to dictate the killing of
Gram-negative bacteria, whereas hydrophobicity appears to confer the activity against Gram-positive
bacteria [111].
In avian species, a series of SAR studies with chicken CATH1, CATH2, and AvBD2 have
yielded some very interesting observations. Investigations of chicken CATH1 analogs with either
N- or C-terminal deletions revealed that the cationic residues at both N- and C-terminal regions are
dispensable for the antibacterial, LPS-binding, and cytotoxic activities, whereas the C-terminal helix
(Arg21-Lys25) is essential for all three activities [100]. Tryptophan at position 6 (Trp6) is critical in both
LPS binding and cytotoxicity [100,115], but is dispensable for neutrophil chemotaxis [96]. Furthermore,
an omission of Trp6 in CATH1 also resulted in an obvious reduction in its ability to kill bacteria [115]
and induce chemokine synthesis in macrophages [96]. Replacing the kink-causing glycine (Gly16)
with a helix-stabilizing residue, leucine, resulted in no obvious difference in either antibacterial,
LPS-binding or cytotoxic activity [100], indicating that enhancing the helicity of α-helical HDPs may
not necessarily result in an improvement in the antibacterial potency. Simultaneous substitutions of
multiple amino acid residues to make CATH1 nearly perfectly amphipathic surprisingly caused a
loss of the antibacterial potency against certain bacteria and undesirably, an increase in hemolytic
activities [100]. Collectively, these findings suggested that a fine tuning of various structural and
physicochemical parameters including cationicity, helicity, hydrophobicity, and amphipathicity, rather
than a simple alteration of one, will result in an enhancement in the therapeutic potential of α-helical
HDPs, which is in agreement with earlier findings [11,104,105].
Studies with a series of CATH2 analogs with deletions of either N- or C-terminal residues showed
that neither α-helical segment per se is sufficient to bind LPS, kill bacteria or lyse mammalian cells [90].
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Inclusion of four additional amino acids in the central bending region (Arg15-Arg18) beyond either N-
or C-terminal α-helical segment to the α-helical segment was associated with a significant enhancement
in both antibacterial and LPS-neutralizing activities [90]. To directly evaluate the functional significance
of the central bending segment, a substitution of leucine for proline greatly reduced the antibacterial
and hemolytic activities. The abilities to neutralize LPS-induced cytokine production and to stimulate
chemokine synthesis in peripheral blood mononuclear cells were also significantly impaired by such a
proline-to-leucine substitution [97], implying that the bending is critically important in the peptide
interactions with membranes as well as the cell activation receptors. Interestingly, a gradual increase
in cationicity, helicity and amphipathicity among all peptide analogs led to a gradual enhancement in
antibacterial potency and LPS neutralization [90]. Furthermore, substitution of multiple tryptophans
for phenylalanines in an N-terminal, 15-amino acid fragment of CATH2 led to an improvement in
antibacterial and LPS-neutralizing activities [116]. Head-to-tail cyclization of this CATH2 variant
further increased its serum stability with a reduced cytotoxicity [117]. The same study also revealed
that D-amino acid substitutions rendered the peptide completely resistant to trypsin proteolysis [117].
In the case of chicken AvBD2, D-enantiomerization resulted in little difference in the activity
against both Gram-positive and Gram-negative bacteria, suggesting that membrane is the primary
target [91]. However, unlike many mammalian defensins whose structural integrity has a minimum
impact on the antibacterial activity, reducing AvBD2 led to a drastic loss in the activity against
Gram-positive bacteria, but was less prominent against Gram-negative bacteria [91]. Substitution of
alanine for a conserved lysine following the sixth cysteine resulted in an obvious N-terminal structural
modification and a marked decrease in the antibacterial activity against both Gram-positive and
Gram-negative bacteria [91]. Surprisingly, a reduction of disulfide bonds rendered the lysine-alanine
substituted AvBD2 nearly completely inactive in killing bacteria [91]. Therefore, conformational
changes (and subsequent changes in hydrophobicity and/or amphipathicity) are likely the underlying
mechanism behind many of the alterations in the antibacterial activity of AvBD2.
8. Potential Therapeutic Applications
HDPs including avian HDPs can be potentially used in a variety of applications such as
antimicrobial therapy (Figure 7). Additionally, HDPs hold promise in augmenting the efficacy of
vaccines as adjuvants. Although a number of avian HDPs are expressed in both male and female
reproductive tracts and believed to promote sperm maturation and fertility like their mammalian
counterparts [10,118], experimental evidence is yet to prove the link. Therefore, the potential role
and application of avian HDPs in infertility treatment will not be discussed here. To reduce the cost
of delivering synthetic peptides and minimize peptide degradation, endogenous HDPs can also be
induced by certain cost-effective dietary compounds to help the host better fight off infections (Figure 7).
Figure 7. Potential therapeutic applications of host defense peptides (HDPs). Synthetic HDPs
can be directly administered exogenously as antimicrobials, vaccine adjuvants or infertility drugs.
Alternatively, endogenous HDPs can modulated by dietary compounds for antimicrobial therapies.
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8.1. Antimicrobial Therapies
HDPs are active against a broad range of bacteria, mycobacteria, fungi, and parasites [1,8]. Rather
than relying on a single or a limited number of intracellular targets like most currently available
antibiotics, HDPs kills microbes primarily through physical electrostatic interactions and membrane
disruption. Therefore, it is difficult for microbes to gain resistance to HDPs [1,8]. At the same time,
most HDPs have the capacity to recruit and activate immune cells and facilitate the resolution of
inflammation [6,8]. In fact, the antibacterial and immunomodulatory properties of HDPs can be
harnessed separately for antimicrobial therapy, particularly against antibiotic-resistant strains [6,8]. A
few HDPs have been evaluated clinically for their antibacterial efficacy, and several more are currently
at different stages of human trials. Because of a relatively low efficacy as compared with many of the
conventional antibiotics, all clinical trials with HDPs have met a limited success [119]. As a result, no
HDPs have been approved by the FDA to date. More efforts are being shifted toward exploring the
immune regulatory activities of HDPs. Excitedly, several small HDPs with no or weak antibacterial
activities have been proved to be highly efficient in protecting animals from infections by recruiting
and activating neutrophils and/or monocytes [95,120]. Because they act on the host but not on the
pathogens, these immunomodulatory peptides have the potential to control a broad spectrum of
pathogens without triggering resistance.
In avian species, only chicken CATH1 has been evaluated for its in vivo antibacterial efficacy.
A single intraperitoneal administration of a C-terminal, 21-amino acid CATH1 peptide analog,
known as fowlicidin-1 (6–26), led to a 50% increase in the survival of mice from a lethal dose of
methicillin-resistant S. aureus (MRSA), concomitant with a reduction in the bacterial titer in both
peritoneal fluids and spleens of mice [115]. Additionally, fowlicidin-1(6–26) is more potent in inducing
neutrophil chemotaxis and macrophage activation than human cathelicidin LL-37 and a de novo
synthesized peptide, IDR-1 [96]. Because of its ability to induce neutrophil chemotaxis and macrophage
activation, fowlicidin-1(6–26) protected 50% mice if given 4 days prior to an otherwise lethal MRSA
infection, and 100% mice survived if the peptide was received 1 or 2 days before infection [96]. This is
the first HDP that has been shown to protect animals from bacterial infections beyond a 48-h window.
Therefore, fowlicidin-1(6–26) represents an attractive candidate for further exploration as a novel
antimicrobial for both therapeutic and prophylactic applications. Rational design and functional
screening of additional CATH1-related peptides may lead to identification of new peptide analogs
with improved safety and therapeutic potential, particularly against antibiotic-resistant pathogens.
It is worth noting that many HDPs and defensins in particular have obvious antiviral effects by
acting as lectins or by modulating host cell responses. Enveloped and non-enveloped viruses such
as human immunodeficiency virus (HIV-1), influenza A virus (IAV), cytomegalovirus (CMV), herpes
simplex virus (HSV-1 and HSV-2), vesicular stomatitis virus (VSV) , adenovirus, and papillomavirus
(HPV) have been shown to be sensitive to human α-, β- and/or θ-defensins [121,122]. In some
cases, defensins can directly inactivate viruses by disrupting envelop lipid bilayers, aggregating viral
glycoproteins or blocking the binding of viruses to host cell receptors [122]. In other cases, the antiviral
effects of defensins are indirectly mediated by modifying host cell responses such as inhibition of
protein kinase C (PKC) activation or down-regulation of host cell receptor expression [122]. Limited
work exists on the antiviral activities of avian HDPs. Only a few duck β-defensins were recently shown
to inhibit the replication of duck hepatitis virus (DHV) [37,67]. However, the antiviral mechanisms or
the susceptibility of other viruses to avian HDPs remains unknown, but warrant further investigations.
8.2. Vaccine Adjuvants
HDPs have been shown to profoundly impact the development of adaptive immune response by
regulating the migration, maturation, and activation of different immune cell types including dendritic
cells and T and B lymphocytes [5,8,123]. Several HDPs are capable of enhancing antigen-specific
adaptive immune response when co-administered with vaccines [123]. HDPs have been found to
synergize with other adjuvants like CpG DNA and polyphosphazene in potentiating adaptive immune
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response [124–126]. The adjunvanticity of chicken AvBD1, duck AvBD2, and chicken CATH1 have
been experimentally verified. When fused with the infectious bursal disease virus (IBDV) VP2 gene
in a DNA vaccine, chicken AvBD1 increased the VP2-specific antibody titers, CD4+ and CD8+ T
cell populations, and conferred better protection against an infectious bursal disease virus (IBDV)
challenge in chickens [127]. Duck AvBD2 was shown to be chemotactic to T- and B-lymphocytes
in vitro, with the ability to suppress the mRNA expression of an inhibitory receptor, namely dendritic
cell immunoreceptor (DCIR), in duck splenocytes [128]. Chicken CATH1, when co-administered with
chicken ovalbumin (OVA), was found to enhance both IgG1 and IgG2a titers to OVA in mice [96].
Because CATH 1 was more potent than LL-37 or IDR-1 in inducing surface expression of CD86, a
co-stimulatory molecule, on macrophages [96], CATH1 may be more efficient in promoting antigen
presentation and adaptive immunity and therefore, represent an excellent candidate as an adjuvant or
a component of an adjuvant complex.
8.3. Direct Administration vs. Indirect Modulation
The production cost and stability are two major obstacles for in vivo applications of many
peptide-based drugs. Purification from natural sources or chemical synthesis are inefficient and
cost-prohibitive for large-scale production of HDPs. Although recombinant expression of HDPs has
been achieved in bacteria and yeasts, an inclusion of a fusion protein is often needed to reduce
the peptide toxicity to the host and aid in the peptide solubility [129]. In order to achieve the
maximum activity, an extra proteolytic cleavage step and additional production costs are often
unavoidable. Given a short half-life of most natural peptides in vivo, it is desirable to retard the peptide
degradation by chemical modifications that often involves the use of D-amino acids, cyclization or
peptidomimetics [130]. However, it remains unknown how those modifications would impact the
immunomodulatory functions of HDPs, which appear to be receptor-dependent.
To overcome the high manufacturing cost and minimize degradation of HDPs for in vivo
applications, it is advantageous to develop convenient and cost-effective strategies to specifically
induce the synthesis of endogenous HDPs. Several dietary compounds including short-chain fatty
acids and vitamin D3 have shown promise in stimulating HDP synthesis in humans without triggering
inflammatory response [131,132]. Dietary supplementation of HDP-inducing compounds has emerged
as a novel antibiotic-alternative approach to antimicrobial therapy [131,132]. In chickens, butyrate,
structural analogs of butyrate, and cAMP signaling agonists have been shown to be potent inducers
of HDPs [84–86]. Desirably, butyrate and cAMP agonists are synergistic in augmenting HDP gene
expression and bacterial clearance in chickens [86], suggesting their potential as alternatives to antibiotics
for disease control and prevention. However, dietary regulation of HDPs often exhibit gene-, cell-, and
species-specific patterns. HDP genes are differentially regulated in response to a dietary compound,
with some being induced and others unaltered. In chickens, approximately a half number of chicken
HDPs are induced by butyrate [84]. Some HDPs are regulated in a cell-specific pattern. For example,
chicken AvBD9 gene increased by more than 5000-fold in HD11 macrophages, but with only a less
than 10-fold induction in cecal intestinal cells after a 24-h exposure to 4 mM butyrate [84]. The same
compound that show a strong HDP-inducing activity in one animal species, may completely lose its
ability to induce HDPs in another species. A case in point is vitamin D3, which strongly augments
cathelicidin gene expression in human but not mouse cells [75,76]. Therefore, it is important to evaluate
the HDP-inducing efficacy of individual compounds in different species.
9. Conclusions
Birds harbor approximately 20 unique cathelicidins and β-defensin genes in each species.
It appears that most have evolved before divergence of birds from each other. Unlike mammalian
cathelicidins that adopt different tertiary structures, avian cathelicidins are mostly α-helical, with
a hinge around the central region and a flexible N-terminal segment. Besides classical β-defensins,
a group of avian-specific, β-defensin-related peptides, namely ovodefensins, exist with a different
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cysteine-spacing pattern. However, the overall three-dimensional structure of ovodenfensins resemble
that of β-defensins. Coupled with their close chromosomal proximity with the β-defensin gene
cluster, ovodefensins were clearly diversified from a β-defensin ancestral gene, possibly AvBD12, after
separation of the birds from other vertebrate species. Several avian HDPs have been shown to possess
potent, broad-spectrum antibacterial activities with a strong ability to modulate the host response to
infection and inflammation. Structure-activity relationship studies have led to the identification of a
few avian HDPs and their analogs as promising candidates as antimicrobials or vaccine adjuvants.
Because avian HDPs can be induced by dietary compounds such as short-chain fatty acids and cAMP
signaling agonists, dietary modulation of endogenous HDP synthesis may have potential to be further
explored as a novel, cost-effective antimicrobial strategy.
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Abstract: As the key components of innate immunity, human host defense antimicrobial peptides and
proteins (AMPs) play a critical role in warding off invading microbial pathogens. In addition, AMPs
can possess other biological functions such as apoptosis, wound healing, and immune modulation.
This article provides an overview on the identification, activity, 3D structure, and mechanism of action
of human AMPs selected from the antimicrobial peptide database. Over 100 such peptides have been
identified from a variety of tissues and epithelial surfaces, including skin, eyes, ears, mouths, gut,
immune, nervous and urinary systems. These peptides vary from 10 to 150 amino acids with a net
charge between −3 and +20 and a hydrophobic content below 60%. The sequence diversity enables
human AMPs to adopt various 3D structures and to attack pathogens by different mechanisms.
While α-defensin HD-6 can self-assemble on the bacterial surface into nanonets to entangle bacteria,
both HNP-1 and β-defensin hBD-3 are able to block cell wall biosynthesis by binding to lipid II.
Lysozyme is well-characterized to cleave bacterial cell wall polysaccharides but can also kill bacteria
by a non-catalytic mechanism. The two hydrophobic domains in the long amphipathic α-helix of
human cathelicidin LL-37 lays the basis for binding and disrupting the curved anionic bacterial
membrane surfaces by forming pores or via the carpet model. Furthermore, dermcidin may serve
as ion channel by forming a long helix-bundle structure. In addition, the C-type lectin RegIIIα can
initially recognize bacterial peptidoglycans followed by pore formation in the membrane. Finally,
histatin 5 and GAPDH(2-32) can enter microbial cells to exert their effects. It appears that granulysin
enters cells and kills intracellular pathogens with the aid of pore-forming perforin. This arsenal
of human defense proteins not only keeps us healthy but also inspires the development of a new
generation of personalized medicine to combat drug-resistant superbugs, fungi, viruses, parasites,
or cancer. Alternatively, multiple factors (e.g., albumin, arginine, butyrate, calcium, cyclic AMP,
isoleucine, short-chain fatty acids, UV B light, vitamin D, and zinc) are able to induce the expression
of antimicrobial peptides, opening new avenues to the development of anti-infectious drugs.
Keywords: antimicrobial chemokines; antimicrobial neuropeptides; antimicrobial proteins; cathelicidin
LL-37; defensins; dermcidin; hepcidins; histatins; RNases
1. Introduction
Host defense antimicrobial peptides (AMPs) are key components of the innate immune system
shared by both invertebrates and vertebrates. Invertebrates such as insects and crustaceans do not
have adaptive immune systems and innate defense systems serve as the only protective mechanism.
It is now appreciated that innate immune systems also play an indispensable role in vertebrates by
directly killing invading microbes in the early stage. Later, vertebrate AMPs can also help augment the
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adaptive immune system to further handle infections. Thus, host defense peptides may have dual role:
rapid microbial killing and subsequent immune modulation [1–6].
The universality of AMPs is evidenced by the identification of these molecules in a variety of
organisms. Over 2,300 such peptides have been isolated and characterized according to the online
updated Antimicrobial Peptide Database (APD) [7,8]. As of April 2014, there are 233 AMPs from
bacteria (i.e., bacteriocins), six from protozoa, 12 from fungi, 306 from plants, and 1,801 host defense
peptides from animals. AMPs are usually gene-coded and can be constitutively expressed or induced
to fend off invading pathogens. In addition, some bacteria use a second mechanism to assemble
peptide antibiotics by using a multiple-enzyme system, leading to distinct chemical modifications not
observed in gene-coded cases. Most of the AMPs are cationic and short with less than 50 amino acids.
Such features are ideal to target the negatively charged surface of bacteria [1–6].
AMPs also protect humans from microbial infection. They have been identified in a variety
of exposed tissues or surfaces such as skin, eyes, ears, mouth, airways, lung, intestines, and the
urinary tract. While human cathelicidin LL-37 is detected in the skin of new born infants [9], human
beta-defensin 2 (hBD-2) is frequently expressed in older individuals. Human S100 proteins, hBD-2,
human beta-defensin 3 (hBD-3), and cathelicidin are significantly higher in fetal keratinocytes than
in postnatal skin cells [10]. In addition, psoriasin (S100A7), RNase 7, and hBD-3 are differentially
expressed in healthy human skin [11]. When the skin barrier is broken, psoriasin is up-regulated [12].
Lysozyme and lactoferrin have been found in human tears [13]. In addition, β-defensins are expressed
in human middle ear epithelial cells [14]. Drosomycin-like defensin (DLD) [15] is produced in human
oral epithelial cells as part of host defense against fungal infection. Defensins, cathelicidins, and
histatins are important in preventing oral cavity [16]. Apart from antimicrobial activity, human AMPs
such as cathelicidins and defensins possess other functions such as immune modulation, apoptosis,
and wound healing [1–6]. It is now recognized that certain defensins also play a critical role in sperm
fertilization [17–19]. By the time this manuscript was completed, 103 human AMPs were found in the
APD [7,8]. A selected set of these peptides is provided in Table 1. The lengths of these human peptides
range from 10 (neurokinin A) to 149 amino acids (RegIIIα). Their net charges vary from −3 (β-amyloid
peptide) to +20 (antimicrobial chemokine CXCL9). On average, human AMPs have 55 amino acids with
a net charge of +5.6. Thus, both the average length and net charge for the current list of human AMPs
are higher than those averages from all the AMPs (32.4 residues and net charge +3.2). An important
reason for this is the inclusion of human antimicrobial proteins (> 100 amino acids) with high net
charges (on average +10). The sequence diversity of human AMPs directly determines their structural
and functional diversity. This review article highlights the discovery, activity, structure, mechanism of
action, and therapeutic strategies of human host defense peptides selected from the APD.
Table 1. Discovery timeline of select human antimicrobial peptides and proteins 1.



























bone marrow G, V, F, C
[21]
1988 Histatin 1 DSHEKRHHGYRRKFHEKHHSHREFPFYGDYGSNYLYDN saliva F
[22]
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Table 1. Cont.
Year Name Sequence Source Activity 2 Ref.
1988 Histatin 3 DSHAKRHHGYKRKFHEKHHSHRGYRSNYLYDN saliva G, F
[22]








eosinophils V, P [24]




























































platelets G, F [34]
2000 Hepcidin 25 (LEAP-1) DTHFPICIFCCGCCHRSKCGMCCKT plasma,Urine/Liver G, F [35]
2000 Neuropeptide α-MSH SYSMEHFRWGKPV brain G+, V, F [36]
2001 β-Defensin hBD-3 GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK
Skin, salivary



















tract; skin G, F [40]
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Table 1. Cont.








































γδ T cells G, F, V [47]













2012 KDAMP RAIGGGLSSVGGGSSTIKY eyes G- [51]
2013 DEFB114 DRCTKRYGRCKRDCLESEKQIDICSLPRKICCTEKLYEEDDMF epididymis G, F [19]
1 Data from the APD [7,8]. For a complete list of human AMPs, please visit the APD website (http://aps.unmc.edu/AP)
and search in the name field using “human”. 2 In the APD, antimicrobial activities against different types of
microbes are annotated as below: G, bacteria; G+, Gram-positive bacteria only; G-, Gram-negative bacteria only; F,
fungi; V, viruses; P, parasites; C, cancer cells.
2. Identification of Human Antimicrobial Peptides
Antimicrobial substances might have been noticed long time ago [1–6]. Human lysozyme (130
amino acids), discovered in saliva by Alexander Fleming in 1922 [20], is recognized as the first
antimicrobial protein [6]. However, the isolation and characterization of many more AMPs with
defined amino acid sequences did not start until the 1980s (please refer to the annual AMP discovery
plot in ref. [52]). Two major methods were utilized for AMP identification. Initially, chromatographic
approaches were used to isolate and characterize new peptides. With the recognition of peptide
sequence motifs, bioinformatic approaches were later developed to identify AMPs at the genomic
level. In the following, we describe the discovery of the major families of human antibacterial peptides
identified during 1985 and 2013.
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2.1. Human Defensins
Host defense peptides are usually expressed as precursor proteins and the mature form is released
by protease processing. In 1985, the Lehrer group isolated a family of the mature form of α-defensins
from human blood [21]. Based on the source, property and size, these peptides were named as human
neutrophil peptides (HNP-1, HNP-2, and HNP-3). The three defensins have nearly identical amino
acid sequences (Table 1). Compared to HNP-2, both HNP-1 and HNP-3 contain only one additional
amino acid residue at the N-terminus: alanine for HNP-1 and aspartate for HNP-3. This additional
acidic residue in HNP-3 may make HNP-3 less active than HNP-1 or HNP-2 in killing Staphylococcus
aureus, Pseudomonas aeruginosa, and Escherichia coli. A fourth human neutrophil defensin, HNP-4, was
reported in 1989 [23]. It was also purified to homogeneity by chromatographic methods. HNP-4
has a distinct peptide sequence with 33 amino acids. In vitro, purified HNP-4 was shown to kill E.
coli, Streptococcus faecalis, and Candida albicans. Lehrer and colleagues found that HNP-1, HNP-2, and
HNP-3 are abundant in bone marrow, and can be detected in peripheral blood leukocytes, spleen and
thymus by RT-PCR [53].
In 1989, Ouellette and colleagues identified α-defensin genes from mouse Paneth cells [54].
Bevins hypothsized that such orthologs also exist in human epithelial cells as part of the host defense
mechanism. A genetic approach was developed to map additional defensin genes based on the high
conservation of the nucleotide sequences in the signal coding region as well as the untranslated 5′
region. Using the probes from the conserved regions, they cloned the gene of HD-5 from human
Paneth cells [25]. Likewise, HD-6 was identified [26]. These peptides are tissue-specific as they are only
expressed in the Paneth cells of human intestines. The six human α-defensins (Table 1) share the same
disulfide bond pattern. If we number the six cysteines in Roman numbers: I, II, III, to VI, the three
disulfide bonds in α-defensins are CI–CVI, CII–CIV, and CIII–CV. Interestingly, alpha defensins have
been found in the neutrophils of rabbits, rats, hamsters, and guinea pigs, but not in mice or pigs [55].
Members from the human β-defensin family were discovered in the 1990s. Different from
α-defensins, the three disulfide bonds in β-defensins are CI–CV, CII–CIV, and CIII–CVI. Also,
β-defensins have a slightly longer sequence to allow for an additional helical region. The first human
β defensin (hBD-1) was reported by Bensch et al. from human plasma in 1995 [27]. Quantitative
mRNA analysis revealed kidney as the major source for hBD-1 [56]. In addition, different truncated
forms of hBD-1 were also isolated and found to be active against E. coli. The activity of hBD-1
might have been compromised in cystic fibrosis (CF) lung due to its salt-sensitive activity against P.
aeruginosa [57]. Subsequently, hBD-2 was identified from lesional psoriatic skin using the whole E. coli
affinity column [32]. This material was selected for AMP isolation based on the fact that patients with
lesional psoriatic skin have fewer skin infections than expected. This peptide is effective in killing
Gram-negative bacteria E. coli, P. aeruginosa, and yeast C. albicans, but is only bacteriostatic against
Gram-positive S. aureus. Like hBD-1, the activity of HBD-2 is also salt-sensitive [58]. In 2001, both
hBD-3 and hBD-4 were documented [37,38]. Based on this disulfide bond linkage pattern, hBD-3 was
also identified by using a bioinformatic approach [59,60]. In contrast to hBD-1 and hBD-2, hBD-3
remained active against S. aureus and vancomycin-resistant Enterococcus faecium at physiological salt
concentrations [37]. Bioinformatic studies led to the identification of 28 additional human and 43
mouse β-defensin genes in the respective genome [61]. Several of these β-defensins (hBD-6, hBD-26,
hBD-27, hBD-28, and DEFB114) are indeed antimicrobial in vitro [62–64]. This sequence motif-based
peptide prediction may be applied to any other species with a completed genome.
In insects, the activation of TOLL directly leads to the expression of drosomycin against fungal
infection [65]. In 2008, human drosomycin-like defensin was detected in oral mucosa [46,66], indicating
that this ancient innate defense mechanism is conserved. Sequence alignment in the APD revealed
40% similarity to insect drosomycin, which comprises one α-helical and three β-strands. Therefore,
such a combined structure resembles human β-defensins to some extent. This peptide appears to
be specifically effective against filamentous fungi (e.g., Aspergillus spp) as it did not kill tested yeast,
Gram-positive or Gram-negative bacteria. Although the connection pattern of the six cysteines has
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not yet elucidated, the resulting three disulfide bonds are critical for the antifungal activity of human
drosomycin-like defensing [46].
It is interesting to mention that a different type of defensins (called θ-defensins) has been identified
from non-human primates [66,67]. These 18-residue defensins are circular due to the formation of a
peptide bond between the N- and C-terminal ends. Like α- and β-defensins, they are also stabilized
by three sets of disulfide bonds (CI–CVI, CII–CV, and CIII–CIV). These defensins are generated by
liganding two truncated α-defensins. These genes are not expressed in humans due to the existence of
a premature stop codon. Like monkey θ-defensins, synthetic peptides corresponding to these human
counterpart pseudogenes are HIV-1 inhibitory [68–70]. It is uncertain whether the loss of θ-defensins
made humans generally more susceptible to HIV-1 infection.
2.2. Human Histatins: Two Genes Multiple Peptides
Histatins are a family of AMPs rich in histidines. In 1988, histatins 1, 3, and 5 were isolated
from human saliva by size-exclusion chromatography followed by HPLC separation [22]. All three
histatins exhibit the ability to kill the pathogenic yeast, C. albicans. Subsequently, other histatins were
also isolated [71]. However, only histatins 1 and 3 are gene encoded [22,72], since others are the
cleaved products of these two peptides. The histatin genes are located on chromosome 4, band q13
and exclusively expressed in human salivary secretions [73].
2.3. Human Cathelicidins: One Gene Multiple Peptides
The significance of cathelicidins in protecting humans from infection is established by data from
animal models [74–76]. Cathelicidin peptides were first isolated in 1989 [77]. The precursor proteins of
cathelicidins share a highly conserved N-terminal “cathelin” domain, but have drastically different
antimicrobial sequences, ranging from Pro- and Arg-rich peptides, helical peptides, to disulfide-linked
sequences [78]. The word “cathelicidin” was originally used to refer to the entire precursor protein.
However, it is now accepted as the family name for mature AMPs from the C-terminal region. Another
term hCAP-18 is abbreviated from human cationic protein of 18 kDa, representing the precursors prior
to the release of cathelicidin peptides. However, these terms are interchangeably used in the literature.
Based on the conserved sequences in the cathelicidin precursors, Agerberth and colleagues cloned
the only human cathelicidin gene and predicted the antimicrobial peptide as FALL-39 in analogy to
PR-39 discovered in cattle [28]. Using the probes designed based on rabbit CAP-18, Larrick et al. also
cloned the C-terminal antimicrobial peptide [29]. In the same year, Cowland et al. isolated a 19 kDa
precursor protein hCAP-18 from human neutrophils [30]. Subsequently, the European group isolated
the natural form of the mature human cathelicidin peptide from neutrophils [79]. Since the isolated
peptide contains 37 amino acids and starts with a pair of leucines, it was named LL-37, which is two
residues shorter than the initially predicted peptide FALL-39 [28]. Interestingly, ALL-38, another form
of human cathelicidin peptides, was also characterized in 2003 [80]. This alterative form contains
one more alanine at the N-terminus than LL-37. ALL-38 was generated in female vagina due to the
action of gastricsin on sperm hCAP-18. Antimicrobial assays revealed a similar activity spectrum for
LL-37 and ALL-38 against a panel of bacteria, including E. coli, S. aureus, P. aeruginosa, and Bacillus
megaterium. Thus, ALL-38, as well as other active peptides such as SgI-29 [81], plays a defense role
in the human reproductive system. In addition, LL-37 fragments were isolated from human skin by
chromatographic approaches [82]. These fragments have varying activities compared to intact LL-37.
Hence, a single human cathelicidin gene has been processed into different forms of active peptides [83].
This phenomenon, however, is not unique to humans. There is precedence that multiple AMPs are
programmed in a single plant gene [84]. One possibility for this is that different cathelicidin fragments
provide a means to expanding the functional space of the single human cathelicidin gene. A different
model is utilized by sheep, horses, and cattle, which produce multiple cathelicidins with varying
functions [85–88].
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2.4. Human Dermcidin
Besides human cathelicidin LL-37 [89], dermcidin, an anionic defense peptide, was found in
human sweat [39]. Unlike human defensins and cathelicidins that are induced under inflammatory
and injured conditions, dermcidin is constitutively expressed in human sweat [90]. Furthermore,
dermcidin variants as well as fragments were also detected. It appears that the level of dermcidin did
not vary between healthy people and infected patients [91]. In addition, dermcidin may be related to
other human diseases such as cancer and atherosclerosis [92,93].
2.5. Human Hepcidins
Human liver expressed antimicrobial peptide-1 (LEAP-1) was discovered from human blood
ultrafiltrate in 2000 [35]. The same peptide was also found by Ganz et al. from human urine and
named as hepcidin 25 [94]. This liver-synthesized peptide is especially rich in cysteines (32%), leading
to four disulfide bonds in a 25-residue peptide. In 2009, the connection pattern of the four disulfide
bonds was revised to C7–C22, C10–C13, C11–C19, and C14–C22 [95]. This antimicrobial peptide also
plays an important role in ferrous use [96] and single-residue mutations in this molecule are associated
with severe juvenile hemochromatosis, a genetic disease of severe iron overload [97]. Unlike LEAP-1,
antimicrobial peptide LEAP-2, however, is not involved in the regulation of iron use [98].
2.6. Human AMPs Derived from Known Proteins
Some AMPs are derived from known proteins. Park et al. isolated buforin I from amphibians
in 1996 [99]. Sequence comparison revealed that buforin I is a cleaved fragment of histone H2A.
Of interest, this mRNA was also detected in humans, suggesting a possible role of this peptide in
antimicrobial defense [100].
The human airways are essential for the exchange of molecules with the environment. It is
necessary to guard this channel to prevent the infection of microbes in the air. In 2001, Ganz and
colleagues isolated calcitermin primarily targeting Gram-negative bacteria. This 15-residue peptide is
derived from the C-terminus of calgranulin C (a S100 protein). It contains three histidines (His9, His11,
and His13) at the N-terminus and has the potential to adopt a helical conformation in membranes.
These histidines may explain its enhanced activity in acidic buffers (pH 5.4) and in the presence of
micromolar concentrations of ZnCl2 [101].
Another example for protein-derived AMPs is KDAMP, keratin-derived AMPs, which were
identified from bactericidal lysate fractions of human corneal epithelial cells. These molecules are
rich in glycines [51]. The glycines appear to be important for killing P. aeruginosa as substitution of a
string of glycines with alanines reduced peptide potency. A search of the APD reveals that glycine-rich
(>25%) AMPs have also been identified in bacteria, plants, insects, spiders, nematodes, crustaceans,
fish, and amphibians. Thus, glycine-rich peptides constitute a common molecular design for host
defense [102–110].
2.7. Antimicrobial Chemokines and AMPs from Human Immune Cells
The fact that some AMPs possess chemotactic effects inspired the evaluation of antimicrobial
activity of chemokines, which are known for chemotaxis. In 2000, Krijgsveld et al. found antimicrobial
thrombocidins, peptides derived from CXC chemokines in human blood platelets [34]. In 2003,
Oppenheim and colleagues identified 20 antimicrobial chemokines [42] and additional two members
(CCL27 and CCL28) were also reported by Hieshima and colleagues [111]. In 2011, antimicrobial
activity of chemotactic chemerin was also reported [49]. Further studies are required to establish the
in vivo relevance of the in vitro activity of these chemokines. The common nature of chemokines and
AMPs, however, bridges the innate and adaptive immune systems.
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Antimicrobial peptides have also been found in other immune cells. In 1999, Hiemstra et al.
identified ubiquicidin from ribosomal protein S30 in various tissues. This peptide is active against
Listeria monocytogenes, S. aureus, Salmonella typhimurium, and E. coli. Considering the fact that L.
monocytogenes can live within cells, the expression of ubiquicidin in macrophages would limit the
replication of this bacterium. Interestingly, ribosomal protein S30 is identical in rats, mice and
humans [33]. In 1998, granulysin (74 amino acids) was detected in human cytotoxic T cells and natural
killer (NK) cells [32]. Similar proteins called NK-lysins are found in other animals [112]. Granulysin is
active against Gram-positive and Gram-negative bacteria, and fungi, including mycobacteria. Thus,
the human adaptive immune system has incorporated an innate defense molecule for direct disruption
of tumor cells or invading microbes. In addition, human γδ T cells produce antimicrobial peptide
elafin [47]. Like human secretory leucoprotease inhibitor (SLPI), elafin was initially identified as a
protease inhibitor. Elafin shows an inhibitory effect on bacteria, fungi, and viruses [113].
2.8. Antimicrobial Neuropeptides
Antibacterial peptides were also isolated from the neuroendocrine system from cattle. Secretolytin
corresponds to the C-terminal fragment (residues 614–626) of bovine chromogranin B [114]. This
peptide displayed activity against M. luteus and reduced the growth of B. megaterium. Vasostatin-1
is a 76-residue N-terminal fragment of bovine chromogranin A. This peptide is active against both
Gram-positive bacteria and fungi [115]. It is conserved in humans, pigs, horses, mice, rats, and
frogs. Catestatin is a 21-residue AMP derived from human chromogranin A [116]. Subsequently,
cattle enkelytin, the C-terminal fragment corresponding to residues 209–237 of proenkephalin-A was
also found to be antibacterial [117]. A similar proenkephalin system exists in humans although the
processing machinery can differ [118]. Thus, these neuropeptides also play a communication role
between neuroendocrine and the immune system [119].
In 1998, human neuropeptide Y (36 residues) was demonstrated to have antimicrobial
activity [120]. Interestingly, the antifungal activity of this peptide against C. albicans increased several
folds by truncating N-terminal 12 residues, implying the importance of the helical region 14–32. A
more recent study, however, only observed activity against E. coli, but not C. albicans [121]. Future
studies will clarify whether the peptide has direct antimicrobial effects. In 1999, adrenomedullin,
usually expressed on surface epithelial cells, was reported to have antibacterial activity against all
the tested bacteria, but not C. albicans [122]. Alpha-MSH was added to the human AMP list in 2000
as well [36]. These findings extended host defense peptides to the nervous system [123]. Since then,
more antimicrobial neuropeptides have been documented [45,124]. Some of these neuropeptides may
become leads for developing new antibiotics. For example, alarin is a human brain neuropeptide with
activity against only Gram-negative bacteria such as E. coli, but not Gram-positive bacteria such as
S. aureus [124]. In particular, α-MSH showed in vitro antifungal activity against C. albicans at fM to
pM [125], much lower than nM for some bacterial lantibiotics and μM for many cationic peptides.
2.9. Beta-Amyloid Peptides
Beta-amyloid peptides have long been thought to be the culprit of Alzheimer's disease. It is
believed that the β-sheet form, not the helical form of the peptide, is toxic. A recent demonstration
of antimicrobial activity for β-amyloid peptides adds a new research dimension to this worrisome
disease [48]. Further studies along this line could be useful to provide novel insight into the mechanism
of this human disease. In 2012, amylin (human islet amyloid polypeptide, hIAPP) was found bactericidal,
too [50]. Transformation of amylin into toxic fibrils can disrupt cell membranes and lead to β-cell death,
perhaps one of the causative factors of type 2 diabetes mellitus. The aggregated form of amylin is likely
to exert its cytotoxicity by damaging cell membranes [126]. It is noticeable that, when in excess, bacteria
microcin E492 can form fibrils as a storage form and lose antimicrobial activity [127]. Is there anything
in common here from bacteria to humans? Perhaps, this is one mechanism that nature attempts to
remove the toxic effects of an over expressed protein, including antimicrobial peptide.
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2.10. Human Antimicrobial Proteins
There are 14 antimicrobial proteins (>100 amino acids) in the APD database as of March 2014 [8].
This includes the first antimicrobial protein lysozyme [20]. Several eosinophil proteins were purified
in 1990. Both eosinophil-derived neurotoxin (EDN, or RNase 2) and eosinophil cationic protein (ECP,
or RNase 3) possess anti-parasitic activity against Brugia pahangi and Brugia malayi [24]. These two
ribonucleases are also active against respiratory syncytial virus (RSV) with a single-stranded RNA [128].
In addition, RNase 3 has a unique bacterial agglutinating activity [129]. In 2002, RNase 7 was identified
from human skin [40]. Remarkably, it is active against bacteria such as Mycobacterium vaccae and yeast,
even at 4 ◦C [130]. Recombinant RNase 7 exhibited antimicrobial activity against uropathogens (E. coli,
P. aeruginosa, Klebsiella pneumonia, Proteus mirabilis, E. faecalis, and Staphylococcus saprophyticus) [131,132].
In fact, RNase 7 is the most abundant innate defense peptide in the human urinary tract [132], although
the contributions of other human AMPs cannot be ignored [56,133–135]. Human RNase 5, (also known
as angiogenin or ANG) with weak RNase activity, is initially implicated in angiogenesis. It appears
that the nucleus location is necessary for angiogenesis [136]. In 2003, RNase 5 was found to have a
toxic effect on Gram-positive bacteria and fungi [41]. However, another study found little activity
using a commercial material [137]. In 2006, RNase 8 was found to inhibit M. vaccae [138,139]. Therefore,
of the eight human ribonucleases, RNases 2, 3, 5, 7, and 8 appear to play a role in host defense.
Psoriasin is another human protein with multiple functions. It is identical to S100A7, a protein
member of the S100 family. Psoriasin was initially characterized as a Ca2+ binding protein with
chemotactic property from human skin psoriatic lesions [140,141]. Subsequently, psoriasin was found
in cancer lesions, making it a potential cancer biomarker [142]. However, the antimicrobial activity of
psoriasin against E. coli was not demonstrated until 2005 [43].
Three RegIII (regenerating gene family protein III) proteins were initially identified in mice [143].
RegIIIα, a RegIIIγ homolog protein, was found in humans. Different from RegIIIβ from mice, human
RegIIIα only inhibited the growth of Gram-positive bacteria such as L. monocytogenes, Listeria innocua,
and E faecalis [44].
3. Antimicrobial and Anticancer Activities of Human Antimicrobial Peptides
3.1. Antibacterial Activities
Antibacterial activities of human AMPs have been mentioned in the preceding section. This section
provides an overview of the activity spectrum of these peptides. Based on the APD [8], the majority of
human AMPs (90 out of 103) can inhibit the growth of bacteria. They display a broad-spectrum activity
against a variety of Gram-positive and Gram-negative bacteria. However, three human AMPs kill
primarily Gram-positive bacteria. RNase 5 has an effect on S. pneumonia [41], while α-MSH is inhibitory
to S. aureus [36]. A third AMP, RegIIIα, is active against L. monocytogenes, L. innocua, and E. faecalis [44].
In addition, ten human AMPs are inhibitory mainly to Gram-negative bacteria. These include hBD-26,
hBD-27, human calcitermin, psoriasin/S100A7, CCL8, CCL13, CCL19, alarin, HMGN2, and KDAMP
peptides [42,43,51,63,101]. They may control different Gram-negative pathogens. For example, both
calcitermin and HMGN2 were active against E. coli and P. aeruginosa [101,144]. Alarin is active against
E. coli, while the KDAMP peptides are primarily active against P. aeruginosa. Thus, these peptides may
form the basis for developing new antimicrobials with a desired antibacterial activity spectrum.
3.2. Antiviral Activity
Of the 103 human AMPs, 16 are virucidal. They include the six well-characterized human
α-defensins (HNP-1, HNP-2, HMP-3, HNP-4, HD-5, and HD-6), three β-defensins (hBD-1, hBD-2,
and hBD-3), cathelicidin LL-37, histatin 5, α-MSH, elafin, SLPI, CXCL12, RNase 2, and RNase 3. Elafin
is the major antiviral protein in cervicovaginal lavage fluid [113]. Both RNase 2 and RNase 3 inhibit
respiratory syncytial viruses (RSV) [145,146]. SLPI levels in saliva and semen, but not breast milk,
approximate the level required for HIV-1 inhibition in vitro [147]. Although HNP-1 is a lectin that binds
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to gp120 and CD4, it shows an inhibitory effect after HIV-1 entry [148]. It also inhibits non-enveloped
BK virus infection by aggregating virions and blocks binding to host cells [149]. Of the four human
β-defensins, hBD-2 and hBD-3 can be induced by viral infection and block HIV replication by directly
neutralizing the virions and through modulation of the CXCR4 coreceptor [150]. Human cathelicidin
LL-37 is also inhibitory to HIV-1 [151,152]. Wang et al. further dissected the active region of LL-37.
While the central fragment GI-20 showed an optimal therapeutic index, the LL-37 core peptide FK-13
contains the minimal anti-HIV sequence [152]. In the histatin family, only a histatin-5-derived peptide
has an effect on HIV-1 [153]. For a systematic review of AMPs with known anti-HIV activity, interested
readers may refer to a recent review article [154].
3.3. Antifungal Activity
In the APD, 58 human AMPs are fungicidal [8]. Typical examples are human α-defensins,
cathelicidin LL-37, hepcidins, and histatins. In the case of LL-37, protease processing into fragments
such as KS-30 and RK-31 is essential in inhibiting C. albicans [155]. In addition, the antifungal activity of
LL-37 depends on both media and pH. Both LL-25 and RK-31 can rapidily enter the cell cytoplasm [156].
It is likely that these LL-37 fragments target intracellular molecules. It appears that such cathelicidin
fragments in human sweat play a role in human skin innate defense against fungal infection [155].
3.4. Antiparasitic Activity
Some human AMPs also have antiparasitic properties. These include HNP-1, LL-37, granulysin,
CCL2, CCl20, CCL28, CXCL4 (hPF4), CXCL6, CXCL9, CXCL10, RNase 2, and RNase 3. RNases 2 and
3 might be the earliest AMP examples from humans that were demonstrated to have antiparasitic
activity [24]. Other more recent examples are HNP-1 against the promastigotes and amastigotes forms
of Leishmania major [157], chemokine CCL28 against Leishmania mexicana [158], LL-37 against Entamoeba
histol ytica [159], and Platelet factor 4 (hPF4) against malarial parasite Plasmodium falciparum [160].
These examples verify that human defense peptides also play a role in controlling parasite infections.
3.5. Anticancer Activity
There is a growing interest in developing AMPs into anticancer peptides. Magainins, cecropins,
and defensins were all shown to have anticancer effects [161–163]. Many other AMPs possess this
activity as well and some were discussed in previous review articles [164–166]. A more complete
and updated list of anticancer AMPs can be searched in the APD database [8]. The 166 anticancer
peptides cover multiple sources, including animals (105 peptides), plants (48 AMPs), bacteria (seven
bacteriocins), fungi (one peptide), and laboratory synthesis (five peptides).
The anticancer activities of human AMPs have not been widely evaluated since only six members
are annotated as anticancer in the APD [8]. They are HNP-1, HNP-2, HNP-3, hBD-1, LL-37, and
granulysin. Indeed, reduced expression of granulysin in patients is correlated with the progression
of cancer [167]. However, the level of granulysin increased substantially in cancer cells [168]. Similar
observations have been made with human defensins and LL-37. While HNP-1 inhibits the growth of
human lung adenocarcinoma xenograft in nude mice [169], the same molecule can be overexpressed
in tumors [170,171]. HBD-1 can suppress urological and prostate cancers [172,173]. In oral squamous
cell carcinoma, hBD-1 also suppressed tumor proliferation, whereas hBD-2 and hBD-3 showed an
opposite effect [174]. Likewise, human cathelicidin LL-37 is overexpressed in breast, ovarian, and lung
cancers, but it suppresses tumorigenesis in gastric cancer [175]. Such a complex involvement of AMPs
in various cancers deserves additional studies. In particular, it is important to elucidate the factors that
trigger the overexpression of AMPs in certain cancer cells.
Our current knowledge, however, may be utilized to our advantage. For instance, the over-expression
of human cathelicidin LL-37 or defensins may serve as useful biomarkers for cancer diagnosis [176–178].
In addition, the fragments of LL-37 with demonstrated anticancer effects in vitro [179] and in vivo [180]
might constitute useful templates for designing new anti-tumor drugs, especially those resistant to
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existing therapeutics. Anticancer AMPs can work by different mechanisms. The effects may result from
a direct bacterial killing when bacteria could be the culprit of cancer (e.g., gastric cancer) [175]. AMPs
may selectively kill cancer cells in part due to exposed anionic phosphatidylserines (PS) [181]. It is also
possible that some AMPs kill cancer cells indirectly by inducing apoptosis (see below).
3.6. Cytotoxic Effects of Human AMPs
It is accepted that many AMPs target bacterial membranes. While bacteria are abundant in anionic
lipids such as phosphatidylglycerols (PG) and cardiolipin (CL) [83], human cells comprise zwitterionic
phosphocholines (PC) and cholesterol. The differences in membranes of bacterial and human cells to a
large extent determine cell selectivity of cationic AMPs. Indeed, among the 103 human AMPs, only
three peptides are annotated to have cytotoxic effects on mammalian cells. In the case of LL-37, we
found it possible to reduce the peptide cytotoxicity by decreasing peptide hydrophobicity [179,182].
The relatively low cytotoxicity of human AMPs makes them attractive templates for engineering
new antimicrobials.
In addition to membrane differences, human cells could use other mechanisms to reduce or
remove the potential toxic effect of AMPs on themselves. By expressing a peptide called p33 on the cell
surface, the toxic effects of human LL-37 is masked [183]. Instread of directly secreting AMPs, humans
also release exosomes (nanovesicles enriched in host defense peptides) into the urinary tract to keep it
sterile [184]. It may be speculated that such exosomes, similar to artificial AMP-containing liposomes,
could be an effective way to reduce cytotoxicity to human cells.
3.7. Other Biological Functions of Human AMPs
In addition to antimicrobial and anticancer activities, many human AMPs possess other functions
such as chemotaxis, apoptosis, and wound healing:
Chemotactic activity. Currently, 35 human AMPs have chemotactic properties. Examples are
defensins and cathelicidin LL-37. Antimicrobial chemokines were originally identified for chemotactic
activity. A clear difference between chemokines and AMPs is the concentration needed for action.
While the chemotactic effect needs peptides in the nM-pM range, antimicrobial action usually requires
μM peptides [185]. Another difference between chemotactic and antimicrobial activities lies in the
molecular target. While AMPs usually target membranes of invading bacteria, the chemotactic effects
require the association of peptides to host cell receptors. As one example, human LL-37 achieves its
chemotactic ability to monocytes, macrophages, neutrophils, and T cells by binding formyl peptide
receptor-like 1 (FPRL-1) [186].
Apoptosis. Apoptosis is the process of programmed cell death. Different factors can trigger cell
apoptosis. AMPs are one of these factors. Interestingly, apoptosis may be induced or suppressed by
the same peptide depending on the biological context. Human LL-37 induces apoptosis in vascular
smooth muscle cells, primary airway epithelial cells, oral squamous cell carcinoma SAS-H1 cells, intact
rat aorta rings and cultured rat aorta smooth muscle cells, Jurkat T-cells and A549 cells [187–191], while
it suppresses this process in keratinocytes and neutrophils [192,193]. As a consequence, elucidation of
the mechanism to control apoptosis may offer new therapeutic strategies. A recent interesting finding
is that inhibition of human LL-37-induced apoptosis by administrating urothelial glycosaminoglycan
(GAG) analogs can prevent the development of interstitial cystitis (IC) in a mouse model [194].
LL-37 could suppress the lipopolysaccharides (LPS)-induced apoptosis of endothelial cells, thereby
attenuating lethal sepsis/endotoxin shock [195]. In the case of colon cancer, however, activation of
apoptosis suppresses tumorigenesis [196]. It seems that apoptosis requires the major antimicrobial
region FK-16 (i.e., corresponding to residues 17-32) of human cathelicidin LL-37 [179,180].
Wound healing. Human host defense peptides can also promote wound healing, a process of injury
repairs. Salivary histatin 2 can enhance fibroblast cell migration, whereas human LL-37 at 1 μM can
induce cell migration and promote proliferation [197]. It is proposed that these peptides play a role in
fast wound coverage.
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In summary, antimicrobial activity is a common property of human AMPs, although the in vivo
relevance has not firmly established for each polypeptide. Furthermore, human AMPs can perform
other functions depending on the biological context, peptide concentration, proteases, and the
metabolic state. Under diseased conditions, AMPs may have an opposite effect (e.g., cancer suppression
vs. progression). Understanding the elegant balance of AMPs in these processes in the healthy state
as well as the factors that could tilt the balance to a diseased state may yield useful means for
cancer treatment.
4. Three-Dimensional Structures of Human Antimicrobial Peptides
Three-dimensional structure of human host defense AMPs are helpful to understand the function
of AMPs described above. Many short and linear antimicrobial peptides do not have a folded structure
free in solution. However, they may become structured upon interactions with host cells by binding to
a specific receptor to trigger the biological responses to microbial invasion. In addition, such AMPs
may also adopt a defined structure upon association with bacterial targets such as membranes. The
bound structure in either category is not trivial to determine. Membrane-mimetic models are normally
utilized to determine the membrane-bound structures of receptors or AMPs. These models include
organic solvents, detergent/lipid micelles, lipid bicelles, nanodiscs, and lipid bilayers [198,199]. The
known 3D structures of these short peptides are primarily determined by multi-dimensional solution
nuclear magnetic resonance (NMR) spectroscopy [199]. Some AMPs possess a folded structure in
aqueous solutions primarily due to the structural stabilization of disulfide bonds. The structures
of these small proteins can be determined by NMR or X-ray crystallographic methods. When both
methods are applied, similar structures are usually found. In addition, NMR measurements can gain
insight into protein dynamics (i.e., motions). Among the 103 human AMPs annotated in the APD
database, 42 have a known 3D structure (27 determined by NMR and 15 by X-ray) [8].
Although there are different classification schemes [1–6,200], the structures of natural AMPs
fall into four large families (α, β, αβ, and non-αβ) [201]. Peptides in the α family contain α-helical
structure as the major secondary structure. Typical examples are human cathelicidin LL-37, histatins,
dermcidin, and granulysin. The β family is characterized by at least a pair of two β-strands in the
structure. Human α-defensins, hepcidins, and SLPI use this type of structure. The αβ family contains
both α and β secondary structures, whereas the non-αβ family has neither α nor β structure (also
called extended structures). While there are multiple structural examples for the αβ family (Table 2),
no structural example has been found for the non-αβ family of human AMPs. In the following, we
highlight atomic structures of human AMPs from the α, β, and αβ families. These structures are
annotated in the APD database [8] and structural coordinates can be obtained from the Protein Data
Bank (PDB) [202] via the APD links.
Table 2. Properties of selected human antimicrobial peptides with known 3D structure 1.
APD ID Peptide name Length Net charge Pho% Boman index Structure class
2257 Lysozyme 130 +8 40 2.28 α
505 Histatin 5 24 +5 8 4.81 α
780 Lactoferricin 49 +10 36 3.14 α
310 LL-37 37 +6 35 2.99 α
433 Dermcidin 47 −2 38 1.11 α
1161 Granulysin 74 +11 33 3.5 α
2072 Psoriasin/S100A7 101 −1 32 2.3 α
1676 β-Amyloid peptide 1-42 42 −3 45 0.77 α
176 HNP-1 30 +3 53 1.07 β
177 HNP-2 29 +3 51 1.17 β
178 HNP-3 30 +2 50 1.42 β
179 HNP-4 33 +4 51 1.4 β
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Table 2. Cont.
APD ID Peptide name Length Net charge Pho% Boman index Structure class
180 HD-5 32 +4 40 2.6 β
181 HD-6 32 +2 40 1.71 β
192 Hepcidin 20 20 +3 60 0.46 β
193 Hepcidin 25 (LEAP-1) 25 +2 52 0.89 β
2095 SLPI 107 +12 34 1.87 β
451 hBD-1 36 +4 36 1.3 αβ
524 hBD-2 41 +7 36 0.9 αβ
283 hBD-3 45 +11 33 2.87 αβ
811 LEAP-2 40 +4 40 2.94 αβ
2067 RNase 5 125 +11 28 2.99 αβ
2073 RNase 7 128 +16 32 2.16 αβ
2071 RegIIIα 149 +1 33 1.77 αβ
2085 CCL1 73 +10 41 2.25 αβ
2086 CCL8 75 +6 37 2.27 αβ
2088 CCL13 75 +11 36 1.89 αβ
2075 CCL20 69 +8 43 1.34 αβ
2187 CCL27 56 +1 41 1.57 αβ
2076 CXCL1 73 +6 38 1.51 αβ
2080 CXCL10 77 +11 36 2.25 αβ
1 Obtained from the Antimicrobial Peptide Database (http://aps.unmc.edu/AP) [8]. Peptide hydrophobic amino acid
content (percent) is represented by pho% in the table. Protein-binding potential [1] was re-named as Boman index
in the APD database in 2003.
4.1. The α-Helical Family: Histatins, Cathelicidins, Dermcidin, and Granulysin
Histatins. Histatins 1, 3, and 5 are active against C. albicans and their candidacidal activities are
in the following order: histatin 5 > histatin 3 > histatin 1 [203]. Rai et al. investigated the relationship
between sequence length and activity using histatin 5 as the template. They found that the C-terminal
sequence is important [204]. P-113 with 12 residues corresponding to residues 4–15 of histatin 5
retained anti-candida activity [205]. Using histatin 3 as a model, Zuo et al. found increased activity
when the active sequence was expressed in tandem (repeated once) [206]. However, duplication of the
functional domain of histatin 5 did not enhance candidacidal activity [207]. These results suggest that
active domain duplication is not necessary a universal strategy for activity enhancement. Histatin 5
can adopt a helical conformation in the presence of membrane-mimetic agents [204]. However, this
helical structure did not appear to be essential for candidacidal activity as peptides with a less helical
structure (achieved by proline insertion) can be equally active [208]. Histatin 5 contains a consensus
sequence, HEXXH, which is known to bind Zinc. Zinc binding can lead to vesicle fusion and helical
conformation as well [209]. Zinc binding actually potentiates peptide activity against gram-positive
bacteria E. faecalis [210]. An analog of histatin 5 was found to bind DNA and have nuclease activity
due to the synergistic oxidative and hydrolytic activities of the metal-peptide complex [211].
Human cathelicidin LL-37. To understand the structural basis of antimicrobial activity, 3D
triple-resonance NMR spectroscopy was used to solve a high-quality structure for human LL-37
in the presence of sodium dodecyl sulfate (SDS) micelles [182]. LL-37 has a long helix covering residues
2–31, whereas the C-terminal tail is disordered and does not superimpose well to each other (Figure 1A).
This structure is fully consistent with the backbone dynamics measured by an independent NMR
experiment. This amphipathic helical region determined in SDS micelles is responsible for binding
to bacterial outer and inner membranes. Interestingly, the LL-37 tail appeared to be involved in
peptide aggregation [212], which influences LL-37 activity [213]. The N-terminal region of LL-37 is
less important for antibacterial activity since LL-23, a natural fragment of LL-37, is only active against
susceptible E. coli or S. aureus strains. The weak activity of LL-23 is attributed to a hydrophilic residue
Ser9 that splits the hydrophobic face into two clusters [214]. This Ser9 residue also segregates the
hydrophobic surface of LL-37 into two hydrophobic domains. It is established that the central helix
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(Figure 1B) of human LL-37 is critical for antibacterial, anti-biofilm, and antiviral activity (reviewed in
ref [83]).
Dermcidin. Unlike cationic cathelicidin LL-37 (net charge +6), dermcidin (DCD-1) has a net
charge of −2. This peptide also prefers anionic membranes, however. DCD-1L, a variant with one
additional leucine at the C-terminus, showed an enhanced affinity for membranes than DCD-1. In the
membrane bound state, DCD-1L has a helical conformation. It is located on the membrane surface
and can aggregate in the presence of zinc [215]. This oligomeric structure of dermcidin has recently
been determined by X-ray crystallography [216]. A hexameric helix-bundle structure (Figure 1C) is
proposed to insert into bacterial membrane as an ion channel. In the crystal, the Zn2+ coordinates
with a group of acidic amino acids. It should be pointed out that the 3D structure of DCD-1L was also
determined previously by 3D NMR spectroscopy using a 15N-labeled peptide in a 50% trifluoenthanol
(TFE) solution. Four helical regions were identified (α1: 5–7; α2: 10–12; α3: 26–33; and α4: 36–45) [217].
In this case, TFE might have disrupted the oligomeric structure of dermcidin. There are precedents
for such an effect of TFE. For example, the oligomeric structure of a K+ channel did not survive in
TFE but retained in membrane-mimetic micelles such as SDS (reviewed in ref. [198]). These examples
emphasize the importance of determining the 3D structure of AMPs in a proper environment.
Figure 1. Three-dimensional structures of human antimicrobial peptides from the α-helical family:
(A) and (B) human cathelicidin LL-37 determined by NMR spectroscopy (PDB ID: 2K6O); (C) dermcidin
determined by X-ray crystallography (PDB ID, 2YMK); and (D) granulysin determined by X-ray
diffraction (PDB ID: 1L9L). In the case of LL-37, an ensemble of five structures is shown to better view
the disordered C-terminal tail (A), whereas a space-filling model is given to show the segregation of the
hydrophobic surface (gold) into two domains (B) [182]. The longer one corresponds to the central helix
which is important for antimicrobial, anti-biofilm and antiviral activities [83]. Images were generated
by using the software MOLMOL [218]. Further details can be found in the text.
Granulysin. Incorporation of AMPs into cytotoxic T cells might have conferred the ability to lyse
cells. The crystal structure of granulysin is shown in Figure 1D. There are five helical regions (α1: 2–17;
α2: 23–35); α3: 39–61; α4: 66–69; α5: 71–73) [219]. The sequences of human granulysin (74 amino
acids) and other NK-lysins share a low degree of similarity (~35%), but homologous modeling reveals
antimicrobial features (active helices and basic residue positions) are conserved [112]. Although
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granulysin only contains two disulfide bonds, it belongs to the saposin-like protein family [220].
Saposin-like proteins comprise several helices usually stabilized by three disulfide bonds [221]. Twelve
AMPs in the APD [8] from amoebozoa, nematodes, and large animals such as pigs are annotated to
share the saposin-like protein fold [112]. To be antimicrobial, however, neither the entire sequence
nor the protein fold is needed. For example, synthetic peptides and analogs derived from helices 3
and 4 are active against Vibrio cholera [222]. In addition, the peptide based on the helix-bend-helix
motif (residues 31–50) displayed similar antimicrobial activity against Propionibacterium acnes (a
key therapeutic target in acne) when synthesized entirely using D-amino acids [223]. Because short
peptides can be readily synthesized, they provide useful alternatives for topical treatment of such
bacterial infections.
4.2. The β Family: α-Defensins
Alpha-defensins. Structurally, α-defensins consist of three β-strands that form a β-sheet. In the
crystal, a dimeric structure is found for human HNP-1, where two copies of the molecule pack together.
HNP-2 and HNP-3 have a similar structure. Thus, it is primarily due to the single amino acid difference
in these defensins (Table 1) that influences peptide activity. With a more hydrophobic sequence, HNP-4
is more potent against E. coli and C. albicans than other human α-defensins [23]. Using a kinetic
96-well turbidimetric procedure, the relative potencies of six human α-defensins were compared. In
the case of Gram-positive S. aureus, the activity is in the following order: HNP-2 > HNP-1 > HNP-3 >
HNP-4. In contrast, their relative potencies against Gram-negative E. coli is HNP-4 > HNP-2 > HNP-1
= HNP-3 [224]. Thus, the antibacterial activities of these defensins are also bacteria dependent. This
likely reflects the distinct differences in membranes of these organisms. The poor antibacterial activity
of HNP-3 is not surprising considering the presence of an acidic aspartate at the N-terminus of the
peptide, making it unfavorable to target the negatively charged surface of bacteria. HD-5 displayed
a rather potent activity, which is comparable to HNP-2 against S. aureus and HNP-4 against E. coli.
The higher activities of HNP-4 and HD-5 against E. coli are correlated with their higher net charge
of +4 (Table 2). HD-6 has a poor antibacterial activity. In the crystal, it forms a tetrameic structure
(Figure 2B) [123].
Figure 2. Select 3D structures of human antimicrobial peptides from the β and αβ families: (A) HNP-1
(dimeric crystal structure, PDB ID: 3GNY); (B) HD-6 (tetrameric crystal structure, PDB ID: 1ZMQ); (C)
hBD-3 (NMR structure, PDB ID: 1KJ6) and RegIIIα (crystal structure, PDB ID: 4MTH). See the text for
further details.
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4.3. The αβ Family: β-Defensins, Antimicrobial Chemokines, RNases, and RegIIIα
Beta-defensins. Human β-defensins comprise both α and β structures in the same 3D fold.
Figure 2C shows the NMR structure of human β-defensin 3 (hBD-3), which starts with a helical
structure followed by three beta strands [225]. NMR translational diffusion studies revealed a dimer
for hBD-3, but a monomer for both hBD-1 and hBD-2 in solution. The stronger antibacterial activity of
hBD-3 than either hBD-1 or hBD-2 was attributed to the dimeric structure as well as higher charge
density on the protein surface [225]. Interestingly, the disulfide-linked form of hBD-1 is poorly active
and became highly potent against bacteria and fungus C. albicans under reduced conditions where
the disulfide-linked structure was disrupted [226]. It seems that the folded hBD-1 is the stored form,
which can be transformed into an active form when needed.
Antimicrobial chemokines. Chemokines interact with receptors to realize chemotactic functions.
They share a similar fold consisting of a three-stranded sheet followed by one α-helix at the
C-terminus [227–229]. The N-terminal region is frequently disordered (Figure 3A–C).
Figure 3. 3D structures of human chemokines with antimicrobial activity. Shown are (A) CCL1 (NMR
structure, PDB ID: 1EL0); (B) CCL8 (crystal structure, PDB ID: 1ESR); (C) CCL11 (NMR structure, PDB
ID: 2EOT); (D) CCL21 (NMR structure, PDB ID: 2L4N); (E) CCL27 (NMR structure, PDB ID: 2KUM);
(F) CXCL12 (NMR structure, PDB ID: 2KOL); (G) CCL20 (crystal structure, PDB ID: 1M8A); (H) CCL13
(crystal structure, PDB ID: 2RA4); (I) CXCL1 (NMR structure, PDB ID: 1MSH); (J) CXCL10 (crystal
structure, PDB ID: 1O80).
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This can be best seen using a superimposed structural ensemble for CCL20 or CCL27 [230,231]
determined by NMR (Figure 3D,E). The β-sheet appears to separate the N-terminal domain that
interacts with cell receptors and the C-terminal domain that contains the antimicrobial helix for
targeting bacterial membranes (Figure 3F) [232]. Some chemokines can also form oligomers. The
dimeric forms of CCL20, CCL13, CXCL1, and CXCL10 [233–236] are shown in panels G to J of Figure 3.
The dimer interface is normally composed of the C-terminal helix and strand 3. In the case of CCL13,
however, it is the N-terminal region that occupies the interface (Figure 3H). Yung et al. found a direct
binding of antimicrobial chemokines CXCL9 (net charge of +20) and CXCL10 (net charge +11) to the
cell wall of S. aureus likely via the positively charged patches on these protein surfaces [237].
Under certain situations, the antimicrobial peptide is generated by further processing of a
precursor protein. For example, antimicrobial thrombocidin-1 (TC-1) is produced by truncating
two residues from the C-terminus of the parent protein NAP-2 (i.e., neutrophil-activating peptide-2),
which is poorly active. NMR analysis revealed that the C-terminus of TC-1 is mobile. In contrast,
the C-terminus of NAP-2 is less mobile. It was proposed that the additional two residues locked the
C-terminus via electrostatic interactions [238]. The additional Asp residue could have masked the
positively-charged surface of the C-terminal helix that targets bacterial membranes. Likewise, insertion
of an acidic Glu to the N-terminal region of GF-17, a peptide corresponding to the major antimicrobial
region of human cathelicidin LL-37 [179], substantially reduced the peptide activity [239].
RNases. The structures of RNase 3 (Figure 4, panels A and B) and RNase 5 (panels C and D)
were solved by both X-ray diffraction and multi-dimensional NMR spectroscopy. Although RNase
3 is dimeric in the crystal, the protein fold determined by the two techniques is similar. In addition,
NMR studies revealed two conformations for His114 of RNase 5 in solution [240]. The structures of
RNase 2 and RNase 7 are given in Figure 4 (panels E and F). Unlike chemokines discussed above, the
antimicrobial region has been mapped to the N-terminus of RNase 7 [130,241]. In particular, a cluster
of lysines were identified as key elements for antibacterial activity (bold in Table 1). It is proposed
recently that the N-terminal antimicrobial function is conserved in the ribonuclease family [242]. One
may wonder why a protein is created for bacterial defense if only part of the chain is required to kill
pathogens. One possibility is the stability gain as part of the protein. Another possibility is that a
folded protein structure allows for the incorporation of a variety of active sites on the protein surface.
In certain cases, such functional sites may be overlapping [243]. In the case of RNase 7, the adjacent
active site and antimicrobial residues allows us to propose a yet-to-be-proved “peel-and-kill” model.
In other words, binding to bacteria by the cationic amino acids is followed by digestion of pathogenic
nucleic acids. The multiple active sites also enable functional regulation. For example, an endogenous
molecule can bind to RNase 7 and regulates its antimicrobial activity [244]. This could be one of the
unique features of antimicrobial proteins distinct from small antimicrobial peptides.
Antimicrobial lectin RegIIIα. RegIIIα (or HIP/PAP) is a C-type lectin that binds peptidoglycan
carbohydrates of Gram-positive bacterial cell walls. The structural basis of this binding has been
elucidated (Figure 2D) [245]. Different from other C-type calcium-dependent lectins, the binding of
RegIIIα to peptidoglycans is calcium independent (i.e., lacking calcium-binding motif). The binding,
however, requires the “EPN” motif and depends on sugar chain length. However, it seems that this
peptidoglycan binding serves as an early recognition step for the peptide action as it can create a
pore on bacterial membranes. The structure of the oligomeric form of the protein has recently been
determined by combining X-ray structure and electron microscopy data, providing insight into the
lethal step of bacterial killing by this intestine lectin [246].
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Figure 4. 3D structures of human ribonucleases with antimicrobial activity. Shown are (A) RNase 3
(dimeric crystal structure, PDB ID: 4A2O); (B) RNase 3 (NMR structure, PDB ID: 2KB5); (C) RNase 5
(crystal structure, PDB ID: 1B1I); (D) RNase 5 (NMR structure, PDB ID: 1AWZ); (E) RNase 2 (crystal
structure, PDB ID: 2BZZ); and (F) RNase 7 (NMR structure, PDB ID: 2HKY).
5. Mechanism of Action of Human Antimicrobial Peptides
It is generally believed that cationic AMPs target anionic bacterial membranes. In the past
years, significant advances have been made in elucidating the molecular targets of human AMPs. As
described below, human AMPs can interact with a variety of molecular targets either on the cell surface
(including membranes) or within the cells.
5.1. Targeting Bacterial Cell Wall
The molecular targets of AMPs are not limited to bacterial membranes. The assembly of HD-6
on bacterial surface entangles bacteria, providing a new defense mechanism for human innate
immunity [123]. HNP-1 targets lipid II to block the biosynthesis of bacterial cell walls [247]. Böhling
et al. found a close correlation of the hBD-3 activity with cell wall components [248]. A subsequent
study corroborated the binding of hBD-3 to lipid II as well [249]. In the APD [7,8], there are 18 AMPs
that use this mechanism to combat bacteria. Examples are nisins, mersacidin from bacteria, plectasin
from fungi, Cg-Def, an oyster defensin [250–252]. Hence, blocking bacterial cell wall synthesis is a
widely deployed innate defense mechanism. It is possible to identify small molecule mimetics that
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bind bacterial cell walls [253,254]. Although not discussed here, other defensins can directly recognize
specific lipids in fungal membranes [255–257].
RegIII proteins are a family of lectins that can specifically recognize the carbohydrate portion of
bacteria. While RegIIIα targets the peptidoglycan carbohydrate backbone for Gram-positive bacterial
killing [245], mouse RegIIIβ associates with the lipid A portion of Gram-negative bacterial LPS [258].
In the case of murine RegIIIβ, amino acid residues in two structural motifs termed “loop 1” and “loop
2” are important for peptidoglycan and lipid A binding (Arg-135, Asp-142) and for the bactericidal
activity (Glu-134, Asn-136, and Asp-142).
It is well known that human lysozyme not only binds a single peptidoglycan chain but also
cuts the sugar repeats, thereby inhibiting bacterial cell wall synthesis [259]. In addition, some AMPs
can associate with cell surface proteins to interfere with the docking and entry of viruses such as
human immunodeficiency virus type 1 (HIV-1). For example, the association of SLPI with human
annexin II can avoid the attachment of viral lipid phosphatidylserine (PS) to the same protein in human
macrophages [260].
5.2. Targeting Bacterial Inner Membranes
Human cathelicidin LL-37 is a representative member in the helical family. It is proposed that
LL-37 disrupts bacterial membranes. The membrane disruption of LL-37 involves at least three
steps. First, the cationic peptide can recognize and coat the anionic surface of bacteria. With a classic
amphipathic helical structure, this cationic peptide prefers to target anionic bacterial membranes.
Second, LL-37 binds to the outer membranes and cross the outer membrane. Third, the peptide reaches
the inner membrane. It initially binds to the inner membrane parallel to the surface, which is the basis
for the carpet model [261]. At elevated concentrations, the peptide may disrupt the membranes by
micellization. Alternatively, the peptide might take a vertical position to form a pore [262].
The ability of hepcidin 25 (hep-25) and its isoform hepcidin 20 (hep-20) to perturb bacterial
membranes is markedly pH-dependent. The membrane disruption is more evident at acidic pH than at
neutral pH. At acidic conditions, histidines become positively charged and more effective in membrane
disruption [263].
While there is no agreement in the case of human LL-37 regarding the carpet or pore formation,
recent structural determination of dermcidin provides evidence for possible pore formation in bacteria
membranes. In the crystal structure [216], the peptide forms a hexamer, where two trimers are
connected by zinc (Figure 1C). It is proposed that this structure might be directly inserted into bacterial
membranes, serving as an ion channel.
In addition to α-defensins (HD-5 and HD-6), RegIII peptides are expressed to control the
microbiota and keep the bacteria away from the epithelial surface of intestine. In particular, specific
bacteria (e.g., Bifidobacterium breve NCC2950) can effectively induce the expression of RegIIIγ (an
ortholog of human RegIIIα) in the intestine of mice via the MyD88-Ticam1 pathway [264]. RegIIIα
is a lectin that binds to peptidoglycans of Gram-positive bacteria. However, it adopts a hexametic
membrane-permeating pore structure to kill bacteria [246]. Such a pore is reminiscent of other pore
structures solved for toxins [265–267]. The structure also provides a basis for selective killing of
Gram-positive bacteria such as L. monocytogenes, L. innocua, and E. faecalis but not Gram-negative
bacteria. This is because LPS, the major component of the outer membranes of Gram-negative bacteria,
inhibits the pore-forming activity of RegIIIα [246].
5.3. Cell-Penetrating Peptides and Intracellular Targets
There are other AMPs that may work primarily by binding DNA. Buforin is such an example [83].
This is not surprising because this AMP was derived from DNA-binding histone 2A. In addition, SLPI,
a small protein that inhibits elastase and cathepsin G, displayed antibacterial activity against E. coli by
binding nucleic acids [268]. It is also likely that AMPs kill bacteria by more than one mechanism. For
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example, human LL-37 may first damage bacterial membranes followed by DNA binding, leading to
the shutdown of bacterial machinery [83].
Unlike human LL-37, histatin 5 caused only small membrane damaging effects [269]. To interpret
the killing effect of this peptide, two models have been proposed. In the first model, treatment of C.
albicans with histatin 5 induces the efflux of ATP and increases cell permeability to small molecules,
leading to ion imbalance. Thus, C. albicans cells respond by activating the osmotic stress responding
pathways to minimize ion loss. This model is supported by the fact that knocking out the TRK1 gene
that encodes a major K+ uptake system made histatin 5 ineffective. A second model was also proposed
based on the observation that the candida killing ability of histatin 5 is lost using a mitochondrial
respiration mutant or after treatment with sodium azide that inhibits cellular metabolism [270]. In
addition to the requirement of the mitochondrial respiration machinery [271], cellular internalization
of histatins is also facilitated by peptide binding to heat shock protein Ssa2p on the surface of C.
albicans [272]. This interference with mitochondrial respiration chain may be responsible for the
formation of reactive oxygen species (ROS), leading to cell death [273]. Vylkova et al. performed a
DNA microarray study of the effect of histatin 5 and found that these two models can be unified. This
is because the oxidative stress could be produced as a secondary effect of osmotic stress. This proposal
is in line with the observation that the killing of histatin 5 is facilitated in the presence of an osmotic
agent sorbital but not an oxidant agent H2O2 [274]. It should be mentioned that human GAPDH(2–32),
an antifungal peptide derived from the highly conserved protein GAPDH, can also enter C. albicans to
induce apoptosis [275].
As a different mechanism to combat bacterial infection, some AMPs are reported to penetrate
immune cells and activate them to boost immune response. For example, chromagranin A-derived
peptides can penetrate neutrophils, bind to cytoplasmic calmodulin, and induce Ca2+ influx, leading
to neutrophil activation and immune system augmentation [276].
Granulysin is an effector molecule in the cytotoxic granules of cytotoxic T lymphocytes and natural
killer (NK) cells. It can kill intracellular pathogens in infected cells in the presence of perforin and to
induce a cytotoxic effect against tumor cells. Although perforin and granulysin can colocalize [277], it
is unclear how they work together in bacterial killing. A recent study reveals that perforin can form
pores that preferentially allow the entry of cationic molecules [278]. Thus, granulysin might have
entered the cell via the perforin pores, thereby providing yet another mechanism for intracellular
bacterial killing by forming a molecular pair.
6. Concluding Remarks and Potential Therapeutic Strategies
Human antimicrobial peptides and proteins occupy an important niche in the current research on
human host defense and innate immunity [1–6,279]. Except for antimicrobial protein lysozyme, which
was found in 1922, most of short cationic peptides were discovered after 1980 (Table 1). By the time
this article was written, over 100 human AMPs have been identified and characterized. They were
either isolated from human tissues or predicted from the human genome by bioinformatics. Although
genomic prediction constitutes an invaluable method, isolation from natural sources remains important
in determining the exact mature form of AMPs. The discovery story of LL-37 nicely illustrates this
point (Section 2.3). These peptides have diverse amino acid sequences (Table 1) and physical properties
(Table 2), leading to a panel of defense molecules with varying activities (Table 1). While psoriasin
and KDAMP primarily inhibit the growth of Gram-negative bacteria, RegIIIα is mainly active against
Gram-positive bacteria. In addition, histatins and drosomycin-like defensin are primarily fungicidal.
Many human AMPs such as LL-37 and defensins are broad-spectrum peptides against pathogens.
Remarkably, human AMPs are able to hinder bacterial growth by interactions with different
targets, ranging from surface molecules (e.g., cell walls), inner membranes, to intracellular molecules
(Table 3). Some AMPs can interact with two or more molecules. For example, the binding of RegIIIα to
peptidoglycans constitutes only the initial recognition step and subsequent pore formation in bacterial
membranes could be the lethal step [246].
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Table 3. Select human antimicrobial peptides and their proposed targets.
APD ID AMP Structure Molecular target
181 HD-6 β Aggregate on bacterial surface
283 hBD-3 αβ Bacterial cell wall (lipid II)
176 HNP-1 β Bacterial cell wall (lipid II)
2257 Lysozyme α Cell wall carbohydrate
2071 RegIIIα αβ Membrane pores
310 LL-37 α Bacterial membranes and/or DNA
433 Dermcidin α Membranes ion channel
2017 hGAPDH(2-32) Unknown Intracellular targets of fungi
505 Histatin 5 α Intracellular mitochondria
2352 Chromagranin A-derived peptides Unknown Cytoplasmic calmodulin of neutrophils
1161 Granulysin α
Perforin generates a pore to allow
granulysin to enter the cell and kill
intracellular bacteria
For interactions with different molecules, human AMPs are capable of adopting a variety of 3D
structures (Figures 1–4). It is clearly important to determine the structure to high quality so that the
molecular basis of these interactions can be uncovered accurately (reviewed in ref. [52]). It is also
important to correlate the structure with the active state of the peptide. In the case of dermcidin, which
oligomerizes on bacterial surface, the helix-bundle structure determined by X-ray crystallography [216]
should be more relevant. Likewise, the disulfide-bonded structure of HBD-1 does not explain peptide
activity under reduced conditions [226]. Therefore, human AMPs are diverse in terms of amino acid
sequence, 3D structure, activity, and mechanism of action.
Many human AMPs are currently under close examination for their functional roles as well
as potential applications in detection and diagnosis of human diseases. The type and expression
level of human AMPs, if accurately mapped, may have clinical relevance. A clear variation in the
expression level of AMPs can serve as biomarkers for human diseases, such as eczema severity
and cancer [280–283]. In addition, this remarkable array of molecules may be used for detection,
imaging, and diagnosis of bacterial infection. An example of this application is based on the preferential
association of Technetium-99m labeled ubiquicidin with bacteria, enabling the physician to differentiate
infection from aseptic loosening of hip prostheses in 30 min with high accuracy [284–286].
The collection of human AMPs discussed herein also inspires us in developing novel
therapeutics [287]. First, new antimicrobials may be developed using human AMPs as templates.
The rationale is that AMPs have remained potent for millions of years and are thus less prone to
microbial resistance [1–6]. In particular, peptides with different structural scaffolds may kill the
same bacterium by different mechanisms (Table 3). Furthermore, the same peptide sequence can be
tailored into various peptides that selectively target pathogens such as Gram-positive, Gram-negative
bacteria, or viruses [83]. This is highly desirable for selective bacterial elimination without destroying
the probiotic microbial flora. The success of this line depends on whether a selected template will
achieve the desired potency in vivo against a target pathogen, low cytotoxicity to humans, stability to
proteases, and cost-effective production [287]. One can also consider alternative peptide forms. For
instance, a pro-drug can be used to reduce the cytotoxicity of AMPs if a mechanism can be found to
release it when needed [288]. While portions of antimicrobial proteins are preferred to design novel
antimicrobials [222,223,242,289], a whole protein may also be considered. Unlike short peptides, the
folded structure of proteins confers stability to the action of proteases. However, the production of such
a long polypeptide chain may require recombinant expression in bacteria or cell-free systems [199].
Second, new strategies are actively sought to bring the invading pathogens under control. It is
appreciated that different receptors and signal pathways are activated in response to the invasion
of different microbes [65]. Of outstanding interest is that non-pathogen factors can also induce
AMP expression (Table 4). One of the earliest examples might be the light therapy invented by Niel
Finsen [290]. The establishment of a link between light therapy, vitamin D and human cathelicidin
LL-37 expression provides a completely different way for infection treatment. Instead of treating
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patients with traditional antibiotics, doctors may be able to use light or vitamin D [291,292]. Indeed
using narrow-band UV B light, the level of vitamin D was increased in psoriasis patients (psoriasis is
a common autoimmune disease on skin) [293]. In addition, other small molecules such as butyrate
can induce LL-37 expression [294]. Components from Traditional Chinese Medicine may regulate the
AMP expression as well [295]. These factors may induce the expression of a single peptide or multiple
AMPs [296]. It is also possible that certain factors can work together to induce AMP expression.
While cyclic AMP and butyrate synergistically stimulate the expression of chicken β-defensin 9 [297],
4-phenylbutyrate (PBA) and 1,25-dihydroxyvitamin D3 (or lactose) can induce AMP gene expression
synergistically [294,298]. It appears that stimulation of LL-37 expression by histone deacetylase (HDAC)
inhibitors is cell dependent. Trichostatin and sodium butyrate increased the peptide expression in
human NCI-H292 airway epithelial cells but not in the primary cultures of normal nasal epithelial
cells [299]. However, the induction of the human LL-37 expression may not be a general approach for
bacterial clearance. During Salmonella enterica infection of human monocyte-derived macrophages,
LL-37 is neither induced nor required for bacterial clearance [300].
Table 4. Some known factors that induce antimicrobial peptide expression
Factor AMP induced Cells Ref
Bacteria/LPS LL-37, HBD-2 keratinocytes [296]
TNF-α LL-37, HBD-2 keratinocytes [286]
UV Light LL-37, HBD-2, chemerin keratinocytes [286,301]
Vitamin D3 LL-37 neutrophil progenitors andEBV-transformed B cells [302,303]
Lactose LL-37 colonic epithelial cells T84, THP-1monocytes and macrophages [304]
Short-chain fatty acids LL-37; pBD-2, pBD-3,pEP2C, and protegrins
human HT-29 colonic epithelial cells
and U-937 monocytic cells; [305,306]
Isoleucine hBD-1; epithelialdefensins
human colon cells, HCT-116; bovine
kidney epithelial cells [307–309]
Arginine hBD-1 human colon cells, HCT-116 [307]
Ca2+ hBD-2, hBD-3 human keratinocyte monolayers [310]
Zn2+
LL-37; pBD-1,
pBD-2, pBD-3 Caco-2 cell; Intestinal epithelial cells [311]
Butyrate LL-37 colon, gastric and hepatocellular cells [312]
Albumin hBD-1 human colon cells, HCT-116 [307]




epithelial cell line VA10 [298]
Finally, immune modulation peptides may find therapeutic use because they do not act on microbes
directly and thereby are less likely to induce antimicrobial resistance [4,5]. Immune modulation is
activated via peptide binding to host cell receptors that initiate various signal transduction pathways.
Recently, a natural peptide was found to have immune modulating activity but no antimicrobial
activity [313]. Besides engineering peptides with distinct properties, there has been growing interest in
elucidating the bacterial mechanisms in generating resistance to AMPs or by subverting host immune
systems [314,315]. It can be anticipated that new therapeutic approaches will continue to emerge from
our understanding of the host-pathogen interactions. All these strategies will facilitate the development
of AMPs into novel antimicrobials to meet the challenge of antibiotics-resistant superbugs, RNA viral
infections and difficult-to-treat cancers [287].
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Abstract: An intrinsic clindamycin-resistant Enterococcus faecalis, the most common single species
present in teeth after failed root canal therapy, often possesses acquired tetracycline resistance. In these
cases, root canal infections are commonly treated with Ledermix® paste, which contains demeclocycline,
or the new alternative endodontic paste Odontopaste, which contains clindamycin; however, these
treatments are often ineffective. We studied the killing activity of the cyclic antimicrobial peptide
gramicidin S (GS) against planktonic and biofilm cells of tetracycline-resistant clinical isolates of
E. faecalis. The high therapeutic potential of GS for the topical treatment of problematic teeth is
based on the rapid bactericidal effect toward the biofilm-forming, tetracycline-resistant E. faecalis. GS
reduces the cell number of planktonic cells within 20–40 min at a concentration of 40–80 μg/mL.
It kills the cells of pre-grown biofilms at concentrations of 100–200 μg/mL, such that no re-growth is
possible. The translocation of the peptide into the cell interior and its complexation with intracellular
nucleotides, including the alarmon ppGpp, can explain its anti-biofilm effect. The successful treatment
of persistently infected root canals of two volunteers confirms the high effectiveness of GS. The broad
GS activity towards resistant, biofilm-forming E. faecalis suggests its applications for approval in root
canal medication.
Keywords: gramicidin S; Enterococcus faecalis; tetracycline resistance; biofilms; root canal infections;
alarmone ppGpp; polymyxin B
1. Introduction
Teeth with necrotic pulps and periapical radiolucencies indicate the presence of bacteria in
a root canal system. They can cause apical periodontitis, an inflammatory process around the apex
of a tooth root accompanied by bone resorption [1,2]. Root canal infections are characterized by
a wide variety of combinations of a few oral anaerobic bacteria, such as Actinomyces species and
peptostreptococci. The non-oral but environmental bacterium Pseudomonas aeruginosa is frequently
isolated from treatment-resistant cases because of its intrinsic multidrug resistance, including resistance
to tetracycline [3]. However, more and more evidence has been provided on the prevalence of
Enterococcus faecalis in teeth associated with a failed endodontic treatment of root canal infections [2,4–7].
The success rate for the re-treatment of teeth with E. faecalis is lower (66%) than the overall success rate
of re-treatment (75%) [8]. Previous studies reported about up to 77% prevalence of E. faecalis in teeth
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with failed endodontic treatment [7]. E. faecalis can best adapt to and tolerate the conditions in the filled
root canal [6]. This facultative anaerobe is able to grow at 6.5% NaCl and temperatures up to 45 ◦C and
is even able to colonize dentine under alkaline pH and glucose starvation [9]. It has a remarkable ability
to avoid leukocyte-dependent antibacterial mechanisms and to utilize collagen within dentin, using this
property for adhesion within the root canal [2]. A number of other virulence factors in E. faecalis, such as
a plasmid-encoded surface localized adhesion protein, gelatinase (metalloendopeptidase), a serine
protease, hemolysin, which is classified as a type A lantibiotic, and extracellular superoxide, permit
adherence and facilitate invasion [6]. The surface adherence of biofilms is significant in persistent
endodontic infections because it increases the difficulty of eliminating biofilms by conventional
treatment measures [10]. Although the conventional endodontic irrigant sodium hypochlorite (1%–6%)
exhibits more efficient elimination of E. faecalis biofilms in comparison to chlorhexidine, calcium
hydroxide, povidone iodine and ethylendiamintetraacetat [11,12], this intracanal medication was
found to have a limited action against bacterial biofilms [13].
Currently, there are no clinically available compounds that disassemble biofilms of E. faecalis,
although several antimicrobial peptides are in development, such as siamycin I, which affects quorum
sensing, as well as protegrin, and oritavancin that can damage the bacterial membrane [14]. Recently,
the use of the commercially available Ledermix® paste, which contains demeclocycline, or the new
alternative endodontic paste Odontopaste, which contains clindamycin, was reported to be ineffective
in the treatment of E. faecalis infections due to the natural clindamycin and acquired tetracycline
resistance of these bacteria [6,15]. Their dominance in nosocomial infections is based on their ability
to develop multidrug resistance via the acquisition of antibiotic resistance genes on plasmids or
transposons from other bacteria. Notably, surface aggregation facilitates the contact between the
cells, which leads to the exchange of plasmids that carry resistance. Approximately 70% of E. faecalis
isolates from primary endodontic infections showed a resistance to tetracycline [16]. In genomic
analysis, the tetracycline resistance genes tetM and tetL, as well as gelatinase, aggregation substance
and enterococcal surface protein genes, were detected in these E. faecalis isolates.
In this paper, we report the antimicrobial and anti-biofilm activity of the cyclic decapeptide
gramicidin S (GS) against tetracycline-resistant E. faecalis illustrated by two cases of successful treatment
of Ledermix®-resistant root canal infections using this peptide.
2. Results
2.1. Susceptibility of Tetracycline-Resistant E. faecalis to GS
According to the data of the Clinical and Laboratory Standards Institute [17], enterococci
are defined to be resistant to tetracycline if the minimum inhibitory concentration (MIC) values are
≥16 μg/mL and they are called susceptible at MIC ≤ 4 μg/mL. Table 1 shows the resistance of
the E. faecalis DSM 2570, which was isolated from urine and represents a quality control strain for
antimicrobial susceptibility testing [18], the WW4 cheese isolate and four tetracycline-resistant clinical
isolates, designated TRE1–TRE5. For comparison, the clinical root canal isolate WW6, which is susceptible
to tetracycline (MIC < 1 μg/mL) but forms robust biofilms (Figure 1A), was also studied (Table 1).
Tetracycline inhibits protein synthesis, and its action is therefore bacteriostatic. GS is a bactericidal
antibiotic peptide. As shown in Table 1, its MIC, minimum bactericidal concentration (MBC), and
minimum biofilm inhibitory concentration (MBIC90) are mostly in the range of 8–16 μg/mL for all
studied E. faecalis strains. This small difference between inhibitory and bactericidal concentrations
as well as the concentrations required for the inhibition of biofilm formation, explains the great
bactericidal activity of GS, which gives bacterial cells no chance to remain alive or to respond to the
stress caused by GS treatment.
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Figure 1. Anti-biofilm activity of GS. (A) When eight E. faecalis strains were compared using a crystal
violet staining assay, the tetracycline-resistant clinical isolate TRE2 exhibited the strongest biofilm
formation in all three nutrient media; (B1) SEM image of a TRE2 biofilm formed on a hydroxyapatite
disk, which served as a control and as a starting point for antibiotic treatment; (B2) when B1 was
incubated in TH broth, the biofilm is found to re-grow in a suspended form; (C1) SEM image of B1 after
treatment with 400 μg/mL demeclocycline, and (C2) re-growth of a biofilm in suspension; (D1) B1 after
treatment with 400 μg/mL GS; and (D2) no biofilm re-growth was observed after treatment, even when
only 200 μg/mL of GS were used in D1. Reproducible results were obtained in two independent
experiments. The scale on the SEM images is 1 μm.
Table 1. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and
minimum biofilm inhibitory concentration (MBIC) of GS against E. faecalis.
E. faecalis Strain
Resistance/Susceptibility (μg/mL) to
Antimicrobial Activity of GS (μg/mL)
Tetracycline Demeclocycline
MIC a MIC MIC MBC MBIC90
DSM 2570 16 8 8 8 4–8
TRE1 16 16 8 16 -
TRE2 16 32 16 16 8–16
TRE4 16 8 8 8 -
TRE5 16 16 8 16 -
WW4 64 16 8 16 -
WW6 <1 <1 8 16 8–16
a MICs, MBCs and MBICs were determined in at least in two independent experiments, each performed in
triplicate. MBIC was determined only for the three best biofilm-formers (see Figure 1A).
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2.2. Time-Dependent Killing Effect of GS
The bactericidal activity of GS against E. faecalis strains over time was studied in killing assays.
For this experiment, we used stationary cultures, which contained metabolically inactive, slow- or
non-dividing dormant cells that tolerate conventional antibiotics and cause persistent infections [19].
At the time points of 20 min and 40 min after the addition of GS, the undiluted 100-μL bacterial aliquots
revealed no colonies on agar plates. This indicates a prompt and complete reduction of the cell number
in planktonic suspension, which contained 108 CFU/mL cells (Figure 2). Notably, the metabolically
inactive dormant cells were also killed at the studied concentrations, which corresponded to the
5 × MIC and 10 × MIC values (Table 1). The increase from 5 to 10 × MICs led to a decrease in killing
time from 40 to 20 min for the E. faecalis DSM 2570 and WW6. The same killing curve was observed at
5 × MIC values of GS for the best biofilm former, the tetracycline-resistant clinical isolate E. faecalis
TRE2. However, its effective concentration was 80 μg/mL because its MIC value was 16 μg/mL.
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Figure 2. Reduction of the number of E. faecalis bacteria during exposure to GS: (A) control strain
DSM 2570; (B) cheese isolate WW4; (C) root canal isolate WW6; and (D–F) clinical tetracycline-resistant
isolates TRE1, TRE2, and TRE4, respectively. The bacterial number remained unchanged in the controls
(dotted lines), but decreased drastically during exposure to 5 × MIC of GS (solid lines). The dashed
lines show the faster bactericidal effect of 10 × MIC for DSM 2570 and WW6 strains; 10 CFU/mL was
taken as the detection limit although no colonies were grown from undiluted sample. The standard
deviations were calculated from at least two independent experiments.
2.3. Biofilm-Killing Effect of GS
For these experiments, it was necessary to determine the biofilm forming capacity of all E. faecalis
isolates to choose the strongest biofilm formers and the most suitable medium. A standard crystal
violet staining assay was applied to evaluate the mass of the biofilms that were pre-grown for 24 h in
96-well microtiter plates (Figure 1A).
The strongest biofilm growth was found to occur in the Todd Hewitt (TH) broth, which contains
glucose. The Mueller Hinton (MH) broth and minimal medium were less suitable for biofilm formation.
The biofilm-forming capacity of the control strain DSM 2570 was comparable with that of the
tetracycline-resistant WW4 (cheese isolate) and the tetracycline-susceptible WW6 (root canal isolate)
(Table 1). The tetracycline-resistant clinical isolate E. faecalis TRE2 was the best biofilm former. Scanning
electron microscopy (SEM) showed that the cells in this biofilm completely covered the surface of the
hydroxyapatite disc (HAD) and were attached to the HAD nanoparticles (Figure 1B1). After exposure
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to 400 μg/mL of GS for 18 h, the cell morphology of E. faecalis TRE2 was drastically altered (Figure 1D1)
in comparison to the control or to the treatment with 400 μg/mL of demeclocycline (Figure 1C1).
The GS-treated cells decreased in size from 1 to 0.6–0.8 μm, the cell surface got wrinkled, and the
cells detached from the HAD particles (Figure 1D1). Treatment of the pre-grown biofilms with 400
μg/mL of GS led to a disappearance of the matrix layer and to a partial elimination of biofilm cells,
so that the nanoparticles of the HAD were clearly exposed underneath the cells. No re-growth of the
robust TRE2 biofilm in the fresh TH broth was observed, even when only 200 μg/mL GS has been
applied (Figure 1D2). This concentration represents the minimal biofilm bactericidal concentration
(MBBC) of GS against E. faecalis TRE2, because subsequent plating of this non re-grown culture on
nutrient agar did not reveal any viable cells. The control biofilm (Figure 1B2) as well as the biofilm after
demeclocycline treatment (Figure 1C2) were clearly found to re-grow in the fresh TH nutrient broth
after cultivation at 37 ◦C for 24 h. The second strongest biofilm former, the tetracycline-susceptible root
canal isolate E. faecalis WW6 (Figure 1A), did not exhibit re-growth after treatment with 400 μg/mL
demeclocycline, as expected due to its high susceptibility (see Table 1). We note, however, that the
MBBC of GS against this strain was even lower (100 μg/mL) (data not shown).
2.4. GS Penetration into the Bacterial Cells and Binding Affinity to Nucleotides
Microbiological assays helped to elucidate the complex action of GS at the cellular level.
To understand the anti-biofilm activity at the molecular level, we first studied the membrane-penetrating
ability of GS, in order to find out whether it has any access to intracellular targets. For comparative
fluorescent microscopy, we used the dye 5(6)-carboxy-fluorescein-N-hydroxysuccinimide ester (CFSE)
as a control, which cannot penetrate the cell membrane. To detect GS by fluorecscence microscopy,
the photo-switchable GS analog GS-sw(FP) was used, which possesses an intrinsic green fluorescence
upon irradiation with visible light [20]. The fluorescence image of E. faecalis TRE2 stained with CFSE
showed strong fluorescence of only the cell envelope (Figure 3A). On the other hand, bacteria that were
incubated with GS peptide for 30 min (Figure 3B) showed an even fluorescence internally. The same
result was obtained by staining the other E. faecalis strains (data not shown).
The access of cationic GS to the cytoplasm suggests that it may engage in electrostatic interactions
with intracellular anionic targets. A key target could be the alarmon ppGpp, which regulates biofilm
formation [21]. Indeed, the addition of ppGpp to GS at different molar ratios led to their co-precipitation
as a result of mutual binding. At ppGpp:GS ratios of 2:1, 1:1 and 1:2 (Figure 3C), floating white flakes
could be seen, suggesting the presence of large aggregates. A further excess of GS led to the formation
of a stable milky opalescent suspension, which contained smaller nano-rods (Figure 3D). 31P-NMR
analysis of the intrinsic ppGpp phosphate signals confirmed the binding and aggregation, as sharp
signals were observed only in the presence of low concentrations of GS (Figure 3E). The broadening
and disappearance of the 31P-NMR signals with excess peptide indicated the precipitation of the
alarmone/GS complex. Electron microscopy of the milky suspension at a molar ratio of ppGpp:GS 1:8
(Figure 3D) revealed the assembly of GS with ppGpp into nano-rods with 50 nm width and 200 nm
length. The ability of GS to bind to ppGpp and thus to deplete its free cytoplasmic pool may explain
the strong inhibition of biofilm formation by GS described above (see MBIC90 values in Table 1).
Notably, ppGpp is not the only possible intracellular target of GS. In the literature, complex
formation of GS with nucleic acids and adenosine phosphates has already been described [22,23].
Because the triphosphates GTP and ATP are utilized in the biosynthesis of ppGpp, their binding to
GS may further enhance the anti-biofilm effect of the peptide. Using the same 31P-NMR approach as
described above, we also compared the ability of several other phosphorus-containing nucleotides
to bind GS. Judged by the molar ratio at which the 31P-NMR signal disappeared (see Figures in
Supplementary Materials), the studied nucleotides exhibited GS binding affinities in the following
order: ADP < ppGpp < ATP = GTP < GDP. In particular, this means that the ppGpp precursors represent
even stronger complex partners for GS, and their binding to GS should additionally contribute to the
overall inhibitory and bactericidal effects in bacterial biofilms.
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Figure 3. Translocation of GS into the cells and its binding affinity to the bacterial alarmon ppGpp.
(A) Green fluorescence of the E. faecalis cell envelope upon staining with the dye CFSE, which cannot
penetrate the cellular membrane. (B) Fluorescence throughout the interior of the cells is seen upon
staining with a fluorescent GS-sw(FP) analog, confirming that the peptide can translocate across the
cell membrane into the cytoplasm. (C) Co-precipitation of GS and ppGpp is seen to occur at roughly
equimolar ratios, and a stable opalescent suspension is formed when GS is in large (i.e., electrostatic)
excess. (D) SEM showed that the aggregation ppGpp by GS led to the formation of short nano-rods of
about 50 nm width and 200 nm length. (E) When GS was added to ppGpp at different molar ratios,
the 31P-NMR signals of the latter disappeared successively. The pure ppGpp sample (1:0) is shown in
red. The scale on the fluorescent images is 5 μm.
2.5. Medication Reports
Case I of root canal infection: Molar 38 of a 59-year-old female patient (M.B.) was percussion-
sensitive and responded negative to cold testing with CO2 snow. The initial root canal treatment was
carried out in a standard way using irrigation with sodium hypochlorite. An intracanal Ledermix®
Paste dressing was administered. For the next six weeks, the tooth remained percussion sensitive and
painful, so the root canals were again treated in the same way for the next four weeks, but the second
treatment with Ledermix® Paste was also unsuccessful. The pain was stronger and radiated into the
ear and head. At the patient’s request, the tooth was medicated using a mixture of the antimicrobial
peptides GS and polymyxin B (PMB) at a molar ratio of 2:1. The powders were co-dissolved in a drop
of 50% ethanol and applied as an intracanal dressing with a temporary Cavit™ restoration. Alleviation
of pain was experienced after one hour, and a positive healing effect was noted. After a few weeks
without symptoms the tooth was sealed, and in the following five years no recurrence was observed.
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Case II of root canal infection: Decay in molar 36 of a 25-year-old male patient (M.B.’s son)
was observed by X-ray as a radiolucent spot in the pulp region (Figure 4A). Without treatment,
an irreversible pulpitis developed within six months. The root canals were treated in a standard way,
but a painful root canal infection appeared after two months. After the direct application of ~2 mg GS,
which was suspended in sterile isotonic saline, the pain receded within an hour, and the root canals
were sealed (Figure 4B). After treatment, no reoccurrence of root canal infection was observed in the
following five years.
 
Figure 4. Molar 36 of a 25-year-old male patient before and after treatment. (A) The radiolucent area in
the X-ray image indicates decay. (B) The sealed root canals after treatment with GS. The red arrowheads
mark the decayed area and the sealed root canals, respectively.
3. Discussion
The cyclic decapeptide gramicidin S (S = ”Soviet”) was isolated by Gause and Brazhnikova
from soil bacilli and described in Nature and Lancet in 1944 [24,25]. The symmetric structure
of GS is a double-repeated sequence of five amino acids, which are arranged in an antiparallel
cyclic manner (cyclo[phe-Pro-Val-Orn-Leu]2) [26]. GS has an amphiphilic structure, consisting of the
cationic non-canonical amino acid ornithine and the hydrophobic Dphenylalanine, valine and leucine.
As pharmaceuticals, antimicrobial peptides generally exhibit some unfavorable properties, such as
instability, salt sensitivity, high cost of production, and a rather non-specific spectrum of activity,
including hemolytic effects [27]. GS, on the other hand, is a very stable peptide. Its cyclic structure and
the presence of the unusual amino acids ornithine and Dphenylalanine avoid the typical proteolytic
degradation by common proteases. Overall, GS has a high hemolytic activity, which limits its use
to topical applications, though the addition of polyethylene glycol has been shown to prevent its
hemolytic effects [28]. The production of GS via the fermentation of producing Aneurinibacillus migulanus
phenotypes [29] is less costly than the usual chemical synthesis of antimicrobial peptides of non-bacterial
origin. GS is approved as the bioactive agent in Grammidin®Neo, a lozenge used against sore throat
and mouth ulcers, produced by Russian JSC Valenta Pharmaceuticals. Notably, despite a long treatment
history, no clinical cases of bacterial resistance against GS have been reported [30].
The promising observation that GS does not lead to bacterial resistance can be attributed to its
ability to attack multiple targets in bacterial cells at the same time. The first target of GS is the prokaryotic
plasma membrane; therefore, the peptide possesses enhanced activity against Gram-positive bacteria
like Staphylococcus spp., Streptococcus spp., and Enterococcus spp. [31]. In addition to depolarization,
presumably via the formation of short-lived pores at sub-MICs [32], it also inhibits the respiratory
enzymes NADH dehydrogenase and cytochrome bd terminal oxidase in the bacterial membrane [33],
and it detaches several vital peripheral membrane proteins, namely the cell-division regulator MinD, the
Lipid II biosynthesis protein MurG, and cytochrome c [34]. Here, we have shown that GS does not only
interact with the bacterial membrane, which causes structural and functional damage as described above.
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In fact, it can also penetrate into the cytoplasm, where it can bind to ppGpp, the intracellular regulator of
biofilm growth [35], and to its precursors ATP and GTP, as well as the energy metabolites ADP and GDP
(Figures S1–S4 in the Supplementary Materials). These new modes of activity broaden the spectrum of
effects known so far for GS. It is especially important to realize that this multifaceted activity profile
provides GS with unique bactericidal properties toward Gram-positive bacteria irrespective of their
physiological state, virulence, resistance, tolerance and phenotypic variation. Generally, the stationary
phase of a liquid bacterial culture contains a population of metabolically inactive non- or slow-growing
reversible phenotypes, which are known as persister cells. They are tolerant to conventional antibiotics,
even at 100 × MIC [36], because these antibiotics target only growing cells. The ability of GS to disrupt
membrane function and to form complexes with intracellular targets after its rapid penetration into
the cell interior leads to a complete and rapid killing. This was demonstrated in our killing assays of
stationary cells (Figure 2), and in the biofilm re-growth experiments with each of the selected three
strongest biofilm forming strains of E. faecalis (Table 1 and Figure 1).
The origin of E. faecalis in the root canal is unclear, as enterococci do not belong to the normal
oral microbial flora [7]. However, 77% of British-produced cheeses [37], 60% of French soft cheeses,
and 20% of mozzarella, feta and Swiss Tilsiter cheese [38], contain enterococci. A genetic analysis of
saliva, previously treated root canal samples, and of cheeses, using repetitive extragenic palindromic
(REP)-PCR, revealed nine E. faecalis genotypes in all specimens studied. The transitional colonization
of the oral cavity after the consumption of cheese may thus be a possible reason for the prevalence of
E. faecalis in root canal infections [37,38]. Tetracycline-resistant enterococcal or multispecies infections
may provoke treatment failure, requiring tooth extraction, if the therapy using an intracanal Ledermix®
paste dressing is applied [16]. Even if several bacteria cause the infection, a GS-containing dressing
would be an unsurpassable choice for successful treatment due to the broad-spectrum activity of
GS [30]. Although microbiological analysis was not performed in two above described medication
cases, a cure using GS alone and in combination with PMB has been successfully achieved. Recently,
we also reported that these two peptides exert a synergistic effect against multidrug-resistant strains
and against biofilms of P. aeruginosa [39]. In the treatment of root canal infections caused by this
pathogen, which is frequently isolated from treatment-resistant cases, we expect that the combination
of GS/PMB could play a very promising role. Remarkably, the pain-alleviating effect, which we
describe here for both medication cases, had been previously observed in Russian clinical trials as
a characteristic property only of GS but not of the related tyrothricin complex [40]—a peptide mixture
of the lineal gramicidin A and cyclic tyrocidines [41]. This unique property of GS should thus be highly
advantageous in the treatment of painful root canal infections.
Biofilm formation is a key virulence factor in the pathogenicity of persistent E. faecalis infections [42].
Nutrients such as hemin, vitamin K and glucose enhance biofilm formation. The tetracycline-resistant
E. faecalis strain TRE2 was the best biofilm former amongst all clinical isolates. The exposure of its
pre-grown biofilm to an aqueous solution of GS showed a bactericidal effect (no re-growth of biofilms was
observed, and no viable cells were found in this culture upon plating), and some drastic morphological
alterations of the biofilm remnants were observed (Figure 3). Our results thus highlight the promising
potential of GS in the successful treatment of root canal infections caused by tetracycline-resistant biofilms
of E. faecalis. In persistent infections, these bacteria can penetrate the cellular and tissue barrier and thereby
present an imminent risk to human health, causing further non-oral, life-threatening infections, such as
bacteremia or endocarditis [6,43]. Therefore, the successful treatment of root canal infections and their
prevention are vital tasks. GS alone or in combination with PMB offers an opportunity to help patients
with untreatable root canal infections, to save their natural teeth and to avoid high prosthetic costs.
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4. Materials and Methods
4.1. E. faecalis Strains, Antibiotics and the Determination of the Minimum Inhibitory Concentrations
The control strain Enterococcus faecalis DSM 2570 (ATCC 29212) was purchased from the German
Collection of Microorganisms and Cell Cultures (DSMZ). The WW4 isolate from cheese and the root
canal isolate WW6 were a kind gift from William G. Wade (Department of Microbiology, King’s College
London, London, UK). The tetracycline-resistant clinical isolates TRE1-TRE5 were obtained from the
medical laboratory of Staber & Kollegen, Heilbronn, Germany.
GS was produced by fermentation, extracted from producer cells and HPLC purified as described
earlier [28]. Other antibiotics (tetracycline and demeclocycline hydrochlorides) were purchased form
Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany).
The bacterial strains were maintained at −80 ◦C using a Cryobank™System (Mast Diagnostica,
Reinfeld, Germany). To refresh the bacterial cells, single beads were recovered in 10 mL BHI broth
(Becton, Dickinson and Co., Sparks, MD, USA) in an overnight incubation at 37 ◦C and 200 rpm, in the
50 mL culture flasks. Single colonies were obtained by streaking these cultures on BHI agar plates,
which were then stored at 4 ◦C. Subsequently, the colonies were used to inoculate 10 mL MH broth
(Becton, Dickinson and Co., Sparks, MD, USA) to an optical density (OD) of 0.02 at 550 nm, and the
cultures were grown overnight. The test cultures were prepared by inoculating 10 mL MH broth to
an OD550 of 0.2 with the overnight cultures and allowing them to grow until the bacteria reached
OD550 of 1–2 at 37 ◦C and 200 rpm. For inoculation, the test cultures were diluted immediately prior to
the experiment in MH broth to obtain final inoculation doses of 5 × 105 CFU/mL according to the
CLSI recommendations [17].
For the determination of the MIC, the standard broth microdilution procedure [18] was modified
to obtain the uniform medium concentration after the addition of antibiotic stock solutions dissolved
in sterile deionized water (tetracycline and demeclocycline) or in 50% ethanol (GS). Briefly, 50 μL of
the double-strength MH broth was added to the upper row of the 96-well microtiter plates (Nunclon™,
Nunc GmbH & Co., Wiesbaden, Germany). Next, 50 μL of the standard MH broth was added to the
remaining wells, including the columns for the ethanol control and the positive (without peptides)
and negative (sterility) controls. Addition of the antibiotic stock solutions (50 μL) to the upper wells
provided a standard medium concentration and the antibiotic concentration to establish a concentration
gradient. Once the two-fold dilution series of the antibiotic concentration was prepared according
to [44], the plates were inoculated with 50 μL of bacterial suspensions from the exponentially growing
culture to reach 5 × 105 CFU/mL. The plates were incubated for 22 h at 37 ◦C and 5% CO2 without
agitation. To examine bacterial growth, 20 μL of an aqueous 80 μM solution of the redox indicator
resazurin was added to each well. The plates were incubated for another 2 h at 37 ◦C. The respiration
activity was calculated for each well as the difference in the absorbance of resorufin at 570 nm
and resazurin at 600 nm using the microtiter plate reader FlashScan550 (Analytic Jena GmbH, Jena,
Germany) and the WinFlash program. Positive values indicated bacterial growth and allowed the
determination of the lowest peptide concentrations that inhibit bacterial growth. All results were
obtained from several independent experiments, and each was performed in triplicate.
4.2. Determination of the Minimum Bactericidal Concentration (MBC)
Determination of MBC was carried out directly after the MIC assay. The 10-μL samples of all
8 dilution rows of microtiter plates were spotted on the square agar plates and incubated overnight
at 37 ◦C and 5% CO2. The MBC was determined as the lowest concentration at which no bacterial
growth was observed on the two parallel spotted plates in several independent experiments.
4.3. Determination of the Minimum Biofilm Inhibitory Concentration (MBIC)
The MBIC leading to a 90% decrease in biofilm growth (MBIC90) was obtained using the
microdilution procedure in the same way as for the determination of MIC, but the inoculation of the
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wells was performed with bacterial cells from stationary cultures to reach 5 × 107 CFU/mL. In contrast
to the determination of MBIC for the peptide IDR-1018 in [21], we used TH broth as a medium,
which facilitated maximum biofilm growth (Figure 1A). After incubation at 37 ◦C and 5% CO2 without
agitation for 24 h, the planktonic cells were washed and the crystal violet staining method was applied
to evaluate the biofilm growth [45] under the different peptide concentrations. The results were
obtained from two independent experiments, and each was performed in triplicate.
4.4. Determination of the Biofilm-Forming Capacity of the E. faecalis Strains
Three nutrition media—TH broth, MH broth and minimal medium [21], containing 62 mM
potassium phosphate (pH 7.0), 7 mM ammonium sulfate, 2 mM MgSO4, 10 μM FeSO4, 0.4% glucose and
0.5% casamino acids—were used to determine the best biofilm formers and the medium that supported
the best biofilm growth. The central 6 × 3 wells separated by the empty columns in the 96-well
microtiter plates were filled with overnight bacterial suspensions of OD550 = 0.2 in three different
media and incubated at 37 ◦C and 5% CO2 without agitation for 24 h. The adherent biofilms were
washed, dried, fixed in methanol and dried again. The staining was carried out according to previously
described methods [45] in 100 μL of the 0.1% crystal violet solution for 20 min. The excess dye was
removed with water, and the wells were thoroughly dried. The dye absorbed by biofilms was dissolved
in absolute ethanol, and its absorption was evaluated in a microtiter plate reader at 595 nm.
4.5. Determination of GS Killing Activity
The killing activity of GS was monitored during the 60 min after exposure to GS concentrations of
5 × MIC and 10 × MIC if needed. The stationary cultures were diluted up to OD550 = 0.2 calculated
for 1.5 mL culture in MH broth, including the addition of GS stock solution. The 200-μL aliquots were
removed from the cultures, which were incubated in 4 mL culture tubes at 37 ◦C with agitation of
about 220 rpm, at 0 min, 20 min, 40 min and 60 min. For each time point, the culture samples were
diluted 1:10 in 900 μL MH broth and 100 μL of undiluted culture, and each dilution was spotted as
ten 10 μL on the agar plates according to the drop plate method [46]. After the incubation of the plates,
the bacterial growth was evaluated by the enumeration of colonies. The decrease in bacterial number
indicated the killing activity for the each time point.
4.6. Biofilms on HAD: Scanning Electron Microscopy and Re-Growth
The three best biofilm formers were grown on HAD (3D Biotek, NJ, USA), which served as
a tooth-like material. The discs were placed into the 24-well microtiter plates (Nunc GmbH & Co.,
Wiesbaden, Germany) and inoculated with a cell suspension from the overnight stationary cultures,
which were grown in TH broth and diluted to OD550 = 0.2. After 30 h growth at 37 ◦C without
agitation, biofilms on HAD were placed into solutions containing 50 μg/mL, 100 μg/mL, 200 μg/mL
and 400 μg/mL of GS, 400 μg/mL of demeclocycline, or 150 mM sodium phosphate buffer (SPB, pH 7.2)
for 18 h. After that, the biofilms on the HAD were washed in SPB and placed into 1 mL of fresh TH
broth to examine their re-growth. Cultures were incubated at 37 ◦C with agitation at 200 rpm for 24 h.
To determine the number of viable cells after exposure to GS, the 100 μL of TH culture after re-growth
experiment were spotted as described in 4.5. The second series of biofilms on HAD after the treatment
were washed in SPB, fixed for 1 h in 2% glutaraldehyde dissolved in SPB, washed twice in distilled
water and dried in the sample box. The samples were sputtered to obtain a 1-nm platinum layer
using the high vacuum coating system Leica EM MED020 (Leica Microsystems, Wetzlar, Germany).
The biofilm images were obtained with a Supra 55 VP scanning electron microscope (Carl Zeiss,
Ostfildern, Germany).
4.7. Fluorescence Microscopy
The fluorescence of the photo-switchable analog GS-sw(FP), described previously [20], was used
to study GS translocation into the bacterial cytoplasm. Approximately 1 mL of the E. faecalis cell
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suspension adjusted to OD550 = 1.0 was co-incubated with 100 μg/mL of GS-sw(FP) in less active
closed-ring form and incubated at 37 ◦C for 30 min without agitation. To observe the fluorescence this
form was converted to the fluorescent open-ring form upon the irradiation with visible light directly
under the microscope for 5 min. The CFSE dye (Sigma-Aldrich, St. Louis, MO, USA), which cannot
penetrate the cell membrane, was applied for comparison. The bacterial suspension for this staining
was resuspended in the fresh 150 mM NaHCO3 buffer (pH 8.3). This was necessary because at this pH,
the amino groups of membrane proteins remain deprotonated and can better bind to CFSE. The dye
concentration used for the cell staining was 1 μL/mL (stock solution 10 mg/mL in DMSO). The staining
procedure was carried out at the same conditions (37 ◦C, 30 min, without agitation). The fluorescence
was observed using a Axioskop 40 light microscope (Carl Zeiss Light Microscopy, Göttingen, Germany)
equipped with an “A-Plan” objective (100x/1.25 Ph3), a fluorescence filter (type 09, λex 450–490,
λem 515) and a digital camera (PowerShot G5, Canon, Tokyo, Japan). The sensitivity setting ISO 50 was
used in experiments with the highly fluorescent CFSE dye. Due to the low fluorescence quantum yield
of GS-sw(FP), the sensitivity setting was increased to the ISO 400.
4.8. 31P-NMR Spectroscopy of GS with Nucleotides in An Aqueous Environment
The ppGpp solution was purchased from TriLink BioTechnologies (San Diego, CA, USA), and the
nucleotides ATP, ADP, GTP, and GDP were purchased from Sigma-Aldrich (Munich, Germany). 600 μL
of 1 mM or 0.5 mM ppGpp solution in D2O (pH 7.2) were added to lyophilized aliquots of GS, yielding
0.5 mM, 1.0 mM, 2.0 mM, 4.0 mM and 8.0 mM for the end volume of 600 μL and thoroughly vortexed.
Each NMR sample was then allowed to remain without any perturbation at ambient temperature
for at least 2 h to allow precipitate formation. Proton-decoupled 31P-NMR spectra were acquired
on a Bruker AVANCE 400 MHz spectrometer (Bruker-Biospin, Rheinstetten, Germany), operating
at a 31P frequency of 161.974 MHz. The experiments were performed without temperature control
(room temperature) using a Bruker 5 mm BB-PABBO probe. A single pulse (30 degrees, 15 μs) using
a standard pulse sequence zgpg30 (Bruker library) was used. For 1H decoupling, a waltz16 decoupling
sequence (Bruker library) was used. A total of 3500 scans were accumulated for each spectrum with
an interpulse delay of 2 s. Spectra were processed with TopSpin 3.1 software (Bruker) using line
broadening of 5 Hz.
4.9. Medication of the Root Canal Infections
In Case I, lyophilized powders of 9.0 mg GS (1141.4 g/mol) and 5.5 mg PMB-sulfate (1385.6 g/mol)
were placed onto a glass slide, mechanically mixed with a spatula, and suspended by addition a 50 μL
droplet of 50% ethanol. In Case II, about 4 mg of GS powder were suspended by addition a 50 μL
droplet of sterile isotonic saline. A fraction of the resulting slurry was applied to the open root
canal as an intracanal dressing, employing standard filling instruments. The tooth was temporarily
restored by Cavit™. When a few weeks without pain had passed, both teeth were permanently sealed.
Both individual cases studies (of the first author and a family member) were carried out privately and
with full responsibility and awareness of the risks, as the only alternative would have been to have the
decayed tooth extracted. Both the participants in medication signed a “Note of patient consent”.
5. Conclusions
In this study, we have demonstrated the considerable therapeutic potential of GS, which can
be used for the treatment of root canal infections caused by tetracycline-resistant E. faecalis and
by any of its tenacious biofilm-forming strains. The rapid killing by GS is based not only on its
membrane-perturbing activity but also on further intracellular effects. The latter seem to involve the
ability of the peptide to cross the lipid bilayer and bind to anionic intracellular targets (e.g., the alarmone
ppGpp, and energetic nucleotides), as demonstrated here. The persistently infected root canals of
two patients have been successfully treated, exhibiting rapid pain-alleviating effects. The broad activity
spectrum of GS should thus be especially beneficial if the taxonomic status of the bacterial burden in
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root canals cannot be rapidly identified. For multispecies infections containing multidrug-resistant
P. aeruginosa, the combination with PMB can significantly promote the curing effect further. Therefore,
we recommend the approval of GS alone and/or as a complex with PMB for the treatment of persistent
tetracycline-resistant root canal infections.
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/9/3/56/s1,
Figure S1. Binding of ATP by GS; Figure S2. Binding of ADP by GS; Figure S3. Binding of GTP by GS; Figure S4.
Binding of GDP by GS.
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Abbreviations
The following abbreviations are used in this manuscript:
GS gramicidin S
PMB polymyxin B
MIC minimum inhibitory concentration
MBC minimum bactericidal concentration
MBIC90 minimum biofilm inhibitory concentration, 90% inhibition
MBBC minimal biofilm bactericidal concentration
TRE tetracycline resistant enterococci
CFU/mL colony forming units per mL
OD optical density
SEM scanning electron microscopy
CFSE 5(6)-carboxy-fluorescein-N-hydroxysuccinimide ester
HAD hydroxyapatite disc
NMR nuclear magnet resonance analysis
MH Mueller Hinton broth
TH Todd Hewitt broth
BHI brain heart infusion broth
MM minimal medium
SPB sodium phosphate buffer
References
1. Tronstad, L. Recent development in endodontic research. Eur. J. Oral Sci. 1992, 100, 52–59. [CrossRef]
2. Figdor, D.; Sundqvist, G. A big role for the very small—understanding the endodontic microbial flora.
Aust. Dent. J. 2007, 52, S38–S51. [CrossRef] [PubMed]
3. Li, X.Z.; Livermore, D.M.; Nikaido, H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa:
Resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob. Agents Chemother. 1994, 38,
1732–1741. [CrossRef] [PubMed]
4. Wang, Q.Q.; Zhang, C.F.; Chu, C.H.; Zhu, X.F. Prevalence of Enterococcus faecalis in saliva and filled root
canals of teeth associated with apical periodontitis. Int. J. Oral Sci. 2012, 4, 19–23. [CrossRef] [PubMed]
5. Stuart, C.H.; Schwartz, S.A.; Beeson, T.J.; Owatz, C.B. Enterococcus faecalis: Its role in root canal treatment
failure and current concepts in retreatment. J. Endod. 2006, 32, 93–98. [CrossRef] [PubMed]
226
Pharmaceuticals 2016, 9, 56
6. Portenier, I.; Waltimo, T.M.T.; Haapasalo, M. Enterococcus faecalis—The root canal survivor and “star” in
post-treatment disease. Endod. Topics 2003, 6, 135–159. [CrossRef]
7. Vidana, R.; Sullivan, A.; Billstrom, H.; Ahlquist, M.; Lund, B. Enterococcus faecalis infection in root
canals—Host-derived or exogenous source? Lett. Appl. Microbiol. 2011, 52, 109–115. [CrossRef] [PubMed]
8. Molander, A.; Warfvinge, J.; Reit, C.; Kvist, T. Clinical and radiographic evaluation of one- and two-visit
endodontic treatment of asymptomatic necrotic teeth with apical periodontitis: a randomized clinical trial.
J. Endod. 2007, 33, 1145–1148. [CrossRef] [PubMed]
9. Ran, S.; Wang, J.; Jiang, W.; Zhu, C.; Liang, J. Assessment of dentinal tubule invasion capacity of
Enterococcus faecalis under stress conditions ex vivo. Int. Endontic. J. 2015, 48, 362–372. [CrossRef] [PubMed]
10. De Paz, L.C. Redefining the persistent infection in root canals: Possible role of biofilm communities. J. Endod.
2007, 33, 652–662. [CrossRef] [PubMed]
11. Abdullah, M.; Ng, Y.L.; Gulabivala, K.; Moles, D.R.; Spratt, D.A. Susceptibilties of two Enterococcus faecalis
phenotypes to root canal medications. J. Endod. 2005, 31, 30–36. [CrossRef] [PubMed]
12. Dunavant, T.R.; Regan, J.D.; Glickman, G.N.; Solomon, E.S.; Honeyman, A.L. Comparative evaluation of
endodontic irrigants against Enterococcus faecalis biofilms. J. Endod. 2006, 32, 527–531. [CrossRef] [PubMed]
13. Estrela, C.; Sydney, G.B.; Figueiredo, J.A.; Estrela, C.R. Antibacterial efficacy of intracanal medicaments on
bacterial biofilm: A critical review. J. Appl. Oral Sci. 2009, 17, 1–7. [CrossRef] [PubMed]
14. Paganelli, F.L.; Willems, R.J.; Leavis, H.L. Optimizing future treatment of enterococcal infections: Attacking
the biofilm? Trends Microbiol. 2012, 20, 40–49. [CrossRef] [PubMed]
15. Hollenbeck, B.L.; Rice, L.B. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 2012, 3,
421–433. [CrossRef] [PubMed]
16. Lins, R.X.; de Oliveira Andrade, A.; Junior, R.H.; Lewis, M.A.O.; Wilson, M.J.; Fidel, R.A.S. Antimicrobial
resistance and virulence traits of Enterococcus faecalis from primary endodontic infections. J. Dent. 2013, 41,
779–786. [CrossRef] [PubMed]
17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing.
Twenty-Fourth Informational Supplement; Wayne, PA, USA, 2014; PP. 76–79.
18. Wiegand, I.; Hilpert, K.; Hancock, R.E. Agar and broth dilution methods to determine the minimal inhibitory
concentration (MIC) of antimicrobial substances. Nat. Protoc. 2008, 3, 163–175. [CrossRef] [PubMed]
19. Maisonneuve, E.; Gerdes, K. Molecular mechanisms underlying bacterial persisters. Cell 2014, 157, 539–548.
[CrossRef] [PubMed]
20. Babii, O.; Afonin, S.; Berditsch, M.; Reibetaer, S.; Mykhailiuk, P.K.; Kubyshkin, V.S.; Steinbrecher, T.;
Ulrich, A.S.; Komarov, I.V. Controlling biological activity with light: Diarylethene-containing cyclic
peptidomimetics. Angew. Chem. Int. Ed. Engl. 2014, 53, 3392–3395. [CrossRef] [PubMed]
21. de la Fuente-Nunez, C.; Reffuveille, F.; Haney, E.F.; Straus, S.K.; Hancock, R.E. Broad-spectrum anti-biofilm
peptide that targets a cellular stress response. PLoS Pathog. 2014, 10, e1004152. [CrossRef] [PubMed]
22. Krauss, E.M.; Chan, S.I. Complexation and phase transfer of nucleotides by gramicidin S. Biochemistry 1983,
22, 4280–4291. [CrossRef] [PubMed]
23. Krauss, E.M.; Chan, S.I. Complexation and phase transfer of nucleic acids by gramicidin S. Biochemistry 1984,
23, 73–77. [CrossRef] [PubMed]
24. Gause, G.F.; Brazhnikova, M.G. Gramicidin S and its use in the treatment of infected wounds. Nature 1944,
154, 703. [CrossRef]
25. Gause, G.F.; Brazhnikova, M.G. Gramicidin S Origin and mode of action. Lancet 1944, 244, 715–716.
26. Hoyer, K.M.; Mahlert, C.; Marahiel, M.A. The iterative gramicidin s thioesterase catalyzes peptide ligation
and cyclization. Chem. Biol. 2007, 14, 13–22. [CrossRef] [PubMed]
27. Aoki, W.; Ueda, M. Characterization of Antimicrobial Peptides toward the Development of Novel Antibiotics.
Pharmaceuticals 2013, 6, 1055–1081. [CrossRef] [PubMed]
28. Katsu, T.; Ninomiya, C.; Kuroko, M.; Kobayashi, H.; Hirota, T.; Fujita, Y. Action mechanism of amphipathic
peptides gramicidin S and melittin on erythrocyte membrane. Biochim. Biophys. Acta 1988, 939, 57–63.
[CrossRef]
29. Berditsch, M.; Afonin, S.; Ulrich, A.S. The ability of Aneurinibacillus migulanus (Bacillus brevis) to produce the
antibiotic gramicidin S is correlated with phenotype variation. Appl. Environ. Microbiol. 2007, 73, 6620–6628.
[CrossRef] [PubMed]
227
Pharmaceuticals 2016, 9, 56
30. Polin, A.N.; Egorov, N.S. Structural and functional characteristics of gramicidin S in connection with its
antibiotic activity. Antibiot. Khimioter. 2003, 48, 29–32. [PubMed]
31. Salgado, J.; Grage, S.L.; Kondejewski, L.H.; Hodges, R.S.; McElhaney, R.N.; Ulrich, A.S. Membrane-bound
structure and alignment of the antimicrobial β-sheet peptide gramicidin S derived from angular and distance
constraints by solid state 19F-NMR. J. Biomol. NMR 2001, 21, 191–208. [CrossRef] [PubMed]
32. Zhang, L.; Rozek, A.; Hancock, R.E. Interaction of cationic antimicrobial peptides with model membranes.
J. Biol. Chem. 2001, 276, 35714–35722. [CrossRef] [PubMed]
33. Mogi, T.; Kita, K. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. Cell. Mol.
Life Sci. 2009, 66, 3821–3826. [CrossRef] [PubMed]
34. Wenzel, M.; Chiriac, A.I.; Otto, A.; Zweytick, D.; May, C.; Schumacher, C.; Gust, R.; Albada, H.B.; Penkova, M.;
Krämer, U.; et al. Small cationic antimicrobial peptides delocalize peripheral membrane proteins. Proc. Natl.
Acad. Sci. USA 2014, 111, E1409–E1418. [CrossRef] [PubMed]
35. de la Fuente-Nunez, C.; Korolik, V.; Bains, M.; Nguyen, U.; Breidenstein, E.B.; Horsman, S.; Lewenza, S.;
Burrows, L.; Hancock, R.E. Inhibition of bacterial biofilm formation and swarming motility by a small
synthetic cationic peptide. Antimicrob. Agents Chemother. 2012, 56, 2696–2704. [CrossRef] [PubMed]
36. Lechner, S; Lewis, K.; Bertram, R. Staphylococcus aureus persisters tolerant to bactericidal antibiotics. J. Mol.
Microbiol. Biotechnol. 2012, 22, 235–244. [CrossRef] [PubMed]
37. Williams, S.C.; Wade, W.G. A comparison of enterococcal genotypes from the human mouth and cheese.
Int. Endontic. J. 2010, 43, 352–353. [CrossRef]
38. Razavi, A.; Gmur, R.; Imfeld, T.; Zehnder, M. Recovery of Enterococcus faecalis from cheese in the oral cavity
of healthy subjects. Oral Microbiol. Immunol. 2007, 22, 248–251. [CrossRef] [PubMed]
39. Berditsch, M.; Jager, T.; Strempel, N.; Schwartz, T.; Overhage, J.; Ulrich, A.S. Synergistic effect of
membrane-active peptides polymyxin B and gramicidin S on multidrug-resistant strains and biofilms
of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2015, 59, 5288–5296. [CrossRef] [PubMed]
40. Sergiev, P.G. Clinical use of Gramicidin S. Lancet 1944, 244, 717–718. [CrossRef]
41. Lapage, G. Gramicidin-S. Nature 1945, 155, 246–246. [CrossRef]
42. Seneviratne, C.J.; Yip, J.W.; Chang, J.W.; Zhang, C.F.; Samaranayake, L.P. Effect of culture media and nutrients
on biofilm growth kinetics of laboratory and clinical strains of Enterococcus faecalis. Arch. Oral Biol. 2013, 58,
1327–1334. [CrossRef] [PubMed]
43. Murray, C.A.; Saunders, W.P. Root canal treatment and general health: A review of the literature.
Int. Endontic. J. 2000, 33, 1–18. [CrossRef]
44. Amsterdam, D. Susceptibility testing of antimicrobials in liquid media. Antibiot. Laboratory Med. 1996, 4,
61–143.
45. Stepanovic, S.; Vukovic, D.; Dakic, I.; Savic, B.; Svabic-Vlahovic, M. A modified microtiter-plate test for
quantification of staphylococcal biofilm formation. J. Microbiol. Methods 2000, 40, 175–179. [CrossRef]
46. Herigstad, B.; Hamilton, M.; Heersink, J. How to optimize the drop plate method for enumerating bacteria.
J. Microbiol. Methods 2001, 44, 121–129. [CrossRef]
© 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





The Role of Antimicrobial Peptides in Influenza
Virus Infection and Their Potential as Antiviral
and Immunomodulatory Therapy
I-Ni Hsieh and Kevan L. Hartshorn *
Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA; inhsieh@bu.edu
* Correspondence: khartsho@bu.edu; Tel.: +1-617-638-5638; Fax: +1-617-638-7530
Academic Editor: Guangshun Wang
Received: 28 June 2016; Accepted: 31 August 2016; Published: 6 September 2016
Abstract: Influenza A virus (IAV) remains a major threat that can cause severe morbidity and
mortality due to rapid genomic variation. Resistance of IAVs to current anti-IAV drugs has been
emerging, and antimicrobial peptides (AMPs) have been considered to be potential candidates for
novel treatment against IAV infection. AMPs are endogenous proteins playing important roles in
host defense through direct antimicrobial and antiviral activities and through immunomodulatory
effects. In this review, we will discuss the anti-IAV and immunomodulatory effects of classical
AMPs (defensins and cathelicidins), and proteins more recently discovered to have AMP-like activity
(histones and Alzheimer’s associated β-amyloid). We will discuss the interactions between AMPs and
other host defense proteins. Major emphasis will be placed on novel synthetic AMPs derived from
modification of natural proteins, and on potential methods of increasing expression of endogenous
AMPs, since these approaches may lead to novel antiviral therapeutics.
Keywords: cathelicidin; defensin; LL-37; histone; amyloid
1. Introduction
IAV presents an ongoing major threat to human health and there is much yet to be learned about
the role of innate immunity during IAV infection [1]. Although IAV elicits strong adaptive immune
responses, it is prone to rapid genomic variation either through small incremental mutations or major
changes resulting from exchange of genome segments with those of animal strains (reassortment).
These genomic changes allow IAV to escape immune responses generated against prior strains.
Generally, the small incremental changes lead to seasonal epidemics, whereas reassortment leads to
pandemics. The presence of animal reservoirs allows introduction of avian or pig strains (or genes
from these strains) into humans resulting in pandemics, as in 2009 [2]. Seasonal epidemics of influenza
virus still contribute tremendous morbidity and mortality including annual mortality in the USA of
~40,000 [3]. Certain groups of individuals are more susceptible to severe outcomes of seasonal IAV:
those at extremes of age, smokers, individuals with COPD, cystic fibrosis or asthma, diabetes mellitus,
cardiovascular disease, or immune compromise. Some otherwise healthy young people die during
seasonal epidemics, sometimes due to bacterial super-infection (e.g., note recent association of IAV
with MRSA pneumonia) [4]. Pandemics cause more indiscriminate mortality in young healthy adults
than seasonal IAV [5]. There is a period of 5–7 days prior to arrival of CD8+ T cells in the lung after
exposure to a new IAV strain and innate defense is critical at this time.
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There is clearly a need for more therapies for IAV infection. Currently there are only two classes of
antiviral drugs active against IAV: inhibitors of the viral proton channel (M protein) and neuraminidase
inhibitors. High level of resistance to amantadines and emerging resistance to neuraminidase inhibitors
have been reported. In this review, we evaluate the potential of antimicrobial peptides (AMPs) as
therapies for IAV through summarizing in vitro and in vivo antiviral and immunomodulatory activity
of natural and modified forms these peptides.
2. Antiviral Activity of Various AMPs in Vitro and in Vivo vs. IAV
IAV is a respiratory tract infection that rarely causes viremia or direct infection of organs
outside the lung. Despite this it can induce severe systemic illness largely through the production
of pro-inflammatory cytokines. Mortality is most often linked to respiratory failure due to acute
lung injury and/or bacterial super-infection. In addition, some deaths occur due to cardiovascular
events likely triggered by the profound inflammatory state resulting from IAV infection in some
vulnerable subjects. There has been extensive interest in development of antivirals for IAV, but also
in designing therapies to dampen inflammatory injury induced by the virus. AMPs are attractive
as potential therapies for IAV since they have antiviral and antibacterial activity and also exert
immunomodulatory effects.
There are two major classes of amphipathic AMPs present in human respiratory lining fluids:
defensins and cathelicidins. There is evidence that both of these classes of AMPs play a role during IAV
infection. We will review the antiviral and immune modulatory activities of defensins, cathelicidins,
and also other peptides that have other important functions but also act as AMPs (e.g., histones
and Alzheimer’s associated amyloid beta). We will then discuss novel modified versions of AMPs
synthesized with the aim of increasing antiviral activity. Finally, we will review potential means of
inducing increased production of endogenous AMPs as an approach to antiviral treatment.
2.1. Defensins and Influenza
There are two major classes of defensins: α- and β-defensins. One group of α-defensins are
packaged in neutrophil granules and these are termed human neutrophil peptides (HNPs) 1–4.
The HNPs are very likely to interact with IAV in vivo since neutrophils predominate in the early
infiltrate in the IAV infected airway and play a pivotal role in initiation of the immune response
to the virus. HNPs are also displayed on neutrophil extracellular traps (NETs), which are formed
in response to IAV infection in vitro [6] and in vivo [7]. Another group of α-defensins is expressed
by epithelial cells, predominantly in the gut and genitourinary tracts. These are termed human
defensins (HDs) 5 and 6. There is less reason to believe that HDs play a role in vivo during IAV
infection, although they are of interest for their strong antiviral activity [8]. β-defensins are expressed
predominantly by epithelial cells and are relevant in particular to IAV since they are expressed by the
respiratory epithelium.
2.1.1. HNPs and IAV
These have strong neutralizing activity for many IAV strains [8–10]. The mechanisms of antiviral
activity of HNPs have not been fully elucidated. We have found that HNPs induce viral aggregation
and inhibit infectivity mainly through direct interactions with the virus [8,10–12]. In our studies,
incubating epithelial cells with defensins pre- or post-infection had minimal inhibitory activity and
direct incubation of HNPs with the virus was needed. In contrast, Salvatore et al. have found that
HNPs also inhibit IAV through binding to epithelial cells and inhibition of protein kinase C [9].
In addition, the viral binding activity of defensins is potentiated by formation of multimolecular
assemblies of defensins [8,13,14]. This may help to account for viral aggregating activity of defensins.
Unlike the collectins and other proteins that bind the viral hemagglutinin (HA), HNPs do not inhibit
HA activity of IAV [10]. Mice do not have neutrophil α-defensins but have other antimicrobial peptides
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that may play a similar role; hence, it has not been possible to use mouse models to test the role of
neutrophil α-defensins.
2.1.2. β-Defensins and IAV
Human β-defensins (HBDs), are produced by respiratory epithelial cells either constitutively or
in response to inflammatory stimuli and also inhibit IAV [8,15,16]. The HBDs are less potent as direct
inhibitors of IAV than the HNPs; however, they may have important immunomodulatory roles during
IAV infection as well. Ryan et al. have demonstrated that mice lacking mouse β defensin 1 (mBD1)
have more severe lung inflammation when infected with IAV although viral titers were not different
compared to control mice [16]. This paper also demonstrated that IAV infection increases production
of mBD1 by plasmacytoid dendritic cells. Further studies of the in vivo contributions of this and other
β-defensins during IAV infection will be of great interest.
2.1.3. Retrocyclins
Of interest, there is a third class of defensins called θ-defensins or retrocylins (because of
their cyclic nature) that are expressed in primates but not humans and have very strong anti-IAV
activity [8,17]. The retrocyclins, like HNPs, can induce aggregation of IAV and they appear to have
stronger intrinsic antiviral activity than HNPs [8]. As with HNPs, it was necessary to directly incubate
the virus with the retrocyclins to achieve optimal inhibition of infectivity in our studies. There is
evidence that retrocyclins and other defensins can act as lectins binding to viral carbohydrates [18,19],
and this may be an important contributor to their activity against viruses.
2.1.4. Potential for Paradoxical Activity of Defensins
HD5 and HD6 have been found to promote infection by human immunodeficiency virus (HIV)
in vitro by increasing viral entry [20]. These defensins also counteract anti-HIV effects of polyanion
microbicides [21]. HNP1 was also reported to increase HIV infectivity by facilitating transfer of the
virus across epithelial barriers [22]. Note that other studies show an ability of these defensins to inhibit
HIV [23–25]. No studies have indicated promotion of infection of IAV by defensins.
2.2. LL-37 and Influenza
A distinct group of antimicrobial peptides is called the cathelicidins and the one representative of
this class in humans is LL-37. Recent reviews have discussed the extraordinary range of activities of
LL-37, which include direct antimicrobial and antiviral activities, chemotactic activities for various
immune cells, modulation of macrophage responses to inflammatory stimuli, and modulation of
dendritic cell responses [26,27]. It is very likely that LL-37 participates in the host response to IAV.
LL-37 resembles HNPs in that it is packaged in neutrophil granules and released upon cellular
activation. LL-37 is also displayed on NETs where it can interact with IAV, which binds to NETs [6].
Like HBDs, LL-37 is produced by respiratory (and other) epithelial cells in response to various
stimuli [26]. Leukotriene B4 (LTB4) has been shown to promote defense against IAV probably through
its ability to stimulate release of LL-37 and β-defensins from respiratory epithelial cells [28].
As with other AMPs there is considerably more literature about the anti-bacterial activity than
there is about the antiviral activity of LL-37. Recently, however, LL-37 has been found to inhibit
several viruses including IAV, adenovirus, respiratory syncytial virus and HIV [29–32]. Several studies
have recently established a role of LL-37 during IAV infection. Barlow et al. first demonstrated that
LL-37 has direct antiviral activity against IAV and contributes to host defense against the virus in vivo
both by limiting viral replication and virus-induced inflammation [33]. There is also a single murine
cathelicidin, called CRAMP, which also inhibits IAV in vitro and in vivo [33,34]. Our laboratory then
reported on the mechanism of antiviral activity of LL-37 that is distinct from that of collectins or
defensins [34]. As with the defensins, direct incubation of the virus with LL-37 was needed to cause
optimal inhibition of viral replication. Adding LL-37 to cells before or after infection was less effective.
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In contrast to the HNPs, LL-37 did not induce viral aggregation. In addition, LL-37 did not alter viral
uptake by epithelial cells, although it markedly limited subsequent viral replication in the cells. Using
electron microscopy, there was evidence of viral membrane degradation that could alter infectivity
after viral internalization. This is consistent with the known membrane perturbing activities of LL-37.
A similar finding was obtained by Currie et al. with respect to neutralization of RSV by LL-37 [35].
2.3. Other Peptides with Antiviral Activity for IAV
Fragments of other host defense molecules or peptides not commonly known to serve host defense
functions have been showed to have AMP like activity with regard to bacteria and viruses.
2.3.1. Histones
Histones are cationic peptides that resemble AMPs in some regards. There is increasing evidence
that histones serve a host defense role vs. various organisms [36]. Histones are mainly known for
their ability to bind to and regulate expression of DNA. However, histones are also found in cytosol
and extracellular fluids where they appear to serve other functions, including antimicrobial activity.
There are several reasons to believe histones may participate in the immune response during IAV
infection. Like defensins and LL-37, histones are a major component of NETs [37]. In addition, histones
are released into respiratory lining fluids during a variety of lung inflammatory states [38].
The bulk of studies of the antimicrobial activity of histones have focused on antibacterial activity.
The lysine rich histones, H2A and H2B, have generally been found to have stronger anti-bacterial
activity than the arginine rich histones H3 and H4 [39]. Several studies have demonstrated antiviral
activity for histones as well [36,40]. We have recently reported that histones are able to neutralize
influenza A viruses, with H3 and H4 having greater antiviral activity than H1, H2A and H2B [40].
The antiviral effect of the H4 was mediated by direct interaction with the virus rather than the host
cells. In addition, H4 did not cause cell injury in a wide range of concentrations that reduced viral
infectivity. H4 was able to strongly aggregate viral particles and this was associated with reduced
uptake of the virus by target cells. Further studies of antiviral mechanisms of histones are warranted.
2.3.2. Amyloid Beta (Aβ) Peptides
Aβ peptides are mainly known for their key role in the development of Alzheimer’s disease.
However, Aβ peptides resemble some anti-microbial peptides or AMPs in their structure [41,42].
Aβ peptides are similar to the porcine AMP, protegrin, in ability to form channels in membrane
structures, which is believed to be one of the anti-bacterial and anti-fungal mechanisms of AMPs.
Soscia et al. demonstrated antibacterial and antifungal activity for Aβ peptides [43]. In addition,
this study showed that Aβ isolated from the brain of AD patients had antimicrobial activity and that
incubation of these brain derived samples with antibodies to Aβ ablated the antimicrobial activity.
We recently reported that Aβ peptides also have antiviral activity against IAV [44]. A study by
Bourgade et al. also showed inhibition of herpes simplex virus by Aβ peptides [45]. In our study and
that of Soscia et al., Aβ1-42 was found to have greater antimicrobial or antiviral activity than Aβ1-40.
We demonstrated that Aβ1-42, but not Aβ1-40, caused viral aggregation which appears to contribute
to its antiviral effects. This implies a possible connection between the ability of Aβ1-42 to assemble
into oligomers and its antiviral activity, since this peptide has a greater propensity to form oligomers
and fibrils than Aβ1-40. An important recent study showed that Aβ peptides exert protective effects
in mouse and worm models in vivo [46]. This study demonstrated that the antimicrobial mechanism
of the peptides involved direct binding and then agglutination of the bacteria and fungi.
3. Immunomodulatory Effects of AMPs
In addition to their direct antimicrobial and antiviral effects, AMPs have important modulatory
effects on responses of many immune cells (see Table 1).
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Table 1. Antiviral and immunomodulatory activity of AMPs with respect to IAV.
AMP Principle Human Lung Source Antiviral Activity a Immune Modulation b
























Amyloid Beta (Aβ) Unknown Seasonal strains: 2+Pandemic strains: 2+
Neutrophils:
increased viral uptake,








Lactoferrin peptides Neutrophils Seasonal strains: 4+Pandemic strains: ND ND
a Antiviral activity for seasonal and pandemic IAV strains are indicated by a scale of 0 to 4+ to give a general
idea of the relative potency of the different peptides. In some instances activity against pandemic strains were
not determined (ND). b Results for immune modulation are not comprehensive.
3.1. Effects on Viral Uptake, Respiratory Burst and NET Formation by Neutrophils
We have studied extensively the ability of AMPs to modulate viral interactions with neutrophils.
HNPs, retrocyclins, histones and Aβ1-42 increase viral uptake by human neutrophils ([8,12,44] and
unpublished data). We obtained similar results with human monocytes ([11,44], and unpublished
data). It appears likely that the ability of these AMPs to increase viral uptake is linked to their
viral aggregating activity. Consistent with this interpretation, LL-37 did not alter viral uptake by
neutrophils [6]. The AMPs have varied effects on respiratory burst responses of neutrophils. IAV itself
stimulates a respiratory burst response characterized by H2O2 production. Pre-incubation of IAV with
HNPs reduced this H2O2 response, whereas histones, Aβ1-42, and LL-37 potentiated the response.
LL-37 and Aβ1-42 also increased NET formation in response to IAV [47]. LL-37 has several known
receptors on phagocytes, including formyl peptide receptor 2 (FPR2), CXCR2, the epidermal growth
factor receptor and the P2X7 receptor [48]. By use of a specific inhibitor for FPR2 and other means we
were able to show that the enhanced H2O2 and NET response to IAV caused by LL-37 is mediated
by FPR2 [6].
3.2. Effects on Cytokine Responses to IAV
IAV is a potent stimulator of neutrophil IL-8 production and monocyte or macrophage
pro-inflammatory cytokine production (e.g., TNF or IL-6). Pro-inflammatory cytokine production
in vivo correlates with symptomatology and with lung injury caused by IAV. A major goal of current
IAV research has been to reduce inflammatory effects of the virus to reduce lung injury [49]. In mouse
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models, lung injury can be reduced even when viral loads are unaffected in some cases [49]. LL-37 has
been reported to reduce cytokine responses to various stimuli [50–54], and, indeed we found that it
reduced neutrophil IL-8 responses to IAV and LPS [6]. We are in the process of studying the effects of
the various AMPs on monocyte and macrophage cytokine responses to IAV. As noted, LL-37 treatment
of mice infected with IAV reduces cytokine responses [33]. This effect appeared be in part independent
of reduction of viral load by LL-37 in vivo.
HNPs released from dying neutrophils have been shown to mediate anti-inflammatory effects [55].
In addition, HNPs can be taken up by macrophages during bacterial infection where they inhibit
macrophage inflammatory cytokine production by restricting protein translation [56]. The relevance
of these findings to IAV infection has not been evaluated thus far. As noted also, deletion of HBD-1
resulted in greater inflammatory reaction to IAV, despite no change in viral titers. HBD 3 has been
shown to have strong anti-inflammatory effects as well in an LPS model [57,58]. It will be of interest to
test this peptide in the context of IAV infection. Even though Aβ1-42 has been extensively studied
as a pro-inflammatory stimulus [59], we found that it reduced inflammatory cytokine production
triggered by IAV in monocytes in vitro [44].
Overall, these results indicate that maximizing anti-inflammatory effects as well as antiviral
activity should be considered when designing novel AMPs for treatment of IAV. A contrasting
perspective has arisen from several studies in which increasing inflammation prior to IAV or SARS-CoV
infection was protective [60–62]. In the study by Wohlford-Lenane et al. intranasal instillation of
retrocyclin 1 alone induced lung inflammation and this was associated with protection vs. SARS-CoV.
In another study, direct instillation of HNPs into the airway of mice had pro-inflammatory effects
independent of infection [63]. Note that in other models listed above HNPs had anti-inflammatory
effects. Hence, further study is needed to determine how to best administer AMPs in vivo and whether
possible pro-inflammatory effects would be harmful or beneficial with respect to infection.
Although histones have antimicrobial and antiviral activities, they have been considered to
instigate several systemic inflammatory diseases and tissue injuries, including sepsis, peritonitis,
pancreatitis, stroke, acute lung injury, liver injury and kidney injury [36]. The injection of histones
into mice can stimulate pro-inflammatory cytokine/chemokine release (e.g., IL-6, IL-8 and TNF) and
leukocyte infiltration, resulting in sepsis-like pathology [64–67]. In these cases histones function as
damage-associated molecular pattern molecules, and possible mechanisms for them to induce cytokine
storm may be through the interactions with toll-like receptors (TLR), especially TLR2, -4 and -9,
and the NLRP3 inflammasome [68]. Knowing the possible detrimental pro-inflammatory effects of
histones, further study is needed to investigate the roles of histones during severe IAV and IAV-related
lung injury.
3.3. Effects of AMPs on Adaptive Immune Responses
AMPs have been termed “alarmins”, in that they are able to trigger recruitment and activation
of immune cells. AMPs modulate adaptive immune responses in various ways. This topic is beyond
the scope of this paper; however, we refer the reader to other reviews [48,69]. As examples, HBDs
and other defensins bind to receptors on lymphocytes and act as chemoattractants [70,71] and LL-37
facilitates presentation of antigens to by DCs to T cells [48,72]. α-defensins have been shown to
potentiate neutralizing antibody responses to enteric viral infection [73]. The contribution of these
activities to IAV infection have not been studied but certainly are valuable areas for future research.
3.4. Effects on Bacterial Superinfection
Bacterial superinfections are a major contributor to mortality during pandemics and seasonal
epidemics of IAV [4]. These bacterial superinfections are difficult to treat with antibiotics. As a result
there is great interest in identifying the cause of bacterial superinfection and how to intervene
to prevent or treat these infections. The role of AMPs in bacterial superinfection, or for possible
treatment of bacterial superinfection, has not been studied. However, given the combined antiviral
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and antibacterial activity of many AMPs they are attractive candidates for treatment of combined IAV
and bacterial infection.
3.5. Interactions of AMPs with Other Host Defense Proteins
It is likely that the activity of AMPs in vivo reflects complex interactions among various AMPs
and other host defense molecules [74,75]. We found that HNPs 1-3 bind to the lung host defense and
surfactant regulatory protein, surfactant protein D (SP-D) [10,74]. The importance of this binding
in vivo is not clear; however, HNPs inhibited antiviral activity of SP-D and caused precipitation of SP-D
out of human BAL fluid. Since SP-D has anti-inflammatory properties in the uninfected and infected
lung, this property of HNPs could account for inflammatory responses seen upon instillation of HNPs
in the lung [63]. On the other hand, SP-D might aid in clearance of HNPs after neutrophil infiltration.
Of note, we found that LL-37 and HBDs do not bind to SP-D [8], which may be advantageous when
considering use of these peptides for therapy in the lung. Retrocyclins and LL-37 had additive antiviral
effects when combined with SP-D [8,34].
Histones have been considered to augment inflammatory responses and promote thrombosis and
thus can be responsible for IAV-related acute lung injury as noted above. There is evidence that other
host defense proteins can bind histones and modulate their potential adverse effects. Little is known
about the relationship between histones and SP-D. Evidence suggests that SP-D can simultaneously
bind to both pathogens and NETs [64], and we recently found that SP-D can bind to histones and
inhibit histone-induced respiratory burst in neutrophils (unpublished data). C-reactive protein (CRP),
an acute phase reactant, is another host defense protein that is usually elevated during infections
or inflammation, and CRP treatment in mice has been found to alleviate histone-induced toxicity,
including endothelial damage, thrombosis and lung edema [76]. Other proteins like thrombomodulin
have similar effects [77]. These findings suggest some possible modulators for histones, but further
studies are needed [76].
4. Production of Modified Synthetic AMPs with Increased Antiviral Activity
4.1. Novel Cyclic or Alpha Defensins
There has been extensive research into ways to modify or mimic the structure of defensins in order
to improve anti-bacterial or antiviral activity. Results of some of these studies are summarized in Table 2.
Even single amino acid substitutions can potentiate antiviral activity. For instance, replacement of
a single arginine with a lysine in retrocyclin 1 resulted in increased binding to, and inhibition of, HIV [14].
This modified retrocyclin also had increased IAV neutralizing activity [27]. Similarly, replacement of a
single amino acid in HD5 resulted in increased activity vs. HSV [78]. The strong activity of retrocyclins
also inspired construction of a panel of cyclic peptides by Ruchala and Lehrer [11]. The intent was to
retain or improve on antiviral activities of naturally occurring retrocyclins with cyclic peptides that are
easier to synthesize. These peptides were termed hapivirins and diprovirins and they incorporated
systematic substitutions of key cationic or hydrophobic residues and also incorporated several synthetic
amino acids. Several of the hapivirins and diprovirins had markedly increased neutralizing activity
for IAV [11]. In addition, the peptides retained the properties of viral aggregation and increasing viral
uptake by neutrophils. Like the retrocyclins, they did not interfere with the viral neutralizing activity
of SP-D. In the case of the hapivirins, substitutions that increased hydrophobicity caused clear increase
in antiviral activity, indicating that hydrophobicity is as important a feature as cationic charge for
antiviral activity. The most active hapivirins and diprovirins also had strong ability to suppress TNF
generation by human monocytes.
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Table 2. Therapeutic Directions: Creation of Novel AMPs.
Prototype Peptide Antiviral Activity Immune modulation
β Defensin Novel p9 peptide has increased antiviralactivity against human and avian IAV strains Mediate anti-inflammatory effects
Cyclic defensins Hapivirins and Diprovirins have increasedantiviral activity against seasonal IAV
Cause increased neutrophil uptake compared with
HNPs and suppress TNF generation by monocytes
LL-37 GI-20 gains activity against pandemic strain Have similar immunomodulatory effects to LL-37
Lactoferrin
Shorter peptide fragments show increased
anti-IAV activity for seasonal and mouse
adapted strains
Not tested
BPI 27 amino acid N-terminal fragment of humanBPI inhibits infectivity of various IAV strains
Inhibit monocyte cytokine production
in response to IAV
4.2. Novel β-Defensins
A recent paper by Zhao et al. took the approach of preparing a series of fragments of mouse
beta defensin 4 and testing their activity against a panel of clinically important respiratory viruses,
including human and avian IAV strains, SARS-CoV and MERS-CoV [79]. A 30 amino acid fragment
of mBD4 (termed P9 by the authors) was found to have activity exceeding that of the full 40 amino
acid protein both in vitro and in vivo in mice. In fact, 100% of mice survived lethal challenge with
a mouse adapted H1N1 viral strain when they were pretreated with 50 μg/mouse of P9 intranasally.
The P9 peptide also reduced lung inflammation and viral loads in the mice. P9 also increased survival
of mice infected with a lethal dose of avian H5N1 or H7N9 and had in vitro antiviral activity against
SARS-CoV and MERS-CoV. All of these respiratory viral strains are of great concern due to pandemic
potential and severe outcomes of infection in humans. The mechanism of action of P9 was found
to include binding to H1N1 IAV, entering the cell along with the virus and impairing endosomal
acidification and hence viral escape from endosomes. This study provides and interesting example of
a shortened fragment of a naturally occurring defensin having greater activity than the parent peptide.
4.3. LL-37 Derived Peptides
In a similar vein, shortened or subtly modified version of LL-37 have been tested for antiviral
and antibacterial activity. A 20 amino acid fragment, termed GI-20, was found to have retained the
antiviral activity of the full molecule against seasonal IAV [80] and against HIV [81]. Another fragment
called K-13 had no activity for IAV, despite the fact that it inhibits HIV and has anti-bacterial activity
as well [82,83]. Two N-terminal fragments (LL-23 and LL-23V9) that have anti-bacterial activity [84]
failed to inhibit IAV [85]. The GI-20 fragment incorporates the central helix of LL-37 and differs by one
amino acid from the LL-37 sequence (isoleucine 13 is changed to glycine). Of note, pandemic H1N1 of
2009 was inhibited in vitro by GI-20, but not by LL-37 or the other peptides [85]. This provides another
example of a shortened version of a natural AMP with increased antiviral activity compared to the
parent peptide. GI-20 also retained the ability of LL-37 to increase neutrophil respiratory burst and
NET responses to IAV, while also suppressing neutrophil IL-8 response to the virus [80]. The ability
of GI-20 to increase virus induced respiratory burst and NET responses was also mediated through
binding to FPR2. Using molecular modeling GI-20 was found to incorporate the domain of the protein
predicted to bind to the FPR2 receptor.
4.4. Lactoferrin and Bacterial/Permeability Increasing Protein (BPI) Based Peptides
Lactoferrin is an evolutionarily conserved innate immune protein present in breast milk and other
mucosal secretions that is cationic and has activity against bacteria and several viruses, including
IAV [86]. Lactoferrin has two lobes (the N and C lobes) both of which contain an iron binding
site. Although the N and C lobes have similar structures they have distinct sequences within
them. The two lobes can be separated by proteolytic cleavage and shown to have distinct functional
activities [87]. A recent study by Ammendolia et al. showed that all of the anti-influenza activity of
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bovine lactoferrin is in the C lobe and that shorter peptide domains within the C lobe have picomolar
activity against IAV [88]. These peptides had greater antiviral activity in vitro and greater selectivity
indices (a measure that combines antiviral activity and cellular cytotoxicity) than the whole lactoferrin
protein. The antiviral activity of lactoferrin was related to binding to the HA2 subunit of the viral
hemagglutinin (which contains the fusion domain).
A 27 amino acid N-terminal fragment of human BPI was recently shown to inhibit various IAV
strains (including H1N1, H3N2 and H5N1 strains) in vitro through a direct action on the virus [89].
Of interest, the murine homolog of this peptide lacked anti-IAV activity. In addition, the human
peptide inhibited IL-6 and TNF responses of monocytes triggered by IAV.
5. Potential for Resistance of IAV to AMPs
Mechanisms of resistance to AMPs have been well described in bacteria; however, there are
no similar data for viruses. As noted above we found that pandemic IAV was not inhibited by
LL-37 (although the GI-20 fragment was inhibitory). Similarly we found that the murine cathelicidin
CRAMP [85] and human histone H4 did not inhibit pandemic H1N1 of 2009 [40]. HNP-1 had reduced
activity for the pandemic strain as well. The mechanism of resistance of the pandemic strain is not
clear since all of these AMP have activity against seasonal or mouse adapted strains of IAV. Using
reverse genetics a viral strain was prepared having only the HA of the pandemic strain but all other
gene segments from a seasonal H1N1 strain and this re-assorted strain was sensitive to LL-37, CRAMP
and histone H4. This indicates that resistance is not mediated by the hemagglutinin of the pandemic
strain. Further studies will be important to determine which components of the pandemic strain confer
resistance to several AMPs.
6. Induction of Endogenous AMPs
One of the challenging features of developing AMPs as therapeutics is determining how to
administer them. As noted above, there is evidence that direct administration into the airway may
induce inflammatory responses. Another approach under exploration is increasing endogenous
production of AMPs through various means [90]. Results of these studies are summarized in Table 3.
As noted, LTB-4 can potentiate generation of both LL-37 and HBD in the respiratory tract [28,91].
LL-37 generation by epithelial cells is regulated by vitamin D; hence, repletion of vitamin D may
have host defense benefits. LL-37 generation is also enhanced by histone deacetylase inhibitors (e.g.,
phenylbutyrate) [92]. This approach was found to improve outcomes when added to standard
antibiotic treatment of mycobacterium tuberculosis infection in humans [93]. An interesting report
also showed that supplementation with the amino acid isoleucine can increase HBD expression [94].
Further studies of this phenomenon will be of special interest given the low toxicity of this approach.
IL-17 and IL-22 have been shown to induce expression of HBD and S100 peptides (another group of
AMPs) in human keratinocytes [95]. One paper reported on endogenous generation of retrocyclins in
human cells after exposure to aminoglycoside antibiotics [96]. Human cells actually contain the gene
for retrocyclins but they are not expressed due to a premature stop codon in the signal sequence [97].
Clearly the study of AMP induction is in its infancy. However, there are several tantalizing findings
that certainly support further exploration of this approach.
Table 3. Therapeutic Directions: Increase endogenous AMP generation.
Mediator AMPs Effected
LTB4 Increase LL-37 and β Defensin generation
HDAC inhibitors Increase LL-37 generation
Vitamin D Increase LL-37 generation
Isoleucine Increase HBD expression
IL-22, IL-17 Increase AMP expression
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7. Conclusions
IAV causes many deaths or severe illness every year in seasonal outbreaks and has the potential
to cause massive morbidity and mortality during pandemics. Resistance to two classes of drugs
that are currently used for IAV treatment has been emerging, so there has been extensive interest in
developing new antiviral treatment for this virus. Deaths caused by IAV infection mostly resulted from
acute lung injury, systemic inflammation or bacterial superinfection, suggesting that new treatments
with anti-viral, anti-bacterial and anti-inflammation effects would be ideal. AMPs are antimicrobial
peptides that not only play important roles as host defense against pathogens but also modulate
inflammatory responses, and thus they are potential candidates for IAV treatment. We discussed the
interactions of two classes of classical AMPs (defensins and cathelicidins) and two non-classical AMPs
(histones and Aβ) with IAVs in this paper. For the most part, these AMPs possess anti-IAV activity
by direct interacting with the virus, although in some instances direct interactions with mammalian
cells may contribute to antiviral effects. All of AMPs we discussed also have immunomodulatory
effects, with some up-regulating and others down-regulating inflammation. We provide some
examples (e.g., hapivirins and diprovirins or GI-20) in which novel synthetic AMPs or AMP fragments
have improved anti-IAV or immunomodulatory activities, suggesting that modification of AMPs is
an attractive strategy. Further studies are required to determine the interactions between AMPs and
other host defense proteins in the lung, the best methods to administer or induce generation of AMPs,
and to explain instances of resistance of pandemic IAV strains to AMPs.
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Abstract: The concurrent increases in global population and sexually transmitted infection (STI)
demand a search for agents with dual spermicidal and microbicidal properties for topical vaginal
application. Previous attempts to develop the surfactant spermicide, nonoxynol-9 (N-9), into a vaginal
microbicide were unsuccessful largely due to its inefficiency to kill microbes. Furthermore, N-9 causes
damage to the vaginal epithelium, thus accelerating microbes to enter the women’s body. For this
reason, antimicrobial peptides (AMPs), naturally secreted by all forms of life as part of innate
immunity, deserve evaluation for their potential spermicidal effects. To date, twelve spermicidal
AMPs have been described including LL-37, magainin 2 and nisin A. Human cathelicidin LL-37 is the
most promising spermicidal AMP to be further developed for vaginal use for the following reasons.
First, it is a human AMP naturally produced in the vagina after intercourse. Second, LL-37 exerts
microbicidal effects to numerous microbes including those that cause STI. Third, its cytotoxicity is
selective to sperm and not to the female reproductive tract. Furthermore, the spermicidal effects
of LL-37 have been demonstrated in vivo in mice. Therefore, the availability of LL-37 as a vaginal
spermicide/microbicide will empower women for self-protection against unwanted pregnancies
and STI.
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1. The Need for New Types of Contraceptives
As the world population continues to grow at an exponential rate, so does the need for
novel contraceptives. Oral contraceptive pills (OC), formulated with a balanced combination of
estrogen and progestin, are praised for their highest contraceptive efficacy and reversibility. The high,
non-physiological dosages of estrogen and progestin in OCs induce an imbalance of reproductive
hormones in the hypothalamus-pituitary-ovary axis, and subsequently a failure in ovulation. Progestin
also thickens the cervical mucus, thus impeding sperm from swimming into the uterus and oviduct.
These features empower women to protect themselves from unwanted pregnancies and therefore have
become the most widely used form of contraception. However, these sex steroid based pills are not
without risks, as estrogen and progestin are also involved in other physiological processes outside of
ovulation and pregnancy. Excess circulating amounts of either hormone can lead to undesirable side
effects. The most common minor side effects include nausea, weight gain and acne formation, whereas
major side effects can include thromboembolism, hypertension, hyperlipidemia, cardiovascular disease,
and breast and cervical malignancies. Long-term exposure to these hormones has also been shown
to cause vaginal atrophy, which can lead to local symptoms and predisposition to infection. Women
with a personal or family history of the aforementioned medical abnormalities or those who engage
in high-risk behaviours such as smoking are medically advised against the use of OCs [1]. Estrogen
and/or progestin can also be systemically administered via transdermal patch, subdermal implant,
intradermal injection, vaginal ring, or intrauterine device (IUD). Regardless of the administration
route, the side effects associated with estrogen/progestin are similar. Recent studies further suggest
that the intradermally injected progestin, depo-medroxyprogesterone acetate (DMPA), may induce the
thinning of the vaginal epithelium, and therefore increase the infection risk of microbes [2,3]. What is
more, there is now growing concern about bioaccumulation of these hormonally based contraceptives
and their associated negative impact on ecologic systems of all scales [4,5]. Therefore, development of
reversible, locally acting and non-hormonal contraceptives should be considered.
As the global population increases, so does the rate of sexually transmitted infection (STI).
HIV/AIDS continues to be a prevalent condition, affecting approximately 37 million people worldwide
(http://www.who.int/hiv/data/epi_core_july2015.png?ua=1). The vaginal mucosa is the portal by
which HIV from semen of seropositive men infects women following intercourse [6]. Many other viruses,
bacteria, yeasts and protozoa also cause sexually transmitted infection (Table 1) via this route. Physical
barriers such as male and female condoms prevent transmission of potential pathogens between both
sexes. STI-induced microorganisms, as well as sperm, cannot penetrate through the condom layer,
made from polyurethane or polyisoprene [1]. Therefore, the use of condoms is considered part of a
safe sex practice for both men and women, as they are protected against unwanted pregnancies and
STIs. However, the main drawback of condom use is decreased sensation and sensual pleasure during
intercourse. Also, improper use and breakage during intercourse are concerns of the contraceptive
efficacy of condoms [1]. Development for chemical spermicides and microbicides for vaginal use is
therefore much needed.
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Table 1. Common microorganisms that cause sexually transmitted infection and genitourinary
tract infection.
Sexually Transmitted Infection Vaginitis Urinary Tract Infection
Viral Infection
‚ Human immunodeficiency virus (HIV)
‚ Herpes simplex virus 1 & 2 (HSV-1 & HSV-2)
‚ Human papillomavirus (HPV)
































2. Vaginally Administered Compounds with Dual Actions as Spermicides and Microbicides
Clearly, compounds with dual spermicide/microbicide action need to be developed. Various
approaches to this can be considered, including microbicide screening against compounds with known
spermicidal activity. Indeed, this was the approach taken for the spermicide, nonoxynol-9 (N-9).
However, the final development of N-9 into a vaginal microbicide was not successful due to its
deleterious effects on the vaginal epithelium as well as its microbicide inefficacy. Apparently, the
development of N-9 into a spermicide over 50 years ago did not take into account the physiology of
sperm function, the knowledge of which has been slowly unfolding over the past decades. Details of
the current knowledge on sperm physiology/biochemistry are therefore given herein for consideration
of the development of the next generation of vaginal contraceptive/microbicide compounds.
2.1. Mechanisms on How Mammalian Sperm Gain Fertilizing Ability
The fertilizing potential of sperm in the ejaculate correlates with a number of basic parameters
including motility, concentration, total sperm number, and sperm morphology [7]. However, sperm
can fertilize eggs only after they undergo the capacitation process. This occurs naturally in the
female reproductive tract, and can be mimicked in vitro by incubating isolated sperm relatively
free of seminal plasma in a medium containing calcium, bicarbonate and albumin. “Capacitation”
defines the overall biochemical and physiological changes that allow sperm to bind to the egg and
then enter into its cytoplasm. During capacitation significant changes occur on the sperm plasma
membrane [8]. This is partly attributed to a cholesterol efflux [8,9], which subsequently increases
overall sperm plasma membrane fluidity, preparing sperm for the two membrane fusion events
essential for completing the fertilization process. The first event is part of the onset of the acrosome
reaction. The acrosome is a membrane enveloped cap-like structure that is underneath the plasma
membrane of the sperm head anterior. Upon exposure to stimulators such as zona pellucida (ZP)
glycoproteins and progesterone, calcium is rapidly transported into sperm, and the acrosome reaction
is initiated with the multi-site fusion between the sperm anterior head plasma membrane and the
outer acrosomal membrane. This membrane fusion results in the pore formation in the sperm head
anterior and finally exocytosis of the acrosomal content, mainly composed of hydrolytic enzymes,
into the surrounding. These hydrolytic enzymes digest the egg vestments (networks of cumulus
cell layers composed of proteo-glycosaminoglycans and the egg extracellular matrix-the ZP), thus
facilitating sperm to swim towards the egg plasma membrane [8]. Without the completion of the
acrosome reaction, fertilization cannot take place [8,10]. On the other hand, if the acrosome reaction is
completed prematurely, sperm will have problems penetrating the egg vestments and also binding to
the egg ZP.
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Once acrosome reacted sperm penetrate through the ZP, they reach and bind to the egg plasma
membrane. At this time the second membrane fusion event occurs between the plasma membrane
of the head (post-acrosomal) region of an acrosome reacted sperm and the egg plasma membrane.
This fusion is immediately followed by incorporation of the whole sperm into the egg proper and this
signifies that fertilization has occurred.
The increase of the membrane fluidity due to cholesterol efflux also leads to a change in the sperm
movement patterns. Sperm swim with a progressive forward pattern before capacitation. Capacitated
sperm, however, swim with “hyperactivated motility” patterns, which are whiplash like with a high
amplitude of lateral head (ALH) displacement. These swimming patterns endow sperm with a high
thrusting force, facilitating them to penetrate through the egg vestments [8,11]. CatSper calcium cation
channels play an integral role in sperm acquisition of hyperactivated motility patterns [12]. Male mice
genetically deleted of CatSperδ are infertile; despite normal sperm production, sperm of these knockout
mice cannot move with hyperactivated motility patterns [13]. Changes in the sperm plasma membrane
composition during capacitation also lead to the exposure of sperm head surface molecules that are
responsible for binding to the egg ZP in a species specific manner [8]. These ZP binding molecules are
localized to the sperm anterior head plasma membrane overlying the acrosome. To date, more than
15 proteins, as well as a male germ cell specific sulfoglycolipid, sulfogalactosylglycerolipid (SGG, aka
seminolipid) [14–16], have been shown for their affinity for the egg ZP. Results from knockout mouse
studies indicate that most of these proteins and SGG are not essential for sperm fertilizing ability, since
the knockout male mice remain fertile [17]. These results can be interpreted by the possibility that
these proteins/SGG have backups for one another, as the fertilization process is of utmost importance
for the maintenance of life in the next generation within a species [18]. Supporting this concept is
the fact that sperm head surface proteins with ZP affinity exist together as high molecular weight
complexes, which have direct ZP binding ability [19,20].
With sperm physiological events described above, it is logical to search for compounds that
disable sperm fertilizing ability through the following processes: forward motility in non-capacitated
sperm, and hyperactivated motility, acrosome reaction and sperm-ZP binding in capacitated sperm.
However, targeting each individual event may be a complicated task, especially at the step of sperm-ZP
binding in which numerous sperm surface molecules are engaged. Hypothetically, inhibiting sperm
capacitation would result in inability of sperm to fertilize eggs. However, there are several challenges
towards this approach. First, compounds used to inhibit sperm capacitation should be specific to
only this sperm event, so as to minimize unrelated side effects. Second, sperm swim out from the
seminal plasma in the vagina through the cervix and into the uterine cavity to undergo capacitation at
different rates. Therefore, it is important that the tested compounds administered in the vagina can
travel through the cervix into the upper part of the uterine cavity.
2.2. Unsuccessful Attempts to Develop the Spermicide, Nonoxynol-9, as a Microbicide
Since the search for spermicides started over 50 years ago before the significant unfolding of the
molecular mechanisms on how sperm gain fertilizing ability, a simple Sander-Cramer assay based on
sperm immotility was implemented at the time for spermicide screening. Compounds are considered
as spermicides if they can completely inhibit motility of sperm in the diluted semen suspension within
20 s. However, these criteria are unlikely to represent the physiological events occurring during
conception. First, motile sperm swim out from the liquefied semen in the vagina to enter the cervix
and then the uterine cavity, while most of the seminal plasma is left in the vagina along with sperm
that have much less progressive motility. Given this scenario, a spermicide needs to target those
motile sperm with only residual amounts of the seminal plasma. In contrast, in the Sander-Cramer
assay, semen is diluted three to four-fold with medium, leaving 20%–25% of seminal plasma in the
sperm suspension. The seminal plasma contains high amounts of amyloid peptide complexes, which
surround sperm in the ejaculate [21]. In general, this makes it hard for compounds added exogenously
to reach the surface of sperm in the seminal plasma. As such, only compounds that have the strength
to immediately disaggregate the amyloid complexes, such as harsh surfactants, can accomplish the
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task. Thus, the major compound identified by the Sander-Cramer assay for its spermicidal effects
is nonoxynol-9 (N-9), which is a non-ionic detergent with a very similar structure to Triton X-100
(Figure 1). At 0.0075% to 0.012%, N-9 can irreversibly immobilize human sperm in a saline/medium
diluted semen suspension (3-4 fold dilution) within 20 s [22–24], and therefore it has been used for
more than 50 years as a spermicide in condom coating and in various vaginal contraceptive devices
(i.e., foams, suppositories, creams, gels and films). As a detergent, it is not surprising that N-9 exerts
microbicidal effects in vitro against various types of STI-induced microbes as well as HIV [25–29]. N-9
formulated foam was further shown to prevent rhesus macaques from SIV and SHIV infection, albeit
in a very small cohort of monkeys (<10) [30,31]. Nonetheless, these results paved the way to clinical
trials on the anti-STI activity of N-9 in women. However, a systematic review using meta-analyses of
10 respectable clinical trials, including 5909 participating women, failed to demonstrate significant
protective effects of N-9 against a wide range of STI-induced microbes including Neisseria gonorrhoeae,
Chlamydia trachomatis, HIV, Candida albicans and Trichomonas vaginalis [32]. In fact, in one clinical trial,
the HIV infection rate was shown to increase twofold in women using N-9 gel, compared with those
without any application [33] and in another clinical trial, the gonorrhoea infection rate was shown to
be higher in N-9 vaginal gel users [34]. These increased rates of STI are likely due to the “detergent”
action of N-9 on cervicovaginal surface membranes. In most of the clinical trials, vaginal toxicity
including irritation, ulcerations, histological inflammation as well as vulvitis was observed in women
who were vaginally exposed to N-9 in various forms (e.g., N-9 formulated gels, films, sponges and
suppositories, and N-9 coated condoms) [35–40]. Vaginal epithelial disruption was in fact observed by
colposcopy in women frequently using N-9 vaginal suppositories [41]. Similar results were observed
in mice intravaginally inoculated with N-9 [42]. These cervicovaginal epithelial disruptions likely
facilitate the entry of HIV and possibly also other microbes through the genital mucosa. In addition,
specific cytokines are produced in N-9 using women with cervicovaginal inflammation, resulting in
recruitment of immune cells, which are typical HIV host cells, to the vaginal lumen. Essentially, this
enhances HIV replication [43]. Currently, N-9 is not promoted for its use as a microbicide and most
established pharmaceutical companies have stopped coating condoms with N-9. However, all vaginal
products, such as foam and cream, which contain N-9 (can be up to 28%), are still available over the
counter for contraceptive use, although the products contain a warning message against their use in
women who are prone to HIV and other microbe exposure. Scientifically, it is hard to understand why
N-9, a detergent, was even developed as a spermicide with a false hope that its disruption effect would
be specific to sperm membranes, and not cervicovaginal epithelial cell membranes. Nonetheless, the
adverse outcomes of the attempts to develop N-9 as vaginal microbicides provide a valuable lesson
to the scientific/medical community. Namely, the integrity of the female reproductive tract must be
considered for all future microbicide/spermicide development.
 
Figure 1. Similarity of the chemical structure of nonoxynol-9 and Triton X-100.
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3. Antimicrobial Peptides as Spermicides
An alternative approach to search for compounds with both spermicidal and microbicidal
actions can be taken by screening for spermicidal properties of known microbicidal agents. However,
conventional antibiotics must be excluded in this pursuit due to the growing antibiotic resistance [44,45].
In this regard, antimicrobial peptides (AMPs) have been appropriately considered, as they are
small peptides (<10 kDa) produced by all domains of life as part of innate immunity. In humans
and eutherian mammals, AMPs are produced by neutrophils and other immune cells as well as
epithelial cells of various tissues especially those that are connected or exposed to an external
environment (e.g., genitourinary tract, lung, skin) [46,47]. As natural compounds, resistance against the
microbicidal activities of AMPs is less anticipated and AMPs are considered to be the next generation
of anti-infectives [45]. The broad spectrum activity against Gram positive and Gram negative bacteria,
fungi, viruses and certain protozoa is another attractive property of AMPs [46–48]. In addition to the
direct microbicidal properties, AMPs can abrogate the action of lipopolysaccharides (LPS), a pathogen
associated molecular pattern (PAMP) from Gram negative bacteria [47], through their affinity for
LPS [49–51]. Therefore, the binding of LPS to the host cell surface Toll-like receptor 4 and subsequent
cell signalling events that lead to inflammatory responses cannot occur [52]. AMPs can also act as
immune modulators with various positive consequences to the target cells (reviews [53–55]). For this
reason, AMPs are also referred to as host defence peptides [46,55]. Immunomodulatory effects of
AMPs, which are relevant to the health of the lower female genital tract tissues include wound repair,
angiogenesis and cell proliferation [46,48,52,56–59], as these processes would be beneficial to the
vaginal mucosa after intercourse that often induces abrasion to the mucosal surface.
Most of AMPs are cationic and amphipathic peptides. To date, over 2500 natural AMPs
with diverse sequence, structure and property have been archived in the APD3 database
(http://aps.unmc.edu/AP/ [60]). Based on the types of secondary structures, AMPs are categorized
into four classes (α, β, αβ, and non-αβ) [61]. Because less than 12% of the AMPs in the APD3 database
have a 3D structure, covalent bonding patterns of polypeptide chains are also used to categorize AMPs
into four classes: linear (UCLL, with no covalent bonds between different amino acids in the polypeptide
chain, e.g., human cathelicidin LL-37 and frog magainins), side-chain linked (UCSS, covalent bonds
between different amino acid side chains, e.g., disulfide bonded defensins and lanthionine ether bonded
lantibiotics), sidechain-backbone linked (UCSB, such as those present in bacterial lasso peptides), and
backbone-backbone connected circular peptides (UCBB, such as those present in plant cyclotides) [62].
In addition, specific properties have been used to define AMP families. For example, cathelicidins
are AMPs, where their precursors contain a conserved cathelin domain in the N-terminal region [46].
Examples include LL-37 in humans, CRAMP in mice, indolicidin in cows. Another family of AMPs
containing disulfide bonds is called “defensins”, which are sub-classified to the α, β and θ groups. The
α- and β-defensins are differentiated from each other based on the positions of the disulfide bonds (α
having CI–CVI, CII–CIV and CIII–CV, whereas β having CI–CV, CII–CIV and CIII–CVI). So are θ-defensins,
which possess three different disulfide bonds (CI–CVI, CII–CV and CIII–CIV). Interestingly, most of
defensins with known 3-D structure (α: HNP-1, HNP-2, HNP-3, HNP-4, HD-5 and HD-6; β: hBD-3; θ:
RTD-1) have β-sheet secondary structure, while hBD-1 (human β-defensin-1) contains both α-helix
and β-sheet structures. In addition, “bacteriocins” is used to define AMPs produced by bacteria.
Notably, a number of bacteriocins contain intramolecular lanthionine or methyl lanthionine ethers
(formed through thioether linkages between serine/threonine and cysteine); such bacteriocins are
referred to as lantibiotics and lantipeptides depending on whether they have antibacterial activity [63].
In addition, some bacteriocins such as gramicidin A contain D-amino acids [64]. Both lanthionines
and D-amino acids contribute to the 3-D structure of bacteriocins [65]. It is notable that a number of
bacteriocins differ substantially from cationic cathelicidins and defensins. For example, gramicidin A
has a net charge of zero and consists of essentially all hydrophobic amino acids, allowing it to insert
into bacterial membranes as an ion channel. In addition to structural categorization, APD3 classifies
AMPs according to their functions (e.g., antimicrobial (as expected), anti-HIV, antimalarial, wound
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healing). Relevant to this review is the spermicidal activity of certain AMPs, at least in vitro. These
AMPs are referred to as spermicidal AMPs.
Being positively charged, AMPs first bind to anionic molecular components of the cell wall of
Gram positive bacteria (i.e., lipoteichoic acid) and outer membrane of Gram negative bacteria (i.e.,
LPS) [66]. This initial binding results in destabilization of these outer surfaces, thus allowing AMPs to
reach and bind to anionic molecules of the bacterial cell membrane (i.e., phosphatidylglycerol (PG)
and cardiolipin (CL)). Initially, AMPs may lie horizontally through their affinity for PG and CL on the
bacterial cell membrane. Since AMPs are amphiphathic, clusters of their hydrophobic amino acids
would then interact with the hydrocarbon chains of lipids in the membrane bilayers. This may result
in the vertical insertion of AMP peptides into the lipid bilayer. AMPs adjacent to each other also tend
to polymerize through the interaction of their hydrophobic domains. Alternatively, these peptides may
intersperse in the membranes by preferentially interacting with anionic lipids. All of these could lead
to pore formation in the bacterial cell membrane and the eventual loss of cellular homeostasis, and
finally death [46,48,67]. In addition, some AMPs can inhibit bacterial cell wall synthesis [67], while
others can enter the bacteria to bind to their ribosomes, resulting in inhibition of protein translation [60].
The fungicidal, virucidal and protozoacidal mechanisms, however, are less understood [48].
The desire to use AMPs as spermicides has been in place for decades, although in the early phase
of work, the selective action of AMPs on sperm and not on epithelial cells of the vagina (the most
logical site for their administration) may not have been well considered. Mammalian sperm are known
to have a negatively charged surface [68,69] in the head region. This is due to the specific presence of
SGG in the outer leaflet of the plasma membrane. The level of SGG is at 10 mole% of total sperm lipids
with the main molecular species having C16:0 in both its sn-1 alkyl chain and sn-2 acyl chain [70,71]
(Figure 2). SGG is a structural analog of sulfogalactosylceramide (SGC, aka sulfatide) (Figure 2), which
is known to be an integral component of membrane lipid rafts. Likewise, SGG is a major lipid in sperm
lipid rafts; it exists together with its lipid binding partner, cholesterol [72,73]. Our lab has shown
that lipid rafts in capacitated sperm, housing a number of ZP binding proteins [19,20,74], are surface
platforms on sperm for the ZP binding [72]. SGG itself also has a direct affinity for the ZP, contributing
to the ZP binding ability of sperm lipid rafts [15,16]. It is expected that positively charged molecules,
including AMPs, would interact electrostatically with SGG on the sperm head surface and thus reduce
the sperm-ZP binding process. In addition to SGG, polysialyated glycoproteins found in the sperm
plasma membrane endow negative charges to the sperm surface [75,76].
Figure 2. Chemical structure of sulfogalactosylglycerolipid (SGG) and sulfogalactosylceramide (SGC).
Table 2 lists all spermicidal AMPs described in the literature and the antimicrobial peptide
database (http://aps.unmc.edu/AP/ [60]), with their sequences and relevant biochemical properties
described in Table 3.
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In addition to these 12 AMPs, cecropin D2A21 was mentioned but without any data on its
spermicidal effects in the publication describing its chlamydiacidal property [111]. Seven of these
AMPs are produced in humans and animals, i.e., LL-37-humans; maximin 1, maximin 3, magainin 2,
dermaseptin S1 and dermaseptin S4-lower vertebrate animals (frogs and toads); and sarcotoxin
Pd-invertebrates (insects). The other five AMPs (nisin A, pediocin CP2, gramicidin A, subtilosin A and
lacticin 3147) are bacteriocins produced by various bacteria species. Interestingly, gramicidin A has
been used for decades in humans in Russia [105], although the scientific and medical details of this
use are not available in the literature. Except for our work on LL-37, the screening for the spermicidal
action of AMPs listed in Table 1 was based primarily on their ability to immobilize sperm in the
suspension that still contained 20%–25% of seminal plasma within 20 s of treatment (Sander-Cramer
test). As discussed above, this approach is likely an “overkill”, since motile sperm swim out of
the seminal plasma and carry only residual amounts of seminal plasma into the cervix and uterine
cavity. Rather “swim-up” sperm and “Percoll-gradient centrifuged”, prepared in a laboratory, would
be more representative of motile sperm that swim through the cervix into the uterine cavity [23].
Swim-up sperm are simply prepared by overlaying semen placed in a tube with appropriate medium.
Swim-up sperm are motile sperm that have swum up into the medium layer that still carry a small
amount of seminal plasma [112]. Percoll-gradient centrifuged sperm are prepared by loading semen
onto a discontinuous gradient of Percoll solutions (usually 45% and 90%) followed by centrifugation
at ~600 g. Motile sperm have “clean” morphology (devoid of membranous vesicles and having
compact chromatin) with a higher specific density than immotile/morphologically abnormal sperm,
and therefore they sediment as a pellet, which can then be resuspended in a medium for experimental
use. Percoll-gradient centrifuged sperm have the highest fertilizing ability [113] and therefore they
should be used for the screening of a candidate spermicide. However, an assay for human sperm
motility that is more physiologically representative is to observe the rate of sperm to swim through
cervical mucus collected from women in the middle of their menstrual cycle (ovulation time) and
placed in a capillary tube [7,114]. The cervical mucus fluid is viscoelastic due to the abundance
of proteo-glycosaminoglycans. Sperm must have sufficient motility force as well as biochemical
components to digest the proteo-glycosaminoglycan networks in order to swim through the cervical
mucus column, a situation that does not exist in sperm resuspended in medium [11,115]. This
sperm-cervical mucus assay was performed with gramicidin A treated human sperm. This assay,
however, is impractical to be used for screening of spermicide compounds due to the restriction in
obtaining sufficient quantities of mid-menstrual cycle cervical mucus from women.
Among all spermicidal AMPs listed in Table 2, LL-37, magainin 2 and nisin A are the only AMPs
with confirmed in vivo contraceptive effects in experimental animals. The outcome of zero pregnancies
is considered the gold standard indicator of contraceptive effects of these AMPs. Our group performed
this in vivo work on LL-37 in mice [79], whereas Reddy & Aranha’s group examined the effects of
nisin A in rats and rabbits [98,99], and magainin 2 in rabbits and monkeys [82,84]. Experimentation
in animal models is essential in the screening of vaginal spermicides and/or microbicides, since it
is a means not only to confirm the spermicidal/microbicidal effects in vivo but also to determine
whether there are any adverse effects of the compounds on the female reproductive tract. Selection
of appropriate animals for these in vivo studies is also critical for the next clinical trials in humans.
Monkeys are animals with reproductive physiology closest to the human system. However, one
may only use a restricted number of monkeys for each trial. In addition, it is important to preserve
the female monkey lives after the experiment. Therefore, the examination of any adverse effects on
the reproductive system in female monkeys can only be done in an indirect manner (e.g., assessing
types and quality of cells from vaginal smears). Such is the case for the study on in vivo spermicidal
effects of magainin 2 in monkeys [82]. In contrast, histology of the female reproductive tract can be
evaluated directly in smaller animals including rabbits, rats and mice following their sacrifice and
tissue removal for fixing and processing. Histology images should be explicitly shown such as those
described in the studies for LL-37 in mice [79] and nisin A in rabbits [100]. However, interpretation
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of results from spermicidal and microbicidal studies in female rabbits, rats and mice must be made
with caution that the reproductive systems in these animals differ from that of humans in a number
of aspects. While insemination in rabbits occurs in the vagina like the situation in humans, rabbit
females do not have a reproductive cycle (estrus or menstrual cycle) with peaked estrogen, which
enriches the vaginal/cervical secretion and microflora [116]. Therefore, rabbit vaginal microflora
are rather simple and in fact contain only residual amounts of lactobacilli [116], which are found
abundantly in the human vagina and responsible for acidifying the vaginal luminal milieu due to
lactate production [117]. The pH in the rabbit vagina is in the neutral range [118] in contrast to the
pH 4 in the human vagina [119,120]. With no defined reproductive cycle, ovulation in rabbits is
not hormonally regulated but rather induced by coitus [121], a process so markedly different from
human ovulation. The reproductive processes in rats and mice, as well, differ from those in humans in
a number of aspects despite the fact that rodents do have a reproductive estrus cycle. Although rodent
semen is first deposited in the vagina, sperm together with seminal plasma are swept into the uterus
within minutes [11]. In addition, the mouse vaginal pH is at ~6.5, more basic than that of the human
vagina. This is due to lower numbers of lactobacilli colonies in the rodent vagina [122]. Regardless,
rodents are less expensive to purchase and maintain and the in vitro fertilization procedures in rodents
are well described, allowing the assessment of candidate spermicides for their direct inhibitory effects
on fertilization in vitro. While it is logical that various animal models should be used to validate
spermicidal and microbicidal effects of the candidate compounds, human vaginal and cervical cell
lines as well as reconstructed human vagina models should also be employed in the spermicide and
microbicide ex vivo studies. The former include immortalized cell lines derived from human vaginal
epithelia (Vk2/E6E7), human ectocervical epithelia (Ect1/E6E7) and human endocervical epithelia
(End1/E6E7), all established by Deborah Anderson, Brighams and Women’s Hospital, Inc. [123],
and available from ATCC. For the latter, MatTek Inc. has produced various types of organotypic
vaginal-ectocervical tissue models through reconstruction of human vagina and cervix tissues [124].
Vk2/E6E7, Ect1/E6E7 and End1/E6E7 cell lines have been widely used for the studies of candidate
microbicides [125–127]. Likewise, MatTek human vaginal-ectocervical tissue models have recently
been used for studies on the properties of potential vaginal anti-HIV agents [128–130]. To date,
there are no publications on the use of immortalized Vk2/E6E7, Ect1/E6E7 and End1/E6E7 cells
for studies of spermicidal AMPs. MatTek organotypic vaginal-ectocervical tissue models were used
only in subtilosin A study (Table 2). On the other hand, HeLa cell lines (derived from cervical cancer
cells obtained from Henrietta Black over 60 years ago [131]) were used for evaluating cytotoxicity of
dermaseptin S4, sarcotoxin Pd and nisin A (see Table 2). However, HeLa cells are highly transformed
and may not have the expected properties of human cervical epithelial cells [131].
As discussed above, the acidic pH in the healthy human vagina is attributed to the presence of
commensal lactobacilli. The vaginal acidity is essential in inhibition of unwanted proliferation as
well as infection of pathogenic microbes such as Gardnerella vaginalis, Prevotella bivia and HIV [132].
Depletion of lactobacilli in the vagina leads to bacterial vaginosis. In this regard, caution must be
taken in the selection of AMPs with no microbicidal effects on lactobacilli for further development
into vaginal microbicides. This is the case for nisin A, which has been used as a food preservative
for human consumption and shown to be an effective contraceptive in rabbits and monkeys ([98,99],
Table 2). However, nisin A is not a good candidate to be developed into a vaginal microbicide, since it
exerts microbicidal activity on vaginal Lactobacillus spp [132,133].
While the microbicidal effects of AMPs in general are of a broad spectrum, it is most desirable
to search for spermicidal AMPs that also have anti-HIV properties. Among spermicidal AMPs listed
in Table 2, LL-37 [134–136], maximin 1 [80], maximin 3 [80], dermaseptin S1, dermaseptin S4 [137]
and gramicidin A [105] have been shown to possess anti-HIV properties. Therefore, they should be
considered for further research studies and development into vaginal contraceptives/microbicides.
Most of these HIV infection studies were performed using HIV lab strains in CD4+ T cells, T-cell
leukemia cell lines or T4 lymphoblastoid cell lines, and in some cases monocyte derived dendritic cells.
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In order to validate the physiological significance of the anti-HIV properties of these AMPs, work
should be comprehensively repeated using dual tropic clinical isolates of HIV at sufficiently high titers.
In addition, the inhibitory effects of the candidate AMPs on HIV infection in the human cervicovaginal
epithelium should be directly assessed using MatTek human vaginal-ectocervical tissue models. On the
other hand, since gramicidin A has been used as a spermicide in Russia [105], a population study
should be carried out to determine whether women who have been using gramicidin A vaginally and
are more prone to exposure to HIV have a lower rate of HIV infection.
The 3D structures of a number of spermicidal AMPs or their close homologs have been determined
by NMR spectroscopy. These include human LL-37 [77], frog maximin 4 (homolog of maximin 1) [81],
magainin 2 [83], dermaseptin S4 [91], bacterial nisin A [138], gramicidin A [64], subtilosin A [108] and
lacticin 3147 (chain A1 and A2) [110].
Figure 3A shows the 3D structures of these AMPs. Interestingly, LL-37, maximin 4, magainin 2,
dermaseptin S4 and lacticin 3147 chain A2 contain an alpha helical structure in a significant length of
their sequences. A short helix also exists in subtilosin A and nisin A (Figure 3A). However, lacticin
3147 chain A1 (which has a minimal spermicidal activity) does not have an alpha helical structure [110]
and is therefore not displayed in Figure 3A. On the other hand, gramicidin A has a β-helical structure
(Figure 3A). The helical wheel projections of LL-37 (both the whole peptide and the sequence from
amino acids 10-37), maximin 1, maximin 3, maximin 4, magainin 2, dermaseptin S1 and dermaseptin
S4 (all from humans and animals) reveal an amphipathic feature of the helix, with hydrophobic amino
acids enriched in approximately one half of the top view helical circle and hydrophilic amino acids in
the other half (Figure 3B). Such an amphipathic feature can also be seen in Figure 3A, especially for
LL-37, magainin 2, and dermaseptin S4 peptide analog. It is remarkable that both LL-37 and magainin
2 possess 3-4 aromatic phenylalanines on the hydrophobic surfaces. NMR studies have demonstrated
that the four phenylalanines all interact with acyl chains of anionic PGs [77]. This amphipathic helical
structure of AMPs may be required for spermicidal activity. If this is proven, this requirement would
be analogous to that needed for AMPs for full exertion of microbicidal activity [135,139,140].
Bacteriocins utilize specific features to maintain their 3D structure. Lacticin chain A1 does not
have any helical structure but its 3D confined structure is attributed to the existence of both D-amino
acids and lanthionine ethers in its sequence [110]. These two structural components also exist in
lacticin 3147 chain A2 with an apparent alpha helical structure [110]. Nisin A and subtilosin A also
contain lanthionine ethers [46,141], which contribute to their 3D structure (Table 3). On the other
hand, gramicidin A does not contain any lanthionines but it possesses five D-amino acids in its
15-mer sequence (Table 3). This unique feature endows gramicidin A a β-helical structure, which is
further stabilized by dimerization, and this allows gramicidin A dimer to form a cation channel in
lipid bilayers [64]. The channel and pore formation in the membranes by gramicidin A and other
spermicidal bacteriocins like subtilosin A and lacticin 3147 chain A1 is unlikely to be initiated with
the electrostatic binding between these AMPs and the negatively charged surface molecules of the
microbes, since these AMPs have a net charge of zero or even minus values (Table 3). A close look
at the helical regions in these bacteriocins (Figure 3E, G, and H) reveals a lack of amphipathic nature
observed with human LL-37, magainin 2 and dermaseptin S4 (Figure 3A,B).
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Figure 3. Structures of selected antimicrobial peptides with spermicidal activity annotated in the
APD3 [142]. (A) 3D structures shown as ribbon diagrams of (a) human LL-37 (PDB ID: 2K6O);
(b) frog maximin 4 (PDB ID: 2MHW); (c) magainin 2 (PDB ID: 1MAG); (d) a close analog of truncated
dermaseptin S4 (amino acids 1-13; PDB ID: 2DD6); (e) bacterial nisin A complexed with lipid II (PDB
ID: 1WCO); (f) gramicidin A (PDB ID: 1MAG); (g) subtilosin A (PDB ID: 1PXQ); and (h) lacticin 3147
(structural co-ordinates were provided by Dr. John Vedaras, University of Alberta, according to his
published work [110]). Except for gramicidin A, the N-terminus of the peptide is positioned at the top.
In the case of gramicidin A (f), its dimer is shown. The two N-termini of each dimer are positioned
next to each other in the middle, whereas the C-termini are exposed and their four tryptophans
approximate the lipid head group regions of the lipid bilayers for membrane positioning and ion
channel conductance (f). Note that the C and N-termini of subtilosin A approximate in the structure (g).
The side chains of human LL-37, magainin 2, and the dermaseptin S4 analog are selectively labeled
to illustrate the amphipathic nature of these AMPs. Images were generated using MOLMOL [143].
(B) Helical wheel projections of selected spermicidal AMPs expressed in eukaryotes: LL-37, maximin
1, maximin 3, maximin 4, magainin 2, truncated dermaseptin S1 and dermaseptin S4. All of these
AMPs show an amphipathic structure, with hydrophobic amino acids (blue circles) organized in
approximately one half of the wheel and the hydrophilic residues in the other half. For LL-37, the wheel
projections are shown for both the whole LL-37 sequence (amino acids 1–37) and the sequence from
amino acids 10–37. This is because the helical structure of the whole LL-37 sequence has a kink at Ser9.
The LL-37 peptide (amino acids 10-37) actually shows a better distribution of hydrophobic amino acids
in one half of the helical wheel. Although maximin 4 has not been shown for the direct microbicidal
effects, as demonstrated for maximin 1 and maximin 3, its helical wheel projection is shown herein
to corroborate its 3D structure shown in (A) and also for a comparison with the wheel projections of
maximin 1 and maximin 3. The wheel projections of truncated dermaseptin S1 and dermaseptin S4 are
both for their truncated sequence (amino acids 1-13). Again, this is to corroborate the 3D structure of
the close analog of the truncated dermaseptin S4 peptide shown in (A).
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4. LL-37, the Most Promising Spermicidal AMP
Cationic antimicrobial peptide LL-37 is coded by the only human cathelicidin gene [46,47,144].
LL-37 or its very close homologs are also present in non-human primates. Chimpanzees possess
LL-37 identical to the human sequence, whereas in Gorillas and orangutans, two and three spots
in the human LL-37 sequence are replaced by other amino acids [145]. The name “LL-37” denotes
a peptide that contains 37 amino acids with the Leu-Leu sequence at the N-terminus. LL-37 is
produced as a propeptide, hCAP-18, by neutrophils [50,146], other immune cells [147,148], normal and
inflammatory skin cells [149–151], and epithelial cells of various tissues, especially those that connect
with the external (male reproductive tract [152,153], urinary tract [154,155], gastrointestinal tract [156],
lung [157,158], gingiva [159], eye [160], nasal cavity [161,162]) (for reviews see [149,163,164]). Of
significance to this review is the expression of hCAP-18 by the human epididymal epithelial cells
followed by its secretion into the epididymal lumen. This makes hCAP-18 a component of seminal
plasma with a physiological concentration range of 2 to 10 μM [152,153,165]. hCAP-18 (MW:16442)
is expressed by neutrophils and released during degranulation together with proteinase 3, which
immediately processes hCAP-18 at physiological pH into LL-37 (MW:4493) with full microbicidal
activity [166]. In skin, LL-37 is generated from hCAP-18 through the proteolytic activity of kallikrein 5
also at the neutral pH. Both kallikrein 5 and kallikrein 7 (also present in the skin surface) then further
cleave LL-37 into smaller fragments (i.e., RK-31, KS-30, KS-22, KR-20, LL-29), which have higher
antimicrobial activity than LL-37 [151]. However, the processing of hCAP-18 is more complicated.
It does not occur in the male reproductive tract or in the ejaculate. Sorensen et al. [153] identified
gastricsin, secreted from the prostate gland and thus also a component of seminal plasma, to be
the enzyme responsible for processing hCAP-18 in seminal plasma into ALL-38 (LL-37 + Ala at the
N-terminus) at a pH optimum of approximately 4. Therefore, gastricsin cannot function in seminal
plasma, which has a high buffering capacity at neutral pH. Following ejaculation in the vagina, seminal
plasma changes the normally acidic pH of the vagina (pH 4) into the neutral range. It takes 2-6 h
post-ejaculation for the vaginal lumen to resume its acidic pH and it is only at this time that gastricsin
becomes active to process hCAP-18 into ALL-38, with microbicidal activity [153].
However, immediately after semen liquefaction, typically 30 min post-ejaculation, sperm
instantaneously swim out from seminal plasma through the cervix into the uterine cavity. Only
feeble sperm are left behind together with seminal plasma in the vagina. Therefore, motile sperm with
fertilizing ability are never exposed to ALL-38, which is generated long after their movement from
the vagina (Figure 4). It is likely that the production of ALL-38 is meant for protection of the vaginal
epithelium against microbes introduced during intercourse [167]. As a very close analog of LL-37,
ALL-38 should possess all properties described for LL-37. For example, they have identical antibacterial
activity against all the organisms tested [153]. LL-37 has been shown for its direct microbicidal effects
against numerous Gram negative and Gram positive bacteria, yeast and viruses (including HIV)
(Table 4), but not on lactobacilli [168–170], which are essential for maintaining acidic pH and thus
health of the vagina (see Section 3).
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Figure 4. ALL-38 is processed from hCAP-18 post-ejaculation. (A) Processing of hCAP-18 to ALL-38
by gastricsin occurs at the optimum pH of 4. Although both hCAP-18 and gastricsin are seminal
plasma components, this processing does not occur in the seminal plasma due to its high buffering
capacity at neutral pH. (B) Immunoblotting showing that processing of hCAP-18 to ALL-38 can occur
in acidified seminal plasma. Anti-LL-37 antibody used in immunoblotting was produced against the
whole LL-37 sequence [79] and therefore, it recognized only ALL-38 and hCAP-18, but not cathelin.
Before acid treatment (BA), seminal plasma contains hCAP-18 and its oligomers (Oligo; ~60 kDa), as
well as a 14 kDa band (presumably a cleaved product of hCAP-18). Upon acidification of seminal
plasma with HCl to pH 4, hCAP-18 is processed to ALL-38; this is due to the activation of gastricsin.
AA = after acid extraction. (C) ALL-38 is produced 2–6 h post-ejaculation. Upon ejaculation, seminal
plasma neutralizes the vaginal pH, and it takes 2–6 h post-ejaculation for the vagina lumen to resume
its acidity. Only at this time, ALL-38 is produced from hCAP-18 via gastricsin activity. However,
immediately after semen liquefaction (30 min post-coitus), motile sperm in the ejaculate swim into
the uterine cavity. Therefore, motile sperm are never exposed to ALL-38. The drawing is based on
Sørensen et al. [153].
260
Pharmaceuticals 2016, 9, 13






Adenovirus (Ad) V Gordon et al. [160]: 111 μM
Acinetobacter baumannii B´ Moffatt et al. [171]: 1.1 μMGarcia-Quintanilla et al. [172]: 0.67 μM
Actinobacillus B´ Ouhara et al. [173]: ~0.26–0.52 μM
Actinobacillus
actinomycetemcomitans B´ Tanaka et al. [174]: ~2.2–2.7
Actinobacillus
actinomycetemcomitans B´ Ouhara et al. [173]: 2.2 μM
Bacillus anthracis B´ Thwaite et al. [175]: 22 μM
Borrelia burgdorferi Not applicable 3 Lusitani et al. [176]: 8.8 μM
Borrelia spp Not applicable 3 Sambri et al. [169]: 100 μM
Burkholderia pseudomallei B´ Kanthawong et al. [177]: 100 μM
Burkholderia thailandensis B´ Kanthawong et al. [178]: 100 μM
Candida albicans Y Tsai et al. [179,180]: 8.9 μM
Capnocytophaga gingivalis B´ Tanaka et al. [174]: 2.0 μM
Capnocytophaga ochracea B´ Tanaka et al. [174]: 2.4 μM
Chlamydia trachomatis B´ Tang et al. [181]: 20 μM
Clostridium difficile B+ McQuade et al. [182]: 10.7 μM
Enterococcus faecalis B+ Leszczynska et al. [183]: 12.5 μM
Escherichia coli B´
Benincasa et al. [184]: 5 μM
Smeianov et al. [168]: 25 μM
Leszczynska et al. [185]: 5.6 μM
Chen et al. [186]: 0.07 μM
Kai-Larsen et al. [187]: 20 μM
Nagaoka et al. [188]: ~1-2 μM
Fusobacterium nucleatum B´ Ouhara et al. [173]: 0.22 μMLeszczynska et al. [183]: 49.8 μM
Haemophilus influenzae B´ Leszczynska et al. [183]: 12.5 μMLysenko et al. [189]: 2.2 μM
Helicobacter pylori B´ Leszczynska et al. [183]: 6.2 μMLeszczynska et al. [185]: 2.2 μM
Herpes simplex virus type 1 V Gordon et al. [160]: 111 μM
HIV-1 V
Wang et al. [135]: 1.6 μM
Bergman et al. [134]: 11.1 μM
Influenza A virus (IAV) V
Tripathi et al. [190]: 13 μM
Barlow et al. [191]: 11.1 μM
Tripathi et al. [192]: 6.7 μM
Klebsiella pneumoniae B´ De Majumdar et al. [193]: >11.1 μM
Moraxella catarrhalis B´ Leszczynska et al. [183]: 6.2 μM
Neisseria gonorrhoeae B´ Bergman et al. [194]: 0.8 μM
Neisseria meningitidis B´
Leszczynska et al. [183]: 12.5 μM for strain B
Leszczynska et al. [183]: 24.9 μM for strain C
Jones et al. [195]: 10 μM
Peptostreptococcus anaerobius B+ Leszczynska et al. [183]: 49.8 μM
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Porphyromonas gingivalis B´ Leszczynska et al. [183]: 49.8 μMOuhara et al. [173]: 11.1 μM
Prevotella intermedia B´ Ouhara et al. [173]: 1.1 μM
Pseudomonas aeruginosa B´
Bergsson et al. [196]: 5.6 μM
Dean et al. [197]: 0.22 μM
Dosler and Karaaslan [198]: ~14.2–28.4 μM
Gordon et al. [160]: ~11.1–22.2 μM
Leszczynska et al. [183]: 99.7 μM
Respiratory syncytial virus V Currie et al. [199]: 5.6 μM
Staphylococcus aureus B+
Leszczynska et al. [183]: 6.2 μM
Noore et al. [200]: 2 μM
Chen et al. [186]: 0.67 μM
Senyurek et al. [201]: 11.1 μM
Nagaoka et al. [188]: 1 μM
Gordon et al. [160]: ~11.1–22.2 μM
Staphylococcus epidermidis B+
Leszczynska et al. [183]: 12.5 μM
Gordon et al. [160]: ~11.1–22.2 μM
Streptococcus mitis B+ Ouhara et al. [173]: 2.2 μM
Streptococcus mutans B+
Ouhara et al. [173]: 0.22 μM
Leszczynska et al. [183]: 6.2 μM
Streptococcus pneumoniae B+
Nagaoka et al. [188]: 1 μM
Leszczynska et al. [183]: 3.1 μM
Streptococcus pyogenes B+ Leszczynska et al. [183]: 3.1 μM
Streptococcus salivarius B+
Ouhara et al. [173]: 1.1 μM
Leszczynska et al. [183]: 6.2 μM
Streptococcus sanguis B+
Ouhara et al. [173]: 0.22 μM
Leszczynska et al. [183]: 6.2 μM
Streptococcus sobrinus B+ Ouhara et al. [173]: 1.1 μM
Tannerella forsythensis B+ Leszczynska et al. [183]: 49.8 μM
Treponema pallidum B- Sambri et al. [169]: 100.1 μM
Ureaplasma parvum NA 3 Xiao et al. [202]: 22.2 μM
Ureaplasma urealyticum NA 3 Xiao et al. [202]: 22.2 μM
Vaccinia virus V Howell et al. [203]: 20 μM
Varicella zoster virus (VZV) V Crack et al. [204]: 0.1 μM
1 Highlighted microbes: blue causing STI; green causing vaginitis; Red causing UTI; Pink causing vaginitis and
UTI. 2 Concentrations of LL-37 given are those that exert microbicidal effects on ě90% of the microbes. In some
cases where this information is not clearly described in the publication, estimated concentrations are given.
3 NA = not applicable; Borrelia spp. and Ureaplasma spp. do not react well with the Gram stain.
Besides the direct microbicidal activity, LL-37 possesses other properties including anti-endotoxin
activity [49–51], immunomodulation (reviews [53–55]), angiogenesis [59] and wound healing [56–58].
If the anti-endotoxin and immunomodulatory properties are confirmed in the female reproductive tract
system, it will strengthen the possibility that LL-37/ALL-38 can be used as vaginal microbicides that
can clear infection and minimize infection-associated inflammation. Angiogenesis and wound healing
properties would also aid in the repair of minor vaginal tissue damages occurring during intercourse.
Further studies on LL-37’s direct microbicidal effects must also be carried out in all microbes that
are causes of STIs and vaginitis, as well as urinary tract infection (UTI). The vagina and its normal
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microbiota represent an important barrier against uropathogenic bacteria (Table 1). Perturbations of the
normal vaginal microbiota, such as depletion of lactobacilli, can promote colonization of uropathogens,
such as uropathogenic E. coli (UPEC), within the vagina [205]. The vagina can then become an
extra-urinary uropathogen reservoir and in turn increase the risk of UTI [206].LL-37 exerts microbicidal
effects on most of the STI-inducing microorganisms including HIV (causing life threatening AIDS
with no cure), HSV-1 (causing genital herpes with no cure), Neisseria gonorrhoeae (causing gonorrhoea,
curable), Treponema pallidum (causing syphilis, curable) and Chlamydia trachomatis (causing cervicitis,
salpingitis and endometriosis, curable) (Table 4). Although gonorrhoea, syphilis and chlamydia
infection are curable, a number of complications are associated with these three STIs. They all increase
the risk of infertility. A higher susceptibility to HIV transmission is also associated with gonorrhoea
and syphilis. Salpingitis and oviductal tubal blockade caused by chlamydia infection can also lead
to ovarian cancer. For gonorrhoea, resistance to antibiotics used for the treatment has increasingly
become a problem. As listed in Table 1, LL-37 needs to be tested for its microbicidal activity against
a number of additional microorganisms that cause STI (viruses:HPV, hepatitis A and C; protozoon,
Trichomonas vaginalis) and bacterial vaginosis (Gardnerella vaginalis, Bacteroides spp., Mycoplasma hominis
and Mobiluncus spp.), prior to its development as a vaginal microbicide. Further testing against
uropathogenic microorganisms (Table 1) will also allow LL-37 to be developed for therapeutic and
prophylactic uses for urinary tract infection in this system. LL-37 formulated gel administered into
the vagina would exert microbicidal action on uropathogenic microbes that opportunistically form
a reservoir in the vagina. The vaginal secretion, which can travel upwards into the urinary tract, would
also likely contain LL-37 released from the gel, which then can fight against microbes in this tract (see
the list in Table 4).
The majority of sperm co-existing with seminal plasma, which contains 2-10 μM of hCAP-18 [153],
remain motile in ejaculated semen of fertile donors. Interestingly, despite the negatively charged
surface of sperm and the overall positive charge of hCAP-18 (+6, pI = 9.25), hCAP-18 is present at
a residual amount on human sperm [79]. However, since motile sperm with fertilizing ability are never
exposed to ALL-38 produced from seminal plasma (Figure 4), it raises a possibility that ALL-38/LL-37
may have a deleterious effect on sperm, possibly after the deposition of ALL-38/LL-37 onto the sperm
surface. Although hCAP-18/LL-37 is also produced by cervicovaginal epithelial cells, its amount
is 1000x less than ALL-38 originated from seminal plasma (i.e., 1.3 nM [136] versus 2–10 μM [153],
respectively). Therefore, we asked the question of whether LL-37 when added exogenously to a sperm
suspension could bind to sperm with a deleterious consequence on their fertilizing ability. Also, if
sperm-LL-37 binding did occur, was it dependent on the interaction of LL-37 with a negatively–charged
SGG existing specifically on the mammalian sperm head surface? The latter question is relevant in
terms of possible development of LL-37 into a spermicide with specificity to sperm and not to other
somatic cells such as cervicovaginal epithelial cells. Our results revealed that LL-37 bound to SGG
and its anionic lipid analog, sulfogalactosylceramide (SGC), as well as phosphatidylserine (also
negatively charged), all immobilized separately in a well of a microtiter plate, in a specific manner.
Kd values of the binding of LL-37 to these three anionic lipids were 456, 157 and 24 nM, respectively.
In contrast, LL-37 did not bind to neutral lipids, phosphatidylcholine and galactosylglycerolipid
(GG—the desulfated form of SGG) [79]. Direct binding of LL-37 to Percoll-gradient centrifuged mouse
and human sperm resuspended in medium was further demonstrated. For the reason described
in Section 3, Percoll-gradient centrifuged sperm were first used in all studies, and in the case of
human sperm replicate experiments were performed with swim-up sperm. The partial dependence of
LL-37-sperm interaction on SGG on the sperm surface was then demonstrated by a decrease in LL-37
binding to sperm that were pre-incubated with anti-SGG antibody [79]. Pretreatment of capacitated
mouse sperm with 3.6 μM LL-37 resulted in a complete loss of sperm ability to fertilize eggs in vitro.
This 3.6 μM of LL-37 is equivalent to the concentration of SGG in the mouse sperm suspension used
for the treatment [71,79], further corroborating the concept that SGG was involved in LL-37 binding.
Notably, 100% of mouse sperm treated with 3.6 μM LL-37 became immotile within 5 min of treatment,
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and this result would be one of explanations for the inability of these LL-37 treated sperm to fertilize
eggs in vitro. Likewise, human sperm lost their motility when treated with LL-37, although 10.8 μM of
LL-37 was needed for the majority of sperm to become immotile. Furthermore, when non-capacitated
sperm and partially capacitated sperm, both human and mouse, were treated with the same LL-37
concentrations as used for fully capacitated sperm, the inhibition of their motility was similarly
observed [79]. Non-capacitated sperm, partially capacitated sperm and fully capacitated sperm were
prepared in the lab by resuspending sperm in the medium without bicarbonate, calcium and albumin,
with bicarbonate and calcium but no albumin, and with all of these three components, respectively. The
prepared non-capacitated sperm represent sperm that have just swum out from the seminal plasma
in vivo, whereas partially capacitated sperm resemble those that are swimming through the cervix.
Finally, the prepared capacitated sperm are equivalent to sperm that have swum into the uterine cavity
and their cholesterol is induced to release by albumin and HDL present in the uterus [8,207].
The loss of sperm motility upon LL-37 treatment can be from the direct interaction of LL-37 with
the axoneme, the motility apparatus, in the sperm tail [8]. However, this possibility is discounted by
the lack of binding of LL-37, added exogenously to the sperm suspension, to the sperm tail [79]. It is
also unlikely that the mechanism of the effects of LL-37 on sperm motility is through its direct effect on
CatSper, the cation channel responsible for sperm hyperactivated motility [12], since LL-37 also induces
immotility in non-capacitated sperm, which normally do not have hyperactivated motility patterns.
Rather, immotility of LL-37 treated sperm may come from the loss of intracellular homeostasis due to
the LL-37 induced damage on the sperm surface, a situation that is parallel to that observed on the
microbial membrane [46,67]. This postulation was confirmed by the observation that LL-37 treated
sperm became positively stained with Sytox Green (a membrane impermeable DNA fluorescent dye),
an indication that the surface membranes of these treated sperm were compromised. Pharmacokinetic
studies further indicated that the sperm plasma membrane damage induced by LL-37 occurred prior
to the loss of sperm motility. Finally, LL-37 treated sperm became acrosome-reacted, thus markedly
lowering their ability to bind to the egg. Transmission electron microscopy confirmed that the damages
on the sperm plasma membrane and the outer acrosomal membrane as well as the loss of the acrosome
and in some cases the inner acrosomal membrane were the adverse effects of LL-37 on sperm [79].
In contrast, our unpublished results reveal that LL-37 at the spermicidal concentration range did not
have any adverse effects to mouse eggs and embryos. Mouse eggs treated with 3.6 μM LL-37 were
normally fertilized by sperm collected from a fertile animal, and mouse two-cell embryos treated with
the same LL-37 concentration developed into blastocysts at the same rate as untreated two-cell embryos.
We have further demonstrated the loss of sperm fertilizing ability in vivo. Mouse sperm treated
with LL-37 were transcervically injected into female mice naturally cycling to the estrous phase in
the reproductive cycle. None of these female mice (n = 26) became pregnant, whereas pregnancy
was observed in 92% of female mice (n = 26) injected with untreated sperm. Significantly, the female
reproductive system of mice injected with LL-37 + sperm did not show any apparent changes, as
compared with that of control females (injected with medium + sperm) (Figure 5A). In females that
were exposed to LL-37, the histology of their vagina and uterus as well as the dimension, shape
and color of their reproductive tissues did not differ from those of control females (unexposed to
LL-37) (Figure 5A). There were no signs of immune cell recruitment (implicating inflammation) to the
vaginal/uterine tissues of these LL-37 exposed females (Figure 5B). This was in contrast to female mice
transcervically injected with 2% N-9, whereas numerous neutrophils were apparent in the vaginal
epithelium (Figure 5B). In fact, female mice transcervically injected with sperm + LL-37 for three estrus
cycles with no pregnancy outcomes could resume their fecundity as shown by pups delivered by
these females following their natural mating with fertile males two weeks after the last transcervical
injection with LL-37.
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Figure 5. (A) Left panel: Normal histology of the vagina and uterus of female mice transcervically
injected with LL-37 + sperm. The female reproductive tract tissues were collected for fixing and paraffin
embedding one day after the transcervical injection of LL-37 + sperm, or sperm alone (control). Sections
of the vagina and uterus revealed that the vaginal stratified epithelial cell layers and the uterine single
epithelial cell layer (denoted as the area between the two arrows) as well as the corresponding lamina
propria of the LL-37 treated and control animals did not differ from each other. Bar = 20 μm. This image
was taken from our published article [79]. Right panel: The anatomy (shape, dimension and color)
of the vagina/cervix and uterus, dissected from females injected with LL-37 (3.7or 5.4 μM) + sperm
(n = 3 each) or sperm alone (control) (n = 3) one day after the injection, was the same among the three
groups of the animals. (B) Absence of immune cell recruitment to the vaginal epithelium of mice
transcervically injected with LL-37 + sperm. Sections of the vagina were prepared as in (A). The vaginal
epithelium and lamina propria of both the control and LL-37 treated mice similarly show minimal
numbers of immune cells, indicating no recruitment of these cells to the vagina as a consequence of
LL-37 injection. In contrast, when females were transcervically injected with 2% nonoxynol-9 (N-9),
numerous neutrophils were recruited into the vaginal epithelium. The polymorphonuclear structure of
neutrophils is apparent in the close-up image (denoted by asterisks). Triangles point to the N-9 induced
rupture of the vaginal epithelial surface. Bar = 20 μm.
We have further confirmed that LL-37 had minimal adverse effects on the immortalized human
cervicovaginal epithelial cell lines, i.e., Vk2/E6E7 (vaginal), Ect1/E6E7 (ectocervical) and End1/E6E7
(endocervical) cells. Cytotoxicity MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assays showed no significant differences of percent viable cells of these three cell lines upon treatment
with LL-37 at concentrations up to 3.6 μM (Figure 6A). Sytox Green incorporation assays for the
membrane intactness of these cell lines revealed similar results. In all of these three cell lines, less than
10% of cells incorporated Sytox Green into their nuclei upon treatment with 3.6 μM. However, these
percentages increased to 20, 25 and 40% in Ect1/E6E7, End1/E6E7 and Vk2/E6E7 cells, respectively,
following treatment with 10.8 μM of LL-37 (Figure 6B).
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Figure 6. Low adverse effects of LL-37 on human vaginal and cervical cell lines. Vk2/E6E7 (vaginal),
Ect1/E6E7 (ectocervical) and End1/E6E7 (endocervical) cells cultured as previously described [123]
were treated with various concentrations of LL-37 (24 h, 37 ˝C, 5% CO2) and subjected to a cytotoxicity
MTT assay (A) or a membrane intactness assay using Sytox (B). (A) Treatment of all three cell lines with
LL-37 up to 3.7 μM did not change percentages of viable cells. In contrast, the percentages of viable cells
were only 50% or less upon treatment with 2% NaN3. (B) Sytox Green staining was observed in less
than 20% of all three cell lines upon treatment with LL-37 up to 3.7 μM. When the LL-37 concentration
was increased to 10.8 μM, the numbers of Sytox Green stained cells became higher, although for both
End1/E6E7 and Ect1/E6E7 cells, the percentages were still <20%. For Vk2/E6E7 cells, this percentage
was 40%.
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While the higher susceptibility to LL-37 in the vaginal epithelial cell line should be a matter of
concern, the situation in vivo may not be as unfavourable as that observed in vitro. Cells of the upper
layer of the vaginal epithelium continue to slough off into the lumen and it is possible that those
cells with compromised membrane intactness due to LL-37 exposure may undergo this sloughing at
a higher rate than normal cells.
In summary, we have shown that LL-37 possesses spermicidal effects in both human and mouse
sperm with minimal adverse effects on the female reproductive tract epithelia. This spermicidal
property with molecular mechanisms described above appears to be unique to LL-37. A number
of defensin AMPs are secreted by epididymal epithelial cells (examples-human: HE2β1 (aka
SPAG11D) [208], DEFB126 [209–211], DEFB118 [212,213], DEFB114 [214], DEFB1 [215]; -rodents: Bin1b
(aka SPAG11E) [216,217], β -defensin 22 [218]) and some of them deposit onto the surface of transit
sperm to endow fertilizing ability (e.g., HE2 β 1, DEFB126, DEFB118 and HBD1 in humans, and Bin1b
in rodents). We have shown that both HE2 β 1 and Bin1b could bind to SGG/SGC in vitro, but sperm
incubated with excess amounts (18 μM) of these two defensins were still motile with intact acrosome
and in the case of mouse sperm that were treated with these β-defensins, they could still fertilize eggs
at 50% control values (our unpublished results).
The physiological significance of LL-37 as a microbicide and an immunomodulatory and wound
healing peptide is well documented. In particular, LL-37 exerts microbicidal effects on a number of
microbes responsible for STI, vaginitis and UTI (Table 4). With these microbicidal and spermicidal
properties, LL-37 warrants further attempts to be developed as a vaginal contraceptive/microbicide.
As a natural peptide, its repeated and long-term use will likely create minimal side effects and
microbicidal resistance. Further studies, however, are needed in a number of aspects in potential
application of LL-37 in the vagina. First, an effective method to deliver LL-37 into the vaginal lumen
has to be established. Careful studies on any adverse effects of LL-37, following its repeated/long-term
administration, must also be performed at both topical and systemic levels. Regardless, the cost of
chemical synthesis of LL-37 for this use is a challenge, and the shortest truncated LL-37 peptide or its
mimetic, which still bears spermicidal and microbicidal activity, has to be discovered. In a separate
avenue, ultrashort cationic lipopeptides with high antibiotic activity [219–221] may be screened for
spermicidal effects. However, the selectivity of the deleterious effects of these lipopeptides to sperm
and not to the female reproductive tract epithelial cells must be considered. Nonetheless, success in
finding the most cost-effective form of LL-37 as a vaginal contraceptive/microbicide will undoubtedly
provide women with empowerment in having a healthy and safe sex practice—the ability to protect
themselves from unwanted pregnancies and microbial infections.
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